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SUMMARY
Circadian rhythms are known to be entrained to the 24h day primarily by the light- 
dark cycle. In the increasing urban population many individuals have limited 
exposure to natural daylight, particularly in the temperate regions where daylength is 
extended by artificial light. In constant low level illumination humans exhibit free- 
running rhythms with periods usually in excess of 24h.
The main aim of this thesis was to investigate the ability of timed melatonin 
administration and/or scheduled light:dark cycles of varying intensity to prevent free- 
run or to resynchronise already free-running rhythms. An isolation unit equipped with 
a controlled lighting system, where subjects could be maintained as a group, was 
used for all the studies reported. A baseline study ascertained that sighted, normal, 
healthy males would exhibit free-running rhythms when maintained as a group in 
constant dim light, but with knowledge of clock time. The subjects did not 
synchronise as a group but displayed distinct individual periods. The average 
endogenous tau, as measured by core body temperature and urinary 6- 
sulphatoxymelatonin, was 24.26 ± 0.05h.
5mg melatonin administered at 20:00h had weak zeitgeber effects. When given as a 
first treatment, shortly after entering the isolation unit, it was able to maintain 
apparent synchrony (or “stabilisation”) of the sleep-wake cycle to 24h. The core 
body temperature rhythm was not convincingly synchronised and in some individuals 
the demasked temperature tau appeared to be shortened by the melatonin 
treatment. When administered to already free-running individuals, 5mg melatonin at 
20:00h was able to resynchronise the sleep-wake cycle by phase advance. It was 
less successful at re-entraining rhythms by phase delay. The direction of 
resynchronisation was dependent on the circadian time of administration as 
predicted by the PRC for melatonin. Mathematical demasking of the temperature 
data did not affect the calculated overall periodicity although it did alter the 
acrophase time.
12:12 light-dark cycles of 20 lux and 200 lux intensity were unable to maintain 
synchrony of human circadian rhythms to 24h. 1000 lux was able to prevent free-run 
but was not able to resynchronise already free-running rhythms convincingly. This 
was possibly due to an insufficiently long time series. Combined melatonin 
administration and 1000 lux lighting schedule maintained entrainment to 24h in all 
the parameters measured. There was significantly less variance in the data than 
with melatonin alone, but little if any difference when compared to 1000 lux alone.
Under certain conditions melatonin administration caused fragmented sleep patterns. 
This was possibly due to the timing of the dose in relation to the temperature rhythm. 
A further experiment was carried out to test this hypothesis, and irregular sleep was 
seen in 4/6 individuals.
Overall this thesis suggests that melatonin has useful “chronobiotic” properties. It 
was most effective when combined with light treatment.
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CHAPTER 1
GENERAL INTRODUCTION
20
1.1 NATURAL RHYTHMICITY
Virtually all living organisms, from unicellular algae to man, are subject to repeating 
patterns or rhythms in their environment which influence their way of life. The major 
influence in nature is the light-dark cycle which changes both on a daily basis, as the 
earth rotates about its axis, and seasonally as the earth completes its yearly orbit 
about the sun.
The perceived daylength, or photoperiod, is the amount of time each day that the sun 
is above the horizon. The change in daylength with the seasons in temperate zones 
and at the poles, is caused by the earth tilting towards and away from the sun, 
whereas at the equator the daylength remains constant all year. The photoperiod 
length is an important signal for the timing of functions such as seasonal breeding to 
ensure that animals produce their young when food is at its most plentiful (Arendt, 
1995). It can also act as a signal to prepare the animal for hibernation to facilitate 
survival through the long cold winters when food is scarce.
It is very important for survival that the phase (time) relationships between 
physiological rhythms and the environment are co-ordinated such that the correct 
responses are seen at the right time of day or year. The most obvious rhythms are 
those which repeat approximately every 24 hours. When these are internally 
generated they are known as circadian rhythms from the Latin circa about and diem 
day. However, there are multiple periodicities in endogenous rhythms with 
frequencies varying from fractions of a second (e.g. firing of nerves) to years (e.g. 
population variations).
When the environmental time cues (zeitgebers) are removed a number of biological 
rhythms persist, usually with an altered periodicity. The occurrence of these self- 
sustaining rhythms indicates the presence of internal rhythm generating mechanisms 
or clocks which are entrained to the external environment by time cues such as the 
light dark cycle. Although the existence of repeating patterns or rhythms throughout 
the natural world has been recognised since prehistoric man, it is only during the last 
20 - 30 years that much progress has been made in understanding the underlying 
control mechanisms. With the development of cell culture techniques, individual cells 
from different organs could be examined, and with the advent of molecular biology
21
the role of individual molecules could be investigated. Now, a number of steps in the 
control of circadian rhythms have been elucidated, although there are still several 
missing links.
1.2 REGULATION AND CONTROL OF CIRCADIAN RHYTHMS
1.2.1 Genetic
The periodicity of the internal clock is an inherited characteristic, which implies 
genetic control. This has been examined in a number of different organisms where 
mutant strains were produced which exhibited different periodicities (tau t )  compared 
to the wild type strain. This has been shown to be a feature of prokaryotic 
cyanobacteria (Kondo et al., 1994), Drosophila (Konopka et al., 1971) and 
Neurospora (Dunlap, 1993, Merrow & Dunlap, 1994). Mutations in the per (period) 
locus in Drosophila controlling locomotor activity and hatching from the pupa, and the 
frq (frequency) locus in Neurospora controlling formation of conidiospores, have 
produced arryyhthmicity (null mutants) or strains with shorter or longer periodicity. 
Transcription of both Per and Frq has been shown to exhibit a circadian rhythm with a 
period matching that of the organism (Aronson et al., 1994a & 1994b; Hardin et al., 
1990 & 1992) . frq mRNA concentration rises in the morning resulting in peak levels 
of Frq protein during the day. Per protein concentration rises at the beginning of the 
circadian night peaking in the latter half of the night, several hours after the peak of 
per mRNA. Immunoreactive staining has shown that Per is found in the nucleus, 
suggesting a role as a transcription regulator. As Per does not possess a recognised 
DNA-binding motif it is believed to dimerise with Tim, (the protein product of Timeless 
gene) to gain entry to the nucleus (Huang et al., 1993; Vosshall et al., 1994 and 
Curtin et al., 1995).
The evidence collected to date suggests a core circadian oscillator composed of a 
transcription/translation based negative feedback loop. The clock genes, such as per 
and frq are rhythmically expressed, producing cycling levels of clock RNA's and 
proteins. These proteins have a negative effect by feeding back to depress their own 
transcription, perhaps by blocking elements that increase clock gene transcription 
such as white collar-1 and white collar-2 found in Neurospora and eye and Jrk (dCLK)
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in Drosophila. Mutations in these genes {wc-1, wc-2, eye and Jrk) eliminate 
expression of frq, per and tim indicating that they are an essential requirement in the 
production of sustained rhythms. These genes all possess PAS domains, named 
after the 3 proteins in which this structural motif was first recognised: Drosophila Per, 
mammalian Arnt (a dimérisation partner of the dioxin receptor) and Sim (the product 
of the fruit fly single-minded gene), (Sassone-Corsi, 1997) which dimerise with other 
PAS-domain containing proteins, thus providing a possible mechanism of action 
(Crosthwaite, Dunlap & Loros, 1997, Huang et al., 1993). The per gene contains a 
clock control region with sequences for PER-dependent negative feedback and 
PER-independent positive transcriptional regulation. The region contains a promoter 
sequence termed an E-box, a binding site for some transcription factors and essential 
for the positive component of transcriptional regulation (Hao, Allen & Hardin, 1997). 
Possible mechanisms of action are shown in Fig 1.1.
The involvement of these processes in the control of circadian rhythmicity is clearly 
demonstrated as the expression of frq can be phase shifted by light following a phase 
response curve (Sargent & Briggs 1967) and a similar model could be applied to per 
transcription.
In mammals two mutant strains exhibiting periodicities different from the wild type 
have been studied:- the tau mutant hamster (Ralph & Menaker, 1988) and the eloek 
mutant mouse which has a phenotype affecting both the periodicity and persistence 
of circadian rhythms (Vitaterna et al., 1994). The eloek gene encodes a DNA binding 
protein with a basic helix-loop-helix (bHLH) domain and a PAS domain (King et al., 
1997) as do per and frq, leading to the proposition that it may regulate circadian 
rhythms in mammals. This has been demonstrated by Gekakis et al., (1998), who 
have found co-expression of eloek and mper with bmal1 transcripts in the mouse 
SCN and retina, known sites of the circadian clock in mammals. Human and mouse 
per genes {hper and mper) which are highly homologous to c/Per have been identified 
and shown to code for PAS domain containing polypeptides (Tei et al., 1997). mPer 
shows an autonomous circadian oscillation in expression in the suprachiasmatic 
nucleus. In a further development Shigeyoshi et a/.(1997), found that mPer1 is rapidly 
induced within the SCN at both light sensitive and light insensitive oscillator sites, by 
short duration exposure to light sufficient to reset the clock. Dose-response curves 
show a strong correlation with phase-shifting of the rhythm and thus mPer1 closely
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resembles the Neurospora clock gene frq. A putative mechanism for genetic control 
of circadian rhythms in mammals has been proposed by Dunlap, (1998) and is 
illustrated in Fig 1.1.
1.2.2 Mammalian Biological Clocks
To qualify as an endogenous central timing mechanism a structure must be able to 
show self-sustaining circadian oscillations in the absence of external time cues. The 
mammalian suprachiasmatic nuclei and retina both demonstrate this ability and 
therefore can be classified as true biological clocks. The retina and SON are linked 
via the retino-hypothalamic tract (RHT), originating in the retina, and the geniculo- 
hypothalamic tract (GHT) arising from the intergeniculate leaflet (IGL), a retino- 
recipient nucleus of the lateral geniculate body (Groos & Meijer, 1985 and Pickard, 
Ralph & Menaker, 1987). (Fig 1.2). The light stimulus is received by a photoreceptor 
in the eye and transmitted to the SCN. Visual responses require a lower light 
intensity than do phase-shifting responses (Takahashi et al., 1984). It was originally 
thought that the photic regulation of circadian rhythms was dependent on the rod 
photoreceptors and their photopigment rhodopsin, which is most sensitive to light of 
SOOnm wavelength (Takahashi et a/., 1984). However, Provencio & Foster (1995) 
have demonstrated that the retinally degenerate (rd) mice, who do not have any rods, 
can still be phase-shifted by light, suggesting the involvement of cone photoreceptors 
(M-cones; lmax= 511nm and UV-cones; Xmax= 359nm). Experimental data collected to 
date leaves the possibility that an as yet unknown ocular photoreceptor might be 
involved.
1.2.2.1 Suprachiasmatic nuclei
The suprachiasmatic nuclei (SCN) are a pair of ovoid nuclei ventrolateral to the base 
of the third ventricle in the anterior hypothalamus, dorsal to the caudal border of the 
optic chiasm (Rusak & Zucker, 1979). Their role as a biological clock has been clearly 
shown in a number of elegant in vitro experiments where cultured rat hypothalamus 
SCN slices generate stable, near 24h oscillations in neuronal firing rate in phase with 
the biological clock of the donor animal (Green & Gillette, 1982; Gillette et a/., 1995). 
Light treatment of the donor animals immediately prior to decapitation produced
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phase-shifts in the SCN neuronal firing rhythm, much greater in magnitude than those 
seen in intact animals due to the isolation of the culture (Gillette 1986).
Fig 1.2 Central rhythm generating system in the SCN.
Melatonin feeds back on the SCN and possibly 
the retina. Adapted from Arendt, 1993.
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melatonin
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The peak of the firing rate occurs near midday, and during the subjective day the 
SCN slices exhibit periods of sensitivity to cyclic AMP, serotonin, neuropeptide Y and 
to melatonin at dusk. During the subjective night, periods of sensitivity to glutamate, 
cyclic GMP and neuropeptide Y are followed by a second period of sensitivity to 
melatonin at dawn (Gillette et al., 1993). These changes must be generated within 
the clock of the SCN as the tissue is maintained in constant conditions and isolated 
from afferents. Individually cultured SCN neurons are able to express free-running 
circadian rhythms of electrical firing, suggesting that each neuron may be able to act 
as an independent clock (Welsh et a/., 1995).
Further evidence for the role of the SCN as a biological clock has been obtained from 
transplantation studies and surgical destruction of the SCN (Rusak & Zucker, 1979) 
or blocking of the retino-hypothalamic tract. Moore and Klein in 1974 showed that the 
circadian rhythm in the pineal serotonin N-acetyl transferase activity was abolished if 
the retino-hypothalamic projection to the SCN was severed leaving the rest of the 
optical tract intact.
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SCN grafts into SCN lesioned animals restored free-running rhythms in constant 
darkness provided various neuropeptides (vasoactive intestinal polypeptide (VIP), 
neuropeptide Y (NPY), and vasopressin (VP)) were present (Lehman et al., 1987). In 
some recipients grafts received retinal input and appeared to send efferents to the 
host brain. The SCN transplants were able to restore locomotor activity but did not 
produce gonadal regression in the absence of light, nor phase-shift or entrain to a 
light stimulus. This was confirmed by Matsumoto et al. in 1996. Initial transplants 
used foetal anterior hypothalamic tissue which, whilst it did contain SCN tissue, 
contained other hypothalamic tissue as well. The transplantation of SCN 
“micropunches” proved sufficient for restoration of locomotor rhythms in hamsters 
(LeSauter et al., 1996) while micropunches of other hypothalamic tissue were not 
effective.
The discovery of the tau mutant hamster (Ralph & Menaker, 1988) with an intrinsic 
period of 20h in the homozygote, allowed implantation of SCN tissue from animals 
showing a significantly different tau. Foetal SCN tissue transplanted into the third 
ventricle of completely SCN lesioned hamsters restored locomotor activity with a 
period identical to that of the donor animal (Menaker & Vogelbaum, 1993). 
Transplants into partially lesioned animals produced chimeras exhibiting periodicities 
from both host and donor animals (Vogelbaum & Menaker, 1992).
The major influence on the biological clock is the light dark cycle. When the SCN is 
exposed to light, transcription is initiated. This involves phosphorylation with 
activation of the cAMP responsive-element binding protein (CREB) and induction of 
the immediate-early genes c-fos and egr1 (Kornhauser et al., 1996 and Hastings et 
al., 1995). Light-induced c-fos gene expression in the SCN is altered by the 
photoperiod length in hamsters suggesting that the SCN may be involved in 
photoperiodic time measurement as well as circadian time keeping (Sumova et al., 
1995).
A suggested pathway for resetting or phase shifting the clock via light from the retina 
has been proposed by Ding et al., 1994. Exposure of rat SCN slices to glutamate 
(Glu), N-methyl-d-aspartate (NMDA), or nitric oxide (NO) generators produced phase 
shifts of the circadian rhythms, whilst NMDA antagonists or calcium-dependent nitric 
oxide synthase (NOS) inhibitors in vitro and in vivo blocked light resetting of the
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rhythms. This information indicated that the phase resetting of the clock involves Glu 
release, NMDA receptor activation, NOS stimulation and NO production. The 
application of glutamate to hamster SCN cultures induced Fos and Egr 
immunoreactivity (Hastings, 1997). These two observations indicated a possible 
transduction cascade where NMDA receptors are activated by glutamate allowing an 
influx of Ca ions, activation of CaM Kinase II resulting in phosphorylation of CREB 
leading to the transcription of immediate-early genes (Hastings, 1995). However, this 
is not the whole picture, as the SCN can be reset by non-photic cues without 
induction of this transcriptional response.
1.2.2.2 Retina
In mammals the SCN are considered to be the major biological clock, but in lower 
vertebrates the photoreceptors of the lateral eyes and pineal gland are capable of 
expressing self-contained circadian oscillators. The mammalian pineal gland is no 
longer an autonomous oscillator and photoreceptor. However, the mammalian retina 
does exhibit some rhythmical properties with self-sustaining circadian oscillations in 
visual sensitivity associated with rod-outer segment disk shedding, inner segment 
degradation, melatonin and dopamine synthesis and electrophysiological responses 
(Terman & Terman, 1985; Reme, Wirz-Justice & Terman, 1991).
Tosini & Menaker, (1996) have cultured hamster retina and shown the expression of 
circadian oscillations by measuring melatonin synthesis. The retinal clock ran with a 
period close to 24h when cultured at 27°C but not if cultured at 37 °C. The authors 
concluded that since the rhythm was still expressed at 27°C the clock must be 
temperature compensated. But this begs the question that if the retinal clock is 
temperature compensated why does it not function when cultured at 37 °C. The 
period could be entrained by the light dark cycle and was free-running in constant 
dark. Retina from tau mutant hamsters ran with a period of 20h indicating that the 
mutation affects a common element of the circadian oscillator and is not specific to 
the SCN.
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1.3 HUMAN CIRCADIAN RHYTHMS
1.3.1 Early Human Studies - pre 1980
The knowledge that the control of rhythms in the plant and animal world could be 
divided into two components - the endogenous clock and the effect of external time 
cues, led experimenters to investigate whether human circadian rhythms were 
controlled in the same manner, and to attempt to measure the period of the 
endogenous clock. In order to do this it was essential that subjects were completely 
isolated from external influences. The original experiments were carried out in caves 
(Halberg et a/., 1965; Siffre, 1965; Mills 1964) or underground bunkers (Aschoff & 
Wever,1962) with no natural light and constant temperature. The primary rhythm 
measured was that of sleep-wake, where sleep times were noted by an experimenter 
or the subject (Mills, 1964) when clock time was known. In all subjects studied the 
sleep-wake free-ran with an average period of approximately 24.5h. Mills and 
Aschoff and Wever also measured urine volume and constituents, which again 
showed a free-running rhythms, although in the longer experiment of Mills the various 
urinary electrolytes became desynchronised (Lewis & Lobban, 1957).
To allow for more controlled experiments with better living conditions, purpose built 
isolation units were constructed in nine different locations. The majority of 
experiments were carried out by Wever & Aschoff in their unit at Andechs where over 
200 subjects were studied (Aschoff, 1965; Wever, 1979). Throughout all the Andechs 
experiments core body temperature (via a rectal probe) and sleep-wake parameters 
were recorded, to allow comparison of the periodicities of these rhythms under 
varying experimental conditions.
Circadian rhythms were known in a large number of human physiological processes. 
Most however are unsuitable for use as phase markers. Some are simply differences 
due to sleep or wake states e.g oxygen consumption. Many are difficult to measure 
continuously e.g blood pressure. They may be very heavily influenced by external 
forces, such as variations in glucose, insulin, fatty acids and triglycerides, or fluctuate 
too widely, as with urinary electrolytes (Minors & Waterhouse, 1981). Measurement 
of any of these factors over a long term study is impracticable, hence the choice of 
core body temperature and the sleep-wake cycle by Aschoff & Wever. Both of these
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rhythms can be monitored for long periods of time with minimum inconvenience to the 
subjects and minimum interaction with experimenters. The rhythm of core body 
temperature was also seen to show less daily variation and slight, if any, differences 
in profile between entrained and free-running conditions (Mills et al., 1974; Czeisler, 
1978 and Wever 1979).
1.3.1.1 Free-running rhythms
Three main types of isolation experiments were carried out : a. free-running; b. non- 
24h days and c. rapid changes in time as in a phase-shift simulation (Mills et al., 
1978a). A number of general conclusions were drawn from these experiments 
(Wever, 1979).
1. The average free-running period of the endogenous clock was 25 ± 0.5h and was 
unaffected by sex or age.
2. Change in intensity or wavelength of constant illumination did not affect the period.
3. The amount of imposed work (physical or mental) had no effect.
4. The period could be lengthened by allowing self-selected light-dark schedules.
5. Maintaining subjects in small groups lengthened tau, all individuals in each group 
exhibiting the same period (Wever, 1975).
6. Period could be shortened by exposure to a continuous electromagnetic field (10 
Hz AC).
7. In the absence of any electromagnetic field, the longer the free-running period the 
higher the incidence of internal desynchronisation (rhythms running with different 
periodicities in the same individual).
These results led to a number of assumptions about the relative strengths of the 
different zeitgebers.
1.3.1.2 Zeitgeber effects
1.3.1.2.1 Light-Dark cycle
Wever concluded from his experiments that the light-dark cycle had only weak 
zeitgeber effects on endogenous circadian rhythms. This was at variance with results 
reported from a number of other workers noting changes in the timing of hormone
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excretion between the seasons (Mills & Waterhouse, 1973), in the Arctic (Sharp, 
1960) and shifted sleep-wake cycles (Orth et al., 1969). Early work in the blind also 
suggested that they exhibited rhythms of lower amplitude and greater irregularity of 
phase (Tokura & Takagi, 1974; Krieger & Rizzo, 1971) and Orth et al., (1979) 
reported free-running plasma cortisol rhythms in one blind individual.
Wever considered that blind individuals had greater variance in their rhythms 
because they were more dependent on social factors for entrainment which would 
vary greatly between individuals. A number of circadian rhythms were assessed in 
individuals under a regulated 16h light 8h darkness cycle and then under constant 
darkness, with no difference in phase, leading to the assumption that the light-dark 
cycle was unimportant. However, the time series in constant darkness was too short 
to allow free-run. Finally, some subjects isolated from time cues free-ran in the 
presence of a regulated 24h light-dark cycle, again suggesting that light was not an 
important zeitgeber. Retrospective analysis of the data shows that these individuals 
had access to auxiliary lighting which was self-controlled and therefore the length of 
light exposure could be extended each day.
1.3.1.2.2 Sleep-Wake cycle
The sleep-wake cycle in humans can be regarded as the activity rhythm. However, 
man is able to adjust his sleep-wake pattern, as and when required, to fit in with his 
social requirements. Rhythms expressed in terms of their relationship to mid-sleep, 
or sleep onset or offset times were found to give a more accurate measure of their 
phase (Czeisler, 1978; Mills et al., 1978b; Aschoff, 1979) than comparison to the 
activity-rest rhythm as a whole. It was concluded that the period of sleep had a 
stronger effect on rhythms than the period of activity.
1.3.1.2.3 Knowledge of clock time
Knowledge of clock time in the ‘real world' did not appear to have a strong influence 
on circadian rhythms. Mills, (1964) reported that an individual living in isolation with a 
wrist watch did not adhere to a regular sleep-wake routine, as when he attempted to 
sleep at the same time each day he was unable to sleep. His sleep-wake rhythm free- 
ran with a period of 24.5h. The knowledge of clock time was therefore not a strong 
enough zeitgeber to ensure entrainment to 24h as it was irrelevant to the prevailing 
living conditions. The added social impetus of a scheduled routine, such as work or
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social engagements, was needed as a reinforcement to override the natural tendency 
to delay. This is not always the case as many blind individuals, who have a regular 
schedule, still exhibit free-running rhythms (Sack et a/., 1987 & 1989; Lockley et al., 
1997a).
1.3.1.2.4 Mealtimes
No conclusive evidence was obtained in these early experiments to suggest 
entrainment of the circadian system by meal times. For example circadian rhythms 
were unaffected when normal meals were replaced by 4 identical meals or a single 
meal taken in the morning or evening (Apfelbaum et al., 1976). Shift-workers did not 
change their pattern of food intake, although other circadian parameters appeared to 
have adjusted to the new sleep-wake cycle (Reinberg et al., 1979). Free-running 
rhythms occurred throughout a period of irregular sleep-wake in spite of a regular 24h 
schedule of meal timing (Minors and Waterhouse, 1980).
1.3.1.2.5 Social factors
Wever and Aschoff considered that the results from their isolation studies implicated 
social factors as the most important zeitgeber in man (Aschoff, 1979; Wever, 1979). 
The evidence for this was that subjects kept together showed free-running rhythms of 
identical period, even when they became internally desynchronised (Wever, 
1975).This was considered unlikely to happen by chance and was therefore due to 
social interaction between the subjects. When regular gong strokes were introduced 
into a controlled light-dark cycle, activity and core body temperature rhythms were 
entrained to day lengths of from 23-27h. Gong strokes alone were also reported to be 
a successful synchronising signal (Aschoff et al., 1971), however, the signals 
indicated a period of scheduled activity which had a masking effect on any underlying 
rhythms and the study period was only four days in length.
This insistence on the part of Aschoff and Wever that social factors were the most 
effective zeitgeber in man influenced a great number of researchers until challenged 
by Czeisler et al. (1981). Extending the theory of the importance of social factors in 
entrainment, maladaptation to night-shift work was considered to be due to 
continued social interaction between the night-shift workers and normal society 
(Aschoff et al., 1975). It was also recommended that adaptation to time zone
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changes could be accelerated by increasing social interaction in the new time zone 
(Klein & Wegman, 1974; Aschoff ef a/., 1975).
1.3.1.3 Two oscillator theory
The internal desynchronisation which occurred between the rhythm of core body 
temperature and the sleep-wake cycle, led to the proposal of a two oscillator system 
to control human circadian rhythms (Wever, 1976). These oscillators are said to be 
slaves to, and controlled by, the central biological clock. An oscillator has to have a 
regular repeating cycle with a measurable waveform of definite shape and 
measurable amplitude. Sequential points in the cycle have a definite phase position 
in relation to each other, described as the phase angle. One complete cycle period is 
360°, and for state variables (the cycle is always identical) the oscillator function can 
be determined from a complete description of the waveform (Friesen et a/., 1993). In 
circadian rhythms there are no state variables, they are described as indicator 
variables as the cycles vary but are indicative of the rhythm of the oscillator 
controlling it. The two oscillators have been described as van der Pol oscillators and 
mathematical models have been developed (Kronauer et al., 1982- , 1983 ; Gander 
et al., 1984a, 1984b) to predict their behaviour, van der Pol oscillators are the 
simplest mathematical representation of oscillations which incorporate amplitude as 
well as phase descriptors.
This mathematical model assumes that there are two interacting endogenous 
circadian oscillators, x (temperature) and y (rest-activity) which exhibit their own 
intrinsic period, x is described as a strong oscillator with a period close to 24h, and is 
little affected by external factors. However, the x oscillator cannot be in total control of 
the temperature rhythm, as sleep is known to effect temperature directly, leading to 
interaction or coupling of the x and y oscillators, y is a weak oscillator with a much 
longer period and can be strongly influenced by external factors. The influence of 
external zeitgebers (z) acting only on the y oscillator has been included in the model 
and both phase and amplitude of the oscillator have been incorporated. 
Desynchronisation occurs when the intrinsic periods of the two oscillators become so 
disparate that the coupling mechanism is no longer capable of maintaining 
synchrony.
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An alternative system with a single circadian oscillator controlling all rhythms has also 
been suggested (Daan & Beersma, 1992), where differences can be accounted for 
by waveform distortion due to masking and fitting procedures.
1.3.1.4 Morning & evening oscillators
The phenomenon of splitting of the activity rhythm into two peaks has been seen in 
birds (Aschoff, 1966) and several species of mammal (Pittendrigh & Daan, 1976). 
Under natural conditions the two peaks frequently occur close to dawn and dusk. In 
constant light conditions of varying intensities, finches show different circadian 
periods and duration of activity, but the two peaks maintain the same relationship to 
the activity time. This suggests that the two peak pattern is due to the oscillating 
circadian system.
In hamsters (Pittendrigh & Daan, 1976), splitting of the activity band into two 
components, which are stably coupled in anti-phase, occurred in constant lighting 
conditions with an intensity of less than 100-200lux. On moving the hamsters from 
L;D to D:D the two activity peaks showed different periodicities for a few days, 
suggesting the presence of two different oscillators. These two oscillators are called 
the E (evening) and M (morning) oscillators. The E oscillator is affected by the 
decrease in light levels at twilight and the M oscillator is controlled by the increase in 
light intensity at dawn. These two oscillators are of interest as they signal the change 
between day and night which is important to both diurnal and nocturnal species 
(Rusak, 1989). They are also capable of recognising the change in daylength critical 
for photoperiodic breeders (Bartness & Goldman, 1989).
Whilst the effect of varying photoperiods in animals is well documented, the effect on 
humans of artificially shortening the day length has only been reported by Wehr et al. 
(1993). Exposure to 14h nights as opposed to 8h nights increased the duration of 
melatonin secretion, increased prolactin secretion and sleep whilst lengthening the 
period of nocturnal low rectal temperature. The rate of change of the various rhythms 
on switching from short to long nights was not the same, indicating that they could be 
under the control of different oscillators. Evidence from previous experiments in 
humans (Lewy et al., 1985a; Buresova et al., 1991) suggested that the melatonin 
onset and offset could be controlled by different oscillators as they exhibited different
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responses to light. To relate this data to the evidence from animal experiments 
(lllnerova & Vanécek, 1982) it was proposed that the offset of activity and onset of 
melatonin secretion in man is controlled by the evening oscillator (E) whilst the onset 
of activity and offset of melatonin secretion is influenced by the morning (M) 
oscillator.
Hashimoto et al. (1997) exposed normal individuals to 6h bright light (5,000 lux) 
between 11:00 - 17:00 on three consecutive days against a background illumination 
of < 200 lux with 8h sleep in darkness. This produced a significant phase advance in 
the melatonin onset time but not melatonin offset. The resulting increase in the 
duration of the melatonin profile added support to the theory of morning and evening 
oscillators controlling the melatonin rhythm. Further evidence in support of this 
proposal was demonstrated by Wehr et al. (1995), where six women exhibited clear, 
reproducible evening and morning peaks in melatonin secretion.
Cagnacci et al. (1997) found that morning treatment with melatonin counteracted the 
phase advancing effect of bright light on the offset of melatonin secretion (M) but 
increased the phase advancing effect on the evening onset of melatonin (E). Thus 
when morning bright light exposure was combined with morning melatonin 
administration the duration of melatonin secretion increased. Wehr (1997) has 
postulated that individuals who failed to respond to experimental or natural changes 
in the scotoperiod are those in whom the M-oscillator fails to respond to morning light. 
Possible explanations for this are: 1. Insufficient exposure to morning light, 2. The M 
oscillator is blind, 3. It is too closely coupled to the E oscillator or 4. It has an intrinsic 
period shorter than 24h and so is always phase advanced.
1.3.1.5 Phase markers
In order to study any changes in the period of the endogenous clock it is essential to 
have a reliable and consistent phase marker which is unaffected by the external 
environment.
In the original human experiments core body temperature was chosen as the marker 
of choice (Wever, 1979). However, the temperature rhythm is now known to be 
masked by a number of external influences (Wever, 1983; Aschoff, 1988; Minors &
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Waterhouse, 1988). The major masking effect on body temperature is sleep, where 
the temperature trace shows a rapid decline at sleep onset followed by a rapid rise at 
sleep offset. Several mathematical methods have been developed to demask 
temperature data to account for the effects of sleep (Minors et al., 1994; Folkard, 
1989; Carrier and Monk, 1997). A full description is given in Chapter 5.
Whilst sleep is the main factor affecting the temperature rhythm, exercise, meals and 
showers can all cause an increase in core temperature. Under normal conditions 
these influences can distort the data resulting in incorrect estimates of phase position 
and period. Alternatives to mathematical demasking are the constant routine 
procedures devised by Mills et a/. (1978o^ Czeisler et al. (1986 ); Moog and 
Hildebrandt (1986) and Krauchi and Wirz-Justice (1994). During a constant routine, 
individuals are maintained under constant conditions which may vary slightly between 
protocols. Subjects are kept under constant bedrest, or seated with constant 
illumination, temperature and humidity, with identical snacks every hour. The 
constant routine is an ideal tool to investigate the effects of a particular study 
protocol. Evaluation of the endogenous temperature rhythm, using the constant 
routine, before and after experimental manipulation, allows any change in the rhythm 
to be calculated. However, constant routines are not applicable to field studies or 
when long term monitoring is required.
Various hormones, especially cortisol, have been used as phase markers (Minors & 
Waterhouse, 1981). Many exhibit a pulsatile secretion profile and some are excreted 
in a specific relationship to the sleep-wake cycle (e.g. growth hormone & prolactin). 
Cortisol is affected by both stress and meals, such that masking of the endogenous 
rhythm by exogenous factors is again a problem.
The hormone melatonin, has been shown to have a distinct circadian rhythm. 
Normally levels rise in the plasma during the evening, reach a peak at approximately 
2:00am and decline in the early morning and therefore it is a useful measure of 
circadian phase (Wever, 1989; Shanahan & Czeisler, 1991). Light exposure induces 
comparable phase-shifts in the core body temperature rhythm and the plasma 
melatonin rhythm (Shanahan & Czeisler, 1991) so the use of either as a phase 
marker should give identical results. The major urinary metabolite, 6- 
sulphatoxymelatonin, has also been investigated as a phase marker, since urine
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collection is non-invasive and samples can be collected at timed intervals over long 
experimental protocols. 6-sulphatoxymelatonin (aMT6s) is a good quantitative and 
qualitative reflection of melatonin secretion exhibiting a clear circadian rhythm 
(Arendt et al., 1985; Bojkowski et al., 1987a; Deacon & Arendt, 1994o^oss et al., 
1995) and therefore is suitable for use as a phase marker.
The use of melatonin and aMT6s as phase markers has many advantages. The 
profile has been shown to be extremely reproducible in a single individual, although 
there is great interindividual variation (Arendt, 1986; Coetzee et al., 1989 and 
Waldhauser & Dietzel, 1985). Melatonin is less subject to masking problems than 
temperature or cortisol. The only exogenous factors known to influence melatonin 
levels (apart from drugs) are bright light which is able to suppress melatonin (Lewy et 
al., 1980) and to a small extent posture (Deacon & Arendt 1994f^and exercise (Van 
Reeth et al., 1994a: Buxton et al., 1997). A recent review by Shanahan et al. (1997), 
proposes that since low light intensities, activity, posture and photoperiod may affect 
the melatonin rhythm, the entire melatonin profile be considered when using the 
rhythm as a marker of circadian phase. Changes in the amplitude, duration or shape 
of the profile may provide information about the phase resetting process in humans. 
Plasma melatonin can only be used for acute monitoring of phase (such as during 
constant routines) due to the constraints of blood sampling volume, whereas urine 
collections may be made for indefinite periods.
A recent paper (Brown et al., 1997) has proposed a mathematical model for the 
diurnal variations in human plasma melatonin levels, which claims to give results 
comparable to those already obtained by experimental means. The model 
incorporates the circadian control of melatonin onset and offset, the rate of synthesis, 
infusion into the plasma and clearance by the liver, error due to the melatonin 
immunoassay and the lighting conditions in force when the rhythm was measured.
In summary, constant routines with rectal body temperature and plasma melatonin 
sampling are the method of choice for measurement of acute changes of phase 
position after discrete experimental protocols. For long term studies measurement of 
urinary 6-sulphatoxymelatonin is the more suitable phase marker.
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1.4 THE HUMAN CIRCADIAN SYSTEM AND LIGHT
The light-dark cycle is now thought to be the strongest zeitgeber involved in the 
maintenance of circadian rhythms. The intrinsic period of the human biological clock 
is on average longer than 24 hours and is reset each day primarily by exposure to 
phase-advancing light in the early morning, counteracting the tendency for it to delay.
Many experiments carried out since 1980 have shown the importance of the light- 
dark cycle in phase-shifting and entrainment of the human circadian system. The 
effects of light are dependent on the intensity, duration and timing of the exposure. 
With hindsight many early experiments can be criticised for insufficient control of 
ambient lighting conditions, or incorrect timing of light exposure, both of which are 
now known to have a crucial impact on the results obtained. In many of the studies 
carried out to investigate the effect of light on human circadian rhythms the 
parameters used to measure phase-shift are the core body temperature rhythm and 
melatonin secretion. Melatonin levels are also an indication of the acute influence of 
light as its production is suppressed by light exposure of sufficient intensity.
1.4.1 Autonomous Rhythms & Desynchronisation Experiments
The intrinsic period of the biological clock was thought to be approximately 25h 
(Wever, 1979) but this was determined when individuals were allowed to self-select 
their light dark cycle by means of auxiliary lighting. Subjects were continually being 
exposed to light during the phase delay portion of the phase response curve (PRC) 
due to the timing of sleep episodes but were not exposed to light during the phase 
advance portion of the curve. Thus, the intrinsic endogenous period was augmented 
by a phase delay due to light exposure.
When controlled lighting regimes of gradually changing length (10-15min per 'day') 
were in force (Wever, 1989) a range of entrainment was calculated for the vegetative 
rhythms such as core body temperature and behavioural rhythms such as the sleep- 
wake cycle. The temperature rhythm was entrained to periods between 23h and 27h 
whilst the sleep-wake rhythm remained entrained over all period lengths studied (15h 
- 48h). If the imposed experimental conditions included a period greater than 27h 
then internal desynchronisation occurred. Spontaneous internal desynchronisation
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was seen in free-running individuals under constant illumination. The range of 
entrainment is centred about the free-running period (Wever, 1983) and therefore 
showed individual variability with longer free-running periods resulting in wider ranges 
of entrainment. The range of entrainment was also increased by raising the 
illumination levels (Wever ef a/., 1983).
The spontaneous internal desynchronisation of the temperature and sleep-wake 
cycle was not seen when subjects were permitted to nap. In all the temporal isolation 
experiments reported by Wever (1979, 1989) subjects were instructed not to nap and 
to eat three meals a ‘day’ in normal sequence. This resulted in monophasic sleep. 
But if allowed to nap subjects may exhibit polyphasic sleep (Campbell, Dawson & 
Zulley, 1993) as seen in many animal species. When individuals were allowed to nap 
under the same conditions of self-selected light-dark cycles the intrinsic period was 
not significantly different from 24h.
An estimate of the intrinsic period was made under more controlled conditions by 
Czeisler et al. (1995a) using the forced desynchrony protocol of Kleitman (1939). A 
28h activity-rest cycle was imposed with light levels of 10-15 lux during the “day” and 
0.02 lux at “night”. The circadian pacemaker is unable to entrain to the 28h day and 
becomes desynchronised from the sleep-wake cycle. As the sleep episodes were 
scheduled, the time of light exposure was controlled. In these conditions a shorter 
intrinsic period of 24.17h was recorded for temperature, melatonin and cortisol. 
Mathematical modelling (Klerman et al., 1996) of these experimental results indicated 
that room light of ~ 150 lux should be sufficient to entrain the circadian clock to 24h if 
the intrinsic period is between 23.4-24.8h. The calculated range of entrainment 
increasing with light intensity as shown originally by Wever et al. (1983).
The ability of an enforced light-dark cycle to entrain endogenous rhythms under field 
conditions with conflicting 24h zeitgebers was investigated by Eastman & Mieske,
(1990). Evening and morning bright light treatments were used to extend the 
daylength and 74% of subjects tested entrained to the 26h day.
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1.4.2 Visual Sensitivity
1.4.2.1 Wavelength
The two major effects of light exposure that can readily be measured are phase- 
shifting of circadian rhythms and suppression of melatonin. Investigation of the 
spectral sensitivity for phase-shifting of the locomotor activity in rats indicated that 
light with a wavelength of SOOnm produced the maximum phase shift after a 15min 
light pulse (Takahashi et al., 1984). Early animal experiments (Cardinali et al., 1972; 
Brainard et al. 1984, lllnerova, 1988) suggested that the wavelength most effective in 
suppressing the melatonin rhythm in rodents was blue fluorescent light, with a 
wavelength of approximately SOOnm, with green light of wavelength 530nm being the 
next most effective. This indicated that the retinal photopigment mediating the 
response was rhodopsin or some other chromophore with similar sensitivity. The 
timing of exposure was also important. In rats green light suppressed pineal and 
plasma melatonin to daytime levels when given at 24:00h, but red light did not, while 
both green and red light exposure caused suppression of pineal melatonin and a 
decrease in plasma melatonin when given at 04:00h (Honma et al., 1992). The work 
of Brainard et al. (1985 & 1988), showed that humans were most sensitive to light of 
509nm wavelength, which gave 64% suppression of nocturnal melatonin levels with a 
dose dependent relationship to the total irradiance received, again suggesting that 
the response was mediated by a rhodopsin-like chromophore. The effect of light on 
the pineal gland is also affected by the pupillary diameter (Gaddy et al., 1993) and 
the head and eye motion (Dawson & Campbell, 1990). Adler et al. (1992) 
demonstrated that light of 1000 lux caused similar suppression of melatonin when the 
light was perceived centrally or peripherally. Studies in colour blind humans (Ruberg 
et al., 1996) have shown no significant difference in melatonin suppression between 
red-green colour blind individuals and normal controls indicating that the normal 
three-cone visual system is not necessary for photic regulation.
Indeed, the work of Provencio and Foster, (l 995) with retinally degenerate mice 
suggests that neither rods nor cones are required for photic regulation of the 
circadian or neuroendocrine system. Some blind individuals with no conscious light 
perception, loss of pupillary reflex and no recordable electroretinograms still show 
melatonin suppression when exposed to 6000 lux white light at night (Czeisler et al..
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1995c). An insight to a possible mechanism has recently published by Zeitzer, 
Kronauer and Czeisler (1997). Individuals were exposed to red light of a wavelength 
outside the scotopic system but of sufficient intensity to induce phase shifts in a 
photopically based circadian system. The human circadian pacemaker was reset by 
this light, indicating that the cone pigments involved in colour vision may well be 
involved in circadian vision as well. Another indication that light near the red end of 
the visible spectrum and infrared light may be involved is that, as humans age, the 
crystalline lens in the eye develops a yellow pigmentation that reduces the amount of 
light reaching the retina, especially light of the shorter wavelengths. The amount of 
visible red light and infrared light reaching the retina does not decrease with age 
(Brainard et al., 1997).
The increase in use of bright light treatment for various disorders such as seasonal 
affective disorder (SAD), adaptation to shift-work or time zone transitions has led to 
some concern over ocular safety. Remé & Rol (1996) have made recommendations 
suggesting standardisation of lamps and treatments to avoid damage due to UV 
light. They propose that the spectral characteristics of lamps should be controlled by 
use of plastic diffusing screens, glasses with UV blockers, blue light attenuation and 
side shields. Patients should also be screened for existing eye damage or 
ophthalmic susceptibility to damage. When light treatment is used to alleviate the 
symptoms of SAD individuals may be exposed to possible damage over a period of 
years.
The specific photoreceptor system in the mammalian eye involved in the control of 
circadian rhythms or the suppression of melatonin has yet to be identified, but the 
breeding of mice with deficient visual systems has introduced a new model system for 
systematic detective work.
1.4.2.2 Photoperiod
In photoperiodic species the change in the length of daylight experienced can signal 
changes in animal behaviour (hibernation), coat growth and reproductive status. In a 
normal environment the change in photoperiod is reinforced by changes in the 
ambient temperature and food availability (Arendt, 1995, Arendt 1998a). Sheep for 
example are short day breeders in that the shortening of daylength, or increased
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duration of melatonin secretion, in the autumn brings the ewes into oestrous ready to 
breed during the winter period, so that lambs are born in the spring when food is 
plentiful and the temperature warmer. Hamsters are, in contrast, long day breeders 
so that a decrease in daylength, or increase in the melatonin profile, induces 
shrinking of the gonads with recrudescence of the testes as daylength begins to 
increase in the spring.
These effects are mediated by the pineal gland and the response to daylength can 
be removed by pinealectomy. The effect of photoperiod can be demonstrated 
experimentally by subjecting the animals to artificial long or short days. This can be 
achieved by manipulation of the light-dark cycle, or the duration of melatonin 
secretion. Early work investigating the effect of melatonin duration on reproductive 
function used implants (Reiter, 1980). Later work involved infusion of melatonin into 
pinealectomised animals to mimic specific photoperiods in an intact animal (Carter 
and Goldman, 1983; Karsch et al., 1984 & 1988; Bartness et al., 1993). The 
melatonin signal Was read as a continuous one, provided breaks in the presence of 
the hormone did not exceed 2h (Bartness and Goldman, 1989).
The response seen depends on the previous daylength or melatonin secretion profile. 
An increase in melatonin secretion from lOh to 14h will indicate short days, as will a 
change from 6h to 8h (Hastings et al. 1989). Seasonal breeders can therefore be 
brought into season by manipulation of the lighting schedule or melatonin secretion 
profile. If animals are maintained in either long or short days for long periods of time 
the seasonal response is lost and the animals become refractory. A period of 
exposure to the opposite daylength is required to reinstate thel photoperiodic response.
Artificial manipulation of the duration of melatonin secretion by means of implants is 
of commercial use. Sheep can be induced to come into oestrous early resulting in 
early lambs which fetch a higher market price. In a similar way coat growth can be 
accelerated in mink, cashmere goats and foxes (Arendt, 1995).
Humans are not obviously seasonal creatures although the remnants of a 
photoperiodic response has been shown under some environmental conditions. A
bright light skeleton photoperiod induced a marked phase advance of the melatonin 
rhythm during the Antarctic winter (Broadway et al., 1987). The advanced melatonin
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secretion profile resembled that seen during the summer months. The daily rhythms 
of salivary melatonin and cortisol and axillary body temperature were measured in the 
summer, autumn and winter at latitude 60° N where there is a significant difference in 
daylength with the seasons (Laakso et al., 1994). The melatonin and cortisol rhythms 
were delayed in midwinter compared to summer and autumn.
Wehr (1991) and Wehr et al. (1993) stated that humans possessed a conserved 
photoperiodism as shown by an increased duration of melatonin secretion when kept 
on a regular regime of 14h dark lOh light. In a similar study Buresova et al. (1992) 
compared the melatonin secretion profile during 8hL:16hD with that of 16hL:8hD, 
incorporating a skeleton photoperiod of 3h bright light in the morning and evening to 
create an artificially long day. This shortened the melatonin secretion profile by 3h. 
The long day effect persisted for 3 days after the light treatment ceased (lllnerova et 
al., 1993a).
In a follow up experiment ( Wehr et al., 1995) looked at the secretion profile of 
melatonin, cortisol and thyrotropin and low levels of rectal temperature in subjects 
living a normal life exposed to both natural and artificial light at 39° N. Measurements 
were made during a 24h constant routine in low light levels during the summer and 
winter. No difference was seen in any of the parameters measured, despite the 
difference in natural daylength with the seasons at that latitude suggesting that the 
use of artificial light suppresses any photoperiodic response which might occur. 
When the number of subjects was increased and women were included, a difference 
was seen between winter and summer plasma melatonin profiles. Statistics 
suggested that 1 in 3 women and 1 in 8 men were responsive to the change in 
photoperiod with the seasons (Wehr, 1997).
1.4.2.3 Effects of twilight
In the normal environment the light dark-cycle does not exhibit an abrupt change from 
darkness to high light intensities. There is a gradual increase during the dawn period 
followed by a gradual decline through the dusk twilight. Experimental protocols have 
not incorporated gradual changes in illumination to mimic dawn and dusk so until the 
development of the dawn-dusk simulator it was impossible to determine whether 
mammals or humans responded to it.
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The use of the dusk-dawn simulator has highlighted a number of different responses 
between species. Hamsters show increased upper limits of locomotor entrainment 
and therefore experience a strengthened light-dark zeitgeber when exposed to 
twilight simulations, as opposed to rectangular-LD transitions, all animals remaining 
entrained up to 26h (Boulos, Macchi & Terman, 1996a)The ability to control totally the 
amount of light exposure permits close scrutiny of the phase-shifting effect of light. In 
hamsters the same phase shift was produced by either a naturalistic 1h dusk or dawn 
ramp or 1h rectangular exposure where the total photon exposure was the same 
(Boulos, Terman & Terman, 1996). When the dusk-dawn simulators were used with 
squirrel monkeys there was no increase in strength of the L:D zeitgeber or effect on 
the circadian entrainment mechanisms. The only differences observed between the 
gradual twilight transitions and a rectangular L:D cycle was an increase in locomotor 
activity at dusk with a secondary peak at dawn accompanied by a gradual increase in 
body temperature throughout the day which were, most likely, a direct effect of the 
light intensity (Boulos et a/., 1996b)
This dusk-dawn simulation has been used to produce phase advances in the dim 
light melatonin onset in normal volunteers (Danilenko et al., 1997). It has also proved 
successful in alleviating the symptoms of SAD (Terman et al., 1989 & Terman 1997). 
The presentation of a simulated spring dawn during the long winter nights phase 
advanced the melatonin rhythm, and was sufficient to switch off melatonin production 
although the maximum light level reached was only 250 lux. The dusk-dawn 
simulator is a powerful tool in the investigation of the complex effects of changes in 
light intensity on the circadian system.
1.4.2.4 Popliteal light
The most intriguing discovery of the last year was that exposure to popliteal (behind 
the knee) light can phase shift human circadian rhythms (Campbell & Murphy, 1998). 
Subjects were exposed to 3h of bright light (13,000 lux) at varying times via bili- 
blankets used to treat jaundice in babies. Ambient light conditions were kept below 
50 lux and equivalent phase-shifts were seen in both the rectal temperature rhythm 
and the dim light melatonin onset (DLMO). The mode of action of such extra-ocular 
light is unknown, although a possible theory has been proposed. These observations 
require confirmation.
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1.4.3 Phase Response Curves for Light
Single light exposures were first shown to reset the circadian clock in the 1950’s 
(Pittendrigh & Bruce, 1957). The direction and size of the phase shifts were 
dependent on the intensity and duration of the light exposure as well as the circadian 
phase. Since that time phase response curves (PRC) to light have been described 
for a wide variety of organisms. They all exhibit the same properties, namely that 
light exposure in the early subjective night induces phase delays, light exposure in 
the late subjective night or early subjective morning produces phase advances and 
light exposure during the subjective day produces minimal phase shifts. Winfree 
(1980) described two types of PRC, weak type 1 resetting with a low amplitude and 
maximum phase shifts of a few hours, and strong type O resetting which had a high 
amplitude with phase shifts as large as 12h,
A number of different phase response curves for light in humans have been 
produced. In general they show good agreement, with similar shapes and phase 
shifts produced. Czeisler et al. in 1986 showed that light acted directly on the 
endogenous pacemaker rather than indirectly, by influencing the sleep-wake cycle, 
as phase shifts occurred irrespective of the timing of the sleep episode. Honma et al. 
(1986 and 1988), produced two PRC’s for single pulses of bright light, where the 
phase shifts produced were measured by changes in the timing of sleep onset. The 
subjects were free-running with self-controlled lighting schedules of 300-500 lux. The 
phase shifts seen in sleep were small. Shifts in the rectal temperature rhythm were 
reported to be much greater but no figures were given. Czeisler et al. published a 
more controlled PRC in 1989. Individuals were subjected to 3 bursts of bright light 
(5h, ~ 10,000 lux) on successive days and the phase shift produced was determined 
by comparison of the time of core temperature minimum, measured during constant 
routines before and after light treatments. The magnitude and direction of the phase 
shift seen was dependent on the timing of the initial light treatment with the maximum 
shift seen when the mid point of the light treatment fell at the temperature minimum. 
The PRC produced suggested strong type O resetting of the clock.
Minors, Waterhouse and Wirz-Justice (1991) (Fig 1.3) established a PRC to light in 
humans starting from a ‘steady state’ where individuals were kept in an isolation unit 
on a fixed 24h schedule for 5 days before exposure to a bright light pulse, and also
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when individuals were allowed to free-run before the light pulse. Both single pulses 
and three consecutive pulses of bright light (5,000 or 9,000 lux) were used. 3 pulses 
of bright light produced larger phase shifts in the rectal temperature rhythm (4-7h) 
than single pulses (2h). It has been argued that a single pulse PRC is a more 
accurate measure of the resetting of the circadian clock than multiple pulses. 
Dawson et a/., (1993) using a single 4h pulse of 12,000 lux, in normally entrained 
subjects, produced maximum shifts of 2.5h, with the larger shifts occurring when the 
midpoint of the light exposure fell close to the temperature minimum.
The last PRC performed to date was a single pulse PRC of 3h duration and 5,000 lux 
intensity (Van Cauter et a/., 1994) (Fig 1.3). The induced phase shifts in plasma 
thyrotropin, melatonin and cortisol levels and core body temperature were measured 
during a 38h constant routine: individuals were not permitted a sleep period in 
darkness before determination of the phase shift. In a similar study Buresova et al.,
(1991) had shown approximately 2h phase advances in the melatonin onset and 
offset times after 6h of bright light (3,000 lux) between 03:00 and 09:00h. The Van 
Cauter protocol involved exposure to the bright light stimulus against a background of 
dim light during constant routine conditions after a 7 day period of ‘steady state' with 
regular sleep-wake cycle. The phase shifts measured occurred within 24h of the 
stimulus. They averaged 1h, with larger delays than advances, and cross-over from 
delay to advance occurring when the midpoint of light exposure was 1h after the 
temperature minimum. This protocol could be described as producing the purest 
phase response curve to light with a minimum of exposure to external factors. The 
PRC produced is more indicative of a weak type 1 resetting with relatively small 
phase shifts and no change in amplitude.
The results obtained from these various PRC protocols have led to opposing opinions 
as to whether the phase resetting of the circadian clock by light is weak type 1 or 
strong type O. The single pulse PRC’s are more indicative of weak type 1 whilst the 
multiple light exposure PRC’s are suggestive of strong type O resetting (Beersma & 
Daan, 1993 and Kronauer et al., 1993). The discrimination between the two types of 
resetting is based on mathematical models where the weak type 1 resetting can be
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Fig 1.3 Human phase-response curves for light, derived
from Minors et al., 1991, and Van Cauter eta!., 1994.
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explained by a single oscillator with additive effects from subsequent light exposure. 
Strong type O resetting is based on the assumption that the resetting mechanism is 
more complicated and requires the interaction of two oscillators and amplitude to be 
considered.
The timing of exposure to bright light is very important when looking at the phase 
shifts induced. Winfree (1970 & 1987) found in Drosophila that when a stimulus of 
critical strength (between that capable of inducing type 1 and that capable of inducing 
type O resetting) was applied at critical time the circadian oscillator was driven close 
to its singularity and displayed an amplitude close to zero. The human circadian 
pacemaker is most sensitive to light at the time of minimum core body temperature. 
Jewett et al. (1991 & 1994), used this to investigate whether light centred at this 
circadian time would affect the amplitude of endogenous rhythms. Bright light 
exposure was composed of a single long (8-9h) pulse (7,000 -12,000 lux) or 2 (5- 
6.2h) pulses. Sleep was timed to occur during the normal wake period. When the 
light stimulus was centred around the temperature nadir large phase shifts were 
produced with amplitude suppression. The first light treatment induced weak type 1 
resetting, two light treatments on consecutive days induced critical resetting, possibly 
with amplitude reduction, whilst 3 consecutive light treatments induced strong type 0 
resetting. If the light treatments are scheduled to occur away from the temperature 
nadir smaller phase shifts are induced with less effect on the amplitude of the rhythm.
The results from this experiment would appear to reconcile the differing results 
obtained from the various PRC’s. Namely that a single pulse of bright light induces 
weak type 1 resetting whilst consecutive light pulses produce strong type 0 resetting 
of the human circadian pacemaker.
1.4.4 Light Intensity
The effect of light on the human circadian system can be divided into two distinct 
areas. 1. Phase shifting of the endogenous clock and 2. Suppression of melatonin 
secretion.
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1.4.4.1 Phase shifting of the endogenous clock
It was originally assumed that bright light in excess of 2,500 lux was needed to 
phase-shift the human circadian clock. This was based on the lack of entrainment to 
the light-dark cycle in Wever’s (1979) original isolation experiments and Lewy's 
discovery that light of 2,500 lux was needed to suppress melatonin secretion (Lewy et 
al., 1980).
The phase-shifts produced by exposure to 3 consecutive light pulses of varying 
intensity (0.03; 180; 1260 & 9500 lux) against a low light intensity background (~ 10- 
15 lux) have been investigated (Boivin at ai. 1994 & 1996; Khalsa et a!., 1997; 
Klerman et a/., 1997). A further study was carried out to determine whether 
intermittent light treatment was as efficient in phase-shifting the circadian clock as a 
continuous pulse (Rimmer et a/., 1995). All experimental protocols were identical 
apart from the intensity or duration of the light pulse.
Phase shifts produced were measured by determination of the temperature minimum 
during two constant routines, before and after light treatment. The phase-shift 
produced showed a dose-dependent relationship for the resetting of the human 
circadian clock by light (mean phase shift +1.16 ± 0.96h; +2.69 + 0.69h and +4.49h ± 
0.36h after exposure to ~ 180 lux, ~ 1260 lux and ~ 9,500 lux respectively with the 
control group exhibiting a phase delay of -1.05 ± 0.38h). The phase delay seen in 
the control group was commensurate with an intrinsic period slightly longer than 24h. 
The phase-shifting ability of light intensity as low as ~ 180 lux calls into question 
results from previous experiments which were carried out against a background of 
normal artificial light (~ 300 lux). Indeed, a recent report suggests that the resetting 
response to bright light is modulated by the timing of background room light (Jewett 
et a/., 1997). Data from this report also suggests that the human circadian 
pacemaker is sensitive to light at virtually all circadian phases with no dead zone. 
Thus, the entire light exposure across the 24h day could contribute to the effects of 
light on the circadian clock, including the long periods spent in artificial lighting below
1,000 lux by the increasingly numerous urban populations.
The majority of experiments investigating the phase-shifting effects of bright light 
exposure in humans have used pulses of 3h duration or more. It was unknown
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whether the duration of exposure was important in determining the phase shift 
produced. Honma et al, (1988) reported the same phase shift with 3h or 6h of light 
treatment at the same circadian time. In contrast, Rimmer et al. in 1995, found that 
intermittent pulses of bright light produce proportionately less shift.
Results from these experiments indicate that the human circadian clock is as 
sensitive to light as other mammalian clocks and the phase shifts produced depend 
on the timing, the intensity and the duration of the light pulse.
1.4.5 Acute Effects of Light
1.4.5.1 Melatonin suppression
Prior to 1980 humans were considered to be insensitive to light and that light 
exposure in the evening was unable to suppress melatonin secretion(e.g. Arendt, 
1978; Vaughan et al., 1979). It was therefore concluded that humans had lost their 
responsiveness to light during the evolutionary process. However, Lewy et al. in 
1980 succeeded in suppressing nocturnal melatonin using light of an intensity in 
excess of 1500 lux. Since that time the light intensity required to suppress melatonin 
has steadily decreased (Lewy et al. 1981 & 1985b; Boyce & Kennaway, 1987; 
Bojkowski et al., 1987b; McIntyre et al., 1988 & 1989a). The degree of suppression 
is intensity dependent with light of 200 lux giving 16% suppression and 1,000 lux 
suppression to near daytime levels. Light treatment close to melatonin onset did not 
suppress melatonin secretion. A short 15min pulse of light (1,500 lux) at 22:00h or 
23:00h significantly suppressed plasma melatonin levels, although the effect was 
only transitory (Petterborg et ai, 1991g l)
A single burst of bright light in the evening (> 3,000 lux) between 19:00 and 02:00 
can acutely delay the onset of 6-sulphatoxymelatonin excretion in the urine and 
cause a delay in melatonin onset the following evening (Kennaway et al. 1987) 
implying a phase delaying effect on the circadian pacemaker.
A comparison of the results described above for phase-shifting the circadian clock 
and suppressing melatonin secretion suggests that both effects can be achieved by 
light of similar intensity and that both responses are dose-dependent. However, in a
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study reported by Hashimoto et al. in 1996, the threshold for melatonin suppression 
was between 200 - 500 lux but no phase-shift of the melatonin rhythm was seen with
10,000 lux. The lack of phase advance in response to 3h of 10,000 lux light is at 
odds with all other results reported and may be due to previous light exposure.
1.4.5.2 Temperature
The knowledge that bright light exposure at night could suppress melatonin secretion 
led to the assumption that bright light could, therefore, increase core body 
temperature as temperature and melatonin have an inverse relationship. Bright light 
of between 1500 and 5000 lux causes an acute rise in nighttime core body 
temperature by 0.3° C (Badia et al., 1991; Bunnel et al., 1992 and Myers & Badia, 
1993) but does not affect daytime values (Murphy et al., 1991; French et al. 1990). 
The evening decline in body temperature associated with the onset of melatonin 
secretion can be countered by evening exposure to bright light (2,500 lux) for 2-3h 
(Bunnel et al., 1992; Dijk, Cajochen & Borbély, 1991). The elevated core body 
temperature persisted into the sleep episode, with an increase in sleep latency but no 
effects on sleep architecture. Three consecutive nights of bright light treatment 
caused a phase delay in the temperature rhythm but did not significantly affect the 
sleep episodes when sleep times remained set (Drennan, Kripke & Gillin, 1989). The 
elevation of core body temperature by bright light exposure is only seen during the 
period of melatonin secretion and is thought to be due to the suppression of 
melatonin (Myers & Badia, 1993).
1.4.5.3 Alertness & performance
The nocturnal rise in melatonin levels is accompanied by an increase in fatigue, 
lowered alertness and decreased performance. This should be reversed by exposure 
to bright light sufficient to suppress melatonin secretion, although the fatigue effect 
due to prior wakefulness will still be present. A number of groups have looked at the 
influence of varying light intensities (1,000 -5,000 lux) on alertness and performance 
during a simulated night shift (Badia et ai, 1991; Campbell & Dawson, 1990; French 
et a i 1990 and Dollins et ai, 1993afb)Alertness and cognitive performance were 
increased by the light treatment in all studies apart from that of Dollins et a i (1993&+b) 
but the effect did not extend beyond the end of the light exposure. Thus, the effects
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of light on alertness and performance are an acute effect of light exposure. Exposure 
to similar levels of bright light during the day did not increase alertness or improve 
performance (Badia et al., 1991; Daurat et al., 1993). A recent study combined the 
effects of bright light with a stimulant (caffeine) to improve alertness and performance 
during 48h sleep deprivation (Wright et al., 1997). The combination treatment was 
more successful in maintaining alertness but the caffeine load (400mg per night) 
caused a significant increase in sleep latency at the end of the study.
1.4.6 Therapeutic Applications of Bright Light
The known phase-shifting effects of bright light exposure makes it a useful agent in 
the treatment of a number of circadian disorders.
1.4.6.1 Seasonal affective disorder
Seasonal affective disorder (SAD) is characterised by recurrent periods of depression 
in the autumn and winter when the natural daylength is short (Wirz-Justice et al., 
1995). Some possible causes that have been put forward are that the illness is 
caused by a delayed phase position and/or diminished circadian amplitude or that it is 
simply due to the elongation of the period of natural darkness between dawn and 
dusk. Early experiments had shown that bright light treatment improved SAD 
irrespective of the time of administration, the underlying circadian phase or timing of 
sleep (Rosenthal et al., 1984 & Wehr et al., 1986).
The involvement of a circadian phase disorder was discounted by some authors as 
there was no correlation between the circadian phase of the temperature rhythm and 
SAD (Eastman et al., 1993), and neither melatonin suppression (Winton et al., 1989) 
nor melatonin administration (Wirz-Justice et al., 1993j alleviated the symptoms. 
However other data does support the phase delay hypothesis. Bright light treatment 
in the morning had a greater anti-depressant effect than in the evening associated 
with a phase advance of the melatonin rhythm (Lewy et al., 1987).
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1.4.6.2 Shift-work
Shift-work causes major disruption of the circadian system due to a mismatch 
between the internal biological clock and the external time cues. Timed exposure to 
bright light can be used to hasten adaptation to the required shift pattern (Ross et al., 
1995; Eastman 1990 & 1991; Deacon & Arendt 1996a). In a normal environment 
individuals are exposed to conflicting zeitgebers which hinder phase-shifting (Gallo & 
Eastman, 1993) and individual differences are important (Mitchell et ai, 1997).
1.4.6.3 Jet lag
Transmeridian travel, like shiftwork, results in a mismatch between the endogenous 
clock and the environmental zeitgebers. Unlike shift-workers travellers are fully 
exposed to the new environment and therefore adaptation is easier. Timed exposure 
to bright light can aid adaptation, with a corresponding avoidance of bright light at the 
wrong time (Daan & Lewy, 1984). Bright light therapy may also serve to consolidate 
sleep, again hastening adaptation (Cole & Kripke, 1989). Timed bright light exposure 
can be used in the laboratory to phase-shift individuals in simulation of a 
transmeridian flight (Deacon & Arendt, 1996a) allowing for detailed investigation of 
the adaptation process.
1.4.6.4 Sleep disorders
Some sleep disorders are clearly related to the timing of the circadian rhythms. Early 
morning awakening insomniacs are phase advanced, whilst individuals suffering from 
delayed sleep phase syndrome are phase delayed. These two disorders can be 
alleviated by use of appropriately timed bright light. Bright light in the evening (phase 
delay portion of the PRC) prolongs sleep in early morning awakening insomniacs 
(Lack & Wright, 1993) whilst bright light in the morning advances the circadian clock 
and the time of sleep onset in delayed sleep phase syndrome (Lewy et ai, 1985c).
1.4.6.5 Entrainment of free-running rhythms
Hoban et ai, (1989) reported the entrainment of a free-running sighted individual by 
gradually advancing light pulses (2h, 2500 lux) on awakening. The rhythm was then
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stabilised to 24h when the circadian clock had been advanced to the required phase 
provided that the light treatment was maintained.
1.5 NON-PHOTIC ZEITGEBERS
1.5.1 Activity/Exercise
Although the light-dark cycle is known to be the strongest zeitgeber involved in the 
timing and control of circadian rhythms, other factors have been shown to influence 
circadian timing and phase position. Activity, especially in wheel running mammals, 
has a pronounced effect and a PRC and dose response curve (DRC) have been 
constructed for hamsters (Reebs & Mrosovsky, 1989; Janik & Mrosovsky, 1993) with 
tau mutant hamsters showing larger phase shifts and a different shaped PRC 
(Mrosovsky et a/., 1992) compared to the wild type.
Wheel-running in mice can entrain the circadian system when access to the wheel is 
controlled and only occurs at scheduled times (Edgar & Dement, 1991). Mice given 
free access to a running wheel in constant darkness exhibited shorter tau then those 
with restricted access. The timing of wheel running also affected the tau. Animals 
which ran earlier in the subjective night had a shorter tau whilst those running at the 
end of the night had a longer tau (Edgar, Martin & Dement, 1991). A similar 
response is seen in hamsters. Hamsters exercised late in the dark period showed a 
significant delay of entrained phase in L:D and a lengthening of the free-running 
period in D:D (Mistlberger, 1991).
Light-induced phase advances in hamsters can be accelerated if a period of enforced 
wheel-running, about 7h before activity onset, is included in the protocol. On transfer 
to D:D 1 day after the light induced phase shift, those animals exposed to the 
exercise pulse showed a greater phase advance than those receiving purely the light 
stimulus. The exercise induced phase advance persists. This was demonstrated by 
giving all the hamsters a light pulse at the same time after 8 days in D:D. The 
animals that had exercised phase advanced whilst the control animals delayed 
(Mrosovsky, 1989). When exercise was timed to coincide with the light stimulus the 
resulting phase shift was less than in control animals who did not exercise, thus 
suggesting that the two stimuli are not additive but compete (Ralph & Mrosovsky,
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1992). The strength of the exercise zeitgeber in hamsters was demonstrated by 
Mrosovsky & Janik (1993) who kept hamsters in a 14:10 L:D cycle with a 3h exercise 
pulse 7h before dark onset. On transfer to D:D their activity was split into two peaks 
which fused after several days, thus indicating that the exercise pulse reorganised 
the circadian activity pattern, even in the presence of a L:D cycle.
Little work has been done on the effect of exercise on the human circadian system. 
A 3h burst of exercise, ranging from 5h before to 4h after the temperature minimum 
during a constant routine, produced 1-2h phase delays in melatonin onset and the 
thyroid stimulating hormone (TSH) rhythm the following day (Van Reeth, et a/., 
1994a). The amount of delay was shorter when exercise occurred later in the night 
or early morning. Only moderate or high levels of exercise during the night produced 
phase shifts. Low level activity did not have any effect at any time of day and no 
exercise close to melatonin offset or during the day had an effect. Exercise during the 
evening rise of melatonin decreased melatonin levels whilst exercise during the night, 
when plasma melatonin levels were high, increased melatonin by up to 50% (Carr et 
al., 1981, Theron et al., 1984 & Buxton et al., 1997). These studies were all carried 
out against a background of low light intensity. When the exercise pulse was 
accompanied by a light intensity sufficient to suppress melatonin secretion there was 
no effect on melatonin levels (Monteleone et al., 1992). Results obtained during a 
20h desynchronisation protocol by Rimmer & Czeisler (1997) indicate that moderate 
exercise does not effect the intrinsic period. However, there were three scheduled 
bouts of exercise throughout the wake period falling at all circadian phases which 
may have masked any phase shift caused by a single pulse of exercise during the 
sleep period.
The effect of exercise on melatonin and TSH suggests that exercise during the 
habitual rest period can alter the circadian clock, but the effects are not large or 
robust.
1.5.2 Food
Rats have a separate oscillator controlling the circadian pacemaker called the food- 
entrainable oscillator (FEO) (Stephan 1981,1984 & 1992). The oscillator fulfils the 
requirements to be known as a true circadian pacemaker as it can be phase-shifted
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and has limits of entrainment. Anticipatory activity could be reentrained in animals 
after SCN lesion, suggesting that the FEO is located outside the SON. The 
mechanism of action is unknown but the size of the meal in relation to total daily 
nutrient intake influences its importance as a synchroniser of anticipatory rhythms 
(Mistlberger ef a/., 1990).
Hamsters are also able to be entrained by feeding schedules, even when the SCN 
has been ablated (Rusak et al., 1988; Mistlberger, 1992) and the animals show no 
entrainment to the L:D cycle, thus locating the oscillator involved outside the SCN. 
Hamsters fed in the midlight phase showed a significant advance of the L:D entrained 
phase (Mistlberger, 1991).
The ability of scheduled feeding times to entrain or phase shift rats and hamsters is 
possibly because in the wild they are scavengers and hoarders mainly feeding at 
night. Humans are no longer scavengers and hoarders but expect food to be 
available at all times. Consequently meal times are no longer synchronisers of the 
circadian system.
1.5.3 Conditioned Stimulus
In a novel experiment Amir & Stewart (1996) have shown that non-photic cues that 
are timed to precede the onset of light can, through associative learning, activate 
elements in the SCN which are responsive to photic cues. Rats were subjected to 
Pavlovian conditioning involving a conditional stimulus (CS) the switching on of a fan 
creating a gentle air disturbance, followed by a light pulse, the unconditional stimulus 
(US). The stimuli were administered during the dark phase of a 12:12 L:D cycle when 
light exposure is known to induce Fos expression in the SCN and phase delays in 
free-running rhythms. At the end of the conditioning period when the animals were 
exposed to the CS only, Fos expression was induced in the SCN. Similarly if 
conditioned animals were placed in constant darkness and then exposed to the CS 
alone on day 6 phase shifts were produced in the free-running rhythms of activity and 
temperature. These observations require confirmation.
The findings suggest that a neural stimulus can acquire the ability to activate 
mechanisms in the SCN known to be sensitive to photic entrainment. It is possible
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that the conditioned response could occur in humans where behaviour regularly 
linked with a particular light exposure, such as the switching on of artificial light or 
setting of the sun could acquire the ability to reset the circadian pacemaker.
1.5.4 Social Factors
Phase response curves have been established in hamsters for such non-photic time 
cues as a cage change, or interaction with another animal for half an hour 
(Mrosovsky, 1988), although this was not the case in golden hamsters (Refinetti et 
a/., 1992). Exposure during the subjective day caused a phase advance, whilst 
exposure in the late subjective night induced a phase delay, while repeated social 
interactions at the same time of day entrained activity rhythms.
The circadian rhythm of Syrian hamsters can be phase shifted by arousal due to 
handling alone (Hastings et al., 1992). In investigating the possible mechanism 
behind the phase shift. Mead et al. (1992) discovered that saline injections at specific 
circadian times caused immediate wheel-running, indicating an instantaneous phase 
advance of the circadian clock controlling the activity rhythm, but without c-fos 
expression in the SCN. This result implies that the production of the immediate-early 
gene, c-fos, is not essential for all phase-shifting processes.
In Antarctica, social factors were insufficient to maintain synchrony to 24h during the 
winter without an imposed work schedule (Kennaway & Van Dorp, 1991) whereas on 
an Antarctic base with a structured routine subjects in general remained entrained 
(Broadway et al., 1987). Humans regularly adjust their behaviour and the timing of 
sleep episodes, meals etc. to fit in with their social life. The timing of the endogenous 
clock is overridden to suit the individual. A number of experiments have been carried 
out to investigate whether the deliberate adjustment of the sleep wake cycle and 
meal times can phase shift the endogenous clock.
Honma et al., (1995) investigated the rapidity of entrainment to an 8h phase advance 
of the sleep and social schedule. After a three day baseline with regulated sleep 
(24:00-08:00h), regular meals 08:30, 12:30 and 18:30), regular visits from friends 
(09:00 -12:00, 14:00-17:00h) and exposure to daylight, subjects were required to 
sleep from 16:00h. The sleep schedule, meal times and social contact were all
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advanced by 8h. The rate of entrainment to the new schedule, with and without a 3h 
bright light pulse timed to phase advance, was assessed by measurement of rectal 
temperature and plasma melatonin. Bright light exposure hastened adaptation, but 
individuals were entrained to the new schedule by day 8 in both conditions. It is 
important to note that the background illumination during the wake episodes was 300- 
500 lux, an intensity which has been shown to phase shift human circadian rhythms 
(Boivin etal., 1996).
In another study the sleep schedule and social contacts were shifted by 12h and the 
rate of phase shift of the circadian clock measured by constant routine determination 
of the core temperature minimum (Duffy, Kronauer & Czeisler, 1996). After a three 
day baseline with regular sleep episodes, meal times and social contacts, an initial 
constant routine was performed and the sleep-wake schedule reversed. Subjects 
were then exposed to either a 5h bright light pulse timed to advance or delay, or 5h 
darkness. Two constant routines were performed, after 3 and 6 days of treatment, to 
determine any phase shifts in the timing of the endogenous clock. Both the delay 
and advance light treatments caused significant phase shifts in the endogenous 
temperature rhythm. The control group, who were exposed to 5h of darkness, did not 
show any significant phase shift. The temperature rhythm appeared to delay by 
approximately 0.2h a day, which is comparable to a free-running rhythm and did not 
significantly adapt to the new schedule after 10 days. The background illumination 
throughout the study was 10-15 lux.
From these results it would appear that social factors and inverted sleep-wake cycles 
are insufficient to phase shift endogenous circadian rhythms.
A more accurate way to assess the potency of non-photic stimuli is in blind individuals 
who have no light perception whatsoever. A panel of 15 individuals who had no 
conscious light perception, no pupillary light reflex, a negative electroretinogram and 
negative or abnormal visual evoked-potential testing was established (Klerman et al., 
1998). Some of these individuals exhibited free-running rhythms (6/15) whilst others 
appeared entrained to the 24h day (9/15), despite the fact that all had a negative 
melatonin suppression test. By means of a forced desynchrony protocol and time 
living on a 23.8h day, it was demonstrated that one blind subject had an endogenous 
tau of 24.1 but could be entrained to the 23.8h day by non-photic stimuli.
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Data from a single sighted subject also suggested that social stimuli are sufficient to 
maintain entrainment (Klerman et al., 1997). The individual was maintained on a 
16h:8h L:D cycle with a daytime light intensity of 15-20 lux and a regular schedule of 
rest-activity, meals and social contacts. The subject remained entrained for 25 days, 
suggesting either that the intrinsic period was very close to 24h or that the weak L:D 
cycle combined with the non-photic synchronisers was sufficient to maintain 
entrainment.
It can be concluded that non-photic stimuli are sufficient to entrain some blind and 
possibly sighted individuals to 24h. However, it could be that only those individuals 
who have an intrinsic tau close to 24h are susceptible.
1.6 MELATONIN
Melatonin can be considered as a non-photic zeitgeber or endogenous chronobiotic. 
In all organisms studied to date melatonin is almost exclusively synthesised during 
the hours of darkness and conveys information regarding the temporal position and 
duration of darkness (Arendt and Broadway, 1987; Poeggeler et al., 1989; Vivien- 
Roels and Pevet, 1986, 1993; Poeggeler, 1993; Cassone and Nateson, 1997). 
Melatonin is known to exist in algae and plants (Dubbels et al., 1995 and Fuhrberg et 
al., 1996) but little is known of its function. Melatonin is a readily diffusible compound 
which can cross biological barriers and it has been described as a “fine-tuner of 
organismal physiology” (Ebadi M. et al., 1993).
Since melatonin was first identified by Lerner et al. (1958) great progress has been 
made in understanding its synthesis, site of action and role in living organisms, 
although there are still significant gaps in our knowledge.
1.6.1 Site of Synthesis
The presence of melatonin has been shown in the pineal gland, retina, harderian 
gland and gut by immunohistochemistry (Vivien-Roels et al., 1981) and is synthesised 
in several tissues (Huether, 1993). To date the only sites shown to exhibit rhythmic 
synthesis in non-mammalian vertebrates are the pineal gland and retina. The cells 
involved are the photoreceptive, oscillatory pinealocytes of the pineal gland and the
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rods and cones of retinae. Destruction of the inner retina leaving only photoreceptors 
and pigmented epithelial cells does not affect melatonin synthesis (Cahill and 
Berhase, 1992). The pinealocytes of fish, reptiles and birds (Bernard et a/., 1997) can 
exhibit circadian patterns of melatonin biosynthesis in vitro. The rhythms are 
entrainable to lightdark cycles, indicating the presence of circadian oscillators, 
photoreceptors and melatonin synthesis.
In mammals melatonin biosynthesis occurs in the pineal gland but the pinealocytes 
have not conserved the oscillatory or photoreceptive role seen in most vertebrate 
pineals. Melatonin biosynthesis in the mammalian pineal gland is however a direct 
output of the biological clock, controlled by neural connections linking the SCN to the 
pineal gland. Neural projections from the SCN extend to the paraventricular nucleus 
of the hypothalamus (PVN) with further projections into the sympathetic chain of the 
spinal cord synapsing in the superior cervical ganglion (SCG) (Berk and Finkelstein, 
1981 and Stephan et a/., 1981). Post-ganglionic cells from the SCG stimulate 
melatonin production (Fig 1.4). Destruction and stimulation of this pathway served to 
confirm its role in melatonin production (Klein eta!., 1983 and Yanovski eta!., 1987).
Mammalian retinae do exhibit circadian oscillations (Remé et al., 1991) in outer 
segment disk shedding, inner segment degradation, electrophysiological response to 
light and melatonin biosynthesis. Cultured retinae from hamsters show circadian 
rhythms of melatonin secretion (Tosini and Menaker, 1996) confirming that 
mammalian retinae retain the ability to synthesise melatonin.
1.6.2 Melatonin Synthesis
The many stages involved in the biosynthesis of melatonin are shown in Fig 1.5. 
Melatonin (N-acetyl, 5-methoxytryptamine) is produced from the dietary amino acid 
tryptophan but no effect of diet on pineal tryptophan levels has been demonstrated. 
Tryptophan is hydroxylated by tryptophan 5-hydroxylase to form 5-hydroxytryptophan. 
This is the rate limiting step in the synthesis of serotonin (5-hydroxytryptamine, 5-HT) 
and is dependent on the availability of tryptophan. Indeed, administration of 
exogenous tryptophan can increase levels of serotonin. 5-hydroxytryptophan is 
converted to serotonin by aromatic amino acid decarboxylase. During the night 5-HT
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Fig 1.4 Regulation of Melatonin Production
Circadian rhythms generated by the SCN are 
entrained by light signals transmitted via the 
retina-RHT-SCN pathway. Melatonin synthesis 
is initiated by noradrenaline uptake by the pineal 
a and p receptors via the PVN, hindbrain, spinal 
cord and SCG.
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is N-acetyiated by aryiakylamine N-acetyltransferase (AANAT), forming N- 
acetylserotonin (NAS). The final step is the conversion of NAS to melatonin by 
hydroxyindole-O-methyltransferase (HIOMT). The levels of HIOMT do not vary 
significantly throughout the day and the rate limiting step of the conversion of 
serotonin to melatonin is the N-acetylation. AANAT levels are low during the day and 
increase during darkness but HIOMT can become rate limiting in the presence of 
excess amounts of AANAT.
The influence of 5-HT on the circadian pacemaker has been investigated both in vivo 
and in vitro by means of serotonergic agonists and there is evidence that 5-HT can 
produce phase-shifts in the circadian pacemaker (Prosser et al., 1993 and Edgar et 
al., 1993a). The rhythmic changes in AANAT activity throughout the day are known to 
drive the daily rhythm of melatonin synthesis (Klein and Weller, 1970; Wilkinson et 
ai., 1977 and Ho et al., 1984). AANAT activity is initiated by the release of 
noradrenaline from sympathetic neurons in the pineal gland (Brownstein and Axelrod, 
1974). Noradrenaline binds to p-adrenergic receptors on the pinealocyte, stimulating 
adenylate cyclase activity and an increase in the intracellular second messenger 
cyclic 3',5'-adenosine monophosphate (cAMP, Axelrod and Zatz, 1977). a r  
adrenoreceptors are also involved in AANAT stimulation (Sugden et ai., 1985a, 
1985b and Sugden et al., 1987) by activating the phosphoinositide cycle and protein 
kinase C (PKC) which potentiates p-adrenoreceptor-induced cAMP production (Fig 
1.4). The resulting high levels of cAMP stimulate AANAT transcription and translation 
and maintain the active form of the enzyme (Takahashi, 1994). The rate of 
transcription varies greatly between species (Foulkes et al., 1997).
Increases in cAMP result in activation of cAMP-dependent protein kinase (PKA) and 
the transport of active catalytic sub-units to the nucleus where phosphorylation 
targets include transcription factors that modulate expression of cAMP responsive 
genes. Factors such as CRE-binding protein (CREB) are phosphorylated by PKA 
and become transcription activators. The CRE-modulator (CREM) gene is closely 
related to CREB but can generate the inducible cAMP early repressor (ICER) (Stehle 
et al., 1993). ICER acts as a dominant repressor of cAMP-transcription and is 
controlled by its own intracellular concentration. In this way ICER is part of a negative 
autoregulatory loop, whereby stimuli that switch on CREB phosphorylation result in 
the formation of ICER, which switches off systems turned on by CREB. ICER protein
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FIG 1.5 Melatonin Synthesis
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binds to the CRE (cAMP responsive elements) elements of its own promoter 
constituting a CREM feedback loop, icer MRNA levels reach a peak just before the 
decline of melatonin synthesis and it is possibie that ICER can act as a down 
regulator of melatonin synthesis by repressing c-AMP-induced AANAT transcription 
(Foulkes et al., 1997). Investigations with CREM-null mice and of the promoter of the 
AANAT gene have indicated that ICER controls the rhythmicity and amplitude of 
AANAT. Therefore, it could be a primary factor in the regulation of melatonin 
synthesis (Sassone-Corsi, 1998).
As a result of this systematic work a possible cellular mechanism for the control of 
melatonin synthesis, readily influenced by light, has been proposed. As yet the 
system has only been clarified in rats, but it is thought that a similar control 
mechanism occurs in humans.
1.6.3 Melatonin Receptors
The identification of the sites of action of meiatonin was made possible with the 
availability of 2 -f ^ ^Ijiodomelatonin (^^ l^-Mel). The binding of this melatonin agonist to 
specific areas of the brain identified the location of meiatonin receptors and therefore 
putative sites of melatonin action. Melatonin binding sites have been located in the 
suprachiasmatic nucleus of the hypothalamus, the paraventricular nucleus of the 
thalamus (PVN) and the pars tuberalis (PT) of the anterior pituitary (Krause and 
Dubocovitch, 1990). Specific melatonin receptors are also found in the retinae of 
mammals. Melatonin binding sites are widely distributed throughout the brains of 
lower vertebrates such as the chicken and lizard (Rivkees et al., 1989). Putative 
melatonin receptors in the human were identified by Reppert et al., (1988). 
Receptors found in the SCN probably mediate the circadian effects of melatonin 
(Reppert et al., 1988 and Dubocovich et al., 1996). Receptors found in the outer 
plexiform layer of the retina may be involved in the mediation of melatonin's effects 
on the retina (Blazynski and Dubocovich, 1991), whilst receptors found in the 
mediobasal hypothalamus of photoperiodic mammals may be involved in the control 
of reproduction (Maywood and Hastings, 1995). Melatonin receptors found in the pars 
tuberalis of sheep are possibly involved in controlling the photoperiodic secretion of 
prolactin from the pars distalis (Lincoln and Clarke, 1994; Morgan and Williams, 
1996).
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Several subtypes of melatonin receptor have now been identified and cloned 
(Dubocovich, 1995; Reppert et al., 1996 and Reppert, 1997). The three melatonin 
receptors are all G-protein coupled receptors and cloning has shown that the 
mammalian subtypes exhibit over 80% amino acid identity with each other. There 
are two human receptors the Meha and Mehb. Meha receptors are found in the rodent 
SCN and PT (Weaver et al., 1993), and as such are thought to be involved with the 
circadian and reproductive actions of meiatonin. The Mehb is found in the retina and 
brain and is therefore, most likely, responsible for the retina mediated actions of 
melatonin. A third subtype, Mehc, is found in the chicken, but not in mammals as yet.
Liu et al., (1997) have recently reported the presence of two subtypes of melatonin 
receptor in the mouse SCN, Meha and Mehb. Using a mouse deficient in the Meha 
receptor they have demonstrated that these mice still exhibit melatonin induced 
phase shifts, suggesting that this subtype is involved in the transduction of the major 
neurological effects of melatonin only, whilst the Mehb receptor is implicated in the 
phase-shifting effects of melatonin.
The identification and cloning of these receptors will allow for more detailed analysis 
of the action of melatonin at the molecular level.
1.6.4 Metabolism and Pharmacokinetics
Melatonin is a compound that is rapidly metabolised and excreted. Metabolism occurs 
mainly in the liver where melatonin may be demethyiated to N-acetylserotonin or 
undergo 6-hydoxyiation to 6-hydroxymelatonin which is then conjugated to form the 
glucuronide or sulphate (Kopin et al., 1960 and Young et al., 1985). In humans about 
90% of melatonin is metabolised to the sulphate in urine or plasma with a high first 
pass hepatic metabolism (Lane and Moss, 1985). The measurement of 6- 
sulphatoxymelatonin in the urine accurately reflects the melatonin output from the 
pineal (Bojkowski, et ai, 1987a). A minor metabolic pathway in the brain involves the 
cleavage of the indole ring to form kynuramines (Hirata et ai, 1974) which may be 
physiologically active.
Exogenous melatonin has a very short half-life in humans whether it is administered 
orally or intravenously (Claustrat et ai, 1989). Peak plasma levels are reached on
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average after 1 hour and there is biphasic clearance with a biological half-life of 45 
minutes. There is great individual variation in the peak plasma levels. This is thought 
to be due to differences in absorption with a low bioavailability (0.03-0.76 depending 
on dose) (Waldhauser et al., 1984) and a large hepatic first-pass effect with oral 
melatonin.
Various methods of melatonin administration have been investigated in man. Due to 
the rapid metabolism a slow release preparation would be beneficial in maintaining 
elevated levels. In 1985 Aldhous et al., compared three different methods of oral 
administration 1. Gelatin capsule, 2. Suspension in corn oil and 3. Slow release in 
arachis oil: beeswax. Gelatin capsules and corn oil gave peak plasma concentrations 
after 30-60min with elevated levels for 3-4h. Arachis oil : beeswax extended high 
melatonin levels for 5-7h but the timing of peak values depended on nutritional 
status.
Other methods of administration that have been investigated include transdermal 
patches (Lee et al., 1994), transbuccal patches (Bénès et al., 1993; Rogers et al., 
1997a) and intranasal sprays (Vollrath et al., 1994). An intranasal spray of 1.7mg 
induced sleep within 60mins in most subjects at 9.00am, but no measure was made 
of peak melatonin level or duration. Similarly the transbuccal patch (0.5mg) gave 
elevated aMT6s levels but no indication was given of peak values or duration. The 
transdermal patch was not very successful since, although 2mg melatonin were used, 
it took up to 4h for plasma melatonin levels to exceed baseline values and a steady 
state was not reached within 8h of attachment of the patch. Other slow release oral 
preparations have been tried but as yet none are generally available.
1.6.5 Role of Melatonin and the Pineal Gland
Circadian rhythms are known to be generated by endogenous circadian oscillators in 
the SCN, pineal gland and retina and are entrained to the daily light-dark cycles by 
photoreceptors in the retina, pineal gland and brain. The relative importance of these 
components varies between taxonomic groups (Takahashi and Zatz, 1982).
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1.6.5.1 Non-mammals
In most species of non-mammals studied, such as lizards and birds, the pineal gland 
is of great importance (review - Cassone, 1990). In these animals pinealectomy may 
result in arrhythmia when they are maintained under constant conditions (Underwood, 
1977; Gwinner and Benzinger, 1978 and Arendt, 1995). Some species require both 
pinealectomy and blinding to demonstrate arrhythmia. One species of lizard clearly 
shows two rhythms of activity which are not coupled after pinealectomy (Underwood, 
1981).
In most lower vertebrates melatonin is produced rhythmically by both the retina and 
the pineal with great inter-species variation in the relative importance of the two 
organs. The pineal gland from some lizards and birds has been shown to be an 
independent clock, maintaining rhythmic output in vitro for several days which can be 
entrained by a lightdark cycle.
Melatonin administration can synchronise circadian activity rhythms in some 
pinealectomised birds (Gwinner and Benzinger, 1978). Transplanted pineal glands 
can also restore rhythmicity to pinealectomised birds. Mammals have a different 
circadian control mechanism.
1.6.5.2 Mammals
In some respects the pineal gland is of lesser importance in maintaining circadian 
rhythmicity in mammals. Indeed, free-running rhythms of activity in rats and hamsters 
persist under constant dark conditions after pinealectomy (Richter, 1967 and Quay, 
1968). The SCN acts as the master clock in mammals and the pineal behaves like 
the “hand of the clock” (Moore, 1983).
Originally it was thought that the rhythm of melatonin production was abolished in 
constant light or darkness, but Ralph et al. (1971) noted that, in rats, melatonin levels 
continued to cycle in constant darkness in phase with the locomotor rhythm. This 
suggested that melatonin secreted by the pineal gland might have an important 
feedback effect on the SCN. This was demonstrated by Cassone in 1992, when 
locomotor rhythms of pinealectomised rats disintegrated in constant light or darkness.
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Daily injections of melatonin were able to synchronise the locomotor rhythms of rats 
and hamsters in L:L or D:D (Redman et al, 1983; Armstrong et al., 1986; Chesworth 
et al., 1987; Margraf and Lynch, 1993). The entrainment was dose dependent 
(Cassone et al., 1986). Melatonin administration was thought only to entrain rodent 
locomotor rhythms if given at activity onset but a recent report (Benloucif and 
Dubocovich, 1996) suggested that delays in activity onset could be induced by 
injection late in the subjective night. A full PRC has yet to be produced. The daily 
rhythm of 6-sulphatoxymelatonin can be restored in rats maintained in constant light 
by melatonin administration in drinking water (John et al., 1992).
In vitro experiments (McArthur et al., 1991) have shown that melatonin can reset the 
suprachiasmatic clock in vitro depending on the timing of administration. In a further 
experiment Yu, Rusak and Riggins (1993) discovered that exposure to L:L not only 
suppressed melatonin secretion but also affected the melatonin sensitivity and firing- 
rate rhythms of SCN neurons.
1.7 THE HUMAN CIRCADIAN SYSTEM AND MELATONIN
The study of melatonin in humans has been greatly helped by the development of a 
number of specific assays for its measurement in saliva or plasma and for its 
metabolite 6-sulphatoxymelatonin in urine (Fraser et al, 1983a; Bojkowski et al., 
1987a; Vakkuri , 1985; Markey et al., 1985; McIntyre et al., 1987 and Nowak et al. 
1987).
Melatonin exhibits a clear, robust diurnal rhythm which, has substantial variation 
between individuals, but is very reproducible within the same individual. It is 
characterised by low levels during the day, followed by a marked increase in levels 
during the evening, reaching a peak around 2.00-4.00am, declining in the early 
morning, with a return to baseline levels by mid-morning (Arendt, 1988; Bojkowski et 
al., 1987a; Shanahan and Czeisler, 1991; Wehr, 1991). Some reports (e.g. 
Weinberg et al., 1979) have described episodic secretion with some peaks occurring 
during the day. In early work technical problems with assays make any conclusions 
uncertain. The major masking effects on the melatonin rhythm are bright light and to 
a lesser extent posture as described previously (Section 1.3.1.5 and 1.4).
68
Ingestion of some drugs can also affect melatonin levels. Suppression is found, for 
example, with p-adrenergic antagonists such as atenolol, alcohol, some 
benzodiazepines and others (Arendt et al., 1985; Deacon et al, 199%; Ekman et al, 
1993 and Rodjmark et al. 1993). Many drugs which influence serotonin (5HT) or 
noradrenaline (NA) availability also influence melatonin secretion.
1.7.1 Endocrine Effects
Low doses of melatonin have little or no effect on the circulating levels or secretion 
profiles of growth hormone, lutenizing hormone (LH), testosterone, cortisol, FSH and 
thyroxine (Lissoni et al., 1986; Wright et al., 1986; Waldhauser et al., 1987) although 
small changes in prolactin may occur at certain times of the day. Petterborg et al., 
(1991b)administered varying doses of melatonin to an individual whose pineal had 
been destroyed. Melatonin had no effect on cortisol or testosterone but a robust 
nocturnal peak was seen in growth hormone and prolactin. However, the secretion 
profile of both these hormones is closely related to the timing of sleep, which is more 
influential than melatonin.
Some reports suggest that melatonin levels vary across the menstrual cycle (e.g. 
Wetterborg et al., 1976) with the highest values occurring during menstrual bleeding 
and the lowest values correlating to the LH peak. Others indicate that there is no 
variation across the menstrual cycle (Brzezinski et al., 1988). The treatment of 
infertile women, who have normal menstrual cycles, with oestradiol did not alter 
melatonin secretion (Brzezinski et al., 1994). Women with hypothalamic amenorrhea 
had increased serum melatonin concentrations (Laughlin et al., 1991). 3mg melatonin 
(administered as 3 x Img doses over 4h) enhanced LH and FSH response to 
gonadotrophin releasing hormone (GnRH) during the follicular, but not the luteal, 
phase of the menstrual cycle (Cagnacci et al., 1995a). Long term, administration of 
high levels of melatonin (300mg daily for 4 months) led to a reduction in LH levels. 
This observation led to the proposed use of melatonin as a contraceptive, either 
alone or combined with progestin (Voordouw et al., 1992; Silman, 1993).
Other work suggests that melatonin may modulate ovarian function directly as 
ovarian follicular fluid contains melatonin (Brzezinski et al., 1987). Melatonin
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stimulated progesterone synthesis by human granulosa-lutien cells in vitro (Webley 
and Luck, 1986).
Men with GnRH deficiency appeared to have increased serum melatonin levels while 
hypergonadotrophic hypogonadal males had decreased melatonin secretion. 
Treatment with testosterone normalised the melatonin concentrations in these 
individuals (Luboshitzky et al., 1997). Multiple endocrine abnormalities were detected 
in a single case where the individual concerned had a non-24h sleep-wake disorder 
(Oren et al., 1997). There was little exposure to bright light in his normal environment 
and serum melatonin was undetectable. After entrainment to a 24h schedule by timed 
controlled light exposure a normal pattern of nocturnal melatonin secretion occurred 
and some endocrine responses were also normalised. It could be postulated that a 
complex interaction between light exposure and the circadian system can reversibly 
switch off melatonin secretion.
It is not known whether high (or even low) doses of melatonin for very long periods 
will have any toxic effects (Arendt, 1997 and Weaver, 1997). In the short term 
(weeks) there is little, if any, evidence of toxicity in healthy subjects using up to 5mg 
daily.
1.7.2 Development and Ageing
Melatonin passes easily across the placenta such that the developing foetus is 
exposed to the cycling maternal melatonin (Reiter, 1992; Waldhauser et al., 1993; 
Davis, 1997). There is a suggestion that in humans the maternal melatonin levels are 
higher in pregnant than non-pregnant women especially during the third trimester 
(Kivela, 1991). At birth the infant ceases to receive maternal circadian and 
photoperiodic information (except for breast fed babies, lllnerova et al., 1993b) and is 
without a systemic melatonin rhythm. A rhythm in urinary 6-sulphatoxymelatonin is 
not apparent until 9-12 weeks of age (Kennaway, 1992). The onset of a discernible 
melatonin rhythm coincides with the development of other circadian variables such as 
sleep-wake, body temperature, cortisol and TSH secretion. Peak daily output of 
melatonin occurs between the ages of 1 and 3. Levels then drop gradually 
throughout childhood until adolescence. The output then remains static until the 
decline seen in old age.
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A clear age-related decline in melatonin production is seen throughout puberty 
(Cavallo, 1992). It has been proposed that the decrease in melatonin is involved, and 
indeed causative, in the hormonal changes seen during puberty. High melatonin 
levels have been seen in delayed puberty and low melatonin levels in precocious 
puberty. However, Cavallo et al. (1992) did not find any relationship between 
melatonin levels and testosterone, oestradiol and LH peaks. It is possible that the 
initial decline in melatonin levels with age are not due to a decrease in production, but 
rather an increase in body mass, but results are conflicting. No relationship was seen 
between total aMT6s excretion and body weight or height by Bojkowski and Arendt, 
(1990), but aMT6s declined when expressed as a function of body weight during 
development.
Cagnacci et al. (1995b) reported that although the serum concentrations of melatonin 
were the same in young (22-32y) and aged (54-62y) women melatonin onset time 
was advanced and the temperature rhythm was altered. The nocturnal decrease in 
temperature was reduced and the amplitude of the rhythm was smaller in aged 
women. This alteration in the temperature rhythm profile may be a contributory factor 
in the poorer sleep quality seen in some older subjects.
In old age the amplitude and duration of the melatonin rhythm decreases (Iguchi et 
al., 1982; Sack et al, 1986 and Bojkowski and Arendt, 1990). It has been proposed 
that calcification of the pineal gland in old age leads to decreased amplitude of the 
melatonin rhythm. No relationship was seen between pineal calcification, as 
assessed by lateral skull x-ray, (Bojkowski and Arendt 1990) and melatonin levels. A 
correlation between increasing age and calcification of the pineal and lower nighttime 
levels of melatonin was seen in a post mortem study (Schmidt et al., 1994). A 
suggested reason for the conflicting results was that x-ray was not able to detect the 
smaller particles of calcium deposit which were included in the atomic absorption 
measurement of post mortem samples.
Using the rat as a model, another theory for the decrease in melatonin production in 
old age is the reduction of p-adrenergic receptors on the pinealocyte membrane. 
These receptors are important for the uptake of norepinephrine in the synthesis of 
melatonin (Reiter, 1992). Longevity in the rats was accompanied by preservation of 
melatonin synthesis and a high density of p-adrenergic receptors.
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Results from experiments such as these, and e.g. those of Maestroni, Conti and 
Pierpoali (1989) where mice fed melatonin in their drinking water each day apparently 
lived 20% longer, led to claims for anti-ageing, immunostimulatory and anti-oxidant 
properties of melatonin. However, some of these “anti-ageing” experiments were 
flawed. Exaggerated claims fuelled major media interest and inspired huge sales of 
over the counter melatonin in the U.S.A. There is some evidence for both 
immunostimulatory and anti-oxidant effects. The subject has been extensively 
reviewed recently (e.g. Arendt, 1996; Reppert and Weaver, 1995).
1.7.3 Sleep
There is a clear 24h organisation of sleep-wake in humans. The timing of the sleep- 
wake cycle and variations in alertness and performance during wakefulness are 
dependent on the interaction of two distinct processes (see review Dijk, 1997). 
These are a sleep-wake dependent (homeostatic) component. Process S, and a 
circadian component. Process 0. These two factors have been incorporated into a 
number of models whereby the duration of sleep can be predicted from the amount of 
sleep debt (prior wakefulness) and the circadian phase at the time of sleep onset 
(Borbély, 1982; Daan et al., 1984; Borbély et al., 1989). This model has been 
developed further by Akerstedt and Folkard (1990 & 1991) who have added a third 
component W (wakeup process) to be able to predict sleepiness and alertness.
The circadian aspect of sleep propensity is not directly affected by the sleep-wake 
cycle itself, but is controlled by the SCN (Cohen and Aiders, 1991; Edgar et al., 
1993b). It is phase-locked to the circadian rhythms of core body temperature and 
melatonin secretion. The homeostatic component of sleep propensity waxes and 
wanes with sleep and is immediately affected by sleep deprivation, it is not controlled 
by the SCN (Mistlberger ef a/., 1983; Trachsel et ai, 1992).
The relative involvement of the homeostatic and circadian components of the sleep- 
wake cycle has been studied. The homeostatic component has been investigated 
during sleep deprivation experiments, where it is assumed that the endogenous 
circadian pacemaker does not phase-shift (Borbély, 1994). The influence of the 
circadian pacemaker on sleep regulation was studied by scheduling non-24h sleep- 
wake cycles which are outside the range of entrainment by light or the imposed
72
sleep-wake cycle (Weitzman et al., 1974; Carskadon and Dement, 1975; Lavie, 
1986). Sleep was timed to occur at different circadian phases, but the sleep 
homeostat could be considered to be in a steady state. The effect of the circadian 
pacemaker on sleep propensity and sleep structure was studied by means of a 28h 
forced desynchronisation protocol (Dijk and Czeisler, 1994). Sleep was timed to 
occur at all circadian phases and the interaction of the homeostatic and circadian 
components could be analysed.
Sleep propensity as measured by sleep latency, using the multiple sleep latency test 
(Carskadon and Dement, 1981 & 1992; Werth et al., 1997) and sleep duration (Dijk 
and Czeisler, 1995) appear to be controlled in part by homeostatic mechanisms.
In the absence of environmental time cues sleep onset occurs close to the 
temperature nadir (Zulley et al., 1981). The circadian rhythm of sleep propensity 
gradually decreases as core body temperature rises, reaching a trough during the 
wake maintenance zone or “forbidden zone" for sleep approximately 8h before the 
endogenous temperature nadir (Lack and Lushington, 1996). The circadian drive for 
wakefulness is therefore at a maximum during the “forbidden zone" and at a minimum 
close to the temperature nadir (approximately 06:00h in the entrained state).
The homeostatic and circadian components of the sleep process act together to 
maintain consolidated sleep. Under entrained conditions sleep onset occurs when the 
circadian drive for wakefulness begins to decline and the homeostatic drive for sleep 
is high (approximately 23:00h). During sleep the homeostatic drive for sleep 
decreases but the circadian drive for sleep increases thus maintaining sleep. High 
sleep efficiency and long duration sleeps can only be achieved when sleep is initiated 
close to the minimum circadian drive for sleep (Czeisler et al., 1980).
Melatonin, “the hormone of darkness", and sleep in humans are clearly linked as 
sleep onset normally occurs shortly after the evening melatonin onset and sleep 
offset is associated with a decrease in melatonin levels. Using the “ultrashort sleep 
wake paradigm" Shochat et al. (1997), demonstrated that the opening of the 
nocturnal “sleep gate" was linked to the nocturnal onset of melatonin secretion, with 
an inverse relationship between melatonin and core body temperature, and an out-of­
phase relationship between sleep propensity and temperature.
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The sleep-wake cycle per se has no effect on nocturnal melatonin production, with 
similar amounts secreted during normal sleep or wakefulness (Morris et al., 1990). 
Melatonin production was said to be increased the night after sleep deprivation 
(Salin-Pascaul, 1988) but comparisons of melatonin profiles during normal sleep, 
sleep deprivation and recovery sleep in another study (von Treuer et a!., 1996) 
showed no differences. Episodes of nocturnal wakefulness may be correlated to 
periods of increased melatonin secretion which may then act to restore sleep 
(Birkeland, 1982; Wurtman and Lieberman, 1985).
The duration of endogenous melatonin secretion in humans was increased when 
subjects were maintained on a short-day photoperiod (14h dark:8h light). The 
duration of the sleep episodes was also increased (Wehr, 1991). Administration of 
2mg melatonin in the early evening (17:00h) served to artificially increase the duration 
of the melatonin profile (Arendt et a/., 1984 & 1985; Wright et a/., 1986). The timing 
of sleep initiation was advanced after 4 days due to the earlier rise in melatonin levels 
and onset of sleepiness.
Elderly people often complain of poor quality sleep and Haimov et a/., (1994) have 
reported that this is accompanied by a decrease in 6-sulphatoxymelatonin excretion. 
Those elderly individuals with “normal” melatonin levels did not exhibit sleep 
problems.
A number of differing effects on sleep have been seen in response to melatonin 
administration (Dawson and Encel, 1993 and Dijk and Cajochen, 1997).The 
administration of exogenous melatonin during the day, when endogenous melatonin 
levels are low, shows a dose dependent (0.3-240mg) decrease of sleep latency 
(Cramer et a/., 1974; Lieberman et a/., 1984; Waldhauser et a/., 1990; Dollins et a/., 
1994; Tzischinsky and Lavie, 1994; Zhdanova et a/., 1995 & 1996; and Reid et a/., 
1996). No significant effect on sleep latency was seen when administration time was 
close to melatonin onset and the homeostatic drive for sleep was high. Melatonin 
induced increased sleep spindle activity and reduced slow-wave sleep and slow-wave 
activity by quantitative EEG analysis (Dijk et a/., 1995; Nave et a/., 1996) High 
doses (5mg or more) of melatonin, prior to nocturnal sleep, resulted in an increase of 
REM sleep (Dijk and Cajochen, 1997).
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The soporific effect of daytime melatonin administration is preceded by increased 
theta/alpha power in the EEG when 5mg of melatonin are taken at 13:00 or 18:00h, 
but not when taken near the endogenous melatonin rise. However, both subjective 
and objective measures of sleepiness disappeared when subjects changed from 
supine to standing positions (Cajochen, Krauchi and Wirz-Justice, 1997).
Blind subjects with a non-24h sleep disorder have been shown to have free-running 
melatonin rhythms (Lewy and Newsome, 1983; Aldhous and Arendt, 1991; Lockley et 
a/., 1997a). Daytime naps and decreased nighttime sleep efficiency are seen when 
the melatonin secretion rhythm peaks during the day. Long-term studies in the blind 
indicated that nighttime sleep efficiency was significantly improved when sleep was in 
phase with the melatonin rhythm. The number and duration of daytime naps 
appeared to be associated with the moving melatonin rhythm (Lockley et al., 1997b).
Great individual variation is seen in response to exogenous melatonin, and this is 
reviewed by Zhdanova and Wurtman (1997).
1.7.4 Temperature
Melatonin is known to have a major role in the thermoregulatory processes involved 
in torpor and hibernation (Saarela & Reiter, 1993). In humans there is a clear inverse 
relationship between the daily profile of melatonin levels and core body temperature. 
The onset of melatonin secretion in the evening parallels the decline of core body 
temperature, whilst the morning decline of melatonin levels accompanies the morning 
rise in temperature (Cagnacci et al., 1992; Badia, Myers and Murphy, 1992; Krauchi 
and Wirz-Justice, 1994). The hypothermic effects of endogenous melatonin are 
thought to be accountable for 40% of the amplitude of the circadian rhythm of core 
body temperature (Cagnacci et al., 1992). In constant routine experiments the drop 
in body temperature is still seen during the nighttime and also in internal 
desynchronisation where sleep is moved to the day during shiftwork. The elevation of 
core body temperature caused by exposure to bright light (3000 lux) at night can be 
reversed by oral administration of melatonin (Cagnacci, Soldani & Yen, 1993).
The strict correlation between temperature and melatonin rhythms in entrained 
subjects is also seen during a light induced phase shift (Shanahan and Czeisler,
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1991) and core body temperature and melatonin rhythms maintain a similar period 
during forced desynchrony (Arendt et al., 1985à).
Oral administration of melatonin during the day can produce a decrease in body 
temperature but melatonin levels have to be maintained for some time for the effect 
to become manifest (Cagnacci et al., 1992). This reduction in core body temperature 
is preceded by an increase in heat loss through the extremities (Krauchi, Cajochen 
and Wirz-Justice, 1997). The decrease in body temperature was seen when 
individuals maintained a supine position, but disappeared on standing, suggesting 
that the adaptation to standing overcomes the hypothermic response.
5mg melatonin taken at different times of the day produced differing effects. When 
taken at 18:00h core temperature was depressed to the same extent as when taken 
at 13:00h, but heat loss was less and was accompanied by a reduced heart rate 
(Krauchi et al., 1997) indicating an effect on heat production. It has been postulated 
that the effect on heat production may be related to the phase advance induced in 
the circadian system by melatonin administered at 18:00h (Cagnacci et al., 1997). 
The degree of phase shift and temperature suppression produced by exogenous 
melatonin is dose-dependent (Deacon and Arendt, 1995).
Lower doses of melatonin, said to reproduce physiological levels of melatonin in the 
plasma (0.3 or 0.1 mg) did not reduce core body temperature (Dollins et al., 1994; van 
den Heuvel et al., 1997). An explanation of this has been proposed by Cagnacci 
(1997): pharmacokinetics studies in animals, including primates, suggested that only 
pharmacological levels of melatonin in the plasma were sufficient to increase the 
melatonin levels in the ventricular cerebrospinal fluid to those seen during 
endogenous melatonin production. The cerebrospinal fluid is considered to be the 
route for melatonin to reach the centre for thermoregulatory processes in the 
hypothalamus.
The possible causal relationship between the temperature decline and the melatonin 
rise at night has been investigated by a number of infusion studies (Strassman et al., 
1987 & 1991; Cagnacci et al., 1993 and Myers, 1995). Bright light used to suppress 
melatonin at night caused an increase in core body temperature which could be 
reversed by melatonin infusion. The melatonin had to be given by infusion, or
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repeated oral doses, to maintain high circulating levels. Alternating levels of bright 
and dim light during the nighttime hours produced a rapid reversal of the effects, with 
dim light producing decreased body temperature and increased melatonin levels 
within 30min (Myers, 1995).
In conclusion it can be said that the rhythms of temperature and melatonin are very 
closely linked in the human, but that more research is needed to discover the degree 
of interaction.
1.7.5 Cardiovascular Effects
Img of melatonin administered to young women during the day modified the 
pulsatility index within 90min. Artery blood flow was influenced, blood pressure was 
decreased and noradrenergic activation was blunted (Cagnacci et a/., 1998). This 
effect of melatonin on the circulation needs to be examined further.
1.7.6 Performance
Melatonin is known to decrease alertness and increase feelings of fatigue in suitable 
environments. A variety of effects have been seen on performance tasks, although 
most are transitory. Lieberman et al. (1984) reported a number of effects after 
daytime administration (3 x 80mg 12:00-14:00h) depending on the tests used. 
Reaction time was increased but accuracy, sustained motor performance, memory 
tests or visual sensitivity were unaffected. Daytime administration of a range of 
doses of melatonin (0.1-80mg po) have all been reported as increasing fatigue, 
reducing accuracy in an auditory vigilance task and increasing reaction time (Dollins 
et ai, 1993b & 1994).
The effect of melatonin concentration on performance during the nighttime hours was 
not dose-dependent. Performance on vigilance, reaction time and other tasks 
decreased throughout the night, independent of the light intensity and circulating 
melatonin levels (Dollins et ai, 1993b). More recent studies, looking at the effect of 
melatonin on cognitive tasks reported an increase in decision and response time in a 
reaction time task lasting for 7 hours, but no effects on other measures of 
performance after 5mg melatonin at 12:30 (Rogers et ai, 1997b). 6mg of melatonin
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administered in the late afternoon reduced memory capacity by mean word recall but 
improved DSST (Digit Symbol Substitution Test) results (Jean-Louis, et al., 1997). 
The use of melatonin to hasten adaptation to phase-shift has improved daily mean 
performance efficiency in search and memory tasks (Deacon and Arendt, 1996b).
1.7.7 Phase Shifting
The possibility that melatonin could be used to produce phase shifts was first 
suggested by Arendt et al. (1984 & 1985a) where repeated administration of 2mg 
melatonin at 17:00h appeared to result in a phase advance of sleep, endogenous 
melatonin and prolactin. Subsequent attempts to produce phase-shifts by means of 
melatonin administration were in free-running blind individuals, where the light-dark 
cycle was expected to have little if any influence (Sack et al. 1987). The sleep-wake 
cycle of a free-running blind individual was stabilised to 24h by 5mg melatonin daily 
but other rhythms remained free-running (Folkard et al., 1990).
Only two phase response curves for melatonin have been produced to date (Lewy et 
al., 1992 and Zaidan et al., 1994). A method for assessing the phase position of the 
endogenous melatonin rhythm was published by Lewy and Sack in 1989. It utilised 
the dim light melatonin onset (DLMO) as a marker of the evening rise in melatonin 
secretion. Subsequently the change in DLMO the following evening after melatonin 
administration (0.5mg) at varying times of day, was used to construct a phase 
response curve (Lewy et al., 1992). The PRC was plotted with the time of 
administration recorded as circadian time, with CT14 being the time of dim light 
melatonin onset. The shape of the PRC was 12h out of phase with the PRC for light. 
Melatonin was able to induce advance phase-shifts during the subjective evening and 
phase delays in the subjective morning. Only relatively small phase-shifts were seen. 
The PRC of Zaidan et al. (1994) was determined using a 3h infusion of physiological 
levels of melatonin at 4 different times of the day. The phase-shifts produced were 
similar to those shown by Lewy et al., 1992 (Fig 1.6).
The phase-advancing effects of melatonin were dose-dependent in the range 0.05,
0.5 and 5mg taken at 17:00h (Deacon and Arendt, 1995).
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Fig 1.6 Human phase-response curves for melatonin, derived 
from Lewy et al., 1992, and Zaidan at a!., 1994.
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1.7.8 Therapeutic Uses of Melatonin
The discovery that melatonin was able to alter the timing of the endogenous circadian 
clock opened possibilities for its use in the treatment of disorders of circadian timing 
such as shift-work, jet-lag, blindness and sleep disorders. Several reviews of this 
subject have been published recently (Arendt et al., 1997; Arendt and Deacon, 1997; 
Lewy and Sack, 1997; Sack and Lewy, 1997).
1.7.8.1 Shift-work
Individuals required to do shift-work suffer from a great many problems related to 
circadian desynchrony. They are required to work during the period of lowest 
performance and highest fatigue, and to sleep at an inappropriate circadian phase. 
The most common complaints are sleep and gastrointestinal disorders, and a higher 
incidence of cardiovascular disease (Minors and Waterhouse, 1981; Knutsson, 1989; 
Hampton et al., 1996).
Measures of circadian phase suggest that many night shift-workers do not fully adapt 
their circadian rhythms. Rapidly rotating shift workers do not show marked changes 
in their melatonin rhythm (Touitou et al., 1990; Sack, Blood and Lewy, 1992; Hall et 
al., 1997) whilst permanent night workers assume a phase position more suitable to 
their schedule (Waldhauser et al., 1986). One report (Roden et al., 1993) showed no 
alteration in the profile or phase position of cortisol or melatonin in permanent night- 
shift workers. Koller et al. (1994) found that shifts in cortisol and melatonin were 
related to light exposure in the morning: adaptation was countered by greater 
exposure.
In Antarctica melatonin rhythms became fully adapted to night shift work within 7 days 
(Midwinter and Arendt, 1991; Ross et al., 1995) but had more difficulty adapting back 
to day shift. Recent studies in the North Sea (Barnes et al., 1998a and 1998b) 
suggest that the timing of the shift pattern and therefore the time of light exposure is 
an important influence on phase-adaptation.
Two studies (Sack and Lewy, 1997; Folkard et al., 1993) gave melatonin to 7 day 
rotating shift-workers. 5mg melatonin timed to phase delay improved daytime sleep
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and also, when given to phase advance, helped adaptation back to the normal 24h 
day. Comparisons of the effectiveness of bright light exposure and melatonin in 
hastening adaptation to night shift suggest that bright light is more efficient (Dawson, 
Encel and Lushington, 1995). However, the melatonin group were treated with three 
separate doses, which might have involved disruption of sleep.
1.7.8.2 Jet lag
Modern day society requires individuals to travel across time zones and to work 
immediately on arrival. However, most people experience disorientation and are out 
of phase with the new environment. The effect is similar to that experienced by shift­
workers but travellers are aided in their adaptation by local zeitgebers. Several 
placebo-controlled field studies have been carried out to investigate the ability of 
melatonin to alleviate the symptoms of jet lag (e.g. Arendt, Aldhous and Marks, 1986; 
Arendt et al., 1987; Arendt and Aldhous 1988, Petrie et al., 198 t^; Claustrat et al., 
1992; Comperatore et ai, 1996; Spitzer ef a/., 1997 and Suhneref a/., 1998).
A number of these studies reported that timed melatonin administration was able to 
alleviate the symptoms of jet-lag and hasten adaptation (Arendt, Aldhous and Marks, 
1986; Arendt et al., 1987; Arendt and Aldhous 1988, Petrie et al., 198<?; Claustrat et 
al., 1992; Comperatore et ai, 1996 and Suhneref a/., 1998).
Not all reports have suggested that melatonin is a successful treatment for jet lag. 
Petrie et al. (1993) did not show any improvement in international flight crew with pre 
and post flight treatment. This could be due to the continual changing of time zones 
experienced by flight crew such that the circadian system is never stabilised to a 
particular time zone. Spitzer et al. (1997) found no beneficial effects of 0.5 or 5mg 
melatonin in a group of subjects flying from New York to Norway. Their circadian 
status was unknown, since they were not adapted to New York time. The timing of 
melatonin administration is crucial and in these two cases may not have been 
optimum.
In simulated jet-lag studies melatonin has been shown to accelerate adaptation to a 
rapid 9h phase advance (Samel et ai, 1991) even when individuals were exposed to 
conflicting bright light timed to phase delay (Deacon and Arendt, 1996a and 1996b).
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1.7.8.3 Sleep disorders
There are a number of circadian sleep disorders which are caused by malfunction of 
the endogenous clock. These are;
a. delayed sleep phase syndrome - unable to sleep before 2-3am and difficulty 
awakening.
b. advanced sleep phase insomnia - fall asleep early and wake up early.
c. early morning awakening with normal sleep onset - decreased sleep duration.
d. sleep onset insomnia with normal waking time - decreased sleep duration.
Melatonin has proved successful in advancing the time of sleep onset in individuals 
suffering from delayed sleep phase insomnia (Dahlitz et al., 1991; Alvarez et al., 
1992 and Tzischinsky et al., 1993). In some cases improvement was only seen 
during treatment but in other instances long term benefit occurred. A group of 
children with multiple disabilities, including sleep disturbances, also showed marked 
improvement after melatonin treatment (Jan et al., 1994).
Sleep problems in the elderly appeared to correlate with low levels of endogenous 
melatonin compared to individuals with no sleep problems (Haimov et al., 1994; Hajak 
et al., 1995). Treatment with low dose melatonin has proved helpful in some 
preliminary studies (Garfinkel et al., 1995; Haimov et al., 1995).
Early work using high doses of melatonin (75mg) administered late evening to chronic 
insomniacs (MacFarlane et al., 1991), and in artificially induced insomnia 
(Waldhauser et al., 1990) improved sleep. Lower doses of 1 or 5mg at 21:00h did 
not show any effect on polygraphic recordings (James et al., 1987) or improve sleep 
in subjects suffering from psychophysiological insomnia (Ellis etal. 1996).
1.7.8.4 Blind
Many blind people are able to lead regular lives with no sleep problems. Others suffer 
from bouts of insomnia and daytime fatigue due to the endogenous clock being out of 
phase with the environment (Miles et al., 1977; Nakagawa et al., 1992; Lewy and 
Newsome, 1983; Arendt et al., 1988; Aldhous & Arendt, 1991; Sack et al., 1992; 
Klein et al., 1993). An epidemiological study (Lockley et al., 1997a) discovered that
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there was a correlation between circadian rhythms and light perception of registered 
blind people. Most subjects with light perception (14/19) had normally entrained 
rhythms whilst 22/30 with no light perception had abnormal rhythms, 17 were free- 
running and 5 were abnormally entrained. The abnormal melatonin rhythms were 
associated with disturbed nighttime sleep and increased daytime sleepiness.
Melatonin administration has been used in field studies in the blind in an attempt to 
entrain rhythms to the 24h day (Sack et al., 1987, 1990 & 1991; Arendt et al., 1988 
and Folkard et al., 1990; Tzischinsky et al., 1992). In all cases an improvement was 
seen in the timing of the sleep-wake cycle and in some cases phase advances were 
recorded in the melatonin rhythm. There is no convincing evidence of successful 
entrainment of free-running rhythms (Folkard et al., 1990; Sack et al., 1990; Palm et 
al., 1991 and Lapierre and Dumont, 1995).
1.8 HISTORICAL CONTEXT
The research recorded in this thesis was commenced in 1992, and since that time
rapid advances have been made in all aspects of chronobiology. For this reason it is
important to clarify the relevant knowledge available when the scheme of work was
planned.
1. With one exception isolation studies had involved total isolation from all time cues, 
including knowledge of clock time.
2. Only a few studies had been carried out where subjects were maintained as a 
group (Wever, 1979) and they had exhibited free-running periods with the same 
tau.
3. The endogenous clock had an average period of approximately 25h.
4. Light induced phase-shifts and light PRC’s had been produced, but all had used 
bright light with an intensity in excess of 2,000 lux.
5. Daily administration of 5mg melatonin could synchronise the sleep-wake cycle of a 
free-running blind man, but not other endogenous rhythms.
6. A PRC for melatonin was available.
7. Light and melatonin PRC’s are approximately inverse.
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1.9 RESEARCH PROPOSAL AND AIMS OF THE THESIS
The internal body clock is known to run with a periodicity greater than 24h and is 
synchronised by external zeitgebers or time cues. Light and exogenous melatonin are 
both able to phase-shift the biological clock. It is thought that in a normal environment 
daily early morning light exposure has a phase advancing effect on the clock 
overcoming it s natural tendency to delay, thus maintaining entrainment to the 24h 
day.
In our western modern day society a significant number of individuals spend a great 
deal of their time in low light environments. Indoor artificial lighting is normally in the 
region of 300-500 lux, in marked contrast to a sunny day when outdoor levels can 
reach 100,000 lux. Early isolation experiments had suggested that it was the 
changes in light intensity perceived throughout the day that were important in 
maintaining entrainment to the 24h day. Individuals working in a low light 
environment, especially during the winter months, might experience very little natural 
light exposure or change in illumination throughout the day.
The main aim of the proposed research was to determine whether daily 
administration of melatonin could maintain entrainment or resynchronise free-running 
rhythms, and to investigate the level of light intensity required to maintain synchrony 
to the 24h day.
The design of the isolation unit to be used required that the subjects be kept as a 
group. This would more closely resemble the normal environment. Also, if timed 
medication were to be given, knowledge of clock time was essential. Previous 
experiments where subjects were housed together had resulted in identical free- 
running periodicities, even when internal desynchronisation occurred. This 
synchronisation was thought to be due to social factors, and a baseline study was 
needed to assess the influence of knowledge of clock time and social interaction on 
subjects kept as a group in constant dim light (< 8 lux).
Once it was established that the experimental conditions induced independent free- 
running rhythms in normal volunteers, the ability of light or melatonin to maintain 
entrainment could be investigated. The period of the endogenous clock was to be
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determined by measurement of a number of parameters known to exhibit circadian 
rhythms and to act as reliable phase markers (core body temperature and melatonin). 
Concern was expressed that the subjects might become depressed in the low 
ambient light levels as it was thought that seasonal affective disorder (SAD) is 
caused by decreased light exposure. In order to avoid this, and reduce interpersonal 
tension, it was recommended that mood questionnaires were completed. Subjects 
were requested to comment on how they thought the other individuals were feeling 
and how well they got on with them.
The timing of melatonin administration was crucial, as phase shifts occur according to 
the melatonin phase response curve. Melatonin taken just before the evening onset 
of melatonin secretion should either maintain phase or produce a small phase 
advance. By monitoring a number of circadian rhythms it was possible to ascertain 
whether the endogenous clock timing has been affected or just the behavioural 
rhythms such as sleep wake.
The light intensity required to maintain synchrony to 24h could be investigated under 
isolation conditions where lighting levels could be controlled at all times. Various light 
levels could be tested in a 12:12 L:D cycle, where overnight levels were of sufficient 
intensity for normal waking activities. The period of the endogenous clock could be 
calculated by continuously monitoring core body temperature and the melatonin 
rhythm. A 12:12 light-dark cycle was used as this gave a symmetrical cycle, would 
hopefully avoid the complication of long or short photoperiods and was considered 
comparable to average human natural light exposure.
In a final series of experiments, melatonin administration and light exposure could be 
combined to ascertain whether they complemented each other and worked together 
to maintain synchrony to the 24h day.
Strategies could then be proposed to aid individuals living in a low light environment 
to maintain synchrony to the 24h day.
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CHAPTER 2
GENERAL EXPERIMENTAL CONDITIONS
AND METHODOLOGY
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2.1 OVERALL EXPERIMENTAL AIM
Chronobiology, the study of biological rhythms, has become increasingly relevant in 
modern society where humans are expected to function at any time during the 24 
hour day. Much investigative research has been directed towards enabling humans 
to adjust to the demands of this 24 hour society.
Previous work in this area has investigated the ability of changes in the timing of 
light exposure or intensity, and the timed administration of melatonin or other 
treatments, to cause phase shifts and facilitate adaptation to shift-work and jet lag. 
(Eastman 1990 & 1991; Daan and Lewy, 1984, Folkard et a/., 1993; Petrie et al., 
1984; Claustrat et al., 1992; Arendt et al., 1997) Early isolation studies (Wever 
1979) considered the formal properties and the relationships between various 
circadian rhythms. The limits of entrainment were determined using different 
experimental protocols and a variety of zeitgebers including the light dark cycle 
(Wever 1983,1989). In these experiments individuals were maintained in total 
isolation, with either self controlled lighting or imposed lighting regimes.
The aim of this project was to determine the optimum conditions for maintaining 
synchrony of human circadian rhythms to a 24 hour day under very dim light 
conditions. The parameters manipulated to achieve this were exogenous melatonin 
and the light-dark cycle. A number of studies were conducted to investigate the 
following effects:
a. the timed administration of exogenous melatonin to prevent free-running 
of the sleep-wake cycle
b. the relative ability of various light intensities administered as a 12:12 light 
dark cycle to prevent free run
c. the combined use of timed administration of exogenous melatonin and 
12:12 light dark cycle to prevent free run
To achieve meaningful results from these studies, an initial baseline study was 
necessary to ascertain whether or not normal healthy subjects, maintained as a 
group in constant dim light under partial isolation conditions, but with knowledge of 
clock time, show individual free-running periodicity.
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2.2 EXPERIMENTAL DESIGN
Subjects were required to live in a controlled environment with restricted outside 
influence. An isolation unit with controlled lighting, attenuated sound, temperature 
control and limited social contact was provided by the DERA (Defence Evaluation & 
Research Agency) in Farnborough.
2.2.1 Isolation Facility
The isolation unit comprises two isolated single storey buildings located on the 
airfield at some distance from all other buildings. Flights from the airfield were few 
and at irregular intervals so that although take-offs could just be heard, they were 
apparently insufficient to provide a synchronising signal. The building comprised a 
large living area (6m x 7m) containing 6 beds separated by screens; a kitchen/mess 
area (3m x 4.7m) fully equipped with fridge/freezer, cooker and microwave; 
computer room (3.5m x 3m) containing P.C.’s for computer based performance 
tests; ventilated lavatory/shower/washing area (11.7m x 3m) with individual facilities 
for each subject; a double door lock to allow observer entry without admitting 
external light and a room for observers (3.5m x 3m) containing monitoring 
equipment (see Fig 2.1 Plan A). In later studies the double door lock was moved 
and the observers room was incorporated into the subjects living area providing a 
separate video lounge (see Fig 2.1 Plan B). Observers’ accommodation and 
equipment was moved into an adjacent, previously empty, single storey building.
All external windows were sealed with boards attached to the outside of the building 
and all internal walls and screens were painted white. Air-conditioning units were 
supplied with baffles applied to all external vents to prevent external light entering 
the unit.
Closed circuit television cameras were positioned in all rooms, apart from the 
washroom, to allow monitoring of subject compliance whilst keeping contact 
between subjects and observers to a minimum. An intercom was available for 
immediate voice contact between subjects and observers at all times. A door 
buzzer was fitted to the external door of the double door lock so observers were 
aware of the door opening at any time.
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2.2.2 Measurement & Control of Lighting Leveis
To achieve the range of lighting levels required for the project, a lighting system was 
designed by Siemens Lighting (Witton, Birmingham, U.K.) to give a uniform 
electronically controlled range of illumination from 5 - 2500 lux. Ceiling lights were 
installed in banks to achieve a maximum light level of approximately 2500 lux in 
places, with an average maximum illumination of 2000 lux in each room (maximum 
2659.8 ± 177.8 (SD) lux; minimum 1488.2 ± 203.1 lux; overall mean 2161.5 ± 76.7 
lux; n = 584). In the main living areas the light fitments were backed with specially 
designed aluminium diffusers to avoid point light sources. The lights in each room 
were divided into 4 separate banks with independent controls to allow for uniform 
lighting at all light intensities. One bank of lights per room was fitted with adjustable 
shutters to produce uniform light levels of < 8 lux. A light sensor connected to this 
light bank was installed in all the main living rooms to automatically adjust the 
controls if the light intensity increased above a threshold value set at 10 lux. The 
light controls were in a locked wall mounted box and all lighting changes were made 
by the experimenters. Subjects were unable to change the lighting levels 
themselves.
Osram Biolux, full spectrum white light, fluorescent tubes were used to give an 
emission spectrum comparable to natural light (400-700nm wavelength). Normal 
fluorescent lighting emits light of 550-700nm wavelength.
Wall mounted photocells were installed at eye level in the sleeping room, kitchen 
and video lounge, to electronically record illumination on a Grant Memory Logger 
(Grant Instruments, Cambridge, U.K.). The four photocells supplied by Megatron 
Ltd, London, were connected to an amplifier. Each of the four channels of the 
amplifier had two ranges controlled by a single two position switch. The lower range 
gave a maximum reading of 5.0 volts output at 10 lux and the upper range gave 
maximum output of 5.0 volts at 2000 lux. Each range was linear in output such that 
when the photocells were exposed to 1000 lux the output was 2.5 volts. Levels in 
excess of the maximum value gave an output of 6.5 volts. When no light reached 
the photocell there was an output of < 2.5 mV. These gave “high” and “low” 
readings respectively on the Memory Logger. The Memory Logger was
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programmed to record every 30 minutes to give a continuous record of the light 
levels.
The photocells were, of necessity, wall mounted which did not give an accurate 
overall light measurement throughout the unit. Light intensity was also measured 
manually every other day when light levels were kept constant, or daily when a light- 
dark lighting schedule was in force. Measurements were carried out using a hand 
held digital light meter, Megatron DL4, from Megatron Ltd, London. The light sensor 
was held at approximately eye level when seated as subjects spent the majority of 
their time sitting down. Light intensities were measured at sufficient points in each 
room to determine the average illuminance using CIS Code 1984 (Appendix 11 Field 
measurements of lighting).
2.2.3 General Study Conditions
The same general conditions given apply to all studies: any specific variations are 
detailed in the relevant chapter.
Detailed study protocols were written for both subjects and observers and a meeting 
held to explain the study and answer any questions. The study design was 
approved by the Ethics Committee of the Centre for Human Sciences, DERA, 
Farnborough. Medical cover was provided by qualified doctors who could be 
contacted by telephone at all times.
The subjects were maintained as a group and did not leave the isolation unit 
throughout the study period, except in the rare case (n=2) of medical or family 
emergency. An observer was present at all times to ensure subject compliance to 
the study protocol. After an initial 24 hour acclimatisation period in a normal light 
dark cycle (dark 2300-0700h), light levels were controlled, sound was attenuated 
and daily temperature fluctuations recorded by maximum and minimum 
thermometers in each room, read at the same time each day.
Contact with observers was kept to a minimum and was random and intermittent to 
avoid social time cues. A digital clock was available so that subjects had knowledge 
of clock time but there was no requirement to perform tasks at definite times, apart
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from performance tests every 2 hours when awake and timed treatment with 
melatonin or placebo. Pre-recorded videos were available and any requested 
television programmes were recorded and supplied at irregular intervals. This 
avoided the strong social cues of watching particular TV programmes (e.g. soaps) at 
set times. Individuals were permitted to study or play computer games and listen to 
pre-recorded tapes or CDs. Listening to the radio was permitted as it was used for 
background music only. Newspapers were supplied intermittently, and a telephone 
was available for maintaining contact with family members.
Food was self-selected and cooked by the subjects from a broad range of fresh and 
frozen ingredients and ready-prepared microwaveable meals. Alcohol was 
permitted at the rate of 1 pint of beer or equivalent per person per day. Exercise 
bikes, weights and a punch bag were available if the subjects wished to exercise. 
Participants were permitted to eat and sleep whenever they wished. At no time was 
any individual disturbed whilst sleeping. An incident book was kept throughout each 
study and all observers were asked to record any event which might affect the 
study, any change in subject behaviour, inter-personal problems and any requests 
from the subjects.
2.2.4 Subject Selection & Criteria
Subjects for these trials were normal healthy, male volunteers under no medication 
except for minor analgesics. Ingestion of any analgesics during the trials was noted 
in the incident book. Heavy smokers (>10 per day) and individuals with either a 
personal or family history of psychiatric disorders, migraine, epilepsy, sleep 
disorders or food allergies were excluded.
Potential subjects were screened for melatonin production by collecting 4 hourly 
urine samples with an 8 hour collection overnight for 24 hour. Urine samples were 
tested for urinary 6-sulphatoxymelatonin (aMT6s), the major metabolite of melatonin, 
levels by radioimmunoassay. Screened individuals were considered suitable for 
inclusion in the experiment if their 24h aMT6s output was within the normal range 
(12.81 ± 9.6 pg/24h, n=177) with an acrophase time between 02:00 and 06:00h. 
Plasma dim light melatonin onset was determined for all individuals included in the 
melatonin administration study (see Chapter 6) prior to commencement of the study.
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All subjects gave their written, informed consent and were free to withdraw at any 
time
The majority of subjects were provided by the Army Trials Section personnel posted 
at Farnborough. The remainder were recruited from University of Surrey 
postgraduate students, and from the general public by advertisement.
2.2.5 Melatonin Preparation
The exogenous melatonin administered in early studies was FDA licensed melatonin 
(M5250 FD) for experimental use in normal human volunteers. The compound is 
manufactured synthetically and supplied by Sigma Chemical Co. Ltd., Poole, Dorset, 
U.K. (product W 5318-3). The melatonin was made into gelatin capsules containing 
5mg melatonin with lactose as filler by Penn Pharmaceuticals Ltd., Tredegar, Gwent, 
U.K. Quality control was carried out at the University of Surrey. In later studies 
melatonin capsules were supplied directly by Penn Pharmaceuticals who hold a 
licence from the Medicines Control Agency to manufacture and supply melatonin 
pills on a named patient basis. Prof. J. Arendt, supervisor and a senior investigator 
on the project, holds a Clinical Trials Exemption Certificate from the Medicines 
Control Agency to administer exogenous melatonin to normal healthy volunteers 
(see Appendix 1).
Whilst full clinical trials for melatonin have not yet been carried out, a number of 
studies giving doses ranging from 2-1 Omg over varying time periods have shown no, 
or minimal side-effects (Wright et al., 1986; Arendt et al., 1987; Arendt and Aldhous 
1988; Samel etal., 1991, Jan etal., 1994, Arendt etal., 1997 and Arendt, 1997).
A field study led by Prof. J. Arendt between 1984 and 1994 on the use of melatonin 
to help alleviate problems associated with jet-lag has the largest data base to date 
concerning side-effects reported after taking melatonin. The figures are shown in 
Table 2.1.
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Table 2.1 Percentage of individuals reporting side-effects after taking 5mg 
melatonin to alleviate jet lag.
Side-effect Placebo (n=112) Melatonin (n=474)
Drowsiness 1.78 8.30
Headache 2.70 1.65
Nausea 0.90 0.80
Giddiness 0.00 0.60
Dizziness 0.00 0.80
Side effects Viral infection Mild amnesia
reported only 24h after return Fuzzy head
once Flatulence Dry mouth
Lethargy Thirsty
Reduced appetite Reduced appetite 
Constipation 
Palpitations 
Tearfulness 
Swollen legs 
Transient faintness 
Became whiter after sunbathing 
Sense of remoteness
Food poisoning (husband and 
wife)
Food poisoning
2.3 PARAMETERS MEASURED - METHODOLOGY & 
EQUIPMENT
2.3.1 Core Body Temperature
Core body temperature was monitored continuously by means of a rectal probe 
connected to a Grant Memory Logger (Grant Instruments, Cambridge, U.K.) 
recording every 6 minutes. Probes were worn at all times except when
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defecating/showering/bathing or when discomfort was experienced. Loggers were 
downloaded every 2-3 days and checked daily to ensure that data loss due to 
equipment failure was kept to a minimum.
2.3.2 Sleep/Wake & Activity
Activity levels and sleep/wake parameters were recorded continuously by means of 
a wrist worn accelerometers, (32K MiniMotionloggers) from Ambulatory Monitoring 
Inc., New York. Readings were taken every 20 seconds and actigraphs were only 
removed when showering or washing. The event marking facility was used for 
recording when subjects retired to bed to sleep and when they arose. Data was 
downloaded from the actigraphs every 2-3 days to reduce data loss due to 
malfunction.
2.3.3 Coiiection of Sampies
a. Urine
All urine passed during fixed 4 hourly periods, day or night, was collected into clearly 
labelled bottles (08:00-12:00, 12:00-16:00, 16:00-20:00, 20:00-24:00, 24:00-04:00 
and 04:00-08:00) except for sleep periods longer than 4 hours. The oversleep 
collection was placed in the container appropriate to the 4 hour interval on waking. 
For the purposes of calculation the excretion rate was assumed to be constant 
during the entire sleep period. Observers measured and recorded the volume and 
retained a 5ml aliquot at -20°C for measurement of 6-sulphatoxymelatonin (aMT6s) 
by radioimmunoassay (RIA). Using an identical procedure, calculated phase shifts 
in aMT6s have been shown to correlate closely to those of plasma melatonin 
acrophase or onset (Bojkowski et al., 1987a; Ross et al., 1995; Deacon and Arendt, 
1994a  ^ aMT6s is stable for at least 5 days at room temperature or 4°C and up to two 
years at -20°C with or without preservative (Bojkowski, 1988)
b. Plasma
Blood samples were collected, under dim light conditions (<50 lux) into lithium 
heparin tubes via cannulae inserted in the anti-cubital vein and centrifuged
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immediately at 3000g for 15 minutes. The plasma was transferred carefully into 
clearly labelled plastic vials and stored at -20°C prior to assay.
0 . Saliva
Saliva samples were collected every 3 hours throughout the baseline study (Chapter 
5) for measurement of cortisol. If individuals found difficulty in producing a sample 
they were given Nescofilm, an inert plastic film, to chew on to stimulate production. 
Samples were collected directly into clearly labelled plastic vials and stored at -20°C 
prior to assay. All samples were centrifuged before assay to remove any particulate 
matter and any grossly contaminated with food or highly coloured were noted.
2.4 RADIOIMMUNOASSAY OF MELATONIN, CORTISOL & 
aMT6s
2.4.1 Principles of Radioimmunoassay
Melatonin, cortisol and aMT6s are all measured by a competitive immunoassay 
system, where varying amounts of cold antigen contained in the sample are 
incubated with known constant amounts of radiolabelled antigen and antibody 
specific for the antigen being measured. Thus, the “cold” (unlabelled) and labelled 
antigen are competing for a limited number of antibody binding sites and the amount 
of labelled antigen bound to the antibody will be inversely proportional to the amount 
of antigen present in the sample. The reaction is allowed to continue until 
equilibrium is reached, then either the free (unbound to the antibody) antigen is 
separated using dextran coated charcoal, or antigen bound to the antibody is 
separated using a solid phase second antibody.
The concentration of antigen present in the sample is determined by comparing the 
amount of radioactivity present in the unknown samples to the amounts found in 
standards of known concentration of antigen used to construct a standard curve. 
The radioactivity present in each tube is counted in either a p-counter or a y-counter 
depending on the isotope used. The concentration of antigen contained in each
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unknown sample is calculated by interpolation using the RIAcalc program (EG & G 
Wallac, Wallac oy, P.O. Box 10, FIN-20101, Turku, Finland).
The RIAcalc program automatically calculates the percentage of total counts in 
either the bound or free fraction being measured. These values are then plotted as 
a function of the known concentration of standards. A curve is fitted through the 
standard points based on the smoothing spline calculation method (EG & G Wallac, 
Wallac oy, P.O. Box 10, FIN-20101, Turku, Finland). A continuous curve is fitted to 
each pair of standard points with the minimum number of turning points, using the 
least squares method to give the smoothest possible line of best fit. The 
concentration of antigen in the unknown samples is then read from this curve.
Separate standard curves are performed in each assay and a minimum of 3 quality 
control samples of known concentration, giving 20%, 50% and 80% of maximum 
binding, are run to check the assay performance and to allow calculation of the 
inter-assay variation.
2.4.2 RIA of aMT6s in Urine
6-Sulphatoxymelatonin (aMT6s) levels in urine samples were measured by 
radioimmunoassay (RIA) following the method of Arendt et al. (1985) modified by 
Aldhous and Arendt (1988). The assay has been gas chromatography mass 
spectrometry (GCMS) validated (Aldhous and Arendt, 1988).
a. Materials
Antiserum, ^^®l-aMT6s, charcoal stripped urine (aMT6s free) and aMT6s standard 
were obtained from Stockgrand Ltd., University of Surrey, U.K. All other chemicals 
were supplied by Sigma Chemical Co. Ltd. Poole, Dorset, U.K.
b. Reagents
Buffer: Except where otherwise stated all dilutions were made in tricine buffer
(0.1 mol/L) pH 5.5 containing 0.9% NaCI, 0.1% gelatin and 0.01% sodium azide 
made up in double-glass-distilled water (DGDW) warmed to 50°C to dissolve the 
gelatin.
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Antiserum: The antiserum was supplied as a freeze-dried aliquot which was
reconstituted to 2ml with DGDW. This intermediate dilution of 1:50 was stored in 50 
pi aliquots at -20°C. Each aliquot was made up to 20 mis with assay buffer to give 
the working dilution of 1:20000.
Radioiabei: ^^®l-aMT6s was diluted in assay buffer to give 8-10,000 cpm /lOOpl.
Charcoal stripped urine: This was supplied as lOOpI freeze-dried aliquots
reconstituted with 25ml assay buffer to give the working dilution of 1:250.
aMT6s standards: Standard was supplied as a ready diluted top standard of
200pg/ml in 1:250 charcoal stripped urine. A standard curve was constructed with 
the range of 0 to 50 ng/ml diluting the top standard in 1:250 charcoal stripped urine 
as shown below.
AMT6S Standard Charcoal Stripped Urine 1:250 aMT6s Concentration
200pg/ml (pi) dilution (pi) (ng/ml)
......... 0..................... 500 ............. b.....
5 495 0.5
10 490 1
20 480 2
40 460 4
70 430 7
100 400 10
200 300 20
500 0 50
Dextran-coated charcoai: Norit activated charcoal (2%) was suspended in tricine 
buffer for 5 minutes. After centrifugation for 15 minutes at 4°C lOOOg, the 
supernatant and any fines were discarded. The charcoal was then resuspended in 
the original volume of tricine buffer containing 0.02% dextran T70. After stirring for 
at least 1 hour at 4°C the suspension was stored at 4°C.
Assay protocoi: Quality controls and unknown samples were diluted 1:250 in
assay buffer using a Hamilton MicroLabM automatic diluter (Hamilton G.B. Ltd.,
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Carnforth, Lancashire). Total tubes, non-specific binding (NSB), standards, quality 
controls and samples were all run in duplicate except for zero standard which was 
run in quadruplicate.
Total
(Pl)
NSB
(Hi)
Standard
(Hi)
QC
(Hi)
Sample
(Hi)
Buffer 700
Standard 500
QC 500
Sample 500
Antiserum 200 200 200
Incubate for 3 ]  mins at room temperature
Radiolabel 100 100 100 100 100
Incubate overnight at 4o C
DCC 100 100 100 100
Incubate 10 mins at 4o C
Centrifuge for 15mins at 2500rpm
Decant and count pellet
500|xl aliquots of samples, quality controls and standards were pre-incubated with 
200pl diluted antiserum for 30 minutes at room temperature after mixing. 100pl ^^ ®l- 
aMT6s were then added to all tubes which were then mixed again and incubated 
overnight at 4°C. Free aMT6s was then separated from the bound fraction by 
adding 100|il dextran coated charcoal suspension. Charcoal must be added quickly 
to reduce intra-assay drift and this limits the assay size. Assay tubes were then 
centrifuged at 2500g for 15 minutes at 4°C. The supernatant was discarded and the 
tubes counted for 60 seconds in a Wallac gamma counter. aMTGs levels were 
calculated automatically. Inter-assay variation and limit of detection were calculated 
for each batch of assays performed and will be stated in the relevant chapter. Inter­
assay variation was determined by calculating the coefficient of variation for the 
three quality control samples measured in each assay. Ideally it should not be 
greater than 10%. The limit of detection is defined as the concentration of antigen 
measured by the cpm at two standard deviations of the mean zero binding tubes. 
The analytical limit of detection of the assay is 0.25 ng/ml and the functional limit of 
detection is 0.43 ng/ml (Stockgrand Ltd.).
All urine samples collected from each subject for each experiment were measured in 
two separate assays run on the same day. The assay size was kept consistent to
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reduce assay drift. Samples were assayed in duplicate and the measurements 
repeated if the duplicates varied by more than 10%.
2.4.3 RIA of Cortisol in Saliva
Cortisol levels in saliva samples were measured by radioimmunoassay (RIA) 
following a method adapted from Read (1977), Seth et al. (1978) and Riad-Fahmy 
etal. (1979).
a. Materials
Antiserum (product S004-201) was purchased from Scottish Antiserum Production 
Unit, Glasgow & West of Scotland Blood Transfusion Service, Carluke, Lanarkshire, 
U.K. The separation system, a solid phase second antibody (donkey anti-sheep) 
coated cellulose suspension, was purchased from IDS Ltd., Boldon, Tyne & Wear, 
U.K. Cortisol-3-0(carboxymethyl)oximo^^®l-iodohistamine was supplied by 
Amersham International pic., Amersham, Buckinghamshire, U.K. All other chemicals 
including cortisol (product H-4001) were obtained from Sigma Chemical Co. Ltd. 
Poole, Dorset, U.K.
b. Reagents
Buffer: 0.1M citrate / phosphate buffer pH 4.0. 13.Og citric acid, 8.9g Na2HP04 , 
1 .Og gelatin and 0.2g thiomersal were made up to 1 litre with distilled water. Buffer 
was stored at 4°C for up to one month.
Antiserum: The antiserum was supplied as a freeze-dried aliquot which was
reconstituted with 1ml of DGDW and 7ml assay buffer. This intermediate dilution of 
1:80 was stored in lOOpI aliquots at -20°C. Each aliquot was made up to 10 mis 
with assay buffer to give a working dilution of 1:8000.
Separation phase: Solid phase second antibody coated cellulose suspension,
SAC-CEL, was used directly as supplied.
Radlolabel: Cortisol-3-0(carboxymethyl)oximo^^®l-iodohistamine (74TBq/mmol
specific activity) was diluted in assay buffer to give approximately 10,000 cpm in 
lOOpl.
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Cortisol standards: A stock cortisol standard solution, at a concentration of
1 mg/ml in ethanol, was prepared from cortisol purchased from Sigma. This was 
further diluted in assay buffer to give 1500 nmol/L. 0.5ml aliquots were stored 
frozen at -20°C where they are stable for up to six months. This solution was further 
diluted in assay buffer by doubling dilutions to give working standards of 0, 1.4, 2.8, 
5.7, 11.5, 23, 47, 94, 188, 375 and 750 nmol/L.
Brij’Saiine wash solution: 0.9% NaCI, 0.02% Brij 35 was prepared by dissolving 
9g sodium chloride in 1 litre DGDW and adding 2ml Brij 35.
Assay protocol: Total tubes, non-specific binding (NSB), standards, quality
controls and samples were all run in duplicate except for the zero standard which is 
run in quadruplicate.
200pl aliquots of samples, quality controls and standards were incubated with lOOpI 
diluted antiserum and lOOpI of Cortisol-3-0 (carboxymethyl) oximo ^^^l-iodohistamine 
at room temperature for three hours after mixing. The antibody-bound cortisol was 
separated by the addition of lOOpI of SAC-CEL. The assay was incubated at room 
temperature for 1 hour with intermittent mixing. 1ml Brij-saline wash solution was 
added to all tubes except total tubes followed by centrifugation at 3000 rpm for 10
Total
(Hi)
NSB
(Hi)
Standard
(Hi)
QC
(Hi)
Sample
(Hi)
Buffer 300 150 150
Standard 50
QC 50
Sample 200
Antiserum 100 100 100
Radiolabel 100 100 100 100 100
Incubate for 3 hrs at room temperature
Solid Phase 100 100 100 100
Incubate for Ih r at room temperature with intermittent mixing
Brij Saline 1000 1000 1000 1000
Centrifuge for lOmins at 3000rpm
Decant and count pellet
minutes at ambient temperature. The supernatant was decanted immediately and 
the pellet counted for 60 seconds in a gamma counter. The cortisol content of the 
samples was read automatically from the standard curve. All saliva samples
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collected from each subject for each experiment were measured in two separate 
assays run on the same day. The assay size was kept consistent to reduce assay 
drift. Samples were assayed in duplicate and the measurements repeated if the 
duplicates varied by more than 10%. Quality controls were run in each assay and 
the inter-assay variation and average limit of detection were calculated and will be 
quoted in the relevant chapter.
2.4.4 RIA of Melatonin in Piasma
Melatonin levels in plasma samples were measured by radioimmunoassay (RIA) 
following the direct method of Fraser et al. (1983a). The assay methodology has 
been GCMS validated (Lewy & Markey, 1978; Fraser et a!., 1983b).
a. Materials
Antiserum and melatonin free plasma were obtained from Stockgrand Ltd., 
University of Surrey, U.K.; ^H-melatonin (product TRK-798, specific activity 
3.15TBq/mmol) was obtained from Amersham International pic., Amersham, 
Buckinghamshire, U.K.; 2,5-diphenyoxazole (PPG); 1,4-bis-[2-(5-phenyloxazolyl)j 
benzene (POPOP) and Toluene (low sulphur grade) were purchased from Fisons 
pic., Loughborough, U.K. All other chemicals including melatonin (product M-5250) 
were obtained from Sigma Chemical Co. Ltd., Poole, Dorset, U.K.
b. Reagents
Buffer: Except where otherwise stated all dilutions were made in tricine buffer (0.1 
mol/L) pH 5.5 containing 0.9% NaCI, 0.1% gelatin and 0.01% sodium azide made up 
in double-glass-distilled water (DGDW) warmed to 50°C to dissolve the gelatin. 
Buffer was prepared fresh each week.
Antiserum: The antiserum was supplied as a freeze-dried aliquot which was
reconstituted to 2ml with DGDW. This intermediate dilution of 1:10 was stored in 
50|il aliquots at -20°C. Each aliquot was made up to 20 mis with assay buffer to 
give a working dilution of 1:4000.
Dextran-coated charcoal: Norit activated charcoal (2%) was suspended in tricine 
buffer for 5 minutes. After centrifugation for 15 minutes at 4°C, lOOOrpm, the
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supernatant and any fines were discarded. The charcoal was then resuspended in 
the original volume of tricine buffer containing 0.02% dextran T70. After stirring for 
at least 1 hour at 4°C the suspension was stored at 4°C.
Radiolabel: A stock solution of ^H-melatonin was prepared by diluting 20pl to 2ml 
with absolute ethanol and storing at -20°C. A working solution was freshly prepared 
for each assay by further diluting with assay buffer to give approximately 5000 cpm 
in 100pl.
Scintillation fluid: The toluene based scintillant was prepared by adding 12.5g
PPO and 0.75g POPOP to 2.5 litres of sulphur free toluene.
Melatonin free plasma: Melatonin free plasma, prepared by affinity stripping
plasma collected during the afternoon, was provided in 12.5ml freeze-dried aliquots. 
Each aliquot was reconstituted by the addition of 12.5ml DGDW.
Melatonin standards: Stock melatonin standard at a concentration of 1 mg/ml in 
absolute ethanol was prepared every 3 months and stored at 4°C. The working 
standard was made freshly from this stock for each assay as follows:
lOOp11 mg/ml melatonin solution to 100ml in DGDW to give 1 pg/ml 
500pl Ipg/ml melatonin solution to 50ml in DGDW to give lOng/ml 
120fil lOng/ml melatonin solution to 2.5ml in melatonin free plasma to give 
0.5ng/ml
A standard curve was constructed with the range of 0 - 500pg/ml by diluting the top 
standard in melatonin free plasma as shown below.
Assay protocol: Total tubes, non-specific binding (NSB), standards, quality
controls and samples were all run in duplicate except for the zero standard which 
was run in quadruplicate.
500pl aliquots of samples, quality controls and standards were pre-incubated with 
200pl diluted antiserum for 30 minutes at room temperature after mixing. lOOpI of 
^H-melatonin were added and the assay incubated overnight at 4°C. The antibody-
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bound melatonin was separated from the free fraction by mixing with SOOpI of 
dextran-coated charcoal suspension. The tubes were then centrifuged at 2500g for
Melatonin Standard 
O.Sng/ml (pi)
MT free 
Plasma 
(Hi)
Melatonin Concentration 
(pg/ml)
0 500 0
5 495 2.5
10 490 5.0
25 475 12.5
50 450 25.0
100 400 50.0
200 300 100.0
500 0 250.0
15 minutes at 4°C. The resultant supernatant was decanted directly into plastic vials 
containing 4ml scintillation fluid. The vials were then shaken at room temperature 
for an hour to extract all the melatonin into the organic phase. This allows for the 
detection of radioactivity without quenching due to the presence of plasma. The 
vials were then counted for 5 min or to a total of 4000 cpm in a p counter. The 
melatonin content of the samples was read automatically from the standard curve. 
Inter-assay variation and limit of detection were calculated for each batch of assays 
performed.
Total
(Hi)
NSB
(Hi)
Standard
(Hi)
QC
(Hi)
Sample
(Hi)
Buffer 1200 700
Standard 500
QC 500
Sample 500
Antiserum 200 200 200
Incubate for 30 mins at room temperature
Radiolabel 100 100 100 100 100
Incubate overnight at 4o C
DCC 500 500 500 500
Incubate 10 mins at 4o C
Centrifuge for 15mins at 2500rpm
Decant supernatant, add 4ml scintillant
Shake for Ih r at room temperature and count
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The dim light melatonin onset (DLMO) was calculated by plotting the melatonin 
profile and taking the time at which the plasma melatonin concentration reached 
twice the limit of detection of the assay, or when levels were twice the daytime 
baseline levels, provided two further samples were above these limits.
2.5 BEHAVIOURAL MEASUREMENTS
Behavioural parameters were measured during each study but two different 
methods of recording the information were used. In early studies the Psychology 
section at the DERA was involved in the project and were responsible for this 
section of the work. Sleep logs, mood ratings and alertness were recorded on 
paper, and performance tests were done on P.C.s, all following standard DERA 
procedures. In later studies, hand held computers (Psion Organisers from Psion 
U.K., Greenford, U.K.) were used for most behavioural assessments and the mood 
rating was converted for use on a P.O. using an in-house computer program.
Programs for the Psion Organisers were written and provided by Dr P. Totterdell 
(University of Sheffield, U.K.) and Professor 8. Folkard (University of Swansea, 
U.K.). The programs have been used extensively and are recorded in many 
publications (e.g. Totterdell and Folkard 1992, Deacon and Arendt 19940 .^1995 & 
1996i,).
For completeness all methods will be described here and the actual combination 
used indicated in the relevant chapters.
2.5.1 Subjective Sleep Logs
Subjects completed a sleep log on waking after every sleep period. The questions 
asked were identical for paper or Psion recording and were as follows:
a. time of retiring to bed
b. time of trying to sleep 
0. time taken to fall asleep
d. number of night awakenings
e. estimate of total time awake
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f. time of waking up
g. time of getting out of bed
Sleep quality was assessed by a visual analogue scale (VAS) from worst sleep ever 
to best sleep ever. On paper numbers from 1 - 10  were used to indicate the quality 
of sleep, 1 being worst sleep ever and 10 being best sleep ever.
Worst Sleep Ever 1 2 3 4  5 6  7 8 9 10 Best Sleep Ever
Using the Psion organiser a VAS was used as shown below with the extreme left 
being very poor sleep and the extreme right very good sleep.
— +
Very Poor   Very Good
2.5.2 Subjective Mood Logs
Using paper, alertness was again recorded by circling a number between 1 and 10. 
1 being very sleepy and 10 very alert.
Using paper, the UWIST Mood Adjective Checklist (see Appendix 1), was completed 
every morning and evening to assess whether the conditions in the isolation unit 
were causing behavioural problems. The checklist was comprised of 45 adjectives 
which could be used to describe a person's mood e.g. bright, nervous, placid, 
fearful, angry. After each adjective there were four categories - definitely - slightly - 
slightly not - definitely not. Subjects were required to tick the category which most 
described their mood at the time of completing the list. The responses were scored 
into three categories - energy, tension and pleasure. Adjectives loading positively 
(e.g. cheerful) were given a score of 4 for definitely, 3 for slightly, 2 for slightly not 
and 1 for definitely not. Adjectives loading negatively (e.g. depressed) on a 
dimension were given scores of 1 for definitely, 2 for slightly, 3 for slightly not and 4 
for definitely not. The scores should be high for energy, high for pleasure and low 
for tension. In later studies the test was completed on a P.C. for automatic scoring 
of the answers.
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Mood ratings on the Psion Organisers consisted of three VAS scales as described 
above. The position marked on the VAS scale was recorded numerically. The
moods rated were cheerfulness ( Very sad <----------- ► Very happy), calmness ( Very
calm <------------ ► Very tense) and alertness ( Very drowsy <------------► Very alert).
All mood ratings and sleep logs are subjective and therefore liable to differences in 
interpretation between individuals. This means that subjective ratings cannot be 
compared between individuals but only within individuals, looking for changes with 
treatment or over the length of the study. There were insufficient subjects for 
normalisation of the data.
2.5.3 Daily Activity Diaries
Daily activity diaries were kept each day to indicate reasons for missing data or 
aberrant values found in the raw data. Each 24 hour day was divided into half- 
hourly segments and subjects were required to tick the box indicating the main 
activity of each period (see Appendix 1). The activities listed were:
a. meal/drink
b. shower/wash
c. exercising
d. walking about
e. sitting alert e.g. computer games
f. relaxing e.g. watching television
g. stress
h. sleep
Also noted were any ingestion of analgesics and the time the daily alcohol 
allowance was taken.
2.5.4 Performance Tests
2.5.4.1 DERA test battery
The DERA performance test battery took approximately 30 minutes and was 
reduced in length to about 10 minutes after the baseline study due to complaints
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from the subjects. An outline will be given of all the tests incorporated with 
emphasis on the tests retained for all studies.
Logical reasoning test: This is a test where A-B sentence checking was used.
A statement was made and then a group of letters was shown and the subject has 
to decide whether the statement accurately described the letter grouping.
e.g. A precedes B; BA True or false?
This test shows age-related changes, with older subjects giving generally lower 
performance and a greater susceptibility to sleep deprivation. It has been shown to 
exhibit diurnal variation (Logie and Baddeley, 1983).
Manikin (spatial transformation) test: This is a test to determine spatial ability. A 
stick figure was shown on the screen holding different shaped objects in each hand
e.g. a circle and a square. The subject was asked to indicate which hand was 
holding the square or circle by pressing designated keys on the key board.
Cognitive vigilance test: This test ran for 10 - 15 minutes and was designed to 
test performance on tasks involving sustained attention. It has been shown to be 
influenced by noise and fatigue as well as showing changes across the day and 
after meals. Numbers shown on the screen were continually changing and subjects 
had to decide when the numbers shown were identical. A second vigilance test used 
degraded numbers shown on the screen with the subject deciding when “zero” 
appeared (Craig, Davies and Matthews, 1987).
Serial reaction time test: In this test, there were 4 stimuli which appeared one
after the other in a random order. Each stimulus corresponded to a designated key 
on the keyboard and the time taken to respond and the accuracy of the response 
were measured. The speed with which each stimulus was presented was self- 
paced with a set time interval between each response and the next stimulus of close 
to zero milliseconds. This test can also be called a choice reaction time test as the 
subjects had a choice of responses not a simple yes/no. This gives a longer 
reaction time as two factors influence performance in this test - the number of 
alternative stimuli, and the speed-accuracy trade off (Debecker and Desmedt, 1970; 
Wickens, 1984).
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Sternberg memory scanning test: This test is a measure of short-term memory 
scanning time. Subjects were asked to memorise a short list (2,3,4,or 5) of non­
repeating digits presented on the screen. A fixed set of digits (the test probes) were 
shown and the subject had to indicate whether they were one of the memorised 
digits. The response time and the accuracy of the response were measured.
The mental processes involved in the test can be divided into 4 stages. Stage 1 
transforms the test probe into an internal representation. Stage 2 conducts a serial 
exhaustive comparison of the test probe with the memorised list stored in the short 
term memory. Stage 3 decides the correct response based on the previous 
comparison and stage 4 translates the decision into a response and carries out the 
response. The Sternberg test is relatively insensitive to speed-accuracy trade-offs 
(Sternberg, 1966, 1969 and 1975; Pachella, 1974).
2.S.4.2 Psion based performance tests
Only two performance tests were included in the Psion based test battery.
Serial reaction time test: This was, in essence, the same as the DERA test with 4 
stimuli corresponding to 4 keys on the keypad. However, the stimuli were displayed 
at set time intervals not self-paced intervals. Reaction time and accuracy were 
measured.
Sternberg memory scanning test: This test was very similar to the DERA test. 
The list to memorise was letters (only consonants) not digits and the set sizes were 
1,3,5 and 7 letters. The use of letters as opposed to digits gives wider variability in 
the list to memorise. Reaction time and accuracy were measured.
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CHAPTER 3
PHYSIOLOGICAL AND BEHAVIOURAL
ANALYSIS METHODOLOGY
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3.1 GENERAL ANALYSIS
The general and statistical analysis methods described here have been used to 
analyse data from all the studies in the project. Any specific variations will be 
detailed in the relevant chapter
3.1.1 Editing of Data
3.1.1.1 Activity
Wrist-mounted accelerometers (MiniMotionloggers) were worn continuously 
throughout all the studies. All data files from each subject in each study were joined 
together to give a continuous activity trace. Files were then edited directly in Actions 
( a software program from Ambulatory Monitoring Inc. U.S.A.) to replace zero 
readings with no data values when the actigraphs had been removed for washing or 
showering. Data collected in the 10 minutes before and 10 minutes after the 
actigraphs were downloaded was discarded, to remove any values collected whilst 
the actigraph was not being worn. A printout of the complete activity trace for each 
subject was produced to give a general overall impression of the sleep-wake cycle 
(see Fig 3.1).
The data was then subjected to automatic sleep scoring and cosinor, spectral and 
autocorrelation analysis using Action3 software (Ambulatory Monitoring Inc., New 
York). A chi squared periodogram was fitted to the edited data using the Tau 
program (MiniMitter Inc., Sunriver, Oregon), to determine the overall periodicity of the 
rhythms under investigation.
3.1.1.2 Temperature
Core body temperature readings were collected electronically every 6 minutes by a 
Grant Memory logger. The files were downloaded and converted to text format for 
importing directly into Excel. Data was sorted into separate columns for date, time 
and value. All “low” values i.e. < 25°C were replaced by 9999 as no value readings. 
The data was then sorted by temperature value and all readings less than 35.7°C 
replaced by 9999. 35.7°C was chosen as the minimum acceptable value as it was
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Fig 3.1 Example of a double raster plot of activity data
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the lowest temperature reached during sleep periods and therefore removed all low 
values due to displacement of the probe. Data was then resorted into chronological 
order and the temperature values saved as a .txt file adjusting the first reading to 
coincide with the corresponding actigraph recordings.
The raw temperature data readings were imported into Actions alongside the 
actigraph record. Data was then edited to remove values “masked” by exercise or 
shower according to the daily activity diaries completed by each subject. Masking of 
the endogenous temperature rhythm by exogenous factors such as exercise, 
showering and food intake is a problem when looking at core body temperature and 
will be discussed further in Chapter 5. Temperature readings within an hour of the 
end of an exercise session or shower were replaced with no data entries.
Temperature data was then subjected to cosinor, spectral and autocorrelation 
analysis using Actions, and a chi squared periodogram was fitted to the edited data 
using the Tau program to determine the overall periodicity of the data under 
investigation.
3.1.2 Sleep Onset and Offset Times
Sleep onset and offset times were identified from the sleep logs and activity diaries, 
confirmed by means of the actigraphy records. Sleep logs were not always reliable 
as a few subjects completed several days at once.
3.1.3 Automatic Sleep Scoring
Actions software includes an option to automatically sleep score from the activity 
trace. Automatic sleep scoring uses a general activity-to-sleep algorithm based on 
the activity data collection epoch length. The algorithm uses a method published by 
Cole et al. (1992) which in a normal population gives >80% correlation with 
polysomnography, when calculating the time spent asleep. Constants used in the 
calculation are device and activity channel specific. The constant coefficients are 
used in an equation to generate a sleep or wake score for each one-minute epoch. 
The equation weights each activity minute from 4 minutes before the epoch in 
consideration to 2 minutes after the epoch, and then sums the weighted values. This
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figure Is then adjusted by the device and channel constants to give a final value. If 
the resulting value is > 1 the epoch is scored as wake while values less than 1 are 
scored as sleep.
Time spent in bed was marked manually on the activity traces with reference to the 
subjective sleep logs, activity diaries and event mark channel. Subjects were 
requested to press the event marker button on the actigraph when retiring to bed and 
on getting up in the morning but this was not always done.
These in bed intervals were then automatically sleep scored and the results saved to 
file. The information given was total time spent in bed, total sleep time, number of 
night awakenings, duration of night awakenings (wake after sleep onset) and sleep 
efficiency.
3.1.4 Cosinor Analysis
Circadian rhythms can be described not only by their period (i.e. time taken for the 
rhythm to complete a whole cycle) but also by their amplitude and mean level. The 
terms used to describe the various features of a circadian rhythm are illustrated in 
Figure 3.2.
Amplitude
Period
Mesor
(mean value)
TimeAcrophase 
(time of peak) Nadir
(time of minimum)
Fig 3.2 Terms associated with a circadian rhythm
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Whilst these values can be determined roughly from the raw data this can lead to an 
error in interpretation depending on the frequency of the data points. Single aberrant 
points may completely distort the overall picture. The larger the number of data 
points the clearer the rhythmic profile is.
In this project, the aim was firstly to compare acrophases (time of peak value) from 
different days, to determine whether or not there was a gradual change in the 
acrophase time in the rhythms under investigation; secondly, to ascertain whether 
there was a change in the amplitude of the rhythms over the study period and with 
the different study conditions or treatments. For this reason a clear repeatable 
analysis method was needed to determine rhythm parameters for further 
investigation.
An accepted method of rhythm analysis is to fit a curve of “best fit” to a series of data 
points. This can take into account a certain percentage of missing or irregular data 
points. Cosinor analysis is a curve fitting procedure that assumes the rhythm is 
sinusoidal in shape and fits the best-fitting cosine curve to the data by the method of 
least squares (Nelson et al., 1979, Minors and Waterhouse, 1989). This analysis 
method gives estimates of the amplitude, acrophase, mesor (mean concentration 
within the period), percentage rhythm and confidence limits. Cosinor is the only 
rhythm analysis method in common use which gives a value for all these features.
The analysis method makes two estimates of “goodness of fit” which are used to 
determine the validity of the cosinor derived parameters of acrophase time and 
amplitude. The first is the percentage variability in the data accounted for by the 
cosine curve and is given as a percent rhythm. A 100% rhythm would mean that all 
data points fall on the curve so the larger the percentage the better the fit. The 
analysis also checks on the likelihood of the data points fitting a straight line as 
opposed to a cosine curve or how probable it is that the data could fit the cosine 
curve by chance. A “significant fit” to the cosine curve is deemed to be when there is 
< 5% probability that the data would fit a straight line i.e. p = <0.05. This figure is 
derived by a comparison of variances - the variance of the fitted data about the 
cosine curve and the variance of the cosine curve about its mesor.
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To use cosinor analysis the period of the curve must be known or assumed and for 
this project it was assumed to be 24 hours throughout. However, the period to be 
tested by the cosinor analysis can be altered and by subjecting sections of data to 
periods varying in length by, for example, 0.1 hour it is possible to find the periodicity 
which best describes the data set by giving the highest percentage rhythm and lowest 
probability of a straight line.
Cosinor analysis can also be used to investigate the rhythm parameters of integrated 
samples, e.g. urine samples, collected over a measured time period. This was 
important in these studies as integrated urine samples were collected for 
measurement of 6-sulphatoxymelatonin (aMTGs), the major metabolite of melatonin. 
It was important to measure aMTGs as it exhibits a clear circadian profile which is little 
affected by exogenous factors with the exception of bright light, and to a small extent 
posture, although it can be episodic. Since lighting levels were controlled in all the 
studies, the aMTGs rhythm should be essentially unmasked during the constant dim 
light experiments, therefore giving the most accurate measure of any change in 
period throughout these trials. During the variable light studies and the combined 
melatonin and light experiment the timing and intensity of the light dark cycle was 
known, and therefore could be taken into account.
The major limitation of cosinor rhythm analysis is that it assumes the rhythm fits a 
cosine curve, although some circadian functions do not. External conditions may 
also change the inherent shape of the rhythm. These include transmeridian air travel 
and shift-work where rapid large changes in phase are forced on the individual. In 
this project any change in rhythm would be gradual making cosinor analysis more 
applicable. The length of the data sets available for analysis increases the probable 
accuracy of the results since the effect of aberrant data on some days would be 
reduced. The core body temperature rhythm closely resembles a cosine curve 
especially in the free-running conditions of partial temporal isolation and low light 
levels pertaining to most of the studies reported here. The activity-rest or sleep- 
wake rhythm does not closely resemble a cosine curve. It is essentially a square 
wave with a rapid transition between sleep (no activity) and wake (high activity). This 
is reflected in the fact that the “goodness of fit” to a cosine curve was low for activity 
(30-50% on average) compared to core body temperature (70-90% on average) even 
though the probability of a straight line was low (>0.00001).
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other methods of rhythm analysis are available and have been compared for their 
suitability in determining rhythm parameters. (Klemfuss and Clompton, 1993 and 
Refinetti, 1993). Much of this comparison has been done on artificially generated 
data for running wheel activity from hamsters or rats. This is a rhythm which shows a 
rapid change from low activity to high activity and therefore would not be expected to 
closely fit a cosine curve. Klemfuss and Clompton compared both temperature data 
and wheel running activity and found good correlation between cosinor analysis and 
both modified periodogram and harmonic analysis in determining the overall period or 
tau (x) of the data. As cosinor analysis is the only method which gives an estimate of 
the amplitude of the rhythm, a parameter of interest for this investigation, it was 
decided to use regressive cosinor analysis as the method of choice (see section 
3.2.1). However, whenever possible a comparison has been made with spectral, 
periodogram and autocorrelation analysis.
Acrophase times, amplitudes and overall periodicities determined by cosinor analysis 
were subjected to further statistical analysis.
3.1.4.1 Comparison of cosinor analysis programs
There are many cosinor analysis programs available. For this project the programs 
used were Action3 software from Ambulatory Monitoring Inc., New York, U.S.A. and a 
program written by Dr David Minors, University of Manchester, U.K. The Action3 
software was written for the analysis of activity data whilst the program written by Dr 
Minors was primarily for temperature data but was not suitable for use with the long 
data sets obtained for each individual in the studies reported here. The program 
could only process 7000 data points, requiring the data series to be split in two. A 
comparison was made between the two programs using the cosinor analysis of 
temperature data collected during the baseline study (Chapter 5).
Raw temperature data was edited as described in section 3.1.1 and imported into the 
two cosinor programs. Data was subjected to single day and 3 day moving window 
cosinor analysis as described in section 3.1.4.2.
The results obtained were not significantly different for amplitude, mesor and 
acrophase times for either single day or 3 day moving windows analysis. The only
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difference seen was in the “goodness of fit” or percent rhythm parameter. This 
difference was due to the way of expressing the “goodness of fit”. Actions expressed 
it as the correlation coefficient, multiple R, giving the variance in the data. Dr Minors 
cosinor program quotes the “goodness of fit” as the proportion of variance in the data 
that is explained by the form estimate, i.e. the cosine curve, which is the square of 
multiple R, (R^) and consequently a lower value.
For ease and consistency of analysis Actions was used to perform all cosinor 
analysis on activity and temperature data series. aMTGs data was analysed using a 
cosinor program for urinary data supplied by Dr Minors.
3.1.4.2 Comparison of data bin sizes for analysis
3.1.4.2.1 Activity, temperature and aMTGs
Cosinor analysis can be applied to data bins of any length and gives the acrophase 
time for the first period under consideration. For example if the data for analysis is 
from 01:00 23/09/94 to 01:00 2G/09/94 the acrophase time given will be for 23/09/94. 
Using 3 day moving windows for cosinor analysis causes a smoothing of the data 
and, therefore, it could be argued that a distorted result is obtained. The analysis 
package used assigns equal weighting to all 3 days included in the data bin for 
analysis i.e. weighting 1:1:1. Other data bin sizes possible are single day cosinor, 2 
day non-overlapping windows and 3 day non-overlapping windows. Using Action3 
software cosinor analysis was performed on activity and temperature data collected 
from G subjects over a 21 day period to compare the various data bin sizes. The 
same analysis was carried out on aMTGs data using a cosinor program for urinary 
data from Dr Dave Minors (University of Manchester, U.K.).
Data bins analysed: a. single day
b. 3 day moving window (i.e. D1,2,3; D2,3,4; D3,4,5 etc.)
c. 2 day non-overlapping (i.e. D1,2; D3,4; D5,G etc.)
d. 3 day non-overlapping (i.e. D1,2,3; D4,5,G: D7,8,9 etc.)
The period or tau (x) calculated by linear regression analysis (see section 3.2.1) of 
the acrophase times determined by each method was subjected to 2 way analysis of 
variance with subject and analysis method as the variables. This statistical test
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determines whether the variance between the variables is significantly greater than 
the random variation within them.
Activity, temperature and aMTGs periodicities showed significant differences between 
subjects but no significant differences between the analysis method used (see Tables 
3.1 and 3.3).
All cosinor analysis for each study within the project was performed using 3 day 
moving windows as there were no differences between the data bin sizes, but 3 day 
moving window cosinor analysis smoothes the data and gives a higher percentage of 
significant fits.
3.1.4.2.2 Sleep parameters
Sleep onset and offset times determined by comparison of the actigraph traces and 
subjective sleep logs were analysed using varying data bin sizes. Analysis of the 
total time in bed, total sleep time, wake after sleep onset (WASO) and sleep 
efficiency, determined by automatic sleep scoring of the “in bed" intervals using 
Action3 software, was carried out using the same data bin sizes.
Data bins analysed: a 
b 
c 
d
Single Day
3 Day moving average (i.e. D1,2,3; D2,3,4: D3,4,5)
2 Day non-overlapping average (i.e. D1,2; D3,4; D5,G)
3 Day non-overlapping average (i.e. D1,2,3: D4,5,G)
The derived sleep onset and offset times were subjected to linear regression analysis 
to estimate the periodicity of the sleep-wake cycle. The periods or tau (t) determined 
by each method were subjected to 2 way analysis of variance with subject and 
analysis method as the variables.
The calculated variations in time in bed, total sleep time, wake after sleep onset and 
sleep efficiency, over the study period, for each method of analysis were also 
subjected to linear regression.
Data was analysed over the entire study period (20 days), and excluding the days 
where a clear “end effect” (see Chapter 5) was seen in some subjects (15 days).
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Table 3.1 Summary of periodicities derived by regression analysis of 
different data bin sizes. Data were collected from the baseline 
study (n=6), Chapter 5.
Grouped results Days Activity P Temperature P aMT6s P
1 -20
3 Day Moving Window 24.20 ± 0.08 1.88E-05 24.30 ± 0.03 1.83E-16 24.26 ± 0.04 2.21 E-11
Single Day 24.17 ±0.09 0.001 24.23 ± 0.04 3.84E-10 24.26 ± 0.07 2.82E-07
2 Day no overlap 24.18 ±0.11 0.0055 24.23 ± 0.06 3.28E-05 24.27 ±0.10 0.0003
3 Day no overlap 24.28 ± 0.04 3.57E-05 24.26 ± 0.05 0.0001 24.32 ±0.14 0.003
Grouped Results 1-15
3 Day Moving Window 24.30 ± 0.08 1.36E-06 24.32 ± 0.04 1.03E-10 24.22 ± 0.06 2.92E-06
Single Day 24.27 ±0.12 0.0002 24.28 ± 0.06 1.77E-07 24.27 ±0.11 0.0001
2 Day no overlap 24.29 ± 0.07 2.64E-05 24.27 ± 0.08 0.0001 24.30 ±0.18 0.0057
3 Day no overlap 24.29 ± 0.07 0.0008 24.28 ± 0.08 0.027 24.33 ± 0.24 0.022
Grouped results Days Sleep onset P Sleep Offset P
1 -20
3 Day Moving Window 24.11 ±0.06 0.0018 24.18 ±0.07 5.09E-05
Single Day 24.12 ±0.09 0.015 24.23 ± 0.08 1.99E-05
2 Day no overlap 24.13 ±0.11 0.023 24.25 ±0.12 0.001
3 Day no overlap 24.20 ±0.14 0.016 24.31 ±0.12 0.0017
Grouped Results 1-15
3 Day Moving Window 24.24 ±0.11 0.0003 24.33 ± 0.07 8.03E-08
Single Day 24.24 ±0.13 0.001 24.36 ± 0.07 6.35E-08
2 Day no overlap 24.22 ±0.14 0.009 24.36 ± 0.06 6.57E-06
3 Day no overlap 24.24 ± 0.20 0.03 24.38 ± 0.02 1.14E-05
Data was analysed over the entire study period (20 days), and excluding the days where a 
clear “end effect” (see Chapter 5) was seen in some subjects (15 days).
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There was no significant difference between the methods of analysis but there was a 
significant difference between subjects (see Tables 3.1, 3.2 and 3.3 for detailed 
results).
Table 3.2 Summary of changes each day in sleep parameters derived by 
analysis of different data bin sizes. Data were collected from 
the baseline study (n=6), Chapter 5.
Grouped Results 1-20 Time in Bed (h) Totai Sleep Time (h) WASO (min) Sleep Efficiency (%)
3 Day Moving Window 3.76 ± 2.48 0.005 0.15 ±2.19 0.889 3.61 ± 0.59 1.81 E-10 -0.53 ± 0.07 2.96E-11
Single Day 4.76 ± 3.79 0.017 0.92 ± 3.55 0.591 3.24 ± 1.95 0.0026 -0.46 ±0.16 1.03E-05
2 Day no overlap 1.91 ±5.75 0.465 0.77 ± 3.64 0.634 3.33 ± 1.46 0.0007 -0.47 ±0.19 0.0004
3 Day no overlap 4.82 ± 8.28 0.180 1.33 ±7.31 0.638 3.49 ± 1.98 0.008 -0.46 ± 0.27 0.007
Grouped Results 1-15
3 Day Moving Average 7.05 ± 3.31 0.0005 3.45 ± 0.013 3.60 ± 1.09 7.75E-06 -0.38 ± 0.24 0.004
Single Day 7.21 ±6.17 0.025 3.82 ± 0.154 2.44 ± 3.24 0.128 -0.46 ±0.12 6.81 E-07
2 Day Average no overlap 6.09 ± 6.91 0.07 3.20 ± 0.171 2.86 ± 2.42 0.027 -0.36 ± 0.28 0.017
3 Day Average no overlap 7.26 ± 12.74 0.167 4.32 ± 0.249 2.94 ±3.09 0.057 -0.32 ±0.18 0.012
1
Data was analysed over the entire study period (20 days), and excluding the days where a
clear “end effect” (see Chapter 5) was seen in some subjects (15 days).
Table 3.3 Significant differences between methods of determining tau
Baseline study (n=6), Chapter 5.
Parameter Difference (p) 
Between Subjects
Difference (p) 
Between Analysis Method
Activity 
Temperature 
aMTGs 
Sleep Onset 
Sleep Offset
2.07 E-07 
1.47 E-07 
0.0003 
1.72 E-08 
4.94 E-11
0.8G97
0.8G55
0.4188
0.3273
0.2837
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No significant difference was seen in the results obtained using the various data bin 
sizes for any sleep parameter. Single day values were used for analysis in each 
study. This results in a more accurate representation of the data and more points per 
data series for inclusion in the analysis.
3.1.5 Spectral Analysis
Spectral analysis can be used to investigate the overall period of a set of data 
collected over a long, continuous time period where values are collected at regular 
time intervals. Thus, it is a useful analysis tool where the period is unknown, unlike 
cosinor analysis where the period is assumed. The study conditions throughout this 
project are considered to be free-running conditions with weakened zeitgebers and 
consequently will give rise, in most subjects, to a period in excess of 24 hours. 
Spectral analysis would give an accurate estimate of this period.
A spectral analysis can be performed using Actions software from Ambulatory 
Monitoring Inc. A limitation of this program is that the spectral density plot requires a 
continuous string of data points with no missing or deleted data. If the data string 
does contain deleted or missing data points they are automatically replaced with the 
mean value of the series. This is not problematical if only a small number of data 
points are missing. However, the analysis may be substantially altered by large 
blocks of missing or deleted data. To minimise this limitation the data selected for 
spectral analysis must be carefully screened. The form of spectral analysis 
performed is maximum entropy spectral analysis (MESA).
The basis of spectral analysis is that values recorded at set time intervals are 
selected together and their mean and standard deviation are calculated. If the time 
interval or period (X) under investigation is present in the data series then a set of 
points separated by X hours will be at the same phase of different cycles. This set of 
points will show a low variance about its mean value, but will show large differences 
with sets of points taken at other phases of the cycle. If there is no dominant period 
(X) present in the data then the mean values of all data sets will show a large 
variance about the mean and the mean values of all the data sets will not show much 
variation since they will all be a mixture of phases. The relationship between the 
period and these measures is the basis of power spectrum analysis. The dips in
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variance or peaks in amplitude are taken to represent the most probable period(s) 
present in the data.
A graphical representation of this analysis is drawn by plotting the power of the 
various trial periods as a “wavelength” or time series. The power of any period is 
calculated by expressing the standard deviation of the column means as a proportion 
of the standard deviation of the entire series. A number of peaks can be shown in 
the plot indicating the presence of ultradian or infradian rhythms.
Actions software is used to generate a display of the spectral power across a range 
of frequencies. The spectral analysis option involves several control parameters 
which exhibit complex interrelationships and need to be optimised to give the best 
results. The data series must be long enough to contain several cycles of the 
frequency of interest, in this instance a minimum of 4-5 days. The display frequency 
used is 36 hours as the period of interest is 23 - 26 hours (the power of one cycle per 
day would appear as a 24 hour wavelength). Noise is a problem with spectral 
analysis, leading to a large number of peaks which may mask the dominant period. 
The best results are achieved with a lower number of data points per frequency of 
interest - for a frequency of 24 hours, 24 (hourly) data points give a smoother result 
than 1440 (every minute). The highest frequency that can be estimated is one-half 
cycle per input data point i.e. 2 hours with hourly data points.
The number of data epoch spans for which spectral coefficients are generated also 
influences the result. The most accurate results are achieved when the number of 
data epochs considered covers 2 to 3 cycles of the frequency of interest. For a 
frequency of 24 hours the optimum number of data epochs is between 48 and 72. 
Using this low number of data epochs produces a smoother plot whilst higher 
numbers tends to produce more or sharper spectral peaks. In illustration of this the 
following range of results were obtained from one set of data, see Table 3.4.
The settings used for all the spectral analysis in this project was a data epoch of 
3600 seconds and the number of data epochs of 60 as is recommended for a 
frequency of 24 hours (Action3 software manual). It can be seen from Table 3.4 that 
extremes of these settings will give different results. Decreasing the number and size
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of the data epochs lessens the amplitude and broadens the peak resulting in an 
increase in the range of the calculated tau.
Table 3.4 Variation in results from spectral analysis
Overall Period Amplitude No. data epochs in analysis
24.36 31514.11 20
24.13 341497.09 60
24.13 1206452.88 200
24.13 606849.06 360
24.09 3680489.75 480
Overall Period Amplitude Length of data epoch (secs)
24.40 94393.82 1200
24.13 149144.36 2400
24.13 341497.09 3600
24.13 310793.69 4800
24.13 276590.38 6000
3.1.6 Periodogram Analysis
Periodogram analysis, which can be used to determine the overall period of a rhythm, 
has been the method of choice for animal studies for many years. This is because 
the rhythms which have been studied most extensively are those of wheel running in 
hamsters or rats. This is a square wave rhythm with definite onsets and offsets of 
activity and not a cosine curve.
Periodogram analysis uses the whole data series under investigation and folds the 
time series with a different cycle duration for each trial value of tau. For each fold 
period, observations with the same phase are averaged to produce a waveform 
called a form estimate. The form estimate which best describes the data is selected 
as the best waveform and the fold period is taken as the estimate of tau. A 
periodogram is the plot of the estimate of power as a function of period. The plotting
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of the periodogram allows the relative strength of each period to be seen leading to 
the identification of infradian and ultradian rhythms.
The Tau (MiniMitter Inc., Sunriver, Oregon), program used, performs chi-squared 
periodogram analysis looking for periods between 0 and 96h. In plotting the 
periodogram the value of each data point is the variance of a given periods’ values 
divided by the variance of the entire data set. Thus, the whole data series is used to 
determine the period. The significance of the period (p=0.05) is indicated by a 
diagonal line based on the chi-squared statistic.
Only activity and temperature data were subjected to periodogram analysis as the 
method requires frequent data points at regular intervals.
3.1.7 Autocorrelation Analysis
Autocorrelation is another method of determining the overall tau of a data series and 
can be performed using the Actions program from Ambulatory Monitoring Inc.. 
Autocorrelation as an analysis method is based on the premise that in any data 
series, if a rhythm exists, then the data points in a subset of a given length will have 
the highest correlation with the next subset if the length chosen is the true period of 
the data. Therefore, the period with the highest correlation coefficient must be the 
true period. The correlation coefficients are calculated for a range of periods, (0-48h) 
and plotted graphically. This analysis method again only gives an estimate of the 
overall tau of the data set and may show up ultradian oscillations. It does not give 
any information about phase or amplitude of the rhythm under investigation. Only 
activity and temperature data were subjected to autocorrelation analysis as the 
method is best used with frequent data points.
In conclusion it can be said that cosinor and spectral, periodogram and 
autocorrelation analysis can be used to compliment each other. Cosinor gives an 
accurate measure of the amplitude and phase of the rhythm when a significant fit is 
obtained, whilst regressive cosinor, spectral, periodogram and autocorrelation 
analysis give a measure of the overall period of the rhythm.
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3.1.8 Performance Data
The collection of performance data was the only imposed regime during all the 
studies involved in this project. Determination of any detrimental effects on 
performance caused by the lighting regime or melatonin treatment was a very 
important component of the study. Whilst rhythms can be detected in performance 
they tend to have low goodness of fit and may lack any clearly defined phase 
characteristics, a fact which is accentuated by the low number of test sessions 
collected throughout the day (maximum 7/8 assuming a 16h wake, 8h sleep 
schedule) and the absence of any values for the overnight or sleep period. 
Consequently all analysis of performance data was aimed at ascertaining any change 
in mean daily performance level across the study period.
Daily means were calculated for the accuracy, response time and efficiency of each 
performance task carried out. Accuracy is the percentage of correct responses; 
response time is the time taken to complete the task and efficiency is the 
accuracy/square root of the response time. The daily means across the study period 
or across the various treatments were subjected to statistical analysis by analysis of 
variance (ANOVA). Grouped analysis is difficult to perform as individual performance 
varies greatly with some individuals being naturally slower and more accurate and 
others tending to be faster and less accurate. Therefore, for any grouped analysis 
values were calculated as a percentage of the individual baseline (mean of first 3 
days) values.
On examination of the results from the analysis of performance data collected during 
the baseline study (Chapter 5), melatonin administration study (Chapter 6), 200 lux : 
1000 lux Experiment 2 (Chapter 7), and light and melatonin administration study 
(Chapter 8) it became apparent that in spite of prior practice sessions there was a 
very clear learning effect across the first 10 days of the majority of the studies. This 
clearly influenced any more detailed analysis to determine any effect of study 
condition or treatment.
This learning effect is illustrated by results from the melatonin administration study 
(Chapter 6) shown in Fig 3.3 - 3.5. In this study subjects completed two legs with 
Placebo Days 1-15 (Placebo 1st): Melatonin Days 16-30 (Melatonin 2nd) or Melatonin
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Fig 3.3
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Fig 3.4
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Fig 3.5
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Days 1-15 (Melatonin 1st): Placebo Days 16-30 (Placebo 2nd). The reaction time for 
the serial reaction time test was calculated for each individual as a percentage of the 
mean reaction time from the first three days of both legs of the study. This was done 
as an attempt to minimise the training effect. Fig 3.3 illustrates the difference in 
reaction time between Placebo 1st on leg 1 and Placebo 1st on leg 2 and between 
Melatonin 1st on leg 1 and Melatonin 1st on leg 2. A decrease of 50% in the reaction 
time can be seen across the first 15 days of leg 1 which is not mirrored in leg 2. 
However, the individuals in the two groups on each treatment were different. A 
comparison was then made between the same group of subjects on each leg as 
shown in Fig 3.4. A significant decrease (ANOVA) in reaction time can be seen 
across the first 16 days for both groups during leg 1, with no significant decrease in 
reaction time across the first 16 days on leg 2. Fig 3.5 illustrates the learning effect 
very clearly as the reaction time curves are almost identical for both Placebo 1st leg 
and Melatonin 1st leg 1 and Placebo 1st leg 2 and Melatonin 1st leg 2.
There was less influence of training when accuracy and efficiency were considered 
and also on the parameters measured for the Sternberg memory scanning test, but 
an effect was still present. Consequently the results of the performance analysis will 
not be considered further here. The data will be analysed using specific 
mathematical procedures designed to smooth out the learning effect.
3.2 STATISTICAL ANALYSIS
3.2.1 Linear Regression Analysis
Cosinor analysis (see section 3.1.4) gives measures of the phase of the rhythm under 
analysis including the time of the acrophase or peak value. Daily changes in the 
acrophase times can be used to determine the period of the rhythm. To achieve this 
a continuous data record of several cycles is needed. The longer the data series the 
more accurate the calculated period unless it changes due to a phase-shift.
The acrophase times for activity, core body temperature and aMT6s rhythms 
determined by 3 day moving window cosinor analysis were subjected to linear 
regression analysis to give an estimate of the period or tau of the rhythms under 
investigation. The use of linear regression analysis makes several assumptions
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about the data. Firstly, that the periodicity is close to 24h, secondly that the 
acrophase times change by the same amount each day, and thirdly that under the 
experimental conditions the shape of the curve remains constant and is not altered by 
any change in the phase relationship between the endogenous rhythm and external 
factors.
Linear regression analysis fits a straight line through the data points under 
consideration by the method of least squares. The analysis looks at how a 
dependent variable (acrophase time) is affected by an independent variable (study 
day). The slope of the line is a measure of the change in acrophase time for each 
day e.g. if the slope is 0.25 the period of the rhythm would be 24.25. The correlation 
coefficient is a measure of how closely the values under consideration fit the line. 
The value can range from +1 to -1 corresponding to a 100% positive correlation or 
100% negative correlation respectively. A probability (p) value is given to indicate 
whether there is a significant difference in the acrophase times across the study days 
(i.e. the slope is not zero). Finally, levels are given for the 95% confidence limits of 
the fitted straight line giving upper and lower limits within which 95% of values of 
acrophase time would be expected to fall.
In this project only acrophase times which by cosinor analysis had a probability of 
<0.05 and a percentage rhythm > 40% for activity and > 70% for core body 
temperature and aMT6s were used in the linear regression analysis. Fitting a 
regression line to cosinor data is called regressive cosinor analysis.
Linear regression analysis was carried out on the raw daily sleep onset and offset 
times to ascertain whether they exhibited a periodicity in excess of 24 hours. The raw 
sleep data from automatic sleep scoring of total sleep time, total time in bed, wake 
after sleep onset and sleep efficiency were also subjected to linear regression 
analysis.
The analysis was carried out on both individual data and grouped mean values. 
Periodicities determined by linear regression analysis of acrophase times were 
considered to be significantly different from 24 hours if p = < 0.05 and the upper and 
lower limits at 95% confidence did not overlap 24.00 hours.
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3.2.2 Repeated Measures ANOVA
Linear regression analysis gives a measure of the significance of the period of the 
rhythms under analysis on both an individual and group basis. Repeated measures 
ANOVA can be used to give a more stringent test of the significance of differences in 
group data, the significance level being <0.05. This analysis can only be performed 
on group data, not on individual data.
The acrophase times and sleep parameter values are measured over a number of 
days i.e. repeated measurements of each parameter are taken under the same 
conditions. Thus, the repeated measures recorded from the same subject are 
correlated to each other. Effects involving only the repeated measure (i.e. day) 
are known as within subject effects; whilst effects averaged over subjects and days 
are between subject effects. A drawback of this analysis is that if there are missing 
values for the repeated measure then all of the variables for that subject will be 
removed from the analysis. This results in the population number being reduced. 
This problem was overcome by substituting the mean value of the two figures either 
side of any missing data to complete the series. Repeated measures ANOVA gives a 
measure of the significance of the variation in the repeated measure (e.g. acrophase 
time) with respect to the dependent variable (i.e. study day).
Repeated measures ANOVA was also used to determine significant differences 
between subjects and treatments.
3.2.3 Post hoc Tests - Duncan’s New Multiple Range Test
Post hoc tests can be carried out on the results derived by repeated measures 
ANOVA. The repeated measures ANOVA will give a measure of the significance of 
change in acrophase time across the study period. Post hoc tests such as Duncan’s 
new multiple range test indicate which subjects or treatments are significantly 
different from each other.
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3.3 SUMMARY OF ANALYSES PERFORMED
The same general analysis procedures were carried out on data collected from all the 
studies involved in the project. They can be summarised as follows:
a. edit all temperature and activity data.
b. perform 3 day moving window cosinor analysis on activity, temperature and 
aMT6s data.
c. automatically sleep score "in bed” intervals using Action3 software
d. perform linear regression analysis on acrophase times and sleep 
parameters determined in b and c.
e. perform spectral analysis on activity, temperature and aMT6s data and 
sleep onset and offset times.
f. perform chi-squared periodogram and autocorrelation analysis on activity 
and temperature data.
g. perform repeated measures ANOVA and Post hoc tests on data showing 
any significant variations across the study or with the treatment.
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CHAPTER 4
TECHNIQUES USED TO DEMASK
CORE BODY TEMPERATURE
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/
4.1 INTRODUCTION
The acute changes produced in an underlying endogenous rhythm by the direct 
action of exogenous factors is termed “masking” (Wever, 1985; Aschoff, 1988; Minors 
and Waterhouse, 1988 & 1989) and can be a major impediment to the study of the 
characteristics of the endogenous clock. Core body temperature (Tc) is the rhythm 
most frequently used as a phase marker for the endogenous clock. However, the 
human temperature rhythm is affected by many external influences due to behaviour. 
Exercise, meals and showers can all cause an increase of core body temperature, 
while sleep has a negative effect causing a decrease. Activity causes an increase in 
temperature primarily by raising adrenaline levels and energy consumption which 
results in internal heat production and radiation (Moog and Hildebrandt, 1986). Food 
intake results in a rise in gastrointestinal activity and provision of metabolic fuel which 
probably accounts for the postprandial increase in temperature. It has been 
suggested that the size of the increase varies with the food composition (Hildebrandt, 
1985). The circadian variation in core body temperature has been shown to be a 
consequence of endogenous circadian rhythms in heat production and heat loss 
which are opposite in phase (Krauchi and Wirz-Justice, 1994).
Various methods have been developed for “demasking” the endogenous temperature 
rhythm. Under normal nycthemeral conditions the two components (endogenous and 
exogenous) are closely linked and thought to be approximately of equal size and 
additive (Folkard, 1989). Two experimental methods have been used to separate 
them. These are constant routines originally described by Mills et al, (1978a); 
Czeisler et al. (1995b); Moog and Hildebrandt (1986) and Krauchi and Wirz-Justice 
1994) and desynchronisation experiments (e.g. Wever, 1979; Mills et al., 1977 and 
Klerman et ai, 1996).
During a constant routine individuals are maintained under constant conditions which 
can vary between protocols. Mills et al. (1978a), kept their subjects seated in 
constant lighting, temperature and humidity, with identical snacks every hour. The 
constant routines of Moog and Hildebrandt, (1986) and Czeisler et al. (1995b) were 
similar but required subjects to undergo constant bedrest, with Moog allowing his 
subjects to sleep whereas Czeisler did not. The constant routine most commonly in 
use at present is that of Czeisler. I
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I The constant routine is a very useful experimental tool
when investigating the acute effects of a particular experimental protocol. Constant 
routine evaluation before and after experimental manipulation allows any change in 
the endogenous rhythm to be calculated.
Constant routines are not practical when long experimental protocols or field studies 
are performed. An alternative method of demasking is required, and mathematical 
analysis can be used. A mathematical model was developed based on the internal 
desynchronisation seen in the isolation experiments of Wever (1979). This model 
assumed that for internal desynchronisation to occur there must be two van der Pol 
oscillators which regulate the temperature and the rest activity cycle, and that both 
these oscillators are influenced by a third factor - the external zeitgeber (Kronauer et 
al, 1982; Gander et al. 1984a, 1984b). A similar model using van der Pol Oscillators 
has been developed for use in the study of irregular sleep-wake schedules (Gundel 
and Spencer, 1992). A different type of mathematical model, regression (Spencer, 
1989), has been developed to incorporate corrections for the time since sleep offset 
and the time since sleep onset, as the temperature rhythm is greatly influenced by 
the sleep-wake cycle. All these methods are extremely complex and require 
advanced mathematical knowledge to apply them correctly.
Simpler mathematical models have been developed using data collected under 
constant routine conditions, whereby the effect of various zeitgebers or phase-shifts 
on the recorded temperature data can be predicted (Brown and Czeisler 1985 & 
1992;). All the methods use the same basic principles. Temperature values collected 
under constant routine conditions are compared to those collected under nycthemeral 
conditions. The variation between the two curves is assumed to be due to the 
“masking” effect. The calculated differences can then be used as correction factors 
and applied to data collected under experimental or field conditions when behaviour 
is recorded (Minors et al, 1994; Folkard 1989; Carrier and Monk 1997).
In some studies reported here the protocol has included administration of exogenous 
melatonin. Melatonin, is known to acutely suppress core body temperature (Cagnacci 
et a/., 1992; Deacon et al., 1994; Dollins et al., 1994 and Strassman et al., 1991). 
Recently Dijk et al. (1997) have shown that melatonin causes a reduction in core 
body temperature irrespective of the rest-activity cycle during a forced desynchrony
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study. Consequently, this needs to be taken into account when “demasking” the 
temperature data from studies involving melatonin administration.
All temperature “demasking” reported here followed the method of Folkard (1989) 
and a correction factor for melatonin administration was applied where appropriate.
4.2 METHODOLOGY
Temperature data collected during the melatonin administration study (Chapter 6), 
the fragmented sleep study (Chapter 9) and 200:1000 Lux Experiment 2 (Chapter 7) 
were “demasked” using the following procedures based on the method of Folkard, 
1989.
1. Continuous temperature data for each individual from every study was recorded 
via a rectal probe and squirrel memory logger (Grant Instruments, Cambridge, 
U.K.) with readings every 6 minutes.
2. Data was converted into ASCII files and imported into a spreadsheet for editing. 
All “low” values and those below 35.7° C were converted to give no data readings. 
This removed all data collected when the temperature probe was not being worn 
or was not inserted correctly. The time of the first data point was adjusted to 
coincide with the actigraph record for the same subject.
3. The corrected temperature data was imported into Action3 software alongside the 
actigraph record. Using the information recorded in the activity diaries the 
temperature values were edited to remove all values affected by exercise or 
showers.
4. Edited data was processed to give hourly mean values. Mean values were 
calculated so that the value fell on the hour, every hour. These values were 
retained as the “Masked Hourly Means” and were “demasked” using various 
correction factors.
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5. Correction factors for sleep-wake were supplied by Prof. S. Folkard (Swansea) 
and were based on a normalised endogenous temperature curve derived from 
data collected by Aschoff and Wever, (1980). Rhythms were averaged over a 
number of different studies. Temperature data were collected under three 
different experimental conditions. These were :
“normal” 24h activity/rest cycle, 16h wake, 8h sleep.
i. “sleep deprivation” with constant activity over 24h.
ii. “continuous bedrest” where there was minimal activity, but a normal 
wake/sleep cycle.
The effect of activity on the temperature values was deduced by comparing the 
curves produced under these differing conditions. Between 1200 and 2200 the 
“normal” and “sleep deprivation” curves were identical, and the changes in them 
were paralleled by the “bedrest” values. The difference from “bedrest” in the 
temperature curves was therefore the equivalent of the masking effect of activity 
(0.24°C). By subtracting this from the “sleep deprivation” curve an estimate of the 
endogenous temperature rhythm could be made. If the temperature values of the 
endogenous curve are then subtracted from the “normal” curve an estimate of the 
exogenous component of the temperature rhythm can be made. It is important to 
note that this method assumes that sleep deprivation itself does not have an 
effect on the temperature rhythm, and also that the endogenous and exogenous 
components of the “normal” temperature curve are additive.
The temperature correction factors supplied by Prof. Folkard are shown in Table 
4.1.
Correction factors are calculated for every hour after waking and every hour after 
sleep onset. Correction factors tend to be negative for the wake period and 
positive for the sleep period with a gradual transition between the two.
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Table 4.1 Demasking correction factors
Time of Day Time since Waking
(endogenous) (Exogenous)
08:00 36.70 0 -0.14
09:00 36.74 1 -0.02
10:00 36.79 2 +0.10
11:00 36.85 3 +0.18
12:00 36.91 4 +0.25
13:00 36.96 5 +0.22
14:00 37.01 6 +0.18
15:00 37.05 7 +0.18
16:00 37.08 8 +0.18
17:00 37.09 9 +0.20
18:00 37.09 10 +0.22
19:00 37.08 11 +0.24
20:00 37.05 12 +0.25
21:00 37.01 13 +0.25
22:00 36.96 14 +0.25
23:00 36.90 15 +0.15
24:00 36.84 16 +0.05
01:00 36.79 17 -0.01
02:00 36.74 18 -0.07
03:00 36.70 19 -0.13
04:00 36.67 20 -0.19
05:00 36.66 21 -0.25
06:00 36.66 22 -0.30
07:00 36.67 23 -0.22
6. Problems arise when using “normative” correction factors as there could be a 
wide variation in individual temperature range over the 24h, with greater or less 
reduction due to sleep, or elevation due to wake. To avoid this, mean individual 
hourly temperature values from 3 baseline days for each subject were compared 
to the endogenous temperature curve supplied by Folkard. The differences
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between the two temperature curves gave specific correction factors for each 
separate individual.
The fragmented sleep study protocol (Chapter 9) included 3 days baseline, with 
16h wake and 8h sleep (midnight - 08:00) which were used to determine the 
correction factors. The melatonin administration study (Chapter 6) and the 
200:1000 lux study (Experiment 2, Chapter 7) designs did not incorporate 
baseline days. The first 3 days of treatment 1 (Placebo 1st ) in the Melatonin 
Administration study and the first 3 days under 200 lux lighting conditions were 
considered to be baseline days.
7. Administration of exogenous melatonin has been shown to cause an acute 
decrease in core body temperature, returning to values similar to placebo after 
8h. A correction factor was calculated for each individual to determine whether 
there was a depression in core body temperature due to administration of 
exogenous melatonin (Chapters 6 & 9). The cross-over design of the studies 
enabled a comparison of the first 3 days of placebo and the first 3 days of 
melatonin treatment in the same subjects under the same conditions. Mean 
hourly temperatures for each individual calculated for the first 3 days of placebo 
treatment and the first 3 days of melatonin treatment were compared. The 
difference between the means of the two treatments was considered to be the 
correction factor for each hour during a period of 8 hours after melatonin 
administration. The individual mean and standard deviation was calculated for 
each time point for each subject and the values were only considered to be 
different if the 2 values ± SD did not overlap.
8. These “self-correction” factors and the “normalised” values supplied were 
determined from a regular 16h wake:8h sleep cycle. Under the study conditions 
reported here subjects were allowed to sleep whenever they wished, which 
frequently resulted in sleep periods in excess of, or less than 8h and wake 
periods both longer and shorter than 16h. To accommodate this in the 
“demasking” process an assumption had to be made. This was, that in a sleep 
period in excess of 8h, the core body temperature would not be depressed any 
lower than with an 8h sleep period, i.e. the maximum temperature drop would 
remain the same however long the sleep period was. Similarly, it was assumed
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that the maximum elevation of core body temperature due to wakefulness would 
remain the same, however much greater than 16h the wake period was. For 
sleep or wake periods shorter than the standard 8 or 16h the correction factors 
were applied directly, i.e. for a sleep period of 5h the first 5 correction factors 
after sleep onset were used followed by the correction factor for sleep offset.
The various correction factors needed were calculated. The correction factor 
profile was proportionally expanded to cover the length of sleep or wake present, 
i.e. 9-13h sleep and up to 28h wakefulness, and hourly correction factors were 
determined by interpolation. This was repeated for each individuals’ own “self­
correction” factors and the “normalised” values.
9. The lengths of the sleep or wake periods were determined by reference to the 
activity diaries/sleep logs and actigraph traces. Mean hourly temperature values 
corrected for sleep were then calculated using the “self-correction” and 
“normalised” factors. This adjusted data was then further corrected to allow for 
any suppression in core body temperature caused by melatonin administration 
where applicable.
10. A maximum of six sets of temperature data for each individual for each study 
were created and compared. These are:
i. masked raw data - values every 6 minutes.
ii. masked hourly means.
iii. “demasked” self-corrected for sleep/wake, hourly means.
iv. “demasked” normative correction factors for sleep/wake, hourly means.
V. “demasked” self-corrected for sleep/wake and melatonin administration, 
hourly means.
vi. “demasked” normative correction factors for sleep/wake, self-corrected for 
melatonin administration, hourly means.
11. Each temperature record was then subjected to single and 3 day moving window 
cosinor analysis for each treatment. The 3-day moving window acrophase times 
were then analysed further.
141
13. All significant acrophase times (p<0.05, percentage rhythm > 70%) were 
subjected to regression analysis and the individual tau determined with 95% 
confidence limits for all subjects, for every treatment and every “demasking” 
procedure.
14. Acrophase times for each subject for each treatment and analysis method were 
plotted graphically to show any variations. Group means were calculated and 
plotted (Figs 4.1, 7.2 and 9.2).
15. One way ANOVA was used to determine whether there were any significant 
individual differences between the calculated taus.
16. Repeated measures ANOVA, followed by Duncan’s Multiple Range post hoc test, 
was performed on the significant acrophase times to investigate whether there 
were any significant group differences across the treatment days or between 
analysis methods.
4.3 RESULTS
Only the results from the melatonin administration study (Chapter 6) will be reported 
here. Results from the 200lux:1000lux (Experiment 2, Chapter 7) and fragmented 
sleep study (Chapter 9) will be given in the relevant chapter.
4.3.1 Individual Results
Subject 2 withdrew after 12 days of the Placebo 1st: Melatonin 2nd leg resulting in no 
data for treatment 2 (Melatonin 2nd). Subject 5 did not comply with core body 
temperature recording during the Placebo 1st:Melatonin 2nd leg resulting in no data 
to analyse. Subject 8 was unwell at the beginning of the Placebo 1st treatment and 
whilst he did not have a temperature, tended to sleep more than on Placebo 2nd, 
which may have skewed the self-corrected factors calculated.
By one way ANOVA there was no significant difference between the tau determined 
by the various methods of “demasking” for any treatment. Full details of the tau
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calculated for each subject for each treatment and analysis method can be seen in 
Table 4.2.
Placebo 1st- There was no significant difference between tau or acrophase times 
determined by the various analysis methods as assessed by repeated measures 
ANOVA. There was a significant difference in the tau determined for the different 
subjects (p=0.0001). There was a significant difference in the acrophase times across 
the treatment days (p=0.0001) and between subjects (p=0.0001).
Melatonin 2nd:- There was no significant difference between tau or acrophase times 
determined by the various analysis methods as assessed by repeated measures 
ANOVA. There was a significant difference in the tau determined for the different 
subjects (p=0.0001). There was a significant difference in the acrophase times across 
the treatment days (p=0.0001) and between subjects (p=0.0001).
Melatonin 1st- There was no significant difference between tau or acrophase times 
determined by the various analysis methods as assessed by repeated measures 
ANOVA. There was a significant difference in the tau determined for the different 
subjects (p= 0.0001). There was a significant difference in the acrophase times 
across the treatment days (p= 0.0001) and between subjects (p= 0.0001).
Placebo 2nd:- There was no significant difference between tau or acrophase times 
determined by the various analysis methods as assessed by repeated measures 
ANOVA. There was a significant difference in the tau determined for the different 
subjects (p= 0.0001). There was a significant difference in the acrophase times 
across the treatment days (p= 0.0001) and between subjects (p= 0.0001).
The amplitude of the “demasked” temperature rhythms did not vary significantly 
between treatments or across study days, but subjects 8 and 9 had a tendency to 
show lower amplitudes. The masked temperature data did show significant changes 
in amplitude, with an increase with Melatonin 2nd, (p=<0.0001) and a slight decrease 
with Melatonin 1st, (p=0.05). The amplitude of the masked temperature rhythm also 
showed a significant difference between some subjects (p= 0.0006); between study 
days for different treatments (p= 0.0001) and a slight difference between study days 
for different subjects (p= 0.01).
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Table 4.2
Placebo 1st
Melatonin Administration Study Tau determined by 
various “demasking” techniques.
Subject Masked Masked Hourly Self-Corr Sleep Norm-Sleep
1 24.29 ± 0.05*** 24.37 ± 0.03*** 24.48 ± 0.04*** 24.50 ± 0.05***
2 24.17 ± 0.05*** 24.13 + 0.06*** 24.19 ± 0.10** 24.29 ± 0.14**
3 24.14 ± 0.07*** 24.16 ± 0.08*** 24.16 ± 0.08** 24.17 ± 0.08***
4 24.26 ± 0.03*** 24.31 ± 0.03*** 24.41 ± 0.06*** 24.44 ± 0.04***
5 NO DATA
6 24.43 ± 0.06*** 24.42 ± 0.10*** 24.46 ± 0.10*** 24.46 ± 0.14***
7 24.34 ± 0.09*** 24.23 ± 0.07*** 24.55 ± 0.020*** 24.38 ± 0.07***
8 24.20 ± 0.05*** 24.23 ± 0.04*** 24.29 ± 0.08*** 24.31 ± 0.05***
9 24.26 ± 0.20* 24.30 ± 0.22* 24.54 ± 0.27** 24.50 ± 0.26**
10 24.16 ± 0.06*** 24.06 ± 0.04* 24.22 ± 0.13** 24.11 ± 0.08*
Group 24.25 ±0.03*** 24.27 ± 0.04*** 24.39 ± 0.07*** 24.34 ± 0.03***
Melatonin 2nd
Subject Masked Masked Hourly Self-Corr Sleep Norm-Sleep Self-Corr Norm-Sleep
Sleep & MT & MT
1 23.97 ± 0.08 24.00 ± 0.07 23.99 ± 0.06 23.95 ± 0.08 24.00 ± 0.07 24.00 ± 0.07
2 NO DATA
3 23.80 ± 0.05*** 23.80 ± 0.05*** 23.90 ± 0.07* 23.85 ± 0.06*** 23.89 ± 0.08** 23.83 ± 0.06***
4 24.08 ± 0.07* 24.06 ± 0.06* 24.30 ± 0.12*** 24.24 ± 0.11*** 24.15 ± 0.07*** 24.13 ± 0.11*
5 NO DATA
6 24.95 ± 0.18*** 25.01 ± 0.20*** 25.14 ± 0.32*** 25.07 ± 0.20*** 25.20 ± 0.25*** 23.47 ± 0.18***
7 25.57 ± 0.29*** 25.57 ± 0.30*** 24.37 ± 0.12*** 24.52 ± 0.11*** 24.36 ± 0.12*** 24.40 ± 0.28***
8 23.87 ± 0.12* 23.88 ± 0.11* 23.67 ± 0.11*** 23.83 ± 0.13* 23.52 ± 0.13*** 23.72 ± 0.27*
9 23.97 ± 0.09 23.90 ± 0.30 24.10 ± 0.16 24.00 ± 13.0 24.09 ± 0.18 24.01 ±0 .1 3
10 24.04 ± 0.05 24.04 ± 0.05 24.04 ± 0.08 24.07 ± 0.07 24.03 ± 0.08 24.06 ± 0.06
Group 23.94 ± 0.05* 23.91 ± 0.04*** 23.97 ± 0.07 23.89 ± 0.11* 24.12 ± 0.11* 23.82 ± 0.07***
Melatonin 1st
Subject Masked Masked Hourly Self-Corr Sleep Norm-Sleep Self-Corr Norm-Sleep
Sleep & MT & M T
1 24.14 ± 0.08** 24.15 ± 0.07*** 24.22 ± 0.11*** 24.02 ± 0.09 24.15 ± 0.10** 24.04 ± 0.12
2 23.99 ± 0.09 23.96 ± 0.09 23.74 ± 0.13*** 23.93 ± 0.20 23.85 ± 0.13* 24.01 ± 0.23
3 24.01 ± 0.05 24.05 ± 0.06 23.94 ± 0.08 23.98 ± 0.08 23.94 ± 0.09 23.95 ± 0.09
4 24.00 ± 0.06 23.99 ± 0.05 24.01 ± 0.06 24.00 ± 0.08 24.00 ± 0.05 23.97 ± 0.06
5 24.05 ± 0.09 23.97 ± 0.08 24.01 ± 0.07 23.94 ± 0.06* 24.05 ± 0.10 24.12 ± 0.21
6 24.08 ± 0.04*** 24.06 ± 0.03*** 24.03 ± 0.03* 24.07 ± 0.06* 24.08 ± 0.055** 23.99 ± 0.06
7 24.01 ± 0.08 24.00 ± 0.09 24.06 ± 0.19 24.13 ± 0.09** 24.56 ± 0.15*** 24.38 ± 0.07***
8 23.92 ± 0,07* 23.91 ± 0.07** 23.80 ± 0.17* 23.76 ± 0.07*** 23.97 ± 0.13 23.82 ±0 .13***
9 24.09 ± 0.06* 24.04 ± 0.05 24.00 ± 0.10 24.07 ± 0.07 24.01 ± 0.12 24.08 ± 0.07
10 24.07 ± 0.03*** 24.05 ± 0.03** 24.25 ± 0 .19 * 24.15 ± 0.09** 24.26 ± 0.30 24.15 ± 0.10**
Group 24.03 ± 0.03 24.02 ± 0.02 24.00 ± 0.06 24.00 ± 0.04 24.08 ± 0.10* 24.07 ± 0.05**
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Placebo 2nd
Subject Masked Masked Hourly Self-Corr Sleep Norm-Sleep
1 23.86 ± 0 .1 2 * 23.90 ± 0.13 23.86 ± 0.29 23.96 ± 0.35
2 24.07 ± 0.10 24.10 ± 0.05 24.02 ± 0.12 24.10 ± 0.19
3 24.20 ± 0.04*** 24.19 ± 0.04*** 24.24 ± 0.09*** 24.25 ± 0.07***
4 24.08 ± 0.06** 24.07 ± 0.06* 24.09 ± 0.09 24.10 ± 0.04***
5 24.15 ± 0.07*** 24.11 ± 0.08** 24.05 ± 0.10 24.06 ± 0.13
6 24.19 ± 0.15* 24.25 ± 0.13** 24.00 ± 0.28 24.14 ± 0.07**
7 24.25 ±0 .15 ** 24.22 ± 0.13** 24.66 ± 0.38** 24.28 ± 0.08***
8 24.25 ± 0.07*** 24.17 ± 0.07*** 24.37 ± 0.27* 24.45 ± 0.14***
9 24.28 ± 0.10*** 24.23 ± 0.05*** 24.42 ± 0.12*** 24.32 ± 0.07***
10 24.07 ± 0.10 24.17 ± 0.03*** 24.02 ± 0.08 24.10 ± 0.19
Group 24.16 ± 0.03*** 24.14 ± 0.04*** 24.19 ± 0.06*** 24.20 ± 0.03***
Significance level of fitted regression line *** =<0.001 ** =<0.01 * =<0.05
S2 showed a low temperature amplitude for Melatonin 1st possibly because he had 
fragmented sleep. 88 had a generally low amplitude throughout whilst 86 and 87 
showed a decreased temperature amplitude on Melatonin 2nd due to phase shifts.
4.3.2 Group Results
There were no significant differences in the group tau determined by the various 
analysis methods for any treatment (see Table 4.2 and Fig 4.1). The “demasking” 
procedures have altered the acrophase times without affecting the overall tau. On 
Placebo 1st and Placebo 2nd treatments the acrophase times have been advanced 
by 1-2 hours by correcting for sleep. With the Melatonin 1st treatment, correcting for 
sleep advanced the acrophase times, whilst correcting for sleep and melatonin 
administration resulted in a delay in the acrophase times. The results of “demasking” 
the data from Melatonin 2nd treatment was varied due to the different response 
depending on the circadian timing of the melatonin treatment.
In general, although there were no statistically significant differences seen in the tau 
derived by the various “demasking” procedures, either on an individual or group 
basis, inspection of the tau calculated by regression analysis of acrophase times for 
each individual did show some differences. The calculated tau could be said to be 
different if the 95% confidence limits did not overlap. Using this criterion differences
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Fig 4.1
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in temperature periodicity derived from the various “demasking” techniques are 
shown in Table 4.3.
Table 4.3
Melatonin Administration Study
Subject Differences between “self-corrected’' or “self-corrected + 
melatonin” demasked” tau compared to hourly masked
1 Placebo 1st, longer
2 None
3 None
4 Placebo 1st & Melatonin 2nd, longer
5 None, No Data
6 None
7 Placebo 1st longer; Melatonin 2nd, shorter
8 None
9 None
10 None
Group Placebo 1st & Melatonin 2nd, longer
Due to these differences it was decided to use temperature data “demasked” using 
self-corrected factors for sleep or self-corrected factors for sleep and melatonin 
where appropriate.
4.4 DISCUSSION
All methods used for temperature “demasking “ have limitations and a compromise is 
needed to apply the best available methodology to the data set under investigation.
Constant routines used for studying core body temperature require the subject to 
maintain a constant posture and remain awake for more than 24h. Whilst this 
removes the masking effect due to sleep and activity, it increases any effects due to 
fatigue and sleep propensity. During the constant routine individuals are exposed 
only to internal zeitgebers. This could result in an effect on the marker rhythms. 
Marker rhythms interact with each other (e.g. sleep onset and growth hormone; 
temperature and alertness; adrenaline and melatonin with temperature), and some 
feed back onto the clock (melatonin). Thus, masking due to these interactions is still
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in force during a constant routine, but it is unknown how much of an effect, if any, 
they may have.
Mathematical “purification” techniques assume that there are two components - a 
stable endogenous oscillator and a labile external oscillator, that both describe a 
cosine curve, with a polynomial or linear external zeitgeber. A major assumption is 
that these two components are additive and independent. Calculated correction 
factors are either applied smoothly, (as in the correction for sleep where the decrease 
in temperature caused by sleep is spread across the whole sleep episode, with the 
maximum at the midpoint) or an equal correction is made across the episode, as for 
activity. This assumes that the effect is the same each time sleep or activity occurs 
and therefore the “masking” effects are independent of phase and study day. This 
has been shown not to be the case (Dijk et al., 1997).
Under our experimental conditions the best method for demasking was considered to 
be that of Folkard which only corrects for sleep. Mathematical models were 
unsuitable because they assume a fixed period of a cosine curve for the oscillators. 
As the subjects were free-running the periodicity was unknown. Subjects were held in 
partial isolation under constant dim light or with a controlled lighting schedule. Thus, 
all external influences were kept constant throughout the period of investigation, so 
any effect they exerted on the endogenous rhythm was assumed to be the same 
each day, even if there was internal circadian variation. Each individual was used as 
their own control for calculating the correction factors, thus avoiding the assumption 
that all individuals show the same variation in temperature over a normal 24h cycle. 
Error was also reduced, as the analysis required calculation of the change in the 
temperature acrophase time over many days for each individual. The lack of baseline 
days for the melatonin administration and 200lux:1000lux variable light study could 
have resulted in inaccurate correction factors if subjects took a nap or a sleep 
episode in excess of 8 hours on the days used to calculate the values.
No significant difference was seen between the grouped “demasked” and “masked” 
data or between results from the different correction factors used. This could be due 
to all “demasking” being performed on hourly temperature means which results in a 
considerable smoothing of the data and a removal of rapid changes in temperature. 
Examination of raw temperature data shows a rapid drop in temperature at sleep
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onset, followed by a rapid rise just before sleep offset. The temperature nadir 
determined by finding the mid-point of the ten lowest temperature values tended to 
be 2-3 hours earlier than that calculated by cosinor analysis. A more accurate 
“demasking” technique would appear to be that of Carrier and Monk, (1997), who 
adjusted temperature differentially every ten minutes throughout the sleep period, 
with a greater correction factor for the first hour of sleep. However, “demasked” 
temperature appears to closely resemble “unmasked” (constant routine) data when 
assessing phase position after phase-shift (Shanahan and Czeisler, 1991).
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CHAPTER 5
HUMAN CIRCADIAN RHYTHMS IN CONSTANT DIM
LIGHT
150
5.1 SPECIFIC STUDY DESIGN & RATIONALE
The primary factor in maintaining human circadian rhythms synchronised to the 24 
hour day is the light-dark cycle (Campbell et al., 1995). There is evidence from 
Polar regions that human circadian rhythms free-run in winter (in the absence of 
natural sunlight) with knowledge of clock time but without imposed behaviour 
(Kennaway and Van Dorp, 1991). Many totally blind subjects also show free-running 
rhythms in a normal social environment (Lockley et a/., 1997a). Under normal 
conditions humans are exposed to a wide range of illumination levels during a 24 
hour day. This range can be as extreme as from 100,000+ lux (outside on a sunny 
day) to zero lux during the sleep period. Previous isolation experiments (Wever, 
1989) have used different light intensities to investigate the limits of entrainment of 
the human circadian system. However, the majority of work to date has been to 
study and use the ability of light to phase-shift rhythms, rather than to maintain a set 
period. Results from temporal isolation studies show that constant lighting levels up 
to 3000 lux lead to free-running rhythms. This intensity, administered as a light-dark 
cycle (16h light:8h dark), was able to entrain all rhythms up to an imposed tau of 27h 
(Wever, 1983).
Administration of exogenous melatonin has also been used mainly to investigate 
phase shifting properties and to hasten adaptation to rapid phase shifts such as 
those experienced in jet lag and shift work (Folkard et a/., 1993; Petrie et a/., 1983; 
Claustrat et a/., 1992; Arendt et a/., 1997).
The overall aims of this project were to attempt to establish the minimum light 
intensity, administered as a 24h light-dark cycle, with knowledge of clock time, which 
will prevent free-run and to determine whether timed administration of exogenous 
melatonin can prevent free-run.
In order to achieve this, it was necessary to ascertain whether or not subjects 
maintained as a group in constant dim light levels in our partial temporal isolation 
facility, with knowledge of clock time would show free-running rhythms. The initial 
baseline study was designed to fulfil this role.
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6.1.1 Isolation Facility
The isolation unit was provided by the DERA, Farnborough, and has been described 
in section 2.1.1. The exact layout was as shown in Fig 2.1 Plan A.
The Siemens lighting system was not in place for this study. The lighting was 
Osram Biolux fluorescent tubes and the illumination level was controlled by covering 
the light fitments with aluminium foil.
5.1.2 Subjects
6 normal healthy males aged 26 ± 2.71 years, numbered 81 - 86, were recruited 
from the Army Personnel Establishment Trials Section, Farnborough, U.K. Potential 
subjects were screened as described in section 2.2.4. All individuals tested met the 
imposed criteria and were included in the study. All subjects were healthy, taking no 
medication except for minor analgesics and were non-smokers. Informed written 
consent was obtained from all subjects and the study protocol was approved by the 
Ethics Committee of the Centre for Human Sciences, DERA, Farnborough , U.K.
5.1.3 Study Protocol
Subjects arrived at the isolation facility at midday on Day 1. Equipment was issued 
and recording of data plus collection of samples began at 15:00h. An 
acclimatisation period of 29 hours (darkness 23:00-07:00h) was followed by lighting 
levels being lowered to < 8 lux at 20:00h on day 2. Lighting levels were maintained 
at this intensity for 22 days. Constant dim light levels were 4.09 ± 0.8 (SEM) lux 
(n=645). The ambient temperature range was 21 - 29 °C (mean 25.6 ± 0.9°C SEM 
n=176). Subjects had access to a digital clock so that they were aware of clock time 
throughout the entire study period.
The general study conditions were as described in section 2.1.3. An incident book 
was kept throughout the study to record any significant events, subjects' requests 
and general observations on the subjects’ mood and behaviour.
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5.1.4 Measurements Taken
The following measurements were taken throughout the study.
a. daily maximum and minimum temperatures in each room
b. light levels every 2 days
c. core body temperature via a rectal probe and memory logger
d. sleep-wake/activity via wrist mounted accelerometer - Mini Motionlogger
e. 4 hourly urine collections, except for oversleep periods
f. 3 hourly saliva samples when awake
g. 3 hourly performance sessions when awake using the full DERA test 
battery
h. daily activity diaries
i. subjective sleep logs after every sleep period
j. UWIST mood adjective questionnaire morning and evening
5.2 ANALYSIS OF DATA
5.2.1 Urinary aMT6s
Urinary aMT6s levels were measured using the assay described in section 2.4.2. 
Quality control coefficients of variation (C.V.) were 6.2%, 7.5% and 3.7% for aMT6s 
concentrations of 2.84, 21.67 and 45.23 ng/ml respectively. The limit of detection at 
2 X SD of zero binding was 0.23 ng/ml. The excretion rate for each sample period 
was calculated in ng/hr and these values were subjected to 3 day moving window 
cosinor analysis as described in Chapter 3 section 3.1.4 and spectral analysis as in 
section 3.1.5. Acrophase times and amplitude levels were analysed further by linear 
regression analysis and repeated measures ANOVA as described in section 3.2, 
both on an individual basis and by group mean values.
5.2.2 Salivary Cortisol
Salivary cortisol levels were measured in all saliva samples collected. All samples 
from each individual subject were run in two separate assays on the same day
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following the protocol detailed in section 2.4.3. The initial assay protocol was 
adjusted to measure 200 \i\ samples as the levels of cortisol were very low. Quality 
control C.V.’s were 13.0%, 10.8% and 9.0% for concentrations of 6, 20 and 77 
nmol/L respectively and the limit of detection was 1.02 nmol/L. Values obtained 
were plotted to investigate any change in the timing of peak values across the study 
period.
5.2.3 Temperature and Activity Data
Raw temperature and activity data were edited as described in section 3.1.1. For 
analysis of periodicity, temperature and activity data collected during sleep periods 
of less than 3 hours was discarded. These short sleep periods were regarded as 
naps and tended to be timed to avoid performance test sessions. Sleep parameters 
were determined and analysed as described in sections 3.1.2 and 3.1.3.
Edited temperature and activity data were analysed using cosinor, spectral, 
periodogram and autocorrelation analysis (sections 3.1.4, 3.1.5, 3.1.6 and 3.1.7).
The calculated acrophase times, amplitudes and sleep parameters were then 
subjected to linear regression analysis and repeated measures ANOVA. (Sections
3.2.1 and 3.2.2) both on an individual basis and as group means.
5.2.4 Performance Data
All performance data collected were analysed for any changes across the study 
period using daily means as described in section 3.1.6.
5.2.5 UWIST Mood Adjective List
Daily mood scores were calculated according the methodology described in section
2.5.2.
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5.3 RESULTS
5.3.1 Compliance
Throughout the study subject compliance to the study protocol was very good with 
the exception of performance data. More than 80% of all possible data was 
collected in all the other parameters, when equipment functioned correctly. Data 
lost due to malfunctioning equipment was as follows:
a. activity lost data : S3 - 87 hours, S6 -15-20 hours, S2 -6  hours
b. temperature lost data : S2 and S5 12-15 hours and S3 the last two days. 
SI only provided sufficient data for analysis for days 1-8 due to problems 
wearing the probe.
c. aMT6s: An average number of collections per day was 4.7 ± 0.32 SEM. 
(S1-S4, S6). S5 produced less urine samples per day (3.8 ± 0.28) due to 
his extended sleep periods.
Only 42.3-54.3% of the theoretical number of performance test sessions possible 
were completed. This was partly due to the length of the test battery - 
approximately 30 minutes. Subjects found it extremely boring and therefore tended 
to avoid the sessions as much as possible. This was possible because if they went 
to bed (even if not intending to sleep) they would not be disturbed by the observers. 
It is conceivable that some of the short sleep periods and the time of going to bed 
were deliberate avoidance of performance tests.
Individual periodicities for activity, temperature and aMT6s derived from single day, 
2 day non-overlapping windows, 3 day non-overlapping windows and 3 day moving 
windows cosinor analysis did not differ significantly by ANOVA, as shown in section 
3.1.4.3. Individual sleep characteristics of sleep onset and offset times, wake after 
sleep offset and sleep efficiency derived from single day, 2 day average, 3 day 
average and 3 day moving averages did not differ significantly by ANOVA as shown 
in section 3.1.4.3. All the results selected here for further discussion are from 3 day 
moving window cosinor analysis for activity, temperature and aMT6s and from single 
days for sleep characteristics.
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Periods derived from cosinor analysis (section 3.1.4), spectral analysis (section 
3.1.5), periodogram analysis (section 3.1.6) and autocorrelation (section 3.1.7) 
showed similar periodicities (p > 0.05, 2 way ANOVA) for activity and temperature. 
Periods derived from cosinor and spectral analysis showed similar periodicities (p > 
0.05 students t-test) for activity, temperature, aMT6s, sleep onset and sleep offset.
5.3.2 Individual Data
Summary raster double plots were produced for all subjects giving an overall record 
of the sleep-wake cycle/activity, temperature and aMT6s acrophase times, 
(see Figs 5.1, 5.2 and 5.3). Where long periods of actigraph data were missing due 
to equipment failure, sleep timings were taken from the activity diaries and 
subjective sleep logs. Visual inspection of these plots suggests that free-running 
rhythms were obtained in all the parameters measured except for S3. In the data 
from S3 only aMT6s appears to deviate from 24 hours. Possible desynchronisation 
of the sleep-wake cycle from the aMT6s rhythm is evident in the last few days of the 
study in S4 and S5 and for the second half of the study in subject S6.
No significant changes in mood were seen across the study period as calculated 
from the UWIST mood adjective list.
The full results obtained from linear regression, spectral, periodogram and 
autocorrelation analysis for each parameter and each individual, together with group 
means are shown in Table 5.1. The individual results can be summarised for the 
various parameters as follows:
Activity: 5 subjects SI, S2, S4-S6 deviated significantly from 24 h by cosinor,
spectral, periodogram and autocorrelation analysis. Subjects S4 and 
S5 showed a definite “end effect” apparently adjusting their sleep- 
wake cycle to coincide with the outside world during the last few days 
of the study. Therefore, only days 1-15 and 1-17, respectively were 
used for analysis. Two periodicities were evident in S6. Separate 
analysis of Days 1-11 and 11-21 gave taus of 25.00h and 12.06h 
(spectral analysis) and 24.30h and 12.00h by cosinor analysis, 
respectively.
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Fig 5.3
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Temperature:5 subjects S1, S2, S4-S6, deviated significantly from 24 h by 
regression and periodogram analysis and all subjects free-ran by 
spectral and autocorrelation analysis, including S3.
aMT6s: All the subjects showed a periodicity significantly longer than 24 h by
linear regression and spectral analysis.
Cortisol: No rhythm analysis was performed for the salivary cortisol data as no
overnight samples were collected. On examining plots of the raw 
data the highest cortisol level was seen in the first sample collected 
each day, irrespective of the time of sampling.
In subjects S1, S2, S4, S5 and S6 it was 3-10 days before the activity, temperature 
and aMTGs rhythms showed a steady periodicity which was significantly different 
from 24 h. This was determined by linear regression analysis of the acrophase 
times in sections.
Sleep onset times: SI, 82 and 84 showed a clear free-run longer than 24 h; 83 
remained synchronised. 85 showed a tendency to free-run (p= 
<0.4) whilst for 86 sleep apparently desynchronised from 
temperature and aMTGs.
Sleep offset times: 81, 82, 84, and 85 all showed significant free-run longer than 
24 h whilst for 86 sleep offset times were erratic. 83 did exhibit 
a very slight, but significant, free-run by our criteria.
Sleep parameters: Full results from the linear regression analysis of sleep 
parameters (single day values), excluding naps < 3h, and 
mean values ± 8EM are summarised in Table 5.2. The 
percentage of time spent “sleeping” per 24 h varied in a non- 
systematic manner throughout the study in all subjects except 
for 83 (mean = 41.76% ± 7.26% 8EM). The total time spent in 
bed increased in subjects 84 and 85 but the total sleep time 
did not vary in any individual during the study. Although a 
direct comparison in the same subjects is not possible, it is 
interesting to note that the average total sleep time was 513.54
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Table 5.1 Individual and Group Periodicities Determined 
by Various Analysis Methods
Parameter Subject Days Regression Spectral Periodogram Autocorrelation
Activity 1 1-20 24.45 ± 0.04*** 24.G0 24.51 25.0G
2 1-20 24.32 ± 0.04*** 24.45 24.32 24.40
3 1-20 24.04 ± 0.04 23.92 24.00 23.90
4 1-15 24.37 ± 0.09*** 24.5G 24.38 24.20
5 1-17 24.18 ± 0.07*** 24.15 24.29 24.10
G 1-20 24.17 ± 0.10** 24.30 24.31 24.1 G
Group n=6 1-20 24.20 ± 0.08*** 24.33 24.30 24.30
Parameter Subject Days Regression Spectral Periodogram Autocorrelation
Temperature 1 1-8 24.3G± 0.14*** 24.50 25.70 24.G0
2 1-20 24.19 ± 0.02*** 24.42 24.23 24.70
3 1-20 24.02 ± O.OG 24.10 23.99 24.1 G
4 1-15 24.35 ± 0.05*** 24.42 24.35 24. OG
5 1-17 24.40 ± O.OG*** 24.3G 24.39 24.12
G 1-20 24.35 ± 0.05*** 24.35 24.40 24.30
Group n=6 1-20 24.30 ± 0.03*** 24.35 24.51 24.32
Parameter Subject Days Regression Spectral
aMTGs 1 1-20 24.41 ± 0.07*** 24.4G
2 1-20 24.21 ± 0.19* 24.30
3 1-20 24.19 ± O.OG*** 24.00
4 1-15 24.43 ± 0.10*** 24.82
5 1-17 24.31 ± 0.19** 24.15
G 1-20 24.40 ± 0.12*** 24.G0
Group n=G 1-20 24.2G ± 0.04*** 24.39
Parameter Subject Days Regression Spectral
Sleep Onset 1 1-20 24.51 ± 0.21*** 23.10
2 1-20 24.25 ± 0.13*** 24.25
3 1-20 24.01 ± O.OG 23.85
4 1-15 24.37 ± 0.25** 24.22
5 1-17 24.10 ± 0.23 23.7G
G 1-20 24.09 ± 0.33 23.8G
Group n=G 1-20 24.12 ± 0.10* 23.84
Parameter Subject Days Regression Spectral
Sleep Offset 1 1-20 24.55 ± 0.12*** 25.20
2 1-20 24.37 ± 0.1 G*** 24.1 G
3 1-20 24.04 ± 0.02*** 23.90
4 1-15 24.54 ± 0.21*** 24.30
5 1-17 24.31 ± 0.07*** 24.05
G 1-20 23.99 ± 0.44 24.52
Group n=G 1-20 24.18 ± 0.07*** 24.3G
Significance level fitted regression line *** =<0.001 ** = <0.01 * = <0.05 
Subject 6 showed tau of 24.30; 25.00 days 1-11 and 
12.00; 12.06 days 12-20 (cosinor & spectral)
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min ± 9.33 (SEM), whereas the age and sex matched normal 
value is 424.64 min ± 14.42 (SD) (Williams et al., 1974). 82, 
83 and 84 did show a significant increase in wake after sleep 
onset with a concomitant decrease in sleep efficiency.
Individual graphical representations for each parameter for every subject can be 
seen in Appendix 2.
The timing and duration of sleep periods in relation to the temperature rhythm were 
calculated and plotted (Figs 5.4 and 5.5). The longest sleep periods occurred when 
sleep onset fell between 8 and 4 hours before the temperature nadir. That is on the 
falling part of the temperature curve, with short sleep episodes, on average, 
commencing on the rising part of the temperature curve. The majority of sleep 
episodes spanned the temperature nadir with sleep offset occurring on the rising 
phase of the temperature cycle.
Table 5.2 Mean Value ± SEM & Linear Regression
Analysis of Sleep Parameters (single day)
Subject Days Time in Bed 
(mins)
Total Sleep Time 
(mins)
WASO (mins) Efficiency (%)
1 1 -20 512.53±26.95 476.58±24.26 6.77±0.93 93.23±0.93
■ ^
2 1 -20 545.80i30.78 516.30±29.31 29.50±3.53* 94.55±0.54*
3 1-20 559.53±12.36 498.35±14.25 61.18±6.70** 88.93±1.40**
4 1 -20 608.71 ±28.92* 481.24±19.46 127.48±12.07** 79.69±1.13**
5 1 -20 701.05±28.71* 598.55±21.43 102.50±14.66 85.88±1.65
6 1 -20 563.26±33.9 502.68±29.17 60.58±12.00 89.58±1.63**
GROUP ANALYSIS
n=6 1-20 585±30.80** 513.54±9.33 75.45±6.57** 88.79±0.73***
Significance level of fitted regression line *** = <0.001 ** = <0.01 * = <0.05
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5.3.2 Grouped Data
Grouped mean acrophase times for each day of the study for activity (n = 6), 
temperature (n = 5) and aMT6s (n = 6) were calculated. Group mean sleep onset 
and offset times, total time in bed, total sleep time, wake after sleep onset and sleep 
efficiency were calculated for each day of the study (n = 6).
Activity, sleep onset and offset times, temperature and aMT6s all showed periodicity 
significantly different from 24 h by linear regression analysis, and time dependent 
changes by repeated measures ANOVA ( p = <0.0001, days 1-20, n = 6, factor: day 
of study, degrees of freedom 5,19). This can be seen graphically in Fig 5.6. with the 
periods recorded in Table 5.1.
Total time in bed and total sleep time did not change over the study by repeated 
measures ANOVA, however, wake after sleep onset increased (p = 0.019, days 1- 
20, n = 6, factor: day of study, degrees of freedom 5,19) whilst sleep efficiency 
decreased (p = 0.002, days 1-20, n = 6, factor: day of study, degrees of freedom 
5,19). This is illustrated in Fig 5.7.
Grouped mean amplitude values showed a significant increase for temperature ( p = 
<0.01, by regression and repeated measures ANOVA, days 1-20, n = 5, factor: day 
of study, degrees of freedom 5,19), and for 6-sulphatoxymelatonin only by 
regression analysis (p = < 0.0001, days 1-20, n = 6), in the course of the study. The 
lack of significance for the change in amplitude of the aMT6s rhythm is probably a 
reflection of the wide range in individual levels. There were no changes in the 
amplitude of activity.
There was a strong positive correlation between temperature and 6- 
sulphatoxymelatonin acrophase times (r^  = 0.94, p = <0.0001) with a less striking 
correlation between temperature and aMT6s amplitude values (r^  = 0.55, p = 0.02). 
(see Fig 5.8).
The overall mean periodicity for all parameters as an average of individual cosinor 
and spectral analysis was 24.26 ± 0.049h.
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Fig 5.7
BASELINE STUDY
GROUP MEAN SLEEP PARAMETERS! SEM
750
725
700
675
C/)c 650
E
Q 625
LU00 600
z
LU 575
S
1- 550
-1
< 525Ho
500 -
475 -
450
425
400 -
p = <0.01
0 2
I ' M  "I ' I ' I ' I ' I '
8 10 12 14 16 18 20 22
TRIAL DAY
650
625
600 -
575 -
550 -
^  525 :
LU 500 -
CO 475 -  
_ J
H  450 i
425 :
400 I
n = 6 
p = >0.05
375 -
350
0 2 4  6 8 10 12 14 16 18 20 22
TRIAL DAY
160
140 -
120 -
Z  100 -
80 -
6 0 -
2 0 - n = 6 
p = 0.019
2 4 6 8 10 12 14 16 18 20 22
TRIAL DAY
100
95 -
90 -
L L
85 -
— I
80 -
n = 6
p = 0.002
0 2 4  6 8 10 12 14 16 18 20 22
TRIAL DAY
166
Fig 5.8
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5.4 DISCUSSION
The individuals involved in this study were military personnel who would normally 
lead a very structured life with the requirement occasionally to work long, and/or 
irregular hours. Within the group, one subject was a non-commissioned officer and 
senior in rank to the other five. Given these conditions it was predicted that all 
subjects might attempt to maintain 24 h rhythmicity out of habit, and that they would 
synchronise as a group, as they are used to working as a team. It was possible that 
the senior-ranking subject would attempt to impose a regimented routine on the 
other individuals. However, the results show that none of these possibilities 
occurred.
The records and observations at the time indicate that S2 attempted to remain 
synchronised to 24 h over the first week but was unable to maintain synchrony. 
Subject 3 did manage to maintain a 24 hour sleep-wake cycle but showed a clear 
free-run in melatonin sulphate. Also, although the activity records show a 24 hour 
periodicity in the sleep-wake cycle there was a small, but significant, free-run in his 
sleep offset times and an increase in wake after sleep onset with a concomitant 
decrease in sleep efficiency. This would suggest that he was retiring to bed 
according to clock time, but was in reality not ready for sleep. It is important to note 
that his core body temperature rhythm appeared to be synchronised to 24 h. This 
entrainment was possibly due to masking of the temperature rhythm by the sleep- 
wake cycle. Masking of the temperature rhythm was reduced as much as possible 
by editing out temperature data surrounding periods of exercise or showers but no 
demasking for sleep was performed. A similar phenomenon was seen in S5 on 
days 17-21 when he attempted to resynchronise to the normal day according to 
clock time, prior to leaving the isolation facility. Subject 4 also showed a marked 
"end effect” but there was insufficient temperature data collected over the last few 
days of the study to allow for detailed analysis. 86 showed spontaneous 
desynchronisation between the aMT6s and the sleep - wake rhythm.
During the study all subjects slept for longer periods than is the average for 
individuals of comparable age and sex under normal conditions. This could be a 
result of the low lighting levels, the non-stimulating environment, deliberate
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avoidance of performance sessions or some other unknown cause. It is most likely 
due to a combination of several of these factors.
Investigation of the timing and duration of sleep periods for all six subjects, showed 
agreement with the results of Czeisler et al. (1980). Bedtimes occurring near the 
trough of the temperature cycle resulted in short sleep episodes, with sleep offset 
occurring on the rising phase of the temperature rhythm. The short sleep periods 
tended to coincide with times when individuals might have been deliberately 
avoiding performance test sessions at any time during the study. The majority of the 
longer duration sleep episodes occurred when sleep onset was between 4 and 6h 
before the temperature nadir. Sleep was extended to span the temperature 
minimum with wake times falling on the next rise of the temperature curve. Sleep 
periods initiated at a phase position between 90° and 150° from the temperature 
nadir exhibited great variability in duration. These results suggest that the timing of 
the endogenous circadian clock had more influence on sleep duration in these 
conditions than the period of prior wakefulness.
Melatonin production is masked by sufficient intensity of bright light, and to a small 
extent by posture (Deacon and Arendt, 1994). In this study where the light intensity 
is low and controlled, measurement of melatonin or urinary 6-sulphatoxymelatonin is 
likely to provide a reliable estimate of the endogenous clock, as indicated by Wever 
(1989). This is illustrated by the apparently motivated adjustment of the sleep-wake 
cycle in S3 throughout the study and S4 and S5 towards the end of the study, where 
melatonin continued to free-run but temperature was influenced by the sleep-wake 
cycle.
The total amount of aMT6s excreted per 24 hour day did not alter significantly 
throughout the study, indicating that there was no increase in melatonin production 
in the constant dim light conditions. This could be due to the lighting levels being 
constantly low and therefore providing no information with regard to photoperiod 
length. In rats, hamsters and sheep there is a clear difference in melatonin profiles 
between long summer days with a short nocturnal melatonin signal, and short winter 
days with a long nocturnal melatonin signal. In humans a slight difference in 
nocturnal melatonin duration with the seasons has been seen in Antarctica 
(Makkison and Arendt, 1991) and Sweden (Beck-Friis et a!., 1984 ). An increase in
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the length of the nocturnal melatonin secretion has also been demonstrated in 
humans exposed to short (8 hour) days and long (14 hour) nights where melatonin 
was actively secreted for an extra 1.5-2 hours each day (Wehr et a/., 1993).
Measurement of cortisol levels in saliva did not provide any information regarding 
phase or onset times. This was largely due to the sampling occurring at 3 hourly 
intervals. No accurate timing could be determined, but the peak level for cortisol 
was always seen in the first saliva sample collected each day as would be expected.
The subjects did not synchronise as a group. This is illustrated by the calculated 
periodicities. A more striking method to demonstrate this is the comparison of sleep 
times on particular days. On day 14/15, for example, the subjects' major sleep 
episode occurred (in numerical subject order) at 08:00-16:25; 01:00-14:25; 24:00- 
09:25; 06:00-16:20; 02:30-13:40 and 09:45-17:00 hours. It is possible that in this 
particular group interpersonal relations inhibited group activities. Individuals who did 
not get on may have deliberately avoided each other by going to bed at different 
times. However, in subsequent studies carried out in this project, with similar groups 
and environmental conditions, group synchronisation did not occur.
Recent studies have suggested that exercise, if suitably timed, can induce 
significant phase changes (Van Reeth et al. 1994a; Buxton et al. 1997). In this 
study although exercise facilities were available, 3 subjects (S2, S4 and S5) made 
use of them on only two or three occasions, and no subject exercised after day 5 of 
the study. This minimal amount of exercise is unlikely to have modified the results 
of the experiment.
The group mean free-running periodicity of 24.26h is considerably lower than that 
reported by Wever (1979) for the endogenous pacemaker (24.9 ± 0.2h). This could 
be due to the experimental conditions and the individual subjects. However, shorter 
taus have been reported by other groups. Campbell et al. (1993) reported a shorter 
tau in nappers than non-nappers, with a self-selected light-dark cycle and the ability 
to eat and sleep whenever they liked. Czeisler et al. (1995a) and Klerman et al. 
(1996) also report a shorter tau of 24.1-24.2h for the endogenous clock under dim 
light conditions (<15 lux) using a 28h forced desynchronisation protocol for 33-36 
days and constant routines for the evaluation of the rhythm status. One possible
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reason for the discrepancy in the tau of the endogenous clock is that Wever and co­
workers allowed their subjects to self-select the light-dark cycle. This could have 
resulted in phase delays induced by evening bedside lights. The subjects were also 
instructed to eat regularly three times a day and were not allowed to nap.
It can be concluded that in constant dim light (< 8 lux) with weak time cues, and 
without behavioural impositions, the majority of subjects desynchronise from the 24 
hour day. In 5 out of 6 subjects all variables studied free-ran with individually 
variable periodicity. Deliberate adjustment of the sleep-wake cycle did not entrain 
the endogenous clock as seen by the 6-sulphatoxymelatonin measurements.
A period of 10 days was required for free-run to be manifested as significantly 
different from 24 hours in subjects SI, 82, and 84-86. This finding was important in 
determining the design of subsequent studies investigating the effects of light 
intensity and melatonin administration on human circadian rhythms. The period 
studied for each treatment/lighting condition must be a minimum of 10 days, 
preferably more.
This initial investigation established a suitable model environment for human 
circadian studies. Partial temporal isolation was used, because the aim was 
eventually to give timed medication. Complete temporal isolation implies ignorance 
of clock time and timed administration of medication would compromise the nature 
of the experiment
The experimental approach and conditions established in this baseline study have 
achieved the stated objective. As a result further trials were planned to investigate 
the ability of different light intensities and timed melatonin administration either to 
prevent rhythms from free-running or to re-entrain rhythms which were already free- 
running.
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CHAPTER 6
EFFECTS OF TIMED MELATONIN ADMINISTRATION
ON HUMAN CIRCADIAN RHYTHMS IN CONSTANT DIM
LIGHT
172
6.1 SPECIFIC STUDY DESIGN & RATIONALE
The baseline study reported in Chapter 5 indicated that 5/6 individuals free-ran with 
a mean tau of 24.26 ± 0.05h under our experimental conditions. Subsequently the 
ability of timed administration of melatonin to prevent such free-running rhythms was 
investigated.
Administration of exogenous melatonin has been shown to cause phase-shifts in 
the biological clock, using endogenous melatonin as the phase marker (Arendt et al. 
1984,1985e^/1986), according to a phase response curve (PRC) (Lewy et al., 1992; 
Zaidan et al., 1994). The phase-shift produced is dose dependent over the range
0.05 to 5 mg with the acute administration of melatonin at 17:00h (Deacon and 
Arendt ,1995). It has yet to be shown whether exogenous melatonin is able fully to 
entrain all biological rhythms. Previous investigations have concentrated on the 
effects of timed daily administration of melatonin in free-running blind individuals. 
One such individual, exposed to all ambient time cues apart from the lightdark 
cycle, exhibited stabilisation of the sleep-wake cycle, especially sleep onset, but not 
endogenous melatonin, cortisol or core body temperature rhythms (Arendt et al., 
1988; Folkard et al., 1990). Other published reports (Jan et al., 1994; Sack et al., 
1991; Tzischinsky et al., 1992) have also recorded the ability of timed administration 
of exogenous melatonin to stabilise the sleep-wake cycle in visually impaired 
individuals. However, only one subject has displayed the possible entrainment of a 
strongly endogenous rhythm such as melatonin (Sack et al., 1991).
Arendt et al. (1985) and Wever (1989), using a fractional desynchronisation 
protocol, attempted to increase the limits of entrainment in a 300 lux light dark cycle 
using 5mg melatonin at dark onset. There was some evidence for entrainment of 
behavioural variables (alertness, performance) with this procedure, but no 
entrainment of the underlying circadian oscillator (Arendt et al., 1985a). These 
experiments did, however, serve to show the close coupling of the core temperature 
and melatonin rhythms during free run for the first time.
McArthur et al., (1995) reported that daily melatonin administration entrained a free- 
running sighted individual living in a normal environment. Close inspection of their
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data, however, suggests that full synchronisation was not induced but tau was 
shortened.
This study investigated the effects of timed daily administration of exogenous 
melatonin in sighted normal individuals, maintained as a group under continuous 
dim light conditions in partial isolation, but with knowledge of clock time. The study 
was comprised of two legs designed to investigate the ability of melatonin either to 
prevent free-run, or to resynchronise already free-running rhythms.
The subjects were required to complete two legs of the study, each of 31 days. In a 
double-blind, randomised cross-over design, they received placebo (gelatin lactose) 
at 2000h for the first 15 days of the study (Placebo 1st) and melatonin (5mg in 
gelatin lactose, Penn Pharmaceuticals Ltd., Tredegar, Gwent, U.K.) for the second 
15 days of the study (Melatonin 2nd) or vice versa (Melatonin 1st:Placebo 2nd). The 
treatment order was reversed in the second leg. The study design is shown in Fig 
6.1.
6.1.1 Isolation Facility
The isolation unit was provided by the DERA, Farnborough, and has been described 
in section 2.1.1. The exact layout was as shown in Fig 2.1 Plan B.
An overhead lighting system provided by Siemens Lighting was used. The bank of 
lights in each room were fitted with shutters to reduce the illumination levels to < 8 
lux as described in 2.1.2 was used throughout the study.
6.1.2 Subjects
10 normal healthy males aged 23.90 ± 0.75 years, numbered 81 - 810, were 
recruited from the Army Personnel Establishment Trials Section, Farnborough, U.K.. 
They were under no medication except for minor analgesics and were non-smokers 
or smoked less than 10 cigarettes a day.
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Potential subjects were screened as described in section 2.2.4. Each individual’s 
dim light melatonin onset, as described by Lewy et al., (1989), was determined by 
collecting blood samples every 30 minutes between 19:00 and 02:00h in light levels 
of < 50 lux. Plasma melatonin levels were determined and the dim light melatonin 
onset (DLMO) calculated as described in section 2.4.4.
Screened individuals were considered as suitable for inclusion in the experiment if 
their 24h aMT6s output was within the normal range (12.81 ± 9.6 pg/24h, n=177) 
with an acrophase time between 02:00 and 06:00h and if the plasma dim light 
melatonin onset fell between 21:00 and 24:00h. All the individuals screened fulfilled 
these requirements and participated in both legs of the study.
Table : 6.1 Plasma Dim Light Melatonin Onsets
Plasma DLMO Plasma DLMOSubject
No.
2 X  Limit of Detection 2 x  Baseline Values
1 21:30 22:00
2 20:45 20:45
3 20:55 20:55
4 20:00 21:40
5 21:40 21:35
6 23:00 23:40
7 22:30 22:45
8 21:45 22:30
9 21:15 21:15
10 21:00 21:15
Mean 21:26 21:50
SEM 0.04 0.04
Informed written consent was obtained from all the subjects and the study protocol 
was approved by the DERA Centre for Human Sciences Ethics Committee.
6.1.3 Study Protocol
The subjects were maintained in two groups of 6 and 4 individuals for two legs, each 
of 31 days. The same general study protocol applied to all legs and the mean 
values for light levels and ambient temperature are taken across all 4.
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Subjects arrived at the isolation facility at 10:00h on Day 1. Equipment was issued 
and recording of data plus collection of samples began at 12:00. An acclimatisation 
period of 32 hours was followed by lighting levels being lowered to < 8 lux at 20:00h 
on day 2. Lighting levels were maintained at this intensity for 31 days. Constant dim 
light levels were 4.09 ± 0.8 (SEM) lux (n = 2580). The ambient temperature range 
was 21 - 29°C (mean = 22.5 ± 1.26 (SEM)°C, n = 1240). Subjects had access to a 
digital clock and watches giving knowledge of clock time to enable timed medication 
to be given.
Melatonin or placebo capsules were taken 3 times a day, when awake, during days 
2-31. The administration was timed to occur at 04:00, 12:00 and 20:00h. Those 
capsules taken at 04:00 and 12:00h were always placebo (gelatin lactose). The 
20:00h capsule contained either 5mg melatonin in gelatin lactose or placebo as 
follows: Placebo days 1-15 (Placebo 1st) : Melatonin days 16-30 (Melatonin 2nd) or 
Melatonin days 1-15 (Melatonin 1st) : Placebo days 16-30 (Placebo 2nd). Capsules 
were placed in the isolation unit in clearly labelled vials with separate bottles for 
each subject for each dose time. Experimenters, using video surveillance, were 
instructed to ensure that capsules were taken at the correct time by all subjects who 
were awake. Individuals were never woken to take the pills. Compliance was noted 
and a record kept of which pills were taken.
The general study conditions were as described in section 2.2.3. An incident book 
was kept throughout the study to record any significant events, subjects requests 
and general observations on the subjects mood and behaviour.
The experiments were conducted between September and March with a minimum of 
6 weeks between legs.
6.1.4 Measurements Taken
The following measurements were taken throughout the study.
a. daily maximum and minimum temperatures in each room
b. light levels every 2 days
c. core body temperature via a rectal probe and memory logger
d. sleep-wake/activity via wrist mounted accelerometer - Mini Motionlogger
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e. 4 hourly urine collections except for oversleep periods
f. 2 hourly performance sessions when awake using the shortened DERA 
test battery (serial choice reaction time test and Sternberg memory 
scanning test).
g. daily activity diaries
h. subjective sleep logs after every sleep period
i. UWIST mood adjective questionnaire morning and evening
6.2 ANALYSIS OF DATA  
6.2.1 Urinary aMT6s
Urinary aMTBs levels were measured using the assay described in section 2.4.2. 
Quality control coefficients of variation (C.V.) were 9.6%, 8.9% and 7.6% for 
concentrations of 3.42, 26.71 and 47.87 ng/ml respectively. The limit of detection at 
2 X SD of zero binding was 0.36 ng/ml. The excretion rate for each sample period 
was calculated in ng/hr and these values were subjected to 3 day moving window 
cosinor analysis as described in Chapter 3 section 3.1.4 and spectral analysis as in 
section 3.1.5. During administration of melatonin, (Melatonin 1st and Melatonin 
2nd), urinary aMT6s from exogenous melatonin completely masked the endogenous 
rhythm and no cosinor analysis was performed on this data. Acrophase times and 
amplitude values were analysed further by linear regression analysis and repeated 
measures ANOVA as described in section 3.2, both on an individual basis and by 
group mean values.
6.2.2 Temperature Data
Raw temperature data were edited as described in section 3.1.1. The values were 
then demasked for sleep and melatonin administration as described in Chapter 4. 
The temperature data used for further analysis were hourly means self-corrected for 
sleep during Placebo 1st and Placebo 2nd treatments, and hourly means self­
corrected for sleep and melatonin during Melatonin 1st and Melatonin 2nd.
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The appropriately demasked temperature data were analysed further using cosinor, 
spectral, periodogram and autocorrelation analysis (sections 3.1.4, 3.1.5, 3.1.6 and 
3.1.7).
The calculated acrophase times, were then subjected to linear regression analysis 
and repeated measures ANOVA. (Sections 3.2.1 and 3.2.2), both on an individual 
basis and as group means.
6.2.3 Activity and Sieep Data
Raw activity data were edited as described in section 3.1.1. For analysis of 
periodicity, data collected during sleep episodes of less than 3 hours duration was 
discarded. These sleep periods were regarded as naps, and therefore 
unrepresentative of the sleep-wake cycle. Sleep parameters were determined using 
Action3 software (Ambulatory Monitoring Inc.) and analysed as described in sections
3.1.2 and 3.1.3.
Edited activity data were analysed further using cosinor, spectral, periodogram and 
autocorrelation analysis (sections 3.1.4, 3.1.5, 3.1.6 and 3.1.7).
The calculated acrophase times and sleep parameters were then subjected to linear 
regression analysis and repeated measures ANOVA. (Sections 3.2.1 and 3.2.2), 
both on an individual basis and as group means.
6.2.4 Performance Data
All performance data collected were analysed for any changes in performance 
across the treatment periods and any differences in performance between the 
various treatments, using daily means as described in section 3.1.6. Results from 
the performance data analysis are not reported here for the reasons stated in 
section 3.1.6.
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6.2.5 UWIST Mood Adjective List
Daily mood scores were calculated according the methodology described in section
2.5.2.
6.3 RESULTS
6.3.1 Compliance
Subject 2 withdrew part way through Placebo 1st treatment and Subject 6 withdrew 
during Placebo 2nd treatment. In both cases withdrawal was for family reasons. 
Subject 5 experienced difficulties with the rectal probe during Placebo 1st:Melatonin 
2nd resulting in insufficient data for analysis. Subject 5 was also extremely non- 
compliant with regard to performance tests and was observed reading a book whilst 
completing the tests. Consequently performance data collected from this individual 
was discarded.
The overall mean percentages (± SEM) of the theoretical maximum amount of data 
collected for the various parameters were as follows:
Temperature 75.9 ±2.9%
Activity 92.0 ±1.6%
Sleep 95.6 ±1.2%
aMT6s 88.7 ± 2.4%
Performance 80.1 ±2.6%
Data lost due to equipment malfunction can be summarised as follows:
a. activity iost data: SI Placebo 2nd 84h; S5 Melatonin 2nd 44h; S6 
Placebo 2nd 18h; S9 Melatonin 2nd 73h & Melatonin 1st 77h and S10 
Placebo 1st 62h.
b. temperature iost data: SI Placebo 2nd 144h; S2 Placebo 2nd 21.5h; S4 
Melatonin 2nd 32h & Placebo 2nd 59h; S6 Placebo 1st, Melatonin 2nd 
32h & Placebo 2nd 18h; S7 Placebo 1st 12h; S8 Melatonin 1st 29h; S9 
Placebo 1st 144h, Melatonin 1st 33h & Placebo 2nd 96h and S10 
Melatonin 2nd 67h.
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6.3.2 Individual Data
Summary raster double plots were produced for all the subjects giving an overall 
record of the sleep-wake cycle and activity, temperature and aMTBs acrophase 
times (See Figs 6.2 - 6.11). There were no significant changes in the UWIST Mood 
Adjective List for any subject on any treatment although there was a trend for 
general arousal levels to drop during the course of each leg as a whole.
6.3.2.1 Rest-activity
Visual inspection of these plots indicated that 9/10 subjects free-ran under Placebo 
1st treatment. The sleep-wake cycle was stabilised to 24h in 8/10 individuals, while 
2/10 (Figs 6.3 & 6.6) exhibited highly irregular sleep throughout the period of 
Melatonin 1st administration. However, these two individuals showed a 
consolidated sleep-wake cycle on cross-over to Placebo 2nd and also under 
Placebo 1st treatment. The Melatonin 2nd treatment induced phase advances of 
the rest activity cycle in 5 out of 9 subjects, phase delays in 2 out of 9 and 
stabilisation in 2 out of 9, with the majority of individuals showing a subsequent 
synchronisation or stabilisation to 24h. Subject 7 (Fig 6.8) an initial phase delay with 
Melatonin 2nd treatment, followed by a few days of apparent synchronisation and a 
further rapid phase delay.
6.3.2.2 Temperature
The demasked temperature rhythm free-ran in 9/9 subjects with Placebo 1st 
treatment and 5/9 with Placebo 2nd treatment. Melatonin treatment initially induced 
both phase advances and phase delays in the temperature rhythm. With Melatonin 
1st treatment, 8/10 individuals appeared to remain synchronised to 24h, although a 
shortening of tau without synchronisation is also a possible explanation. Indeed, 
with Melatonin 2nd, 3 subjects showed a continuing free-run in the demasked 
temperature rhythm, albeit with a shortened tau, (Fig 6.12) whilst 1 subject exhibited 
a free-running tau longer than with Placebo 1st treatment. Repeated measures 
ANOVA analysis of the amplitude of the demasked temperature rhythms showed no 
significant differences with treatment.
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The different responses of the temperature rhythm to melatonin administration were 
most likely due to the variable circadian times of administration. The relationship 
between the response and the time of initial melatonin administration relative to the 
calculated core body temperature maximum was expressed as a phase response 
curve. The data used were from 8 subjects on Melatonin 2nd treatment with the 
shift in temperature between days 15 and 16 marking the phase-shift induced by 
melatonin. Values were also obtained from Melatonin 1st treatment using the shift 
from day 1 to day 2. In this case the temperature data was less reliable as only 1 
days worth of data was available for determination of the temperature maximum 
prior to melatonin administration. The phase response curve is shown in Fig 6.13. 
The melatonin treatment time is shown relative to the temperature acrophase 
(hours) and also as circadian phase (degrees), where 0° is the calculated 
temperature nadir (Jewett et al, 1994).
6.S.2.3 aMTBs
The aMT6s rhythm free-ran in 10/10 individuals with Placebo 1st treatment and 5/9 
subjects with Placebo 2nd. The mean endogenous aMT6s per 24h and the mean 
aMT6s excreted per 24h during melatonin treatment for each subject are shown in 
Table 6.2. The endogenous secretion for all subjects was within the normal range 
for age (13.14 ± 9.8|ig/24h to 54.0 ± 6.0pg/24h). There were no apparent 
relationships between the endogenous secretion and the responses observed. The 
excretion of aMT6s during melatonin treatment was used to determine the 
percentage of active pills taken (97.4 ± 0.6%) and to evaluate individual clearance 
rate. Subject 1 showed a delayed clearance, taking 5 days to return to baseline 
levels after cessation of treatment (Melatonin 1st) compared to the group mean of 
48h. This subject had a shorter tau when placebo was administered after melatonin 
than when placebo was administered first.
The aMT6s periodicity was closely correlated to that derived for demasked 
temperature (r=0.63, p=0.02), and there were no significant differences in the 
amplitude of the urinary sulphate rhythm by repeated measures ANOVA, either 
during the course of the study or between Placebo 1st and Placebo 2nd treatments.
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Fig 6.13
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■  Data derived from subjects receiving melatonin as a first treatment after 
1 day in a normal light dark cycle
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The full results obtained from linear regression analysis, spectral analysis, 
periodogram analysis and auto correlation for each parameter and each individual, 
together with group means for all 4 treatments are shown in Tables 6.3 - 6.7.
Table 6.2 Amount of aMTBs excreted (figs)
Subject Mean Endogenous Mean aMT6s
Number aMT6s Excreted per 24h Excreted per 24h during 
Melatonin Treatment
1 28.15 ±1.58 2957.86 ± 194.59
2 22.69 ±1.08 2975.70 ±150.57
3 11.56 ±0.37 3310.82 ±272.70
4 27.11 ±1.82 3445.63 ± 191.80
5 35.55 ±1.63 3284.49 ±213.44
6 15.35 ±1.21 2819.66 ±106.18
7 8.41 ± 0.66 3295.52 ± 270.79
8 6.59 ± 0.47 2379.64 ±172.17
9 18.96 ±1.24 3808.88 ± 353.43
10 20.55 ±1.02 2129.35 ± 143.55
The individual results for each treatment can be summarised for the various 
parameters as follows:
G.3.2.4 Placebo 1st
The individual periodicities for each parameter determined by regressive cosinor, 
spectral, periodogram or autocorrelation analysis, as shown in Table 6.3, were 
subjected to statistical analysis to determine any significant differences between 
subjects or analysis methods. There were no significant differences between 
subjects or analysis methods for activity and temperature tau. For aMT6s there was 
a significant difference between subjects (p=0.01) and regressive cosinor and 
spectral analysis (p=0.03) by 2 way ANOVA, spectral analysis giving shorter tau for 
9/10 subjects. There were no significant differences between subjects for sleep 
onset or offset but there was a significant difference between tau determined by 
regressive cosinor and spectral analysis by ANOVA (p=0.04 sleep onset & p=0.002 
sleep offset), spectral analysis calculating a shorter tau for sleep onset but a longer 
tau for sleep offset. (Table 6.4)
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Table 6.3 MELATONIN ADMINISTRATION STUDY - PLACEBO 1ST
Individual and Group Periodicities Determined by
Various Analysis Methods
Parameter Subject Days Regression Spectrai Periodogram Autocorrelation
Activity 1 1-16 24.12 ±0.05*** 24.22 24.18 24.22
2 1 -12 23.92 ± 0.34 23.85 24.38
3 1-16 24.19 ±0.08*** 24.35 24.17 24.48
4 1-16 24.14 ±0.02*** 24.55 24.18 24.18
5 1 -16 24.14 ±0.07*** 24.00 24.12 24.48
6 1-16 24.47 ±0.12*** 24.50 24.36 25.06
7 1-15 24.15 ±0.14* 24.50 24.00 24.03
8 1-15 24.11 ±0.05*** 24.50 24.14 24.54
9 1 -8 24.20 ± 0.06*** 24.20 24.25 24.42
10 1 -15 24.13 ±0.13* 24.26 24.06 24.12
Group n=10 1-15 24.17 ±0.03*** 24.29 24.18 24.39
Temperature 1 1-16 24.48 ± 0.04*** 24.56 24.39 24.12
2 1 -12 24.19 ±0.10** 24.30 24.20 24.00
3 1-16 24.16 ±0.08** 24.75 24.25 24.36
4 1 -16 24.41 ± 0.06*** 23.70 24.30 24.54
5 1-16 No Data
6 1-16 24.46 ±0.10*** 24.36 24.47 25.00
7 1-15 24.55 ± 0.20*** 24.30 24.24 24.06
8 1 -15 24.29 ± 0.08*** 24.12 24.20 24.28
9 1 -8 24.54 ±0.10*** 24.42 24.24 24.00
10 1 -15 24.22 ±0.13** 24.30 24.21 24.24
Group n=9 1 -15 24.39 ± 0.07*** 24.31 24.28 24.29
aMT6s 1 1 -16 24.40 ±0.17*** 24.42
2 1 -12 24.26 ± 0.22* 24.15
3 1 -16 24.50 ±0.19*** 24.32
4 1 -16 24.40 ±0.18*** 24.30
5 1 -16 24.08 ± 0.09 24.00
6 1-16 24.57 ± 0.09*** 24.72
7 1 -15 24.46 ± 0.29** 24.23
8 1-15 24.28 ± 0.06*** 24.20
9 1 -8 24.70 ±0.11** 24.30
10 1-15 24.17 ±0.09** 24.10
Group n=10 1-15 24.39 ± 0.07*** 24.27
Sleep Onset 1 1 -16 24.26 ±0.16** 24.00
2 1-12 24.40 ± 0.53 24.52
3 1 -16 24.35 ±0.15** 24.28
4 1 -16 24.25 ± 0.08*** 24.12
5 1 -16 24.20 ±0.16* 23.96
6 1 -16 24.39 ±0.21*** 24.32
7 1-15 24.15 ±0.24 24.25
8 1-15 24.22 ±0.12*** 24.00
9 1 -8 24.10 ±0.21 24.05
10 1-15 24.15 ±0.17 23.62
Group n=10 1-15 24.20 ±0.11*** 24.11
Sleep Offset 1 1-16 24.31 ±0.16*** 24.35
2 1 -12 23.99 ± 0.42 24.00
3 1-16 24.16 ±0.09** 24.35
4 1-16 24.13 ±0.11* 24.60
5 1 -16 24.12 ±0.10* 24.30
6 1-16 24.11 ± 0.43 24.62
7 1-15 24.19 ±0.31 24.70
8 1-15 24.15 ±0.07*** 24.30
9 1 -8 24.10 ±0.43 24.34
10 1-15 24.07 ± 0.08 24.12
Group n=10 1-15 24.14 ±0.07*** 24.37
Significance Levei of fitted regression line *** =<0.001 = <0.01 * = <0.05
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Table 6.4 MELATONIN ADMINISTRATION STUDY - MELATONIN 2ND
Individual and Group Periodicities Determined by
Various Analysis Methods
Parameter Subject Days Regression Spectrai Periodogram Autocorrelation
Activity 1
2
16-30 24.00 ± 0.09 
Subject Withdrew
24.02 24.05 24.22
3 16-30 23.66 ±0.14 24.30 23.73 23.54
4 16-30 24.04 ±0.08 24.25 23.97 23.24
5 16-30 23.86 ± 0.08** 24.02 23.90 23.48
6 16-30 24.99 ± 0.30*** 24.60 25.12 25.10
7 16-30 25.44 ± 0.47*** 26.36 25.60 25.57
8 16-30 24.06 ± 0.09 23.72 23.95 24.00
9 21 -30 24.48 ± 0.59 23.73 23.78 24.12
10 16-30 24.02 ± 0.09 24.36 24.00 24.06
Group n=7 16-30 24.29 ± 0.08*** 24.06 23.91 23.81
Temperature 1
2
16-30 24.00 ±0.15 
Subject Withdrew
23.75 23.99 23.10
3 16-30 23.89 ± 0.08** 23.95 23.73 23.00
4 16-30 24.15 ± 0.07*** 23.70 23.97 23.45
5 16-30 No Data
6 16-30 25.20 ± 0.25*** 25.00 25.08 25.00
7 16-30 24.36 ±0.12*** 26.20 25.35 24.00
8 16-30 23.52 ±0.13*** 23.85 23.84 22.48
9 21 -30 24.09 ±0.18 23.92 23.93 24.00
10 16-30 24.02 ± 0.08 24.36 24.02 23.90
Group n=6 16-30 24.07 ±0.12 23.92 23.91 23.32
Sleep Onset 1
2
16-30 24.17 ±0.23 
Subject Withdrew
24.22
3 16-30 23.44 ±0.38** 24.00
4 16-30 24.04 ±0.18 24.15
5 16-30 23.81 ± 0.25 23.95
6 16-30 24.11 ±0.11 24.10
7 16-30 Double Phase Shift
8 16-30 23.77 ± 0.20* 24.00
9 21 -30 23.87 ±0.16 24.16
10 16-30 24.16 ±0.05*** 24.12
Group n=7 16-30 23.99 ± 0.20 24.09
Sleep Offset 1
2
16-30 24.15 ±0.24 
Subject Withdrew
24.32
3 16-30 23.66 ± 0.27 23.85
4 16-30 23.93 ± 0.42 23.75
5 16-30 23.88 ± 0.37 23.96
6 16-30 25.59 ± 0.74*** 24.35
7 16-30 Double Phase Shift
8 16-30 24.00 ± 0.39 24.06
9 21 -30 23.61 ± 0.69 24.10
10 16-30 23.99 ±0.13 24.20
Group n=7 16-30 23.90 ±0.12 24.03
Significance Level of fitted regression line *** =<0.001 ** = <0.01 * = <0.05
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There were no significant differences shown for time in bed, total sleep time, wake 
after sleep onset or sleep efficiency by any individual during the treatment. 
However, there was a tendency for sleep quality to improve over time, with wake 
after sleep onset and sleep latency decreasing. Full results from the linear 
regression analysis of sleep parameters (single day values), and mean values ± 
SEM are summarised in Table 6.7.
6.3.2.S Melatonin 2nd
Statistical analysis of the periodicities determined by the various analysis methods 
showed that for activity there was a significant difference between subjects (p 
<0.001) but not analysis methods. Temperature periodicities varied significantly 
both between subjects (p=<0.001) and analysis methods (p=0.002). There were no 
significant differences in period derived from regressive cosinor, spectral and 
periodogram analysis. However, autocorrelation gave a significantly shorter tau 
than the other 3 methods. There were significant differences between subjects for 
both sleep onset and offset (p <0.001) but there was no significant difference 
between analysis methods for sleep offset. There was a significant difference 
between regressive cosinor and spectral analysis for sleep onset by ANOVA 
(p=0.03). (Table 6.5)
There were no significant differences across the treatment period in any individual 
for time in bed, total sleep time, wake after sleep onset or sleep efficiency. Full 
results from the linear regression analysis of sleep parameters (single day values), 
and mean values ± SEM are summarised in Table 6.7.
G.3.2.5 Melatonin 1st
Although, on an individual basis, variations in the tau determined for the measured 
parameters by the various analysis methods were seen, statistical analysis of the 
calculated periodicities gave no significant differences, either between subjects or 
analysis methods for temperature and activity. There was no significant difference 
between analysis methods for sleep onset or offset but there was a significant 
difference between subjects by ANOVA (p <0.001). (Table 6.6)
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Table 6.5 MELATONIN ADMINISTRATION STUDY - MELATONIN 1ST
Individual and Group Periodicities Determined by
Various Analysis Methods
Parameter Subject Days Regression Spectral Periodogram Autocorrelation
Activity 1 1 -16 24.07 ± 0.04** 23.96 24.05 23.30
2 1-16 . 24.01 ± 0.24 23.75 24.23
3 1 -16 24.05 ± 0.05* 24.26 23.99 24.00
4 1-16 24.07 ± 0.03** 24.00 24.00 23.57
5 1-16 23.94 ±0.10 23.92 24.09 23.48
6 1-16 24.15 ±0.05*** 24.20 24.05 24.06
7 1-15 24.03 ± 0.05 24.26 24.01 24.03
8 1-15 24.02 ±0.10 24.25 24.01 24.00
9 1-15 24.03 ± 0.09 24.15 23.93 23.45
10 1 -15 24.02 ± 0.04 24.02 24.00 23.51
Group n=8 1-15 24.02 ± 0.03 24.14 24.00 23.74
Temperature 1 1-16 24.15 ±0.10** 24.45 24.07 24.21
2 1-16 23.85 ±0.13* 23.92 24.23 24.00
3 1-16 23.94 ±0.09 24.12 23.98 24.54
4 1-16 24.00 ± 0.05 24.00 23.99 24.54
5 1 -16 24.05 ±0.10 23.86 23.95
6 1 -16 24.08 ± 0.05 23.92 24.06 24.00
7 1-15 24.02 ±0.15 24.00 24.00 24.00
8 1 -15 23.97 ±0.13 23.85 23.88 24.00
9 1-15 24.01 ±0.12 23.55 24.05 24.24
10 1-15 24.26 ± 0.30 24.28 24.05 24.00
Group n=8 1-15 24.08 ±0.10* 24.02 24.01 24.19
Sleep Onset 1 1 -16 24.04 ±0.15 23.75
2 1-16 Irregular Sleep Patterns
3 1 -16 24.07 ± 0.24 24.30
4 1 -16 24.02 ±0.16 24.02
5 1 -16 Irregular Sleep Patterns
6 1 -16 24.01 ±0.17 23.90
7 1-15 24.05 ±0.15 23.80
8 1-15 24.02 ±0.19 23.92
9 1 -15 23.91 ± 0.29 23.91
10 1 -15 24.05 ±0.16 23.70
Group n=8 1 -15 24.07 ± 0.08 23.91
Sleep Offset 1 1 -16 24.05 ± 0.08 24.20
2 1-16 Irregular Sleep Patterns
3 1-16 23.98 ± 0.51 24.32
4 1 -16 24.01 ±0.14 24.26
5 1 -16 Irregular Sleep Patterns
6 1-16 23.93 ± 0.29 24.22
7 1-15 24.03 ± 0.20 24.30
8 1-15 23.87 ± 0.26 24.06
9 1 -15 24.00 ± 0.21 23.36
10 1 -15 24.01 ± 0.08 24.10
Group n=8 1 -15 24.01 ±0.12 24.10
Significance Level of fitted regression line *** =<0.001 ** = <0.01 * = <0 05
199
Table 6.6 MELATONIN ADMINISTRATION STUDY - PLACEBO 2ND
Individual and Group Periodicities Determined by
Various Analysis Methods
Parameter Subject Days Regression Spectral Periodogram Autocorrelation
Activity 1 16-30 23.98 ± 0.09 24.70 24.01 24.24
2 16-30 24.15 ±0.18 24.36 24.06
3 16-30 24.19 ±0.08*** 24.45 24.08 24.54
4 16-30 23.92 ± 0.07 24.32 24.00 24.00
5 16-30 24.20 ±0.11*** 24.20 24.21 24.00
6 16-23 24.44 ± 0.26** 24.26 24.56 24.06
7 16-30 24.22 ±0.18* 24.26 24.18 24.24
8 16-30 24.20 ±0.11** 24.15 24.20 24.54
9 16-30 24.30 ± 0.09*** 24.35 24.31 24.42
10 16-30 24.11 ±0.05*** 24.56 24.06 24.18
Group n=8 16-30 24.11 ±0.04*** 24.38 24.18 24.28
Temperature 1 16-30 23.86 ± 0.31 23.96 24.16 23.25
2 16-30 24.02 ±0.12 24.20 24.09 23.70
3 16-30 24.24 ± 0.09*** 24.36 24.20 24.36
4 16-30 24.09 ± 0.09* 24.16 24.14 24.20
5 16-30 24.05 ±0.10 24.05 24.08
6 16-23 24.00 ± 0.28 24.05 24.22 24.00
7 16-30 24.66 ± 0.38** 24.85 24.34 22.00
8 16-30 24.37 ± 0.227* 24.26 24.31 24.30
9 16-30 24.42 ± 0.08*** 24.35 24.31 24.42
10 16-30 24.02 ±0.10 24.12 24.23
Group n=8 16-30 24.19 ±0.06*** 24.26 24.24 23.79
aMT6s 1 16-30 23.91 ±0.18 24.42
2 16-30 24.33 ± 0.33* 24.40
3 16-30 23.85 ± 0.85 23.85
4 16-30 24.29 ± 0.23* 24.30
5 16-30 Insufficient Data
6 16-23 24.22 ± 0.31 24.10
7 16-30 24.24 ±0.22* 24.30
8 16-30 24.11 ±0.09** 24.16
9 16-30 24.37 ± 0.22** 24.15
10 16-30 24.20 ± 0.34 24.15
Group n=8 16-30 24.08 ± 0.07* 24.19
Sleep Onset 1 16-30 24.09 ±0.19 23.86
2 16-30 24.24 ±0.19* 24.15
3 16-30 24.21 ±0.21* 24.40
4 16-30 24.03 ±0.11 24.12
5 16-30 24.30 ± 0.22* 24.52
6 16-23 23.32 ± 1.35 24.20
7 16-30 24.03 ± 0.30 24.10
8 16-30 24.29 ±0.14*** 24.25
9 16-30 24.36 ± 0.36* 24.42
10 16-30 24.03 ±0.18 24.15
Group n=8 16-30 24.12 ± 0.09* 24.19
Sleep Offset 1 16-30 24.09 ± 0.21 24.15
2 16-30 24.20 ± 0.29 24.02
3 16-30 24.10 ±0.24 24.22
4 16-30 24.05 ±0.15 24.10
5 16-30 24.15 ±0.32 24.22
6 16-23 24.59 ± 0.60 24.36
7 16-30 24.03 ± 0.26 24.62
8 16-30 24.20 ±0.14* 24.25
9 16-30 24.29 ±0.19** 24.40
10 16-30 24.16 ±0.22 24.20
Group n=8 16-30 24.11 ±0.06** 24.29
Significance Level of fitted regression line *** =<0.001 = <0.01 * = <0.05
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Table 6.7 Sleep Parameters (single day) Mean Value ± SEM
Treatment Subject Time in Bed 
(mins)
Total Sleep Time 
(mins)
WASO
(mins)
Efficiency (%)
Ftacebo 1st 1 512.1 ±33.2 471.6 ±29.3 40.5 ±7.5 92.5 ±1.1
2 426.3 ±59.3 373.4 ±42.3 52.9 ±21.2 90.0 ± 2.8
3 399.7 ±18.7 390.7 ±19.1 8.9 ± 2.5 97.7 ± 0.7
4 503.9 ± 26.0 480.4 ± 24.2 23.5 ± 4.1 95.4 ± 0.7
5 541.5 ±35.4 453.7 ± 46.5 87.7 ±27.7 83.2 ± 5.6
6 317.8 ±29.6 325.2 ± 26.7 9.4 ±1.5 96.9 ± 0.4
7 601.9 ±49.1 601.9 ±49.1 2.9 ±1.0 99.5 ± 0.2
8 580.5 ± 40.6 554.8 ± 43.3 25.7 ± 5.0 93.6 ± 2.5
9 611.8 ±20.9 568.4 ±17.2 43.4 ±12.3 93.2 ± 1.9
10 611.4 ±19.9 598.7 19.6 12.6 ±4.6 98.0 ± 0.8
Group n = 10 477.1 ± 23.1 460.2 12.8 28.7 ±3.1 94.3 ± 0.6
Melatonin 2nd 1
2
473.8 ± 37.2 429.4 ±31.9 44.4 ±9.2 91.6± 1.4
3 432.5 ± 38.3 410.4 ±36.7 22.1 ± 5.3 94.9 ±1.4
4 428.1 ± 36.2 379.4 ± 30.2 48.7 ±18.2 90.0 ± 2.8
5 566.8 ±41.3 525.8 ± 34.1 41.0± 12.0 93.6 ± 1.4
6 313.3 ±35.7 296.7 ± 32.2 11.8 ±3.0 95.9 ± 0.9
7 488.2 ± 43.8 488.2 ± 43.8 6.8 ± 3.3 98.1 ± 1.0
8 499.4 ± 42.9 479.1 ± 44.4 20.3 ± 3.3 94.8 ± 1.2
9 575.1 ± 32.3 518.9 ±31.6 56.2 ± 9.9 90.2 ± 1.9
10 540.3 ± 32.3 528.3 ± 30.9 12.0 ±2.6 97.9 ± 0.4
Group n = 9 477.1 ±13.0 445.5 ±11.3 28.5 ± 2.9 93.7 ± 0.7
Melatonin 1st 1 552.8 ± 33.1 524.9 ±31.2 27.9 ± 4.0 95.1 ± 0.8
2 432.1 ± 60.7 410.0 ±50.2 22.1 ±12.4 97.0 ±1.4
3 397.9 ± 43.2 388.4 ±41.1 9.5 ± 2.8 98.1 ± 0.4
4 559.5 ± 22.7 532.3 ± 19.8 27.2 ± 6.2 95.4 ±0.9
5 636.8 ± 74.9 579.1 ± 66.0 57.7 ± 11.3 91.3 ± 0.9
6 487.4 ± 25.8 440.4 ± 32.3 25.5 ± 4.1 94.6 ± 0.7
7 565.5 ± 27.0 562.3 ± 27.5 3.3 ±1.1 99.3 ± 0.7
8 480.9 ± 43.0 464.9 ± 40.3 15.9 ±6.9 96.5 ±1.1
9 457.5 ± 45.0 451.2 ±43.8 6.3 ± 1.9 98.8 ± 0.3
10 553.0 ±18.7 538.4 ± 18.8 14.6 ±5.8 97.4 ± 1.0
Group n = 10 512.6 ± 11.5 489.5 ± 9.5 19.5 ±2.5 96.4 ± 0.3
Placebo 2nd 1 604.2 ± 29.9 555.4 ± 25.4 48.8 ±13.8 92.4 ± 2.0
2 391.5 ±45.0 368.2 ± 43.2 23.3 ± 5.9 93.5 ±1.7
3 473.0 ± 28.9 454.8 ± 26.2 18.2 ±5.1 96.5 ± 0.8
4 498.3 ± 22.1 475.8 ±19.7 22.5 ± 5.2 95.7 ± 0.8
5 552.2 ± 38.6 518.2 ±37.1 34.1 ± 6.9 93.9 ± 1.2
6 481.8 ±60.0 461.0 ±58.0 20.8 ± 4.2 95.7 ± 0.7
7 481.8 ±45.1 457.4 ± 46.0 24.4 ± 9.7 94.1 ± 2.3
8 414.1 ±22.7 405.5 ± 22.7 8.6 ± 3.3 97.9 ± 0.7
9 413.7 ±33.2 397.0 ± 32.5 16.7 ±4.0 95.9 ± 1.1
10 575.9 ± 26.8 533.9 ± 20.5 42.0 ±12.7 93.4 ± 1.9
Group n = 10 485.7 ±11.3 459.6 ±12.5 26.1 ± 2.9 94.7 ± 0.6
There were no significant differences over the treatment period shown for time in 
bed, total sleep time, wake after sleep onset or sleep efficiency. However, there was 
a tendency for sleep quality to improve, with wake after sleep onset and sleep 
latency decreasing. Full results from the linear regression analysis of sleep
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parameters (single day values), and mean values ± SEM are summarised in Table 
6.7.
6.3.2.S Placebo 2nd
Statistical analysis of the individual periodicities determined by the various analysis 
methods showed that for all parameters (activity, temperature, aMT6s, sleep onset 
and sleep onset) there were no significant differences, either between subjects or 
analysis methods by 2 way ANOVA. (Table 6.6).
There were no significant differences across the treatment days in time in bed, total 
sleep time, wake after sleep onset or sleep efficiency by any individual. Full results 
from the linear regression analysis of sleep parameters (single day values), and 
mean values ± SEM are summarised in Table 6.7.
6.3.3 Sleep Timing and Duration
The timing and duration of sleep periods in relation to the demasked temperature 
rhythm were calculated and plotted (Figs 6.14 - 6.17). The longest sleep periods 
occurred when sleep onset fell between 8 and 2 hours before the temperature nadir 
on Placebo 1st, Melatonin 2nd and Placebo 2nd, i.e. on the falling part of the 
temperature curve. Short sleep episodes, on average, commenced on the rising part 
of the temperature curve. The sleep episodes during Melatonin 1st (Subjects
S I,3,4,6-10) showed a wider range in sleep onset times from Bh before to 2h after 
the temperature nadir. Subjects 2 and 5 who displayed irregular sleep with 
Melatonin 1st exhibited sleep onset times at all phases of the temperature rhythm 
(Fig 6.18).
The timing of sleep onset and temperature acrophase in relation to melatonin 
administration are shown in Figs 6.19 - 6.21. With Melatonin 1st the temperature 
acrophase occurred between 4 and 1 hours before melatonin administration 
throughout the treatment in Subjects S I,3,4,6-10. In subjects 2 and 5 melatonin 
administration occurred between 0.75h before and 2.2h after the temperature 
acrophase. During the Melatonin 2nd treatment administration occurred between 4
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Fig 6.16
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Fig 6,17
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Fig 6.18
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and 1 hours before the acrophase and 2 and 4 hours after the acrophase with very 
few within one hour of the acrophase.
Statistical comparison of the various treatments gave no significant differences 
between sleep onset time in relation to the temperature nadir for any of the four 
treatments. Melatonin 1st resulted in significantly longer duration sleep periods 
compared to Melatonin 2nd (p=0.04) and Placebo 2nd (p=0.025). Sleep offset time 
in relation to temperature nadir was significantly later with Placebo 1st and 
Melatonin 1st compared to Melatonin 2nd (p=0.03, p=0.0006) and Placebo 2nd 
compared to Melatonin 2nd (p=0.012). Sleep offset time was significantly earlier 
with Melatonin 1st treatment compared to both Placebo 1st (p=2.56E-06) and 
Placebo 2nd (p=8.43E-06).
Sleep onset time was significantly closer to the time of melatonin administration with 
Melatonin 1st treatment compared to Melatonin 2nd (p=0.002). There was also a 
significant difference between the timing of melatonin administration in relation to 
temperature acrophase between Melatonin 1st and Melatonin 2nd (p=0.0005) and
S I,3,4,6-10 Melatonin 1st and S2 & S5 Melatonin 1st (p=0.002). Melatonin 
administration occurred 2.30 ± 0.26h after the temperature acrophase with 
Melatonin 1st and 0.41 ± 0.36h after the temperature acrophase with Melatonin 2nd.
On neither melatonin treatment leg did sleep onset occur immediately after 
melatonin administration. The majority of onsets were 2-6 hours after administration 
with Melatonin 1st and 3-7 hours after administration on Melatonin 2nd.
6.3.4 Grouped Data
An overall grouping of the data for all treatments was not considered to be 
appropriate due to the range of responses to melatonin administration and the 
different circadian times on the day of the initial melatonin dose. Subjects showing 
irregular sleep (S2 & 5) were excluded from the Melatonin 1st and Placebo 2nd 
groups. Subjects 6 and 7 who displayed a phase delay were excluded from the 
Melatonin 2nd group and S2 did not undergo this treatment.
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Fig 6.20
MELATONIN ADMINISTRATION STUDY - MELATONIN 1ST
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Fig 6.21
MELATONIN ADMINISTRATION STUDY - MELATONIN 2ND
SLEEP ONSET & TEMPERATURE IN RELATION TO MELATONIN ADMINISTRATION
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Consequently group data were analysed as follows:
Placebo 1st n = 10 S1-S10
Melatonin 2nd n = 7 81,3-5,8-10
Melatonin 1st n = 8 81,3,4,6-10
Placebo 2nd n = 8 81,3,4,6-10
Group mean plots ± SEM for activity, temperature, aMT6s, sleep onset, sleep offset 
and sleep parameters for the four treatment's are shown in Figs 6.22 - 6.32 and 
group periodicities are recorded in Tables 6.3 - 6.6.
Placebo 1st: Activity, temperature, aMT6s, sleep onset and sleep offset all showed 
significant free-running rhythms (tau > 24h) by regressive cosinor and spectral 
analysis. Repeated measures ANOVA showed significant time dependent changes 
in activity, temperature and aMT6s acrophase times together with sleep onset times 
(p <0.01 days 1-15, n=10, factor day of treatment, degrees of freedom 9,14).
Melatonin 2nd: Only activity showed a free-running rhythm significantly different to 
24h by regressive cosinor analysis (tau > 24h). However, spectral analysis indicated 
a tau greater than 24h for activity, sleep onset and sleep offset. No significant 
changes were seen by repeated measures ANOVA in any parameter.
Melatonin 1st: Only temperature showed a free-running rhythm significantly 
different to 24h by regressive cosinor analysis (tau > 24h). However, spectral 
analysis indicated a tau greater than 24h for activity, temperature and sleep offset. 
No significant changes were seen by repeated measures ANOVA in any parameter.
Placebo 2nd: Activity, temperature, aMT6s, sleep onset and sleep offset all showed 
significant free-running rhythms (tau > 24h) by regressive cosinor and spectral 
analysis. Temperature acrophase times showed a significant time dependent delay 
by repeated measures ANOVA (p <0.001 days 1-15, n=10, factor day of treatment, 
degrees of freedom 9,14).
No significant difference between treatments was determined for time in bed, total 
sleep time, wake after sleep onset, sleep efficiency and number of night
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Fig 6.23
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Fig 6.24
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Fig 6.25
MELATONIN ADMINISTRATION STUDY
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Fig 6,26
MELATONIN ADMINISTRATION STUDY
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Fig 6.27
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Fig 6.29
MELATONIN ADMINISTRATION STUDY 
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Fig 6.30
MELATONIN ADMINISTRATION STUDY
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Fig 6.31
MELATONIN ADMINISTRATION STUDY
GROUP MEAN SLEEP LATENCY ± SEM
S'
I
_l
Q.0)(D
CO
25 
24 
23 
22 
21 
20 
19 
18 
17 
16 
15 
14 
13 
12 
11 ■ 
10 
9 
8 
7 
6 
5 
4 
3 
2 
1 
0 
-1 
-2 
-3 
-4 
-5
Placebo
p = <0.01
n = 10
Melatonin 
p = >0.05
n = S
I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I 
1 3 5 7 9 11 13 15 17 19 21 23 25 27 29 31 
Trial Day
2 4 -
2 3 - Melatonin
p = <0.01
n = 8
Placebo 
p = >0.0521 -  
2 0 -
_j
-4 -
1 3 5 7 9 11 13 15 17 19 21 23 25 27 29 31
Trial Day
222
Fig 6.32
MELATONIN ADMINISTRATION STUDY 
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awakenings, although there was significant variation between the subjects. Sleep 
latency was significantly longer with both Placebo 1st and Melatonin 1st treatments.
Repeated measures AN OVA indicated a significant difference between the 
treatments on the Placebo 1st, Melatonin 2nd leg (p=0.002) and a trend to a 
difference between the treatments on the Melatonin 1st, Placebo 2nd leg (p=0.06) 
whereby both sleep time and temperature were not different from 24h with 
melatonin treatment but free-ran with placebo treatment. Comparison of treatments 
Placebo 1st and Melatonin 1st showed a significant difference for sleep onset, sleep 
offset, activity and temperature acrophases by ANOVA (p<0.001), with rhythms free- 
running with placebo but not melatonin. ANOVA between Placebo 2nd and 
Melatonin 2nd showed a significant difference in activity and temperature acrophase 
times (p <0.001) but no significant difference in sleep onset or offset times.
6.4 DISCUSSION
The dose of melatonin used in this study results in pharmacological levels of 
melatonin in the plasma. It has been used extensively in the treatment of rhythm- 
related sleep disorders ( e.g. Arendt et al., 1987; Dahlitz et al., 1991; Jan et al., 
1994; Suhner et al., 1997) and has been shown to cause greater phase shifts than 
physiological doses in an acute dose-response study (Deacon and Arendt, 1995). 
In view of the published phase response curves for melatonin administration it is 
very important to time the treatment according to each subject’s individual circadian 
phase. However, in this study it was considered to be less disturbing, and more 
practical, if the clock time for administration of the capsules was kept constant for 
all. Details of the exact circadian time of treatment could then be calculated from 
the temperature data collected during the experiment.
Three capsules were administered each day to avoid any possible effects from 
merely taking a pill. The administration time of the active pill chosen was 20:00h. 
The dim light melatonin onset (DLMO) times were determined for all individuals 
(20:00 - 23:00h). The PRC for melatonin indicated that with Melatonin 1st treatment 
the initial dose should occur at, or just before, the DLMO. The anticipated result was 
maintenance of the endogenous phase or a slight phase advance of the melatonin 
rhythm. Under the same experimental conditions, a previous study, (Middleton et al.
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1996, Chapter 5), showed that individuals free-run with a mean tau of 24.26h and 
do not synchronise as a group. Thus, after 15 days of free-run with this average 
tau, dosing at 20:00h clock time would be 15:30h body clock time (CT 8.5 if 07:00h 
= CTO ) and was thus calculated to fall within the phase-advance portion of the 
PRC. Consequently, melatonin administration at 20:00h during Melatonin 2nd 
treatment was timed to produce re-synchronisation by phase-advance. It was also 
calculated that the subjects were likely to be awake at 20:00h every day, and 
therefore be able to take the active dose.
However, two subjects (S6 & 7), free-ran with a long tau (24.52h& 24.51 h mean of 
demasked temperature and aMT6s tau by regressive cosinor) and also had late dim 
light melatonin onsets (22:30h & 23:00h, group mean 21:26 ± 0.04h). As a 
consequence the initial melatonin dose with Melatonin 2nd treatment occurred on 
the phase-delay portion of the PRC. These 2 subjects, received their first melatonin 
treatment 5.15 and 6.2h before temperature maximum, compared to the other 
subjects who were treated from 3.Oh before to 3.Oh after temperature maximum.
All the phase-shifts produced by melatonin administration were calculated with 
respect to changes in the temperature acrophase time, determined from the cosinor 
analysis of demasked temperature data. The mathematical demasking technique 
used is not ideal, as explained in Chapter 4, but the general methodology has been 
validated in both entrained and phase-shifted conditions (Folkard 1988, 1989). The 
maximum phase advances in the temperature rhythm, as a function of the time of 
melatonin administration relative to temperature maximum, correspond to the 
maximum phase advances seen in the PRC of Lewy et al. (1992). The phase shifts 
are also generally consistent with the PRC of Zaidan et al. (1994).
Daily administration of 5mg melatonin at 20:00h from the second day of partial 
environmental isolation in constant dim light appeared to maintain synchronisation of 
the rest-activity/sleep-wake cycle and core body temperature in most individuals. 
Activity and temperature appeared to free-run in subjects SI and 86 with Melatonin 
1st, but with a shorter tau than under Placebo 1st treatment.
Two subjects, 82 and 85, exhibited unexpected irregular sleep patterns with 
Melatonin 1st. This phenomenon may be due to the circadian timing of the initial
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dose of melatonin. S2 and S5 received their first dose between 1 and 2h after 
temperature maximum, whilst the other 8 subjects received it on average 3-4h after 
temperature maximum. Under normal environmental conditions, this administration 
time would be expected to induce a phase advance. However, under normal 
environmental conditions, a combination of zeitgeber effects, including the light-dark 
cycle and social cues would act together to produce a response. The response 
seen in S2 and S5 may be analogous to the suppression of the temperature and 
cortisol amplitude and large phase jumps of the circadian system induced by a pulse 
of bright light given at or near the temperature minimum during a constant routine 
(Jewett et al., 1991). Light and melatonin usually have opposite effects, so that it is 
possible that melatonin administered at, or near, the temperature maximum may 
evoke similar phase jumps (but only in sleep). An alternative explanation may be 
that if there are two coupled oscillators (morning and evening) involved in the timing 
of sleep (Wehr et al., 1993) melatonin administration at a particular time in relation 
to the sleep-wake cycle may be able to uncouple these two components (see 
Chapter 9).
Melatonin administered after a period of free-run can synchronise sleep by phase 
advance when the treatment time falls within the range of 3h before to 4h after 
temperature maximum. This synchronisation of sleep takes place over a number of 
days (Figs 6.2 - 6.11), indicating that melatonin is not a strong and immediate sleep 
inducer. Temperature appeared to be synchronised in 4 individuals, but closer 
inspection of the data suggests that the temperature tau may be shortened rather 
than synchronised. Where temperature tau was indistinguishable from 24h, it is 
conceivable that a very slow free-run was present but could not be detected in the 
length of data series collected. The results obtained with Placebo 2nd treatment, 
where tau, recorded in 6 out of 9 subjects, was shorter than during Placebo 1st, 
suggest that administration of melatonin may have after-effects on endogenous 
periodicity.
The apparent synchronisation of the sleep-wake cycle by phase delay in Subjects 6 
and 7 is less conclusive (Figs 6.7 & 6.8). Synchronisation occurs over a period of 
days, and although sleep onset in S6 has a tau not significantly different to 24h with 
Melatonin 2nd, visual inspection of the data suggests that shortened tau occurs, 
rather than entrainment. The sleep-wake cycle recorded in Subject 7 with
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Melatonin 2nd, shows two phase delays with a transient entrainment to melatonin 
administered shortly after sleep offset. There is no evidence of entrainment of the 
temperature rhythm in either of these subjects, although phase shifts to the initial 
melatonin dose were seen. These two subjects had long individual free-running 
periods and it is possible that the limit of entrainment of the sleep-wake cycle by 
melatonin depends on individual tau. Free-running periods much longer (or possibly 
shorter) than 24h may be beyond these limits. Another possible explanation, is that 
the data series is too short and that synchronisation would eventually occur. In 
Subject 7, the demasked temperature rhythm appears to be unstable with wide 
variations in the acrophase times. The major shifts in the sleep-wake cycle could be 
due to the constantly changing phase of the temperature rhythm.
Investigation of the timing and duration of sleep periods on all four treatments 
suggests that the longest sleep periods occurred when sleep onset time was on the 
falling part of the temperature curve, with the shortest episodes commencing after 
the temperature nadir, sleep offset occurring on the rising part of the temperature 
curve in agreement with Czeisler et al. (1980). A wider range in sleep onset times in 
relation to the temperature rhythm was seen with Melatonin 1st, indeed Subjects 2 
and 5 exhibited sleep onset times at all phases of the temperature rhythm. Sleep 
onset did not occur immediately after melatonin administration with either treatment 
suggesting that melatonin is not an acute hypnotic. Sleep latency was frequently 
recorded as 0 minutes: this is very unlikely to be true. In many cases the zero 
readings are probably due to the actigraph recording the period as sleep due to a 
lack of movement as the subjects were lying in bed. Sleep latency was significantly 
longer with both Placebo 1st and Melatonin 1st. This was most probably due to the 
subjects becoming acclimatised to living in the isolation facility.
In summary, timed administration of melatonin to individuals maintained as a group, 
under partial environmental isolation conditions with constant dim light, appears to 
have weak zeitgeber effects. Melatonin is able to phase shift sleep, and core 
temperature and is able to synchronise (or “stabilise”) sleep-wake to 24 hours. It is 
unable to convincingly synchronise core temperature in most individuals. These 
differential effects on sleep and temperature suggest the possibility of different 
target mechanisms or a major contribution of the acute temperature suppression.
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mild sleepiness, and lowered alertness produced by melatonin administration at the 
appropriate circadian phase to initiate sleep.
Further studies were planned to investigate whether a light:dark cycle combined with 
melatonin administration would produce more robust synchronisation of the sleep- 
wake cycle and temperature rhythm. The phenomenon of irregular sleep was 
unexpected, and a further experiment was planned to establish whether it was due 
to the timing of melatonin administration relative to the phase of the core 
temperature rhythm, as proposed here.
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CHAPTER 7
HUMAN CIRCADIAN RHYTHMS IN LIGHT DARK
CYCLES OF DIFFERENT LIGHT INTENSITIES
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7.1 SPECIFIC STUDY DESIGN & RATIONALE
The periodic light-dark cycle is known to be the primary signal for synchronising the 
human circadian pacemaker (Czeisler et al., 1981; Czeisler 1995b). Timed light 
exposure can be used to reset circadian phase (Czeisler et al., 1986, Czeisler et al., 
1989 and Jewett et al., 1994) or induce phase shifts (Mills et al., 1978a; Broadway et 
al., 1987; Shanahan and Czeisler, 1991; Minors et al., 1994; Deacon and Arendt, 
1995). The phase-shifts produced are dependent, not only on the timing, but also the 
duration and intensity of the light exposure. The phase-shift produced by a particular 
lighting regime can be predicted by use of published phase response curves (Czeisler 
et al., 1989, Minors et al., 1991; Honma and Honma, 1988: Van Cauteref a/., 1994). 
Originally, it was thought that bright light, with an intensity in excess of 2500 lux, was 
needed to produce a phase shift, but recent work has shown that light intensities as 
low as -  180 lux are able to phase shift the endogenous circadian pacemaker in 
humans (Boivin etal., 1994, Boivin et al., 1996).
Experiments during the Antarctic winter (Broadway et al., 1987) have shown that a 
skeleton photoperiod, with light exposure in the morning and evening, was sufficient 
to phase advance the melatonin secretion profile. Intermittent light pulses in place of 
constant light exposure have also been shown to cause phase shifts in the 
endogenous temperature rhythm (Rimmer et al. 1995). However, Gallo and Eastman 
(1993), attempted to use appropriately timed bright light exposure to facilitate the 
adaptation of shift-workers to night shift and found that in the field the competing 
zeitgebers resulted in the temperature rhythm free-running or remaining entrained to 
the natural 24h zeitgebers whilst the sleep-wake schedule shifted.
Some publications have reported the ability of light treatment to entrain human 
circadian rhythms. Hoban et al. (1989), demonstrated that two hours of bright light 
(2500 lux) exposure on waking, in a normal environment, is sufficient to re-entrain 
free-running rhythms of sleep-wake and melatonin in a normal sighted individual 
(n=1). The tendency of the individual to delay was counteracted by the phase 
advances induced by the light treatment. More recently Klerman et a/. {1997) have 
reported the ability of very dim light (20 lux) to synchronise the circadian pacemaker 
to 24h with a scheduled sleep-wake cycle (16hL:8hD), meals and social contact but 
with no other external time cues (n=1). This result may have been due to the
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subject’s intrinsic period being very close to 24h or to the very weak light-dark cycle 
combined with the non-photic synchronisers being strong enough to entrain the 
intrinsic period to a 24h schedule.
The experiments reported here utilised 12:12 L;D cycles of varying intensity (20, 200 
and 1000 lux) with the aim of determining the light intensity required to maintain 
entrainment of human circadian rhythms to 24h under partial environmental isolation, 
but with knowledge of clock time.
7.1.1 Isolation Facility
The isolation unit was provided by the DERA, Farnborough, and has been described 
in section 2.1.1. The exact layout was as shown in Fig 2.1 Plan B.
The overhead lighting system provided by Siemens Lighting was used. The bank of 
lights in each room fitted with shutters to reduce the illumination levels to < 8 lux as 
described in 2.1.2 was used for the overnight periods (20:00 - 08:00h) throughout the 
two experiments. The remaining light banks were adjusted to give overall illumination 
of 20 lux, 200lux or 1000 lux 08:00 - 20:00h according to the lighting regimes 
described in the experimental design.
7.1.2 Subjects
6 normal healthy males aged 23.17 ± 2.48 (SD) years, numbered 31 - 86, were 
recruited from the Army Personnel Establishment Trials Section, Farnborough, U.K. 
for Experiment 1. 6 normal healthy males aged 21.50 ± 4.23 (SD) years, numbered 
SI - S6, were recruited from students at the University of Surrey, Guildford, Surrey, 
U.K., for Experiment 2. All individuals were under no medication except for minor 
analgesics and were non-smokers.
Potential subjects were screened as described in section 2.2.4. All those individuals 
screened fulfilled these requirements and participated in the experiments. Informed 
written consent was obtained from all subjects and the study protocols were 
approved by the DERA Centre for Human Sciences Ethics Committee.
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7.1.3 Study Protocol - Experiment 1
Subjects arrived at the isolation facility at 10;00h on Day 1. Equipment was issued 
and recording of data plus collection of samples began at 12:00h. An acclimatisation 
period of 32h, with sleep in darkness 23:30 - 07:30h, was followed by lighting levels 
being lowered to < 8 lux at 20:00h on day 2. A 12:12 L:D cycle was then imposed for 
10 days. The light levels were 20 lux 0800 - 20:00h and < 8 lux 20:00 -08:00h. The 
illumination was then kept constant at < 8  lux for 10 days (see Fig 7.1). The light 
levels were checked every day when a change in intensity was in force and every 2 
days when lighting was constant. 20 lux light levels were 21.6 ±1.2 (SEM) lux (n = 
470) and constant dim light levels were 5.23 ± 0.7 (SEM) lux (n = 258). The ambient 
temperature range was 17 - 29 °C (mean = 22.20 ± 3.56 (SEM) °C, n = 178). 
Subjects had access to a digital clock and watches giving knowledge of clock time. 
The general study conditions were as described in section 2.2.3. An incident book 
was kept throughout the experiment to record any significant events, any minor 
analgesics administered, subjects requests and general observations on the subjects 
mood and behaviour. The experiment was carried out in May and June.
7.1.4 Study Protocol - Experiment 2
Subjects arrived at the isolation facility at 10:00h on Day 1. Equipment was issued 
and recording of data plus collection of samples began at 12:00h. An acclimatisation 
period of 32h, with sleep in darkness 23:30 - 07:30h, was followed by lighting levels 
being lowered to < 8 lux at 20:00h on day 2. A 12:12 L:D cycle was then imposed for 
13 days. The light levels were 200 lux from 0800 - 20:00h and < 8 lux from 20:00 - 
08:00h. The L:D cycle was changed to 1000 lux from 0800 - 20:00h and < 8 lux from 
20:00 - 08:00h for the following 13 days (see Fig 7.1). The light levels were checked 
every day approximately 1 hour after lights on using a hand held lux meter following 
the CIS Code 194 for determination of average illuminance. 200 lux light levels were 
192.14 ± 8.86 (SEM) lux (n = 470) and 1000 lux light levels were 1016.09 ± 6.9 
(SEM) lux (n = 510). The ambient temperature range was 12 - 32 °C (mean = 24.92 ± 
4.37 (SEM) °C, n = 210). Subjects had access to a digital clock and watches giving 
knowledge of clock time. The general study conditions were as described in section
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2.2.3. An incident book was kept throughout the experiment to record any significant 
events, any minor analgesics administered, subjects requests and general 
observations on the subjects mood and behaviour. The experiment was carried out 
in March and April.
7.1.5 Measurements Taken
The following measurements were taken throughout each experiment.
a. daily maximum and minimum temperatures in each room
b. light levels every day one hour after lights on when a12:12 L:D cycle was in 
force, or every 2 days when the light levels remained constant.
c. core body temperature via a rectal probe and memory logger
d. sleep-wake/activity via wrist mounted accelerometer - Mini Motionlogger
e. 4 hourly urine collections except for oversleep periods
f. 2 hourly performance sessions when awake using the shortened DERA 
test battery for Experiment 1 and Psion test battery for Experiment 2
g. daily activity diaries
h. subjective sleep logs after every sleep period
i. UWIST mood adjective questionnaire morning and evening
7.2 ANALYSIS OF DATA
7.2.1 Urinary aMT6s
Urinary aMT6s levels were measured using the assay described in section 2.4.2. 
Quality control coefficients of variation (C.V.) were 7.9%, 10.0% and 6.9% for 
concentrations of 2.86, 21.83 and 45.36 ng/ml respectively with a limit of detection at 
2 X SD of zero binding of 0.34 ng/ml for Experiment 1. Experiment 2 quality control 
coefficients of variation (C.V.) were 12.2%, 9.6% and 8.5% for concentrations of 
2.38, 23.75 and 49.50 ng/ml respectively with a limit of detection at 2 x SD of zero 
binding of 0.22 ng/ml. The excretion rate for each sample period was calculated in 
ng/hr and these values were subjected to 3 day moving window cosinor analysis as 
described in Chapter 3 section 3.1.4 and spectral analysis as in section 3.1.5. 
Acrophase times and amplitude values were analysed further by linear regression
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analysis and repeated measures ANOVA as described in section 3.2 both on an 
individual basis and by group mean values.
7.2.2 Temperature Data
Raw temperature data was edited as described in section 3.1.1. The values collected 
during Experiment 2 were then demasked for sleep as described in Chapter 4. There 
were no significant differences between tau determined using the various demasking 
methods by repeated measures ANOVA for any subject (see Table 7.1). There was 
a significant difference between subjects 2 and 3 compared to subjects 1,4,5 and 6 
with 200 lux, and between all individuals with 1000 lux. The acrophase times 
calculated by the various analysis methods did not vary significantly, but they did vary 
with study day for both light levels (p = 0.0001), delaying with 200 lux and advancing 
with 1000 lux, and there is a significant difference in the acrophase times between 
200 and 1000 lux by repeated measures ANOVA (p = 0.0001) with 1000 lux having a 
shorter tau than 200 lux..
There were no significant differences in the group tau determined by the various 
analysis methods for either 200 lux or 1000 lux (see Table 7.1 and Fig 7.2). The 
“demasking” procedure whilst not altering the overall tau appeared to advance the 
acrophase times by 2-3 hours with both 200 lux and 1000 lux. On an individual basis 
the calculated tau could be said to be different if the regression analysis 95% 
confidence limits did not overlap. Using this criterion differences in temperature 
periodicity derived from the various “demasking” techniques are shown in Table 7.1.
Temperature data used for further analysis were demasked hourly temperature 
means self-corrected for sleep.
The demasked temperature data from Experiment 2, and the raw temperature data 
from Experiment 1 were analysed further using cosinor, spectral, periodogram and 
autocorrelation analysis (sections 3.1.4, 3.1.5, 3.1.6 and 3.1.7) to determine the 
overall periodicity for each subject under each light intensity.
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The calculated acrophase times, were then subjected to linear regression analysis 
and repeated measures ANOVA. (Sections 3.2.1 and 3.2.2), both on an individual 
basis and as group means.
Table 7.1 200 lux : 1000 lux Variable Light Intensity Study Tau 
Determined by Various “Demasking” Techniques.
200 Lux
Subject Masked Masked Hourly Self-Corr Sleep Norm-Sleep
1 24.15 ±0.09** 24.18 ±0.07** 24.15 ± 0.12* 23.95 ±0.17
2 23.88 ± 0.04*** 23.91 ± 0.04*** 23.79 ± 0.06*** 23.92 ± 0.04**
3 23.98 ± 0.06 23.95 ± 0.07 24.03 ± 0.07 23.78 ± 0.24
4 24.15 ±0.03*** 24.13 ±0.03*** 24.22 ± 0.04*** 24.16 ±0.08**
5 24.16 ±0.05*** 24.15 ±0.04*** 24.25 ± 0.07*** 24.20 ± 0.05***
6 24.12 ±0.06*** 24.09 ± 0.06** 24.16 ±0.06*** 24.09 ± 0.06**
Group 24.07 ± 0.02*** 24.07 ± 0.02*** 24.10 ±0.02*** 24.02 ± 0.04
1000 Lux
Subject Masked Masked Hourly Self-Corr Sleep Norm-Sleep
1 23.76 ± 0.07*** 23.73 ± 0.07*** 23.94 ± 0.08 24.00 ± 0.09
2 24.05 ± 0.05* 24.04 ± 0.04 24.05 ± 0.07 24.03 ± 0.07
3 23.85 ± 0.05*** 23.87 ± 0.06*** 23.95 ± 0.05 23.75 ± 0.09***
4 23.62 ± 0.22** 23.58 ± 0.23** 23.69 ± 0.23* 23.82 ± 0.21
5 23.70 ± 0.32 23.71 ± 0.37 23.80 ±0.18* 23.75 ± 0.26
6 24.17 ±0.16* 24.13 ±0.12* 24.08 ±0.15 24.21+0.13
Group 23.86 ±0.11* 23.84 ±0.11* 23.92 ± 0.07* 23.93 ± 0.08*
Significance level of fitted regression line *** ==<0.001 ** =<0.01 * =<0.05
Subject Differences between "self-corrected’' demasked and hourly
masked tau
Group
1 None
2 None
3 None
4 200 lux longer
5 None
6 None
None
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7.2.3 Activity and Sleep Data
The raw activity data from both experiments were edited as described in section
3.1.1. Sleep parameters were determined using Action3 software (Ambulatory 
Monitoring Inc.) and analysed as described in sections 3.1.2 and 3.1.3.
Edited activity data were analysed further using cosinor, spectral, periodogram and 
autocorrelation analysis (sections 3.1.4, 3.1.5, 3.1.6 and 3.1.7) to determine the 
overall periodicity for each subject under each light intensity.
The calculated acrophase times and sleep parameters were then subjected to linear 
regression analysis and repeated measures ANOVA. (Sections 3.2.1 and 3.2.2), both 
on an individual basis and as group means.
7.2.4 Performance data
Performance data collected during Experiment 1 was not analysed due to poor 
compliance by the subjects. All performance data collected during Experiment 2 were 
analysed for any changes in performance across the treatment periods and any 
differences in performance between the various treatments, using daily means as 
described in section 3.1.6. Results from the performance data analysis are not 
reported here for the reasons stated in section 3.1.6.
7.2.5 UWIST mood adjective list
Daily mood scores were calculated according the methodology described in section
2.4.2.
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7.3 RESULTS
7.3.1 Compliance
Experiment 1: Subject compliance was poor throughout this study, particularly with 
respect to the core body temperature recording.
The overall mean percentages (± SEM) of the possible theoretical data collected for 
the various parameters were as follows:
Temperature 49.2 ± 5.8%
Activity 90.7 ±1.9%
Sleep 93.7 + 1.6%
aMT6s 67.2 ± 3.0%
Performance 67.1 ±2.3%
Data lost due to equipment malfunction can be summarised as follows:
a. activity lost data: SI < 8 lux 36h; S2 20 lux 34h, < 8 lux 32h; S3 20 lux 
36h; S4 20 lux 36h and S5 20 lux 36h, < 8 lux 42h.
b. temperature lost data: S4 20 lux 36h, < 8 lux 48h; S5 < 8 lux 72h and S6 
20 lux 36h, < 8 lux 60h.
Experiment 2: Subject compliance was very good throughout this study, with little 
data lost due to non-compliance.
The overall mean percentages (± SEM) of the theoretical data collected for the 
various parameters were as follows:
Temperature 87.1 ±1.4%
Activity 85.2 ±4.1%
Sleep 95.7 ± 2.4%
aMT6s 73.1 ±5.8%
Performance 86.3 ± 2.2%
Data lost due to equipment malfunction can be summarised as follows:
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a. activity lost data: S3 200 lux 12h; S4 200 lux 47h, 1000 lux 39h; S5 200 
lux 72h, 1000 lux 104h and S6 200 lux 47h.
b. temperature lost data: S2 200 lux 48h; S3 1000 lux 24h; S4 200 lux 48h; 
S5 200 lux 34h and S6 200 lux 47h.
7.3.2 Individual Data
Summary raster double plots were produced for all subjects giving an overall record 
of the sleep-wake cycle and activity, temperature and aMT6s acrophase times. 
(See Figs 7.3 - 7.8). There were no significant changes in the UWIST Mood 
Adjective list scores for any subject at any light intensity.
7.3.2.1 Rest-Activity
Experiment 1: Visual inspection of these plots indicated that 5/6 subjects free-ran 
under the 20 lux (0800-2000h) lighting schedule (Figs 7.S-7.5). S3 (Fig 7.4) 
appeared to remain synchronised to 24h. On switching to constant dim light levels (< 
8 lux) the same five individuals continued to free-run for a further 3-4 days but then 
showed a marked end-effect by attempting to resynchronise their sleep-wake cycle to 
the outside world by following clock time.
Experiment 2: Visual inspection of the summary raster double plots indicated that 
5/6 subjects showed free-running rest-activity rhythms under the 200 lux (0800- 
2000h) lighting schedule (Figs 7.6-7.8). On changing to 1000 lux lighting levels one 
subject (SI) showed two phase advances, two subjects (32 and S3) stabilised to a 
24h rhythm, whilst three subjects (S4-S6) continued apparently to free-run for 
several days. Subjects 4 and 5 then phase jumped but the data series was not long 
enough to confirm whether synchronisation occurred in Subjects 4-6 (see Appendix 
3).
7.3.2.2 Temperature
Experiment 1: Due to the poor compliance over collection of temperature data only 
the raw, masked temperature data was analysed. Insufficient temperature data for 
analysis was collected by SI. The temperature rhythm free-ran in 4/5 individuals
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Fig 7.4
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Fig 7.5
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under 20 lux but appeared to either stabilise to 24h or free-run with a tau less than 
24h under constant dim light conditions. This is most likely due to the masking effect 
of sleep where individuals were attempting to resynchronise themselves to the normal 
environment. S2 exhibited a large phase jump, of approximately 10h, in the 
temperature rhythm on day 3. Inspection of the data shows that this individual 
removed his rectal temperature probe for 10-12h per day from this point onwards 
thus completely invalidating any rhythm analysis.
Experiment 2: The demasked temperature rhythm free-ran in 5/6 individuals with 200 
lux but only 2 (S4 & S5) showed a possible free-run with 1000 lux. The remaining 
individuals appeared to stabilise to 24h.
7.3.2.3 aMTSs
Experiment 1: Only 2/6 subjects with 20 lux and 3/6 individuals with <8 lux exhibited 
free-running rhythms in aMT6s. This can be explained by the overall poor urine 
collections made during the study. The mean endogenous amount of aMT6s 
excreted per 24h was calculated for each subject. These values are shown in Table 
7.2 and are within the normal range for age (13.14 ± 9.8 pg/24h to 54.0 ± 6.0 
pg/24h).
Experiment 2: 3/6 subjects with 200 lux and 2/6 individuals with 1000 lux exhibited 
free-running rhythms in aMT6s. The mean endogenous amount of aMT6s excreted 
per 24h was calculated for each subject. These values are shown in Table 7.2 and 
are within the normal range for age (13.14 ± 9.8 pg/24h to 54.0 ± 6.0 pg/24h).
Table 7.2 Amount of aMTSs excreted (pigs)
Subject Mean Endogenous Mean Endogenous
Number aMT6s Excreted per 24h aMT6s Excreted per 24h 
Experiment 1 Experiment 2
1 9.33 ±1.17 10.23 ±0.81
2 8.20 ±0.84 13.70 ±1.27
3 16.65 ±0.87 10.70 ±0.95
4 4.39 ±0.43 10.96 ±0.68
5 9.02 ± 0.65 9.65 ± 0.62
6 8.56 ±0.89 17.06 ±1.37
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Fig 7.7
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There was no significant difference in the amplitude of the aMT6s rhythm between 
the 200 lux and 1000 lux lighting schedules, thus indicating that there was no overall 
differential suppression of the melatonin rhythm by the higher light intensity .
The full results obtained from linear regression analysis, spectral analysis, 
periodogram analysis and auto correlation for each parameter and each individual, 
together with group means for all 4 lighting schedules are shown in Tables 7.3 - 7.6.
7.3.2.4 Experiment 1 20 lux
Statistical analysis (2 way ANOVA) of the periodicities determined by the various 
analysis methods showed that for activity there were significant differences between 
subjects (p=0.01) and analysis method (p=0.0005). Spectral analysis gave 
significantly longer periods than regressive cosinor (p=0.04) and both spectral and 
periodogram analysis gave a longer tau than autocorrelation (p<0.04). There were no 
significant differences between subjects or analysis method for temperature, aMT6s 
and sleep onset. There were significant differences both between subjects (p=0.02) 
and analysis method (p=0.02) for sleep offset time with spectral analysis giving longer 
tau for all 6 subjects than regressive cosinor. (Table 7.3)
There were no significant differences across study days, shown for time in bed, total 
sleep time, wake after sleep onset or sleep efficiency by any individual. Full results 
from the analysis of sleep parameters (single day values), and mean values ± SEM 
are summarised in Table 7.7.
7.3.2.5 Experiment 1 < 8 lux
Statistical analysis (2 way ANOVA) of the periodicities determined by the various 
analysis methods showed that for activity and aMT6s there was a significant 
difference between subjects (p <0.0006) but not analysis methods. There were no 
significant differences between subjects or analysis methods for temperature, sleep 
onset or sleep offset. (Table 7.4)
There were no significant differences across study days shown by any individual for 
time in bed, total sleep time, wake after sleep onset or sleep efficiency. Full results
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Table 7.3
EXPERIMENT 1 - 20 LUX
Individual and Group Periodicities Determined by
Various Analysis Methods
Parameter Subject Days Regression Spectral Periodogram Autocorrelation
Activity 1 1 -1 4 24.37 ± 0.27* 25.36 24.56 24.54
2 1 - 14 24.40 ± 0.08*** 24.92 24.46 24.06
3 1 -1 4 24.05 ± 0.04* 23.95 24.01 23.54
4 1 -1 4 23.98 ± 0.39 25.76 24.20 24.12
5 1 -1 4 24.62 ± 0.14*** 25.05 24.64 24.50
6 1 - 14 24.23 ± 0.13** 24.90 24.16 24.00
Group n=6 1 -1 4 24.27 ± 0.07*** 24.99 24.34 24.13
Parameter Subject Days Regression Spectral Periodogram Autocorrelation
Temperature 1 1 - 14 No data
2 1 - 14 25.43 ± 0.65** 27.13 24.92
3 1 - 14 24.19 ± 0.12** 23.95 24.14 23.36
4 1 - 14 24.20 ± 0.29 23.96 24.06 24.12
5 1 - 14 24.55 ± 0.09*** 24.66 24.64 24.50
6 1 -1 4 24.18 ± 0.11** 24.46 24.17 24.00
Group n=6 1 -1 4 24.38 ± 0.31* 24.83 24.39 24.00
Parameter Subject Days Regression Spectral
aMT6s 1 1 -1 4 23.98 ± 0.12 24.36
2 1 - 1 4 24.46 ± 0.08*** 24.20
3 1 -1 4 24.17 ± 0.22 24.35
4 1 -1 4 24.17 ± 0.41 23.85
5 1 -1 4 24.63 ± 0.14*** 24.82
6 1 -1 4 23.97 ± 0.27 24.20
Group n=6 1 -1 4 24.24 ±0 .12** 24.30
Parameter Subject Days Regression Spectral
Sleep Onset 1 1 -1 4 24.66 ± 0.48* 24.00
2 1 - 14 24.36 ± 1.95 23.72
3 1 -1 4 23.97 ± 0.25 24.06
4 1 -1 4 23.88 ± 0.9 24.66
5 1 - 14 24.56 ± 0.44* 24.15
6 1 -1 4 24.26 ± 0.58 24.02
Group n=6 1 -1 4 24.28 ± 0.27* 24.10
Parameter Subject Days Regression Spectral
Sleep Offset 1 1 -1 4 24.36 ± 0.16*** 24.95
2 1 - 1 4 24.66 ± 0.31*** 24.85
3 1 - 1 4 24.01 ± 0.08 24.06
4 1 -1 4 24.32 ± 0.61 24.85
5 1 - 1 4 24.62 ± 0.34** 24.82
6 1 - 1 4 24.17 ± 0.27 24.45
Group n=6 1 - 14 24.40 ± 0.15*** 24.66
Significance level of fitted regression line *** =<0.001 ** = <0.01 * = <0.05
249
Table 7.4
EXPERIMENT 1 - < 8 LUX
Individual and Group Periodicities Determined by
Various Analysis Methods
Parameter Subject Days Regression Spectral Periodogram Autocorrelation
Activity 1 1 5 - 2 4 23.71 ± 0.39 23.75 23.87 23.95
2 1 5 - 2 4 22.62 ± 0.28*** 22.22 22.94 22.86
3 1 5 - 2 4 23.95 ± 0.07 24.45 23.98 24.20
4 1 5 - 2 4 24.36 ± 1.06 22.50 23.05 23.40
5 1 5 - 2 4 23.97 ± 0.16 23.76 24.20 23.95
6 1 5 - 2 4 23.86 ± 0.06*** 23.85 23.85 23.70
Group n=6 1 5 - 2 4 23.74 ± 0 .21 * 23.42 23.65 23.68
Parameter Subject Days Regression Spectral Periodogram Autocorrelation
Temperature 1 1 5 - 2 4 No data
2 1 5 - 2 4 23.34 ± 0.30** 19.00 22.25
3 1 5 - 2 4 24.01 ± 0.08 24.10 24.14 24.05
4 1 5 - 2 4 23.48 ± 0.32** 22.95 23.55 23.70
5 1 5 - 2 4 23.93 ± 0.01** 24.12 23.98 24.05
6 1 5 - 2 4 24.05 ± 0.22 24.46 24.22 24.20
Group n=6 1 5 - 2 4 23.80 ± 0.15* 22.93 23.63 24.00
Parameter Subject Days Regression Spectral
aMT6s 1 1 5 - 2 4 24.29 ± 0.16** 24.40
2 1 5 - 2 4 23.80 ± 0.31 23.82
3 1 5 - 2 4 23.70 ± 0.14** 24.25
4 1 5 - 2 4 Insufficient Data
5 1 5 - 2 4 24.16 ± 0.32 24.15
6 1 5 - 2 4 23.54 ± 0.31** 24.20
Group n=6 1 5 - 2 4 24.04 ± 0.15 24.16
Parameter Subject Days Regression Spectral
Sleep Onset 1 1 5 - 2 4 24.44 ± 1.19 23.32
2 1 5 - 2 4 22.95 ± 1.3 22.32
3 1 5 - 2 4 24.07 ± 0.13 24.00
4 1 5 - 2 4 23.02 ± 0.96* 22.12
5 1 5 - 2 4 23.80 ± 0.94 24.35
6 1 5 - 2 4 23.83 ± 0.55 23.35
Group n=6 1 5 - 2 4 23.70 ± 0.31 23.24
Parameter Subject Days Regression Spectral
Sleep Offset 1 1 5 - 2 4 23.82 ± 1.18 24.06
2 1 5 - 2 4 24.83 ± 0.27*** 23.60
3 1 5 - 2 4 24.14 ± 0.09** 24.42
4 1 5 - 2 4 23.14 ± 0.74* 22.50
5 1 5 - 2 4 23.85 ± 0.65 23.25
6 1 5 - 2 4 23.55 ± 0.39* 23.89
Group n=6 1 5 - 2 4 23.89 ± 0.23 23.62
Significance level of fitted regression line *** =<0.001 ** = <0.01 * = <0.05
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from the analysis of sleep parameters (single day values), and mean values ± SEM 
are summarised in Table 7.7.
7.3.2.6 Experiment 2 200 lux
Statistical analysis (2 way ANOVA) of the periodicities determined by the various 
analysis methods showed that for activity, aMT6s, sleep onset and offset there were 
no significant differences, either between subjects or analysis methods. There was no 
significant difference between analysis methods for temperature but there was a 
significant difference between subjects by ANOVA (p <0.01). (Table 7.5)
There were no significant differences across study days shown for time in bed, total 
sleep time, wake after sleep onset or sleep efficiency by any individual. Full results 
from the analysis of sleep parameters (single day values), and mean values ± SEM 
are summarised in Table 7.7.
7.3.2.7 Experiment 2 1000 lux
Statistical analysis (2 way ANOVA) of the periodicities determined by the various 
analysis methods showed that for activity, and temperature there were no significant 
differences between analysis methods but there was a significant difference between 
subjects (p=0.004 & p=0.008 respectively). There were no significant differences 
between analysis methods or subjects for aMT6s, sleep onset and sleep offset. 
(Table 7.6).
There were no significant differences across study days shown in time in bed, total 
sleep time, wake after sleep onset or sleep efficiency by any individual. Full results 
from the analysis of sleep parameters (single day values), and mean values ± SEM 
are summarised in Table 7.7.
251
Table 7.5
EXPERIMENT 2 - 200 LUX
Individual and Group Periodicities Determined by
Various Analysis Methods
Parameter Subject Days Regression Spectral Periodogram Autocorrelation
Activity 1 1 -1 4 24.40 ± 0.10*** 24.25 24.22 24.10
2 1 - 1 4 24.02 ± 0.10 23.92 24.01 24.20
3 1 -1 4 24.09 ± 0.08* 23.36 24.20 24.10
4 1 -1 4 24.12 ± 0.12* 24.50 24.03 25.12
5 1 - 1 4 24.20 ± 0.20** 24.25 24.06 23.45
6 1 - 1 4 24.12 ± 0.15 24.12 24.06 24.12
Group n=6 1 - 1 4 24.18 ± 0.05*** 24.07 24.10 24.18
Parameter Subject Days Regression Spectral Periodogram Autocorrelation
Temperature 1 1 -  14 24.15 ± 0.12* 24.35 24.14 24.00
2 1 -1 4 23.79 ± 0.06*** 23.80 23.89 24.03
3 1 -1 4 24.03 ± 0.07 23.90 23.99 24.12
4 1 -1 4 24.22 ± 0.04*** 24.12 24.22 24.00
5 1 - 1 4 24.25 ± 0.07*** 24.52 24.14 24.12
6 1 -1 4 24.16 ± 0.06*** 24.32 24.14 24.06
Group n=6 1 -1 4 24.10 ± 0.02*** 24.17 24.09 24.06
Parameter Subject Days Regression Spectral
aMT6s 1 1 -1 4 24.31 ± 0.14*** 24.45
2 1 - 14 23.86 ± 0.12* 24.16
3 1 -1 4 23.92 ± 0.15 24.00
4 1 - 14 23.99 ± 0.05 23.72
5 1 - 14 24.16 ± 0.08*** 23.80
6 1 - 1 4 24.12 ± 0.22 23.56
Group n=6 1 - 14 24.05 ± 0.04* 23.95
Parameter Subject Days Regression Spectral
Sleep Onset 1 1 - 1 4 24.28 ± 0.11*** 24.12
2 1 - 1 4 24.09 ± 0.23 24.00
3 1 -1 4 24.14 ± 0.24 24.16
4 1 -1 4 24.11 ± 0.27 24.53
5 1 -1 4 24.19 ± 0.24 24.26
6 1 -1 4 24.12 ± 0.32 24.25
Group n=6 1 - 1 4 24.16 ± 0.15* 24.22
Parameter Subject Days Regression Spectral
Sleep Offset 1 1 - 1 4 24.14 ± 0.19 24.52
2 1 -1 4 23.87 ± 0.20 23.80
3 1 - 1 4 24.15 ± 0.10** 24.10
4 1 - 1 4 24.09 ± 0.20 24.30
5 1 -1 4 24.11 ± 0.14 24.32
6 1 -1 4 24.13 ± 0.15 24.32
Group n=6 1 -1 4 24.07 ± 0.10 24.23
Significance level of fitted regression line *** =<0.001 ** = <0.01 * = <0.05
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Table 7.6
EXPERIMENT 2 -1000 LUX
Individual and Group Periodicities Determined by
Various Analysis Methods
Parameter Subject Days Regression Spectral Periodogram Autocorrelation
Activity 1 1 5 - 2 8 23.58 ± 0.21*** 23.32 23.64 24.08
2 1 5 - 2 8 23.95 ± 0.06 23.80 23.95 24.12
3 1 5 - 2 8 24.03 ± 0.07 23.52 23.98 23.90
4 1 5 - 2 8 23.30 ± 0.45** 22.96 23.27 23.40
5 1 5 - 2 8 23.17 ± 0.72* 21.25 23.74 22.95
6 1 5 - 2 8 24.08 ±0.11 24.22 23.98 24.00
Group n=6 1 5 - 2 8 23.73 ± 0.20* 23.18 23.76 23.74
Parameter Subject Days Regression Spectral Periodogram Autocorrelation
Temperature 1 1 5 - 2 8 23.94 ± 0.08 23.45 23.64 23.80
2 1 5 - 2 8 24.05 ± 0.07 23.52 24.02 24.00
3 1 5 - 2 8 23.95 ± 0.10 24.12 23.89 23.98
4 1 5 - 2 8 23.69 ± 0.23* 23.46 23.65 23.70
5 1 5 - 2 8 23.80 ± 0.18* 22.36 23.74 22.60
6 1 5 - 2 8 24.08 ± 0.13 24.12 24.05 24.12
Group n=6 1 5 - 2 8 23.92 ± 0.07* 23.51 23.83 23.70
Parameter Subject Days Regression Spectral
aMT6s 1 1 5 - 2 8 23.42 ± 0.26** 23.92
2 1 5 - 2 8 23.79 ± 0.14** 23.93
3 1 5 - 2 8 24.12 ± 0.23 23.86
4 1 5 - 2 8 23.97 ± 0.09 23.66
5 1 5 - 2 8 23.94 ± 0.13 24.15
6 1 5 - 2 8 23.94 ± 0.30 23.45
Group n=6 1 5 - 2 8 23.92 ± 0.15 23.83
Parameter Subject Days Regression Spectral
Sleep Onset 1 1 5 - 2 8 23.54 ± 0.41* 24.04
2 1 5 - 2 8 24.01 ± 0.23 23.92
3 1 5 - 2 8 24.02 ± 0.25 24.20
4 1 5 - 2 8 23.45 ± 0.76
5 1 5 - 2 8 23.72 ± 0.59 23.92
6 1 5 - 2 8 23.90 ± 0.30 24.45
Group n=6 1 5 - 2 8 23.76 ± 0.27 24.11
Parameter Subject Days Regression Spectral
Sleep Offset 1 1 5 - 2 8 23.68 ± 0.29* 25.36
2 1 5 - 2 8 23.99 ± 0.16 24.40
3 1 5 - 2 8 24.02 ± 0.20 24.36
4 1 5 - 2 8 23.56 ± 0.59 22.70
5 1 5 - 2 8 23.55 ± 0.53 22.86
6 1 5 - 2 8 23.66 ± 0.27* 23.46
Group n=6 1 5 - 2 8 23.73 ± 0.23* 23.86
Significance level of fitted regression line *** =<0.001 <0.01 * = <0.05
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Table 7.7 Sleep Parameters (single day) Mean Value ± SEM
Subject Time in Bed 
(mins)
Total Sleep Time 
(mins)
WASO (mins) Efficiency (%)
Experiment 1 1 499.9 ± 24.3 468.1 ± 25.1 31.8 ±13.4 94.3 ±1.9
20 lux 2 545.7 ± 36.9 512.7 ±32.8 33.0 ±17.3 94.6 ± 2.5
3 593.8 ± 14.8 582.9 ±14.7 10.9 ±1.2 98.2 ±0.2
4 478.5 ± 35.4 469.9 ± 35.5 8.6 ± 2.2 98.1 ± 0.5
5 536.6 ± 27.3 523.7 ± 26.2 12.9 ±2.7 97.6 ± 0.4
6 597.1 ± 27.0 548.2 ± 25.2 48.9 ±12.9 91.9 ±2.1
Group n = 6 541.93 ±13.85 517.58 ±11.25 24.35 ±5.18 95.8 ± 0.75
Experiment 1 1 568.1 ± 62.0 492.4 ± 60.6 45.3 ± 9.4 92.32 ±1.4
< 8 lux 2 487.1 ± 63.9 467.1 ± 59.9 20.0 ± 7.4 96.5 ± 1.1
3 610.8 ±30.4 587.0 ± 27.06 23.8 ± 7.4 96.4 ± 1.1
4 482.0 ± 44.1 493.9 ± 37.8 24.9 ±11.5 94.3 ± 2.3
5 532.9 ± 27.4 506.3 ± 26.1 26.6 ±10.1 95.2 ±1.7
6 593.4 ±37.3 547.7 ± 29.0 45.7 ± 9.7 92.8 ± 1.1
Group n = 6 541.53 ±24.02 514.08 ±23.58 31.48 ±4.22 94.46 ± 0.69
Experiment 2 1 543.9 ± 28.6 528.6 ± 28.0 15.4 ±2.4 97.4 ±0.4
200 lux 2 483.4 ± 24.2 462.9 ± 23.5 20.4 ± 2.4 95.7 ± 0.5
3 420.6 ± 35.6 402.8 ± 34.4 17.9 ±6.0 95.4 ± 1.5
4 508.1 ± 23.6 470.2 ± 24.7 37.9 ± 8.4 92.3 ±1.7
5 496.7 ± 28.1 473.1 ± 26.9 23.6 ± 3.7 95.3 ± 0.6
6 525.3 ± 28.4 488.7 ± 27.7 36.6 ± 3.2 92.8 ± 0.7
Group n = 6 492.97 ±16.82 468.61 ± 15.62 24.36 ±2.22 94.91 ± 0.4
Experiment 2 1 483.17 ±36.4 460.4 ± 32.2 21.4 ±6.8 95.9 ± 1.1
1000 lux 2 439.5 ± 25.9 416.6 ±23.0 22.8 ± 4.2 95.1 ± 0.7
3 481.3 ±32.6 460.9 ±31.4 20.4 ± 5.5 95.9 ±1.1
4 496.5 ± 45.1 468.8 ± 44.6 27.7 ± 7.2 93.8 ± 2.0
5 446.7 ± 35.9 434.8 ± 35.3 11.9±1.7 97.3 ± 0.3
6 509.7 ± 32.7 481.0 ± 30.9 28.7 ± 7.1 94.2 ±1.4
Group n = 6 473.97 ± 20.73 450.89 ± 19.64 22.81 ± 3.32 95.26 ± 0.6
7.3.3 Sleep Timing and Duration
The timing and duration of sleep periods in relation to the temperature rhythm were 
calculated and plotted for Experiment 2 only (Figs 7.9-7.10). The longest sleep 
periods occurred when sleep onset fell between 5 and 1 hours before the 
temperature nadir with 200 lux and between 5 hours before and the temperature 
nadir with 1000 lux. Short sleep episodes, on average, commenced on the rising part 
of the temperature curve. Indeed, with the 200 lux lighting schedule the sleep period 
decreased in length by approximately 30 minutes for every hour the sleep onset time 
moved closer to the temperature nadir. The sleep duration and onset times were 
more varied with 1000 lux.
254
Fig 7.9
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Fig 7.10
EXPERIMENT 2 - 
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Fig 7.11
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The timing of lights on and off in relation to the sleep-wake cycle is illustrated on the 
summary raster plots (Figs 7.6 - 7.8).
7.3.4 Grouped Data
Experiment 1: Group mean plots ± SEM for activity, temperature, aMT6s, sleep 
onset, sleep offset and sleep parameters for the two lighting schedules are shown in 
Figs 7.11 - 7.13) and group periodicities are recorded in Tables 7.3 and 7.4. With a 
12:12 lighting schedule of 20 lux 0800 - 2000h each day, activity, temperature, 
aMTGs, sleep onset and sleep offset all free-ran with a period significantly greater 
than 24h by regressive cosinor analysis and spectral analysis. Grouped activity and 
temperature data also free-ran (tau > 24h) by periodogram and autocorrelation 
analysis.
During the second half of the study under constant dim light conditions (< 8 lux) the 
results were greatly compromised by the non-compliance of the subjects who began 
attempting to readjust to normal environmental timing 8 days before the planned end 
of the experiment. Consequently any significant group periodicities for this section of 
the experiment were shorter than 24h Indeed, the only group period longer than 24h 
was aMTGs by spectral analysis (24.1Gh).
No repeated measures ANOVA was performed on data from this experiment.
Experiment 2: Group mean plots ± SEM for activity, temperature, aMTGs, sleep 
onset, sleep offset and sleep parameters for the two lighting schedules are shown in 
Figs 7.14 7.1 G) and group periodicities are recorded in Tables 7.5 and 7.G. Subject 2 
was not included in the group plots as he exhibited a free-run with a tau shorter than 
24h with 200 lux.
200 lux: With a 12:12 lighting schedule of 200 lux 0800 - 2000h each day activity, 
temperature and sleep offset free-ran with a period significantly greater than 24h by 
regressive cosinor analysis. Grouped activity and temperature data also free-ran (tau 
> 24h) by spectral, periodogram and autocorrelation analysis. Sleep offset and offset 
also showed a tau greater than 24h by spectral analysis, with aMTGs having a period 
less than 24h by spectral analysis.
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Fig 7.13
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Fig 7.14
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Fig 7.15
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Fig 7.16
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1000 lux: With a 12:12 lighting schedule of 1000 lux 0800 - 2000h each day, activity, 
temperature, aMT6s, and sleep offset all free-ran with a period significantly less than 
24h by regressive cosinor analysis. Grouped activity and temperature data also free- 
ran (tau < 24h) by spectral, periodogram and autocorrelation analysis. Sleep offset 
and aMT6s showed a tau less than 24h, and sleep onset a tau > 24h, by spectral 
analysis.
Repeated measures ANOVA indicated a number of significant differences both 
across the study days and between subjects and lighting levels. There were no 
significant differences in activity or aMT6s acrophase times, total sleep time or sleep 
efficiency across the study days or between subjects or lighting levels. However, 
temperature acrophase times were significantly different over study days and 
between light levels (p=0.002). There was a significant difference in time in bed over 
study day and between light levels (p=0.002), with more time being spent in bed 
under 200 lux than 1000 lux. There was a significant increase in wake after sleep 
onset over study days (p=0.007). There was a significant difference in sleep onset 
time between subjects (p=0.04), over study days (p=0.0004) and with study day and 
light level as factors (p=0.0001), sleep onset occurring later with lOOOlux - but the 
data is very variable. There was also a significant difference in sleep offset time 
between subjects (p=0.015), over study days (p=0.015) and with study day and light 
level as factors (p=0.0001) with increased variability with 1000 lux.
7.4 DISCUSSION
The baseline study (Chapter 5) indicated that a minimum of 10 days was required to 
achieve free-running rhythms with a measurable periodicity. One month was 
considered to be the longest tolerable time span that could be used, thus only 2 light 
levels could be tested in each experiment.
20 lux, 200 lux and 1000 lux were chosen, as a review of the literature suggested that 
while 20 lux would prove insufficient to maintain synchrony, 200 lux should be 
partially effective with weak time cues whilst 1000 lux should successfully entrain all 
subjects. Since these experiments were carried out Klerman et al. (1997), have 
published data suggesting that very dim light of 20 lux is sufficient to synchronise the 
human circadian pacemaker to 24h. It is important to note that during the 25 day
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study the subject had a scheduled cycle of 8h sleep in darkness and associated 
periodic stimuli (meals and social contacts). The combination of these zeitgebers 
may have been sufficient to maintain synchrony in the one individual studied, 
especially if their intrinsic period was very close to or precisely 24h.
It was extremely difficult to obtain any conclusive results from Experiment 1. This 
was due largely to the attitude of the subjects. All the individuals were military 
personnel on secondment to the trials section. Most were awaiting discharge, and 
therefore had no commitment to the project. Under the study conditions of close 
confinement, in partial isolation, non-compliance was contagious. Rectal probes 
were removed for long periods of time which invalidated the analysis. This is clearly 
demonstrated by Subject 2 as shown in Fig 7.2. On day 3 he regularly began to 
remove his probe for 10 -12 hours a day (the same time each day) therefore causing 
an apparent phase jump of 10 hours in his temperature data. Urine samples were 
missed resulting in poor collections and insufficient data. Actigraphy provided the 
best source of continuous data as this did not require any effort on the part of the 
subjects. However, activity does not give reliable information as to the phase of the 
internal clock.
The strong effect of behaviour on the data collection can clearly be seen on the 
summary double plots shown in Figs 7.2 - 7.4. From day 16 onwards subjects were 
getting ready to leave the unit and return to the outside world. The experiment had to 
be terminated earlier than intended for this reason. Bags were packed and equipment 
removed and not replaced, despite negotiations. It is of interest to note that subject 3 
in this experiment had participated in the baseline study reported in Chapter 5. 
During the baseline study he exhibited significant free-running rhythms in activity, 
temperature, aMT6s and sleep offset with an average tau of 24.3h. Throughout 
Experiment 1 he retired to bed at approximately midnight and stayed there until about 
midday thus successfully masking most of the rhythms being measured. Despite this 
masking a free-run with a shortened tau of 24.15h (compared to the baseline study) 
was seen in the temperature data collected.
-180  lux was reported to be sufficient to induce phase shifts by Boivin et a/., (1996). 
Theoretically, therefore it should have been sufficient to entrain the circadian system. 
However, this was not the case under our experimental conditions. This may be due
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to the lack of other strong time cues for our subjects, or the requirement to complete 
certain activities at set times. They did have knowledge of clock time. In the study 
reported by Boivin subjects were maintained in constant dim light (10-15 lux) apart 
from 5h of light exposure centred 1.5h after the temperature minimum over 3 days. 
Any phase shift produced was measured by comparison of the results from a 
constant routine at the beginning and at the end of the study. A phase advance of 
+1.16h was seen but with an SEM of 0.96h compared to a phase delay of -1.05h ± 
0.38 under the dim light control conditions in a different group of subjects. This was 
an acute effect of exposure to a burst of light of -  180 lux and it is possible that over 
a longer period of time this light level would be unable to produce a sustainable 
effect.
All six subjects included in Experiment 2 exhibited free-running periods in one or 
more parameters with the lighting schedule of 200 lux, 0800 - 2000h. One subject 
(82) had an apparent endogenous periodicity of 23.9h and this individual had a much 
earlier demasked temperature nadir than the other 5 subjects. In this subject (82) the 
demasked temperature rhythm phase advanced in relation to lights on during 200 lux 
treatment but synchronised to 24h with 1000 lux.
8ince the 200 lux lighting schedule was insufficient to synchronise the subjects during 
the first half of the experiment, the initial exposure to 1000 lux occurred at different 
phases of the circadian clock. This resulted in a range of responses with phase 
delays, phase advances and synchronisation. Three individuals (81,4 and 5) 
received the first 1000 lux exposures prior to sleep onset and their demasked 
temperature nadir for several days, thus producing phase delays. On some days the 
sleep periods were of such a length that no light exposure was perceived after sleep 
offset which presumably served to strengthen the effect of the “evening” light 
exposure. These subjects then exhibited phase jumps to apparently synchronise to 
the 24h day. Inclusion of these individuals in the group analysis results in distortion 
of the calculated overall group periodicity.
In summary these experiments can be said to show that a 20 lux and a 200 lux light 
dark cycle, with knowledge of clock time, are inadequate for synchronisation. 1000 
lux, in general, appears able to induce synchronisation after a period of transients, 
during which the circadian system adjusts by either phase advance or phase delays
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to the appropriate position. In some cases the data series was of insufficient length 
to guarantee that synchronisation had occurred.
In retrospect, it would have been beneficial to include an experiment where subjects 
were exposed to a 1000 lux lightidark cycle at the beginning of the study to ascertain 
whether this light intensity is sufficient to maintain synchronisation in partial isolation 
but with knowledge of clock time. This shortfall was addressed in a later experiment 
where a 1000 lux lighting schedule was combined with timed melatonin or placebo 
administration (Chapter 8).
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CHAPTER 8
EFFECTS ON HUMAN CIRCADIAN RHYTHMS OF
MELATONIN ADMINISTRATION AND 1000 LUX 12:12
LIGHT DARK CYCLE
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8.1 SPECIFIC STUDY DESIGN & RATIONALE
Studies reported earlier in this thesis (Chapters 6 & 7) investigated the ability of a 
12:12 lighting schedule of varying intensity, and of timed melatonin administration to 
either prevent rhythms from free-running, or to re-entrain already free-running 
rhythms. The results obtained suggested that the most important consideration in the 
use of either light or exogenous melatonin is the timing of treatment.
Experiment 2 reported in Chapter 7 suggested that a lighting schedule of 1000 lux 
08:00 - 20:00h with dim light (< 8 lux) 20:00 - 08:00h, when applied to a group of 
free-running individuals, is able to induce synchronisation after a period of transients. 
Depending on the timing of the light exposure subjects resynchronised by either a 
phase advance or phase delay, whilst some subjects stabilised at the phase position 
exhibited at the time of first light exposure. However, the ability of 1000 lux to 
maintain long term synchronisation, under our experimental conditions of partial 
environmental isolation but with knowledge of clock time, was not examined.
The timed administration of melatonin under constant dim light conditions as reported 
in Chapter 6 appeared to have weak zeitgeber effects. 5 mg melatonin given 
immediately on entering the dim light environment was able to synchronise the sleep 
wake cycle in most individuals. When taken after a period of free-run the sleep-wake 
cycle was resynchronised to 24h by either a phase delay or phase advance 
depending on the individual phase position at the time of the initial dose of melatonin. 
The core body temperature appeared either to have a shorter tau or to be 
synchronised, although not entirely convincingly, in most individuals using melatonin. 
A great deal of variability was seen in the individual responses.
Under normal environmental conditions individuals are exposed to both a strong light 
dark cycle and a daily rhythm of melatonin, rising in the evening and falling in the 
morning. These two influences may compliment each other to maintain 
synchronisation to the 24h day. This investigation determined the effects of timed 
administration of melatonin coupled with a 1000 lux lighting schedule in normal 
sighted individuals maintained as a group under partial environmental isolation but 
with knowledge of clock time.
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The subjects were required to complete two legs of the study, each of 31 days. This 
experiment combined the study design for melatonin administration in constant dim 
light (Chapter 6) with the second half of Experiment 2 (Chapter 7). The study design 
is shown in Fig 8.1.
8.1.1 Isolation Facility
The isolation unit was provided by the DERA, Farnborough, and has been described 
in section 2.1.1. The exact layout was as shown in Fig 2.1 Plan B.
An overhead lighting system provided by Siemens Lighting was used. The bank of 
lights in each room fitted with shutters to reduce the illumination levels to < 8 lux as 
described in 2.1.2 were used for the overnight periods (20:00 - 08:00h) throughout 
both legs. The remaining light banks were adjusted to give an overall average 
illumination of 1000 lux 08:00 - 20:00h from day 5 onwards.
8.1.2 Subjects
7 normal healthy males aged 24.29 ± 1.61 years, numbered 81 - 86, were recruited 
from the general public by advertisement in the local press (the trials section at the 
DERA Farnborough had been abolished). They were under no medication except for 
minor analgesics and smoked <10 cigarettes a day.
Potential subjects were screened as described in section 2.2.4, with the addition of a 
urine screen for drugs of abuse.
Nine potential subjects completed the selection procedure and 6 individuals were 
chosen for inclusion in leg 1. Unfortunately, one subject was unable to participate in 
leg 2 and an alternative subject was found and given the same subject number (84) 
to avoid confusion. Informed written consent was obtained from all subjects and the 
study protocol was approved by the DERA Centre for Human 8ciences Ethics 
Committee.
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8.1.3 Study Protocol
The subjects were maintained as a group of 6 individuals for two legs each of 31 
days. The same general study protocol applied to both legs and the mean values for 
light levels and ambient temperature were taken.
Subjects arrived at the isolation facility at 10:00h on Day 1. Equipment was issued 
and recording of data plus collection of samples began at 12:00. A 3 day baseline 
was introduced at the beginning of each leg. During this time individuals were 
encouraged to leave the unit during the day, but a regular sleep period in darkness 
from midnight to 08:00h was imposed. Isolation commenced at 20:00h on day 4 
when light levels were lowered to <8 lux. A 12:12 lighting schedule was then 
enforced throughout the remainder of the study. The light levels were 1000 lux 08:00 
- 20:00h and < 8 lux 20:00 - 08:00h. The light levels were checked every day, 
approximately 1 hour after lights on, using a hand held lux meter following the CIS 
Code 1984 for determination of average illuminance. Over night dim light levels were 
checked every second night. Dim light levels were 5.84 ± 0.7 (SEM) lux (n = 1240) 
and 1000 lux light levels were 919.52 ± 4.5 (SEM) lux (n = 2322). The ambient 
temperature range was 21 - 29°C (mean = 24.6 ± 0.2 (SEM) °C, n = 540). Subjects 
had access to a digital clock and watches to enable timed medication to be given.
Melatonin or placebo capsules were taken 3 times a day, when awake, days 4-31. 
Administration was timed to occur at 04:00, 12:00 and 20:00h. Those capsules taken 
at 04:00 and 12:00h were placebo (gelatin lactose). The 20:00h capsule contained 
either 5mg melatonin in gelatin lactose or placebo as follows: Placebo days 4-17  
(Placebo 1st) : Melatonin days 18-30 (Melatonin 2nd) or Melatonin days 4 -1 7  
(Melatonin 1st) : Placebo days 18-30 (Placebo 2nd). Capsules were placed in the 
isolation unit in clearly labelled vials with separate bottles for each subject for each 
dose time. Experimenters, using video surveillance, were instructed to ensure that 
capsules were taken at the correct time by all subjects who were awake. Individuals 
were never woken to take the pills. Compliance was noted and a record kept of 
which pills were taken.
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The general study conditions were as described in section 2.2.3. An incident book 
was kept throughout the study to record any significant events, subjects requests and 
general observations on the subjects mood and behaviour.
The experiment was conducted between November and February with 33 days 
between legs.
8.1.4 Measurements Taken
The following measurements were taken throughout the study.
a. daily maximum and minimum temperatures in each room
b. light levels every 2 days
c. core body temperature via a rectal probe and memory logger
d. sleep-wake/activity via wrist mounted accelerometer - Mini Motionlogger
e. 4 hourly urine collections except for oversleep periods
f. 2 hourly performance sessions when awake using the Psion based test 
battery
g. daily activity diaries
h. subjective sleep logs after every sleep period
8.2 ANALYSIS OF DATA
8.2.1 Urinary aMTGs
Urinary aMT6s levels were measured using the assay described in section 2.4.2. 
Quality control coefficients of variation (C.V.) were 7.3%, 6.2% and 10.2% for 
concentrations of 3.94, 21.88 and 47.12 ng/ml respectively. The limit of detection at 
2 X  SD of zero binding was 0.28 ng/ml. The excretion rate for each sample period 
was calculated in ng/hr and these values were subjected to 3 day moving window 
cosinor analysis as described in Chapter 3 section 3.1.4 and spectral analysis as in 
section 3.1.5. During administration of melatonin, (Melatonin 1st and Melatonin 2nd), 
urinary aMT6s from exogenous melatonin completely masked the endogenous 
rhythm and no cosinor analysis was performed on this data. Acrophase times were
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analysed further by linear regression analysis and repeated measures ANOVA as 
described in section 3.2 both on an individual basis and by group mean values.
8.2.2 Temperature Data
Raw temperature data were edited as described in section 3.1.1. The temperature 
data were not demasked and the data used for further analysis were edited raw 
temperature values recorded every 6 minutes. The edited temperature data were 
analysed further using cosinor, spectral, periodogram and autocorrelation analysis 
(sections 3.1.4, 3.1.5, 3.1.6 and 3.1.7).
The calculated acrophase times, were then subjected to linear regression analysis 
and repeated measures ANOVA. (Sections 3.2.1 and 3.2.2), both on an individual 
basis and as group means.
8.2.3 Activity and Sieep Data
Raw activity data were edited as described in section 3.1.1. Sleep parameters were 
determined using Action3 software (Ambulatory Monitoring Inc.) and analysed as 
described in sections 3.1.2 and 3.1.3.
Edited activity data were analysed further using cosinor, spectral, periodogram and 
autocorrelation analysis (sections 3.1.4, 3.1.5, 3.1.6 and 3.1.7).
The calculated acrophase times and sleep parameters were then subjected to linear 
regression analysis and repeated measures ANOVA. (Sections 3.2.1 and 3.2.2), both 
on an individual basis and as group means.
8.2.4 Performance Data
All performance data collected were analysed for any changes in performance across 
the treatment periods and any differences in performance between the various 
treatments, using daily means as described in section 3.1.6. Results from the
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performance data analysis are not reported here for the reasons stated in section 
3.1.6.
8.3 RESULTS
8.3.1 Compliance
Subject 4 did not return to complete leg 2 for employment reasons. An alternative 
subject was located and was introduced from the second baseline day. For ease he 
was also identified as subject 4. Overall subject compliance was extremely good with 
no activity or temperature data lost apart from equipment failure. Two individuals did 
not provide enough urine samples for reliable rhythm analysis despite being 
encouraged to drink more. SI completed a much lower percentage of performance 
tests compared to the other 5 subjects.
The overall mean percentages (± SEM) of the theoretical data collected for the 
various parameters were as follows:
Temperature 85.5 ±2.5%
Activity 89.8 + 1.8%
Sleep 94.7 ±1.8%
aMT6s 79.1 ±2.3%
Performance 78.4 ± 3.3%
Data lost due to equipment malfunction can be summarised as follows:
a. activity lost data: SI Placebo 1st 47h, Melatonin 2nd 56h, Melatonin 1st 
48h; S2 Placebo 1st 72h; S3 Melatonin 2nd 32h; S4 Placebo 2nd 47h and 
S6 Melatonin 2nd 54h.
b. temperature lost data: SI Placebo 2nd 17h & Melatonin 2nd 42h; S2 
Placebo 2nd 24h; S3 Melatonin 2nd 94h & Placebo 2nd 23h; and S4 
Melatonin 2nd 85h.
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8.3.2 Individual Data
Summary raster double plots were produced for all subjects giving an overall record 
of the sleep-wake cycle and activity, temperature and aMT6s acrophase times. 
(See Figs 8.2 - 8.7).
8.3.2.1 Rest-Activity
Visual inspection of these plots indicated that the sleep-wake cycle was stabilised to 
24h in 6/6 subjects for all 4 treatments with consolidated sleep episodes. S4 showed 
a small amount of fragmented sleep over the first 3 days of Melatonin 1st treatment, 
but the phenomenon was only transitory.
8.3.2.2 Temperature
Melatonin administration appeared to cause a shortened masked temperature tau in 
4/6 subjects (S1,S2,S3 and S5). However, a masked temperature tau less than 24h 
was also apparent under Placebo 1st treatment in S2, S4 and in both Placebo 1st 
and Placebo 2nd in S5. S3 shows relative co-ordination with Placebo 1st and a clear 
free-run with a tau greater than 24h with Placebo 2nd.
In the majority of subjects (5/6) the initial melatonin treatment caused a phase 
advance in the temperature rhythm whilst subject 3 maintained phase position or 
showed a slight delay.
8.3.2.3 aMTBs
The aMT6s rhythm free-ran in 2/6 individuals on Placebo 1st and Placebo 2nd with a 
tau shorter than 24h. 84 subject showed a free-running aMT6s rhythm with a tau 
greater than 24h on Placebo 2nd. 2/6 subjects (82 & 85) showed clear phase 
changes in the endogenous aMT6s rhythm after Melatonin 1st, compared to the 
phase position shown under Placebo 1st. The mean endogenous aMT6s per 24h and 
the mean aMT6s excreted per 24h during melatonin treatment for each subject are 
shown in Table 8.1. The endogenous secretion for all subjects was within the normal 
range for age (13.14 ± 9.8^ig/24h to 54.0 ± 6.0pg/24h). The excretion of aMT6s
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Fig 8.3
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Fig 8.4
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Fig 8.6
LIGHT AND MELATONIN ADMINISTRATION STUDY
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Fig 8.7
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during melatonin treatment was used to determine the percentage of active pills 
taken (98.2%) and to evaluate individual clearance. Only 3 active pills were not 
taken, and this was due to the experimenter on duty not supplying the pills, not the 
subjects refusing to take them. All subjects returned to baseline levels of aMT6s 
within 48h of cessation of Melatonin 1st treatment.
Table 8.1 Amount of aMT6s excreted (pgs)
Subject Mean Endogenous Mean aMT6s
Number aMT6s Excreted per 24h Excreted per 24h during
Melatonin Treatment
1 16.87 ±0.71 2937.75 ±198.30
2 16.53 ±0.53 3649.69 ±157.66
3 13.00 ±0.49 2848.19 ± 118.18
4 9.59 ± 0.48 2824.33 ± 143.00
5 18.88 ±0.81 3376.15 ±185.34
6 16.33 ±0.55 2592.75 ± 233.87
The full results obtained from linear regression analysis, spectral analysis, 
periodogram analysis and auto correlation for each parameter and each individual, 
together with group means for all 4 treatments are shown in Tables 8.2 - 8.5. 
Individual tau (x) derived from linear regression analysis of acrophase times, or single 
day sleep onset and offset times, was considered to be significantly different from 24 
h if the fitted regression line had a p value <0.05 and the upper and lower limits at 
95% confidence did not encompass 24h.
The individual results for each treatment can be summarised for the various 
parameters as follows:
8.3.2.4 Placebo 1st
There were no significant differences between subjects or analysis methods for 
activity, temperature or aMT6s tau. There were no significant differences between 
subjects for sleep onset or offset but there was a significant difference between tau 
determined by regressive cosinor and spectral analysis by ANOVA and paired t-test.
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Table 8.2
MELATONIN & LIGHT STUDY -1000 LUX PLACEBO 1ST 
Individual and Group Periodicities Determined by 
Various Analysis Methods
Parameter Subject Days Regression Spectral Periodogram Autocorrelation
Activity 1 3 - 1 7 23.93 ± 0.08 24.10 23.98 24.12
2 3 - 1 7 24.04 ± 0.03** 23.95 24.03 24.18
3 3 - 1 7 24.02 ± 0.07 23.96 24.07 24.30
4 3 - 1 7 23.96 ± 0.05 23.90 23.96 23.57
5 3 - 1 7 23.82 ± 0.09*** 23.72 23.97 24.00
6 3 - 1 7 24.07 ± 0.07 24.30 23.95 24.24
Group n=6 3 - 1 7 23.97 ± 0.06 23.99 23.99 24.07
Parameter Subject Days Regression Spectral Periodogram Autocorrelation
Temperature 1 3 - 1 7 23.95 ± 0.07 24.15 23.97 24.00
2 3 - 1 7 24.03 ± 0.02* 23.80 23.95 24.48
3 3 - 1 7 23.94 ± 0.09 24.02 24.01 24.33
4 3 - 1 7 23.78 ± 0.08*** 23.70 23.82 23.45
5 3 - 1 7 23.89 ± 0.03*** 23.80 23.90 23.51
6 3 - 1 7 23.99 ± 0.03 24.02 23.91 24.27
Group n=6 3 - 1 7 23.93 ± 0.03*** 23.92 23.93 24.01
Parameter Subject Days Regression Spectral
aMT6s 1 3 - 1 7 23.94 ± 0.06 24.20
2 3 - 1 7 23.93 ± 0.06 23.86
3 3 - 1 7 23.90 ± 0.09* 23.86
4 3 - 1 7 23.83 ± 0.06*** 23.80
5 3 - 1 7 23.87 ± 0.17 24.35
6 3 - 1 7 24.10 ± 0.16
Group n=6 3 - 1 7 23.93 ± 0.07* 24.01
Parameter Subject Days Regression Spectral
Sleep Onset 1 3 - 1 7 23.98 ± 0.16 23.85
2 3 - 1 7 23.96 ± 0.06 23.76
3 3 - 1 7 23.95 ± 0.17 23.86
4 3 - 1 7 23.88 ± 0.13 23.65
5 3 - 1 7 24.36 ± 0.66 23.76
6 3 - 1 7 23.98 ± 0.11 23.75
Group n=6 3 - 1 7 24.02 ± 0.12 23.77
Parameter Subject Days Regression Spectral
Sleep Offset 1 3 - 1 7 23.92 ± 0.08 24.20
2 3 - 1 7 24.06 ± 0.09 24.30
3 3 - 1 7 23.98 ± 0.12 24.23
4 ' 3 - 1 7 23.87 ± 0.09** 24.12
5 3 - 1 7 23.88 ± 0.16 24.15
6 3 - 1 7 23.95 ± 0.07 24.30
Group n=6 3 - 1 7 23.94 ± 0.07 24.22
Significance level fitted regression line ***=<0.001 **-<0.01 *-<0 .05
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Table 8.3
MELATONIN & LIGHT STUDY -1000 LUX MELATONIN 2ND 
Individual and Group Periodicities Determined by 
Various Analysis Methods
Parameter Subject Days Regression Spectral Periodogram Autocorrelation
Activity 1 17 -3 0 23.96 ± 0.04 23.62 23.94 24.00
2 17 -3 0 23.95 ± 0.01*** 23.76 23.88 23.70
3 17 -3 0 23.98 ± 0.04 24.35 23.94 23.48
4 17 -3 0 23.94 ± 0.07 23.58 24.00 23.57
5 17 -3 0 24.00 ± 0.05 21.25 23.70 23.99
6 17 -3 0 23.88 ± 0.07** 23.15 23.96 23.70
Group n=6 17 -3 0 23.95 ± 0.02*** 23.29 23.90 23.74
Parameter Subject Days Regression Spectral Periodogram Autocorrelation
Temperature 1 17 -3 0 23.98 ± 0.18 23.71 23.92 24.00
2 17 -3 0 23.97 ± 0.09 23.65 23.87 23.48
3 17 -3 0 24.01 ± 0.08 24.40 23.97 24.03
4 17 -3 0 24.04 ± 0.09 24.00 24.05 23.45
5 17 -3 0 24.03 ± 0.05 23.62 24.01 24.06
6 17 -3 0 24.04 ± 0.06 23.82 23.99 23.57
Group n=6 17 -3 0 24.02 ± 0.04 23.87 23.97 23.77
Parameter Subject Days Regression Spectral
Sleep Onset 1 17 -3 0 23.96 ± 0.15 23.82
2 17 -3 0 24.17 ± 0.15* 23.82
3 17 -3 0 23.99 ± 0.15 23.82
4 17 -3 0 24.04 ± 0.07 23.76
5 17 -3 0 24.05 ± 0.11 23.76
6 17 -3 0 23.91 ± 0.12 23.70
Group n=6 17 -3 0 24.02 ± 0.06 23.78
Parameter Subject Days Regression Spectral
Sleep Offset 1 17 -3 0 23.93 ± 0.14 24.12
2 17 -3 0 23.84 ± 0.07*** 24.10
3 17 -3 0 23.94 ± 0.14 24.06
4 17 -3 0 24.00 ± 0.20 24.02
5 17 -3 0 24.00 ± 0.12 24.12
6 17 -3 0 23.87 ± 0.08** 24.12
Group n=6 17 -3 0 23.93 ± 0.07 24.09
Significance level fitted regression line ***-<0.001 **-<0.01 *-<0 .05
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Table 8.4
MELATONIN & LIGHT STUDY -1000 LUX MELATONIN 1ST 
Individual and Group Periodicities Determined by 
Various Analysis Methods
Parameter Subject Days Regression Spectral
Activity 1 3 - 1 7 24.04 ± 0.07 23.70
2 3 - 1 7 23.94 ± 0.05* 23.75
3 3 - 1 7 23.87 ± 0.04*** 23.76
4 3 - 1 7 23.99 ± 0.11 23.76
5 3 - 1 7 23.95 ± 0.04* 23.82
6 3 - 1 7 23.98 ± 0.04 24.05
Group n=6 3 - 1 7 23.96 ± 0.02** 23.81
Parameter Subject Days Regression Spectral
Temperature 1 3 - 1 7 24.01 ± 0.06 23.65
2 3 - 1 7 23.89 ± 0.10* 24.00
3 3 - 1 7 23.91 ± 0.05** 23.96
4 3 - 1 7 24.04 ± 0.09 23.95
5 3 - 1 7 23.96 ± 0.04 23.86
6 3 - 1 7 23.97 ± 0.04 24.05
Group n=6 3 - 1 7 23.97 ± 0.02* 23.91
Parameter Subject Days Regression Spectral
Sleep Onset 1 3 - 1 7 23.96 ± 0.10 23.56
2 3 - 1 7 23.88 ± 0.17 24.56
3 3 - 1 7 23.85 ± 0.30 23.66
4 3 - 1 7 24.08 ± 0.23 24.30
5 3 - 1 7 24.02 ± 0.24 23.92
6 3 - 1 7 23.94 ± 0.20 23.80
Group n=6 3 - 1 7 23.95 ± 0.04* 23.97
Parameter Subject Days Regression Spectral
Sleep Offset 1 3 - 1 7 23.92 ± 0.19 24.06
2 3 - 1 7 23.96 ± 0.09 24.40
3 3 - 1 7 23.81 ± 0.15* 24.10
4 3 - 1 7 24.10 ± 0.35 24.20
5 3 - 1 7 23.94 ± 0.25 24.15
6 3 - 1 7 23.93 ± 0.10 24.02
Group n=6 3 - 1 7 23.94 ± 0.05* 24.16
Significance level fitted regression line ***=<0.001 **=<0.01
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Table 8.5
MELATONIN & LIGHT STUDY -1000 LUX PLACEBO 2ND 
Individual and Group Periodicities Determined by 
Various Analysis Methods
Parameter Subject Days Regression Spectral Periodogram Autocorrelation
Activity 1 17-30 23.99 ± 0.07 23.86 24.08 24.01
2 17-30 23.90 ± 0.05*** 24.20 23.91 23.94
3 17- 30 24.02 ± 0.16 23.55 24.16 24.24
4 17- 30 24.00 ± 0.09 23.75 24.07 24.03
5 17- 30 24.04 ± 0.08 24.02 23.95 24.03
6 17- 30 23.86 ± 0.08** 24.05 23.97 24.06
Group n=6 17- 30 23.97 ± 0.05 23.91 24.02 24.05
Parameter Subject Days Regression Spectral Periodogram Autocorrelation
Temperature 1 17- 30 23.97 ± 0.19 24.12 24.08 24.51
2 17- 30 24.00 ± 0.06 24.02 23.99 24.03
3 17- 30 24.13 ± 0.08** 24.05 24.11 24.00
4 17- 30 23.97 ± 0.05 23.35 24.05 24.00
5 17- 30 23.90 ± 0.04*** 23.95 23.95 24.06
6 17- 30 23.96 ± 0.05 24.05 24.00 24.30
Group n=6 17- 30 23.98 ± 0.04 23.92 24.03 24.15
Parameter Subject Days Regression Spectral
aMT6s 1 17- 30 23.94 ± 0.10 23.85
2 17- 30 23.97 ± 0.17 23.92
3 17- 30 24.15 ± 0.19 23.92
4 17- 30 24.10 ± 0.09* 24.22
5 17- 30 23.89 ± 0.09* 23.60
6 17- 30 23.78 ±0 .16* 23.76
Group n=6 17- 30 24.00 ± 0.03 23.88
Parameter Subject Days Regression Spectral
Sleep Onset 1 17- 30 23.95 ± 0.15 23.85
2 17- 30 23.97 ± 0.06 23.65
3 17-30 24.06 ± 0.22 23.80
4 17- 30 23.94 ± 0.26 23.76
5 17-30 23.98 ± 0.13 23.75
6 17- 30 23.94 ± 0.12 23.82
Group n=6 17-30 23.97 ± 0.08 23.77
Parameter Subject Days Regression Spectral
Sleep Offset 1 1 - 14 24.01 ± 0.14 24.20
2 1 -1 4 23.90 ± 0.09* 24.12
3 1 -1 4 24.04 ± 0.26 24.00
4 1 -1 4 23.99 ± 0.15 24.20
5 1 - 14 23.92 ± 0.11 24.02
6 1 - 14 23.96 ± 0.14 24.12
Group n=6 1 -1 4 23.97 ± 0.07 24.11
Significance level fitted regression line ***-<0.001 **-<0.01 *-<0 .05
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Sleep onset tau was longer by regressive cosinor (p = 0.02) and sleep offset tau was 
longer by spectral analysis (p = 1.45 E-05).(see Table 8.2)
There were no significant differences across treatment days for time in bed or total 
sleep time by any individual during the treatment. One subject (85) showed a 
significant increase in wake after sleep onset as the treatment progressed (p= 0.02). 
Two subjects (81 & 5) also showed a significant decrease in sleep efficiency over 
time (p=0.04 and 0.01 respectively). Full results from the linear regression analysis of 
sleep parameters (single day values), and mean values ± 8EM are summarised in 
Table 8.6.
8.3.2.5 Melatonin 2nd
8tatistical analysis of the periodicities determined by the various analysis methods
showed that for activity and temperature there were no significant differences
between subjects or analysis methods. There were no significant differences between 
subjects for either sleep onset or offset but there was a significant difference between 
analysis methods for both sleep onset and offset. 8pectral analysis gave significantly 
shorter tau for sleep onset (p =0.0007), but a longer tau than regressive cosinor for 
sleep offset (p = 0.008). (see Table 8.3).
There were no significant differences across the treatment period in any individual for 
wake after sleep onset or sleep efficiency. Two subjects (82,3) showed a significant 
decrease in both time in bed and total sleep time across the treatment period (p 
<0.01). Full results from the linear regression analysis of sleep parameters (single 
day values), and mean values ± 8EM are summarised in Table 8.6.
8.3.2.6 Melatonin 1st
8tatistical analysis of the calculated periodicities gave no significant differences, 
either between subjects or analysis methods for activity or sleep onset. There were 
no significant differences between subjects for temperature or sleep offset. However, 
when analysed as a group by ANOVA there was a significant difference between 
analysis methods (p <0.01) for temperature with autocorrelation indicating a shorter 
tau, but there were no significant differences when treatments were compared on a
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individual basis. Spectral analysis gave significantly longer tau (p = 0.01) for sleep 
offset times than regressive cosinor. (see Table 8.4)
There were no significant differences over the treatment period shown for time in 
bed, total sleep time, wake after sleep onset or sleep efficiency by any individual, 
except for 86 who showed a significant increase in wake after sleep onset (p=0.01) 
and decrease in sleep efficiency (p = 0.0007). Full results from the linear regression 
analysis of sleep parameters (single day values), and mean values ± 8EM are 
summarised in Table 8.6.
Table 8.6 Sleep Parameters (single day) Mean Value ± SEM
Treatment Subject Time in Bed 
(mins)
Total Sleep Time 
(mins)
WASO
(mins)
Efficiency (%)
Baseline 1 479.7 ± 7.3 460.7 ± 9.8 11.7 ±5.0 97.4 ±1.04
2 461.2 ±7.2 413.2 ±9.4 48.0 ± 5.6 89.6 ± 1.2
3 469.3 ± 4.4 441.5 ±5.8 27.8 ± 7.3 94.1 ±1.5
4 440.0 ± 33.4 429.2 ± 34.4 10.8 ±3.6 97.3 ±1.0
6 463.8 ± 6.7 458.3 ± 6.9 5.5 ±1.8 98.8 ± 0.4
6 492.2 ± 7.02 486.8 ± 8.0 20.5 ± 7.9 96.0 ±1.3
Group n = 6 467.69 ± 10.99 448.28 ±10.61 20.72 ±5.19 95.53 ±1.08
Placebo 1st 1 581.9 ±15.4 547.4 ±14.3 33.4 ± 5.4 94.4* ± 0.9
2 595.0 ± 24.6 508.9 ±19.0 67.4 ±15.9 89.2 ± 2.5
3 479.4 ±21.5 469.9 ± 20.4 9.6 ± 2.4 98.1 ±0.4
4 533.5 ± 13.6 514.0 ± 12.6 19.5 ±3.1 96.4 ±0.6
5 493.9 ±21.7 491.4 ± 19.2 12.7* ±3.9 97.3* ±0.8
6 567.7 ± 13.5 567.7 ±13.6 31.3 ±4.7 94.9 ± 0.7
Group n = 6 541.91 ± 18.39 516.55 ± 16.51 28.98 ± 5.91 95.05 ±0.99
Melatonin 2nd 1 624.0 ± 25.7 564.4 ± 18.2 55.0 ± 12.6 91.6± 1.6
2 533.8“  ± 28.6 475.9“  ± 30.8 57.9 ±19.3 89.7 ± 3.6
3 511.4* ±12.8 496.2“  ± 11.5 14.0 ±3.0 97.4 ± 0.6
4 574.8 ± 22.2 535.3 ± 16.5 39.5 ± 7.2 93.5 ± 1.0
5 517.5 ±15.8 491.8 ± 16.9 25.7 ± 9.9 95.1 ± 1.9
6 579.0 ± 15.8 549.7 ±14.7 25.3 ± 5.5 95.6 ± 0.9
Group n = 6 556.73 ±20.14 518.88 ±18.09 36.22 ± 9.59 93.86 ±1.6
Melatonin 1st 1 583.3 ± 20.8 551.5 ±22.7 33.1 ± 7.7 94.3 ± 1.3
2 514.6 ± 16.0 494.2 ± 15.0 20.4 ±5.7 96.2 ± 1.0
3 517.5 ±26.2 484.6 ± 26.7 32.9 ± 6.8 93.6 ± 1.4
4 459.2 ± 44.5 432.0 ± 42.4 28.1 ± 6.3 94.2 ± 1.2
5 478.5 ± 32.0 468.6 ±31.2 9.9 ±3.1 98.0 ± 0.6
6 546.5 ±21.2.0 522.1 ±19.5 24.4** ± 3.3 95.6*** ± 0.5
Group n = 6 516.54 ±26.79 492.17 ±26.24 24.81 ± 5.47 95.31 ± 0.99
Placebo 2nd 1 571.1 ±17.7 535.7 ±18.5 33.9 ± 7.5 94.2 ± 1.2
2 503.5 ± 17.9 460.5 ± 15.4 42.9 ± 9.6 91.8 ± 1.7
3 504.9 ± 24.2 488.7 ± 24.8 16.2 ±4.1 96.8 ± 0.8
4 528.6 ± 22.2 495.4 ±21.9 33.2 ± 5.7 94.0 ± 1.0
5 493.9 ± 11.4 476.0 ± 12.0 17.9 ±4.7 96.2 ± 0.9
6 546.6 ± 14.8 515.9 ±12.1 30.8 ± 5.1 94.4 ± 0.8
Group n = 6 524.8 ±18.0 495.36 ± 17.45 29.15 ±6.12 94.57 ± 1.07
Significance level of changes across treatment *** = <0.001 ** = <0.01 * = <0.05
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S.3.2.6 Placebo 2nd
Statistical analysis of the individual periodicities determined by the various analysis 
methods showed that for activity, temperature and aMT6s there were no significant 
differences, either between subjects or analysis methods by 2 way ANOVA. Sleep 
onset and offset times showed no significance difference between subjects but 
spectral analysis gave a significantly shorter tau for sleep onset (p = 0.002) and a 
longer tau for sleep offset (p=0.02). (see Table 8.5)
There were no significant differences across the treatment days for time in bed, total 
sleep time, wake after sleep onset or sleep efficiency by any individual. Full results 
from the linear regression analysis of sleep parameters (single day values), and 
mean values ± SEM are summarised in Table 8.6.
8.3.3 Sleep Timing & Duration
The timing and duration of sleep periods in relation to the temperature rhythm were 
calculated and plotted (Figs 8.8 - 8.11). All 4 treatments showed the longest sleep 
episodes when sleep onset occurred 5-6h before the temperature nadir. A significant 
shortening of the sleep period occurred as sleep onset times advanced towards the 
temperature nadir (Placebo 1st 48 min /hr; Melatonin 2nd 20 mins/hr. Melatonin 1st 
26 min/hr and Placebo 2nd 27 min/hr).
Statistical comparison of the various treatments determined that there were 
significant differences between sleep onset time in relation to the temperature nadir, 
with onset occurring closer to the nadir on both melatonin treatments compared to 
both placebo treatments (p <0.01) but no significant difference between the two 
placebo or two melatonin treatments. Sleep duration was longer with Placebo 1st 
and Melatonin 2nd treatments than Melatonin 1st (p=0.009, p=0.0006) or Placebo 
2nd (p=0.017, p=0.0006). Sleep offset time in relation to temperature nadir was later 
and showed greater variance with Melatonin 2nd compared to all other treatments (p 
<0.0001) and Melatonin 1st compared to Placebo 2nd (p=0.004). Sleep offset time 
was later with Placebo 1st compared to all other treatments (p < 0.01).
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Fig 8.8
LIGHT & MELATONIN ADMINISTRATION STUDY -
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Fig 8.9
LIGHT & MELATONIN ADMINISTRATION STUDY -
DURATION OF SLEEP PERIODS IN RELATION TO TEMPERATURE RHYTHM
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Fig 8.10
LIGHT & MELATONIN ADMINISTRATION STUDY
SLEEP OFFSET TIME IN RELATION TO TEMPERATURE RHYTHM
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Fig 8.11
LIGHT & MELATONIN ADMINISTRATION STUDY
SLEEP OFFSET TIME IN RELATION TO TEMPERATURE RHYTHM
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Fig 8.12
LIGHT & MELATONIN ADMINISTRATION STUDY - TREATMENT 3 MELATONIN 1ST 
SLEEP ONSET & TEMPERATURE IN RELATION TO MELATONIN ADMINISTRATION
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Fig 8.13
LIGHT & MELATONIN ADMINISTRATION STUDY - TREATMENT 2 MELATONIN 2ND 
SLEEP ONSET & TEMPERATURE IN RELATION TO MELATONIN ADMINISTRATION
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Fig 8.14
LIGHT & MELATONIN ADMINISTRATION STUDY
TEMPERATURE RHYTHM IN RELATION TO LIGHTS ON
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Fig 8.15
MELATONIN & LIGHT STUDY
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8.3.4 Temperature Rhythm, Melatonin Administration & Lights On
The timing of sleep onset and temperature acrophase in relation to melatonin 
administration and lights on are shown in Figs 8 .12-8.15. On Melatonin 1st the 
temperature acrophase occurred 3 hours before melatonin administration throughout 
the treatment in all subjects. During the Melatonin 2nd treatment administration 
occurred between 3 and 4 hours after the acrophase with a greater variance than 
with Melatonin 1st treatment. Sleep onset occurred on average 3.8h after melatonin 
administration on both Melatonin 1st and Melatonin 2nd treatments with a low 
variance, again suggesting that melatonin is not an acute hypnotic.
On both placebo treatments the temperature nadir occurred on average 2.2h before 
lights on with a very low variance, especially with Placebo 1st. With melatonin 
treatment the temperature nadir was on average 3.4h before lights on which is 
considerably earlier than with placebo (2.2h). The variances were much greater 
during the second half of each leg whether it was placebo or melatonin treatment.
Sleep onset time was significantly closer to the time of melatonin administration with 
Melatonin 1st treatment compared to Melatonin 2nd (p=0.003). The timing of 
melatonin administration in relation to temperature acrophase was later with 
Melatonin 2nd than Melatonin 1st (p < 0.0001).
Sleep onset time in relation to lights on was significantly earlier with Melatonin 2nd 
treatment compared to both Placebo treatments and Melatonin 1st (p <0.001).
8.3.5 Comparison with Melatonin Administration Study and 
Experiment 2 Variable Light intensity
A comparison of the variance and mean values for sleep timing and duration in 
relation to the temperature rhythm, and where applicable melatonin administration 
and lights on shows a significant difference between the values reported for this 
study, and those calculated for both the melatonin administration study (Chapter 6) 
and 1000 lux light schedule (Experiment 2, Chapter 7). Variance was much less 
when melatonin administration and a 12:12 L:D schedule of 1000 lux 08:00 - 20:00h
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Fig 8.16 Comparison of Mean Values (± SEM) Between Melatonin
Administration Study/Melatonin + Light/1000 Lux
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Fig 8.17 Comparison of Variance Between Melatonin
Administration Study/Melatonin + Light/1000 Lux
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were combined than for either treatment alone. There were no significant differences 
in the variance of the data collected during Placebo 1st and Melatonin 1st treatments 
of the melatonin + light study. The differences are summarised in Figs 8.16 and 8.17.
8.3.6 Grouped Data
Group mean plots ± SEM for activity, temperature, aMT6s, sleep onset, sleep offset 
and sleep parameters for the four treatment’s are shown in Figs 8.18 - 8.26 and 
group periodicities are recorded in Tables 8.2 - 8.5.
Placebo 1st: Repeated measures A NOVA showed significant time dependent 
changes in activity acrophase times (earlier), sleep offset times (earlier) and sleep 
latency (shorter) (p <0.01 days 4-17, n=6, factor day of treatment, degrees of 
freedom 5,13).
Melatonin 2nd: Repeated measures AN OVA showed significant time dependent 
changes in activity acrophase times (earlier), sleep offset times (earlier), time in bed 
(increase), sleep duration (decrease) and wake after sleep onset (increase) (p <0.04 
days 18-30, n=6, factor day of treatment, degrees of freedom 5,12).
Melatonin 1st: No significant changes were seen by repeated measures ANOVA in 
any parameter.
Placebo 2nd: No significant changes were seen by repeated measures ANOVA in 
any parameter.
Overall repeated measures ANOVA to compare values across study days and 
between treatments highlighted a number of significant differences. There was a 
change in activity acrophase times, sleep offset times, time in bed, sleep duration and 
wake after sleep onset with study day as factor (p <0.04). Time in bed showed an 
increase on Placebo 1st and a decrease on Melatonin 2nd (P <0.05). Melatonin 2nd 
also showed an increase in wake after sleep onset (p=0.019) and a decrease in sleep 
duration (p=0.02). An overall comparison between subjects and across study day 
showed a significant difference between subjects for sleep offset, sleep duration and 
sleep efficiency (p <0.01).
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Fig 8.18
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Fig 8.19
LIGHT & MELATONIN ADMINISTRATION STUDY
GROUP MEAN MASKED TEMPERATURE ACROPHASE TIMES ±  SEM
20 -
19-
® 18-
8ro
0.17-
2Ü<
16-
Placebo 
tau = 23.93
p = <0.001
Melatonin 
tau = 24.02 
p = >0.05
n = 6
''I I I I I I I I I I I I I f I I I I I I I I I I I I I I
1 3 5 7 9 11 13 15 17 19 21 23 25 27
Treatment Day
20 -
8
(0.c
o .
2o<
19 -
18 -
17-
16-
n = 6
Melatonin 
tau =23.97 
p = < 0.05
Mm,
Placebo 
tau = 23.98 
p = >0.05
1 5 I I I I I I I I I I I I I" f I I I I I I I I I I I I I I
1 3 5 7 9 11 13 15 17 19 21 23  25  27
Treatment Day
304
Fig 8.20
LIGHT & MELATONIN ADMINISTRATION STUDY
GROUP MEAN aMT6s ACROPHASE TIMES ±  SEM
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Fig 8.21
LIGHT & MELATONIN ADMINISTRATION STUDY
GROUP MEAN SLEEP ONSET TIMES ±  SEM
2 9 -
2 8 -
2 7 -
2 6 -
2 4 -
O 2 3 -
Q.
21 - Placebo 
tau = 24.02 
p = >0.05 
n = 6
Melatonin 
tau = 24.02 
p = >0.05
2 0 -
19 -
1 3 5 7 9 11 13 15 17 19 21 23 25 27
Treatment Day
30
0
COc
O 23- 
O.
0  22H
CO
21 -  
2 0 -  
19-
^ 1 f  i i
Melatonin 
tau = 23.95 
p = <0.05 
n = 6
I
Placebo 
tau = 23.97 
p = >0.05
1 3 5 7 9 11 13 15 17 19 21 23 25 27
Treatment Day
306
Fig 8.22
LIGHT & MELATONIN ADMINISTRATION STUDY
GROUP MEAN SLEEP OFFSET TIMES ±  SEM
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Fig 8.23
LIGHT & MELATONIN ADMINISTRATION STUDY
GROUP MEAN TIME IN BED ±  SEM
690-
670-
650-
630-
610-
590-
c 570-
'b 550-
? 530-
CO 510-c
490-(D
E 470-
i—
450-
430-
410 -
390-
370-
350-
A
Placebo 
p = >0.05
Melatonin 
p = >0.05
I I I I I I I 11 I I I f I I I I I I I I I I I I I I
3 5 7 9 11 13 15 17 19 21 23 25 27
690-
670-
650-
630-
610-
(0 590-c
£ 570-
"O 550-
(D
CO 530-
c 510-o
E 490-
i - 470-
450-
430-
410^
390
370-
350-
Treatment Day
n = 6
Melatonin 
p = >0.05
Placebo 
p = >0.05
1 '  I M  r  I r I I I I I I I I I I I I I I I I I  I I
3 5 7 9 11 13 15 17 19 21 23  25  27
Treatment Day
308
Fig 8.24
LIGHT & MELATONIN ADMINISTRATION STUDY
GROUP MEAN TOTAL SLEEP TIME ±  SEM
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Fig 8.25
LIGHT & MELATONIN ADMINISTRATION STUDY
GROUP MEAN WAKE AFTER SLEEP ONSET ±  SEM
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Fig 8.26
LIGHT & MELATONIN ADMINISTRATION STUDY
GROUP MEAN SLEEP EFFICIENCY ±  SEM
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Repeated measures ANOVA indicated a significant difference between Melatonin 
2nd and Placebo 1st and Placebo 2nd treatments (p <0.01) with activity acrophase 
times occurring earlier with Melatonin 2nd treatment. Temperature acrophase times 
occurred earlier with both Melatonin treatments compared to Placebo treatments (p =
0.002). There were no significant differences in sleep onset time although there was 
a tendency for sleep onset to occur earlier with Melatonin 2nd compared to both 
Placebo treatments. There were no significant differences between treatments in 
sleep offset time, time in bed, sleep duration, wake after sleep onset, sleep efficiency 
and sleep latency.
8.4 DISCUSSION
The objective of this final study was to combine daily timed melatonin administration 
with a 12:12 light-dark cycle of 1000 lux light intensity. This was to ascertain whether 
a combination of the two treatments would be more successful in maintaining 
synchrony to the 24h day than either treatment alone. The light-dark cycle is a strong 
zeitgeber and entrainment of human circadian rhythms with 1000 lux was expected, 
however it was not seen convincingly in Experiment 2, Chapter 7 due to the varying 
circadian time of the first light exposure. A 3 day baseline was introduced in this study 
to avoid a repetition of the wide range of effects in response to the light schedule. 
During this period subjects were permitted to leave the isolation facility and were 
exposed to normal daylight. A 16h wake:8h sleep schedule was imposed with sleep 
in darkness between midnight and 08:00h. It was anticipated that all individuals 
would then receive the initial light treatment at approximately the same circadian 
phase. The scheduled light exposure and melatonin administration was then timed to 
occur at an appropriate position on the light or melatonin PRC to maintain 
synchronisation to 24h with a minimum of phase-shift.
For all four treatments the significant deviation in tau from 24h was on average 0.1h 
or less. In many cases when the 95% confidence limits of the regressive cosinor 
analysis were taken into consideration the variation from 24h was as little as 0.02h. 
Such tau cannot realistically be considered as different from 24h.
1000 lux (Placebo 1st) and 1000 lux (Placebo 2nd) were both able to maintain 
synchrony to the 24h day, as determined by regressive cosinor analysis, in the
312
majority of subjects for most parameters measured. One subject (S5) showed a 
shortened temperature tau with both treatments, a second subject (S4) had a 
shortened temperature and aMT6s tau with 1000 lux (Placebo 1st), but this subject 
did not complete the second leg. One subject (S3) displayed a temperature tau 
significantly longer than 24h with Placebo 2nd. Inspection of the summary double 
plots for this individual (Fig 8.4) suggest that there could be relative co-ordination of 
the temperature rhythm. However, the shortened or lengthened temperature tau may 
be due to masking of the temperature rhythm by sleep as the data were not 
demasked. The shortened aMT6s tau may also be due to the timing of sleep as this 
may have influenced the collection times of the urine samples. Sleep onset and offset 
did not have a significantly shortened tau in S5 but sleep offset was shortened in S4. 
The group mean aMT6s acrophase times appeared to be earlier with Placebo 2nd 
than Placebo 1st, but the standard errors for the Placebo 2nd acrophase times were 
large. It is possible that the melatonin treatment during Melatonin 1st resulted in an 
earlier acrophase time which would gradually return to normal when treatment 
ceased. The data series collected was not long enough to determine this, but the 
acrophase time was occurring later each day.
1000 lux + melatonin (Melatonin 1st & Melatonin 2nd) was successful in maintaining 
synchrony of most parameters to 24h in the majority of the subjects by regressive 
cosinor analysis. One subject (S3) showed shortened activity, temperature and sleep 
offset tau with Melatonin 1st, and two subjects (82 & 86) showed shortened activity 
and sleep offset tau with Melatonin 2nd. The shortened sleep offset tau is possibly 
due to the melatonin treatment causing better quality sleep, such that subjects 
awoke earlier, feeling more refreshed.
The greatest variance in the data collected was for the parameters which can be 
affected by behaviour such as activity acrophase times and sleep onset and offset 
times. The variation increased during the second half of each experimental leg 
irrespective of the treatment. These effects were most probably due to boredom and 
the feeling that time passes more quickly when asleep. Certainly by spectral analysis 
the sleep offset times became progressively later each day with sleep onset occurring 
slightly earlier. In some subjects this led to an increase in wake after sleep onset and 
a decrease in sleep efficiency, due to individuals staying in bed longer than 
necessary.
313
A comparison of the mean values and variance for a number of parameters (Fig 8.16 
& 8.17) suggested that there was significantly less variation in the data when 
melatonin and light were combined, than for melatonin alone. There were no 
significant differences between data variance with Melatonin + Light Placebo 1st and 
Melatonin + Light Melatonin 1st, with Placebo 1st showing slightly less variance. 
There was, however, significantly greater variance in the data collected during the 
1000 lux schedule in Experiment 2, Chapter 7. The differences seen could be due to 
the wide range of circadian times of melatonin administration or lights on in the 
melatonin administration study (Chapter 6) and Experiment 2 (Chapter 7) compared 
to the melatonin + light experiment reported here.
It can be concluded that timed melatonin administration combined with a 12:12 L:D 
cycle of 1000 lux intensity is sufficient to synchronise the majority of human circadian 
rhythms in most individuals under partial isolation conditions with knowledge of clock 
time. It should be noted that subjects were synchronised to a set phase position by 
an enforced baseline period. If their circadian clocks had been set at widely different 
phase positions at the commencement of treatment, the synchronisation might not 
have occurred, or have been much slower to synchronise.
Under field conditions it may not be convenient to impose a 12:12 L:D cycle. It would 
be interesting to investigate whether skeleton photoperiods or short bursts of suitably 
timed bright light were able to synchronise rhythms to 24h, either on their own, or 
coupled with melatonin administration.
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CHAPTER 9
FRAGMENTED SLEEP STUDY
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9.1 SPECIFIC STUDY DESIGN & RATIONALE
Timed melatonin administration in normal healthy individuals maintained as a group 
in partial isolation, but with knowledge of clock time, produced the unexpected 
phenomenon of fragmented sleep (Chapter 6). Two out of ten individuals showed 
irregular sleep/wake patterns when 5mg melatonin were administered at 20:00h 
immediately on entering the constant dim light environment. This sleep pattern 
persisted throughout the melatonin treatment, but the same individuals exhibited 
consolidated sleep periods when receiving placebo.
Investigation of the data collected during the study suggested that a possible 
explanation for the disruption in the sleep wake cycle might be the timing of the 
melatonin administration in relation to the endogenous temperature rhythm. 
Individuals demonstrating the anomalous irregular sleep patterns received the 
melatonin dose within 0.24 ± 0.23h (SEM) of the demasked temperature acrophase.
An experiment was designed to test this hypothesis and determine whether under 
our experimental conditions 5mg melatonin administered within one hour of the 
temperature acrophase would produce fragmented sleep.
Since irregular sleep, if it occurred, appeared immediately on commencement of 
melatonin treatment in constant dim light, a single leg experiment of 29 days in 
length was designed. After an initial three day baseline each subject received 6 
days of melatonin treatment and 6 days of placebo treatment within the experiment 
in a randomised cross-over design. The treatment periods were separated by 3 
recovery and 3 baseline days, incorporating regular sleep periods in darkness, to 
allow each individual’s endogenous body clock to return to normal phase and timing. 
Temperature acrophase times were immediately calculated for the baseline periods 
to allow timed melatonin administration to fall within 1-2 hours of the core body 
temperature acrophase. During wake periods on the baseline and recovery days of 
the study, subjects were encouraged to leave the unit and thus receive normal 
outdoor light intensities for some of each day to reinforce the sleep-wake cycle. A 
simplified 24 hour constant routine was performed at the start of the experiment, at 
the end of the first treatment period, after the three day recovery period and
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immediately at the end of the second treatment. This was to allow a more accurate 
determination of individual phase. The study design is shown in Fig 9.1.
9.1.1 Isolation Facility
The isolation unit was provided by the DERA, Farnborough, and has been described 
in section 2.1.1. The exact layout was as shown in Fig 2.1 Plan B.
An overhead lighting system provided by Siemens Lighting was used. The bank of 
lights in each room, fitted with shutters to reduce the illumination levels to < 8 lux as 
described in 2.1.2, were used for the two six day periods of constant dim light. The 
remaining light banks were adjusted to give an overall average illumination of 300 - 
400 lux 08:00 - 24:00h on baseline and recovery days.
9.1.2 Subjects
6 normal healthy males aged 25.67 ± 1.33 (SEM) years, numbered SI - S6, were 
recruited. Five were army personnel from the Centre for Human Sciences Trials 
Section, Farnborough, U.K. and one subject was recruited from the general public 
by advertisement in the local press. They were under no medication except if 
necessary for minor analgesics and smoked <10 cigarettes a day.
Potential subjects were screened as described in section 2.2.4. Informed written 
consent was obtained from all subjects and the study protocol was approved by the 
DERA Centre for Human Sciences Ethics Committee.
9.1.3 Study Protocol
The subjects were maintained as a group of 6 individuals for a single leg of 29 days. 
Subjects arrived at the isolation facility at 10:00h on Day 1. Equipment was issued 
and recording of data, plus collection of samples began at 12:00 for a 24 hour 
simplified constant routine in dim light conditions (< 8 lux). After a four hour 
recovery sleep, 12:00 - 16:00h on Day 2, a three day baseline was performed. 
During this time individuals were encouraged to leave the unit between 10:00 - 
12:00h and 14:00 - 16:00h, but regular meal times (breakfast 07:30 - 09:00h; lunch
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Fig 9.1
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13:00 - 14:00h and dinner 19:00 - 20:30h) and a sleep period in darkness from 
midnight to 08:00h were imposed. Isolation commenced at 18:00h on Day 6 when 
light levels were lowered to <8 lux and maintained at that level until 16:00h on Day 
13. Constant dim light levels were checked every second day. The first treatment 
period extended from 18:00h on Day 6 to 12:00h on Day 12 when a second 
simplified constant routine took place.
After a 4h recovery sleep in darkness, individuals had 3 recovery days where the 
same experimental conditions were imposed as for baseline days. A further 
constant routine followed on Day 17. After the recovery sleep, a second three day 
baseline was imposed from 16:00h on Day 18 to 18:00h on Day 22. Light levels 
were then lowered to <8lux for the second treatment period (18:00h Day 22 - 12:00h 
Day 28). A final simplified constant routine was performed (Day 28) and subjects 
were allowed to leave at 12:00h on Day 29.
Dim light levels over the two treatment periods and constant routines were 6.98± 1.2 
(SEM) lux (n = 344) and 3-400 lux light levels were 346.56 ± 27.3 (SEM) lux (n = 
387). The ambient temperature range was 19 - 29°C (mean = 24.40 ±0.17 (SEM)°C, 
n = 270). Subjects had access to a digital clock and watches giving knowledge of 
clock time to enable timed medication to be given.
Melatonin or placebo capsules were taken 3 times a day, when awake, during the 
two treatment periods Days 6-12 and 22-28. Administration was timed to occur at 
03:30, 11:30 and 19:30h. Those capsules taken at 03:30 and 11:30h were always 
placebo (gelatin lactose). The 19:30h capsule contained either 5mg melatonin in 
gelatin lactose or placebo as follows: Placebo days 6 - 1 2 :  Melatonin days 22-28 or 
Melatonin days 6-12 : Placebo days 22-28. Capsules were placed in the isolation 
unit in clearly labelled vials with separate bottles for each subject for each dose 
time. Experimenters, using video surveillance, were instructed to ensure that 
capsules were taken at the correct time by all subjects who were awake. Individuals 
were never woken to take the pills. Compliance was noted and a record kept of 
which pills were taken.
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The general study conditions were as described in section 2.2.3. An incident book 
was kept throughout the study to record any significant events, subjects requests 
and general observations on the subjects mood and behaviour.
The experiment was carried out in October and November.
9.1.4 Measurements Taken
The following measurements were taken throughout the study except for during the 
constant routine protocols.
a. daily maximum and minimum temperatures in each room
b. light levels every 2 days during treatment periods or daily
c. core body temperature via a rectal probe and memory logger
d. sleep-wake/activity via wrist mounted accelerometer - Mini Motionlogger
e. 4 hourly urine collections except for oversleep periods
f. 2 hourly performance sessions when awake using the Psion based test 
battery
g. daily activity diaries
h. subjective sleep logs after every sleep period
During the simplified constant routine protocols the following measurements were 
taken and extra study conditions applied.
Extra study conditions:
1. no caffeine containing drinks were allowed
2. subjects were required to remain in the same room throughout to maintain 
a constant ambient temperature
3. subjects were required to remain seated and awake for the entire 24h 
period, except for visits to the toilet.
Measurements taken:
a. daily maximum and minimum temperatures in each room
b. core body temperature via a rectal probe and memory logger
c. sleep-wake/activity via wrist mounted accelerometer - Mini Motionlogger
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d. 2 hourly urine collections
e. 2 hourly performance sessions using the Psion based test battery
f. activity diaries
9.2 ANALYSIS OF DATA
9.2.1 Urinary aMT6s
Urinary aMT6s levels were measured using the assay described in section 2.4.2. 
Quality control coefficients of variation (C.V.) were 11.6%, 9.6% and 5.6% for 
concentrations of 3.15, 22.88 and 48.35 ng/ml respectively. The limit of detection at 
2 X  SD of zero binding was 0.18 ng/ml. The excretion rate for each sample period 
was calculated in ng/hr and these values were subjected to single day and 3 day 
moving window cosinor analysis as described in Chapter 3 section 3.1.4. During 
administration of melatonin, urinary aMT6s from exogenous melatonin completely 
masked the endogenous rhythm and no cosinor analysis was performed on this 
data.
9.2.2 Temperature Data
Raw temperature data were edited as described in section 3.1.1. During the 
experiment, the edited raw temperature data with values recorded every 6 minutes 
for the two 3 day baseline periods were used to calculate the phase of the 
temperature rhythm and determine the best time of administration of melatonin to 
produce fragmented sleep for each treatment period. At the end of the experiment 
the temperature data were demasked.
Temperature data were demasked as described in Chapter 4. Subject 1 appeared to 
remove his rectal probe when he was permitted to leave the isolation unit during 
baseline days, such that sufficient readings were not always available for 
determining the self-correction factors.
There were no significant differences between demasking methods by repeated 
measures ANOVA for any subject (see Table 9.1 for full details of tau). There was.
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however, a significant difference between subject 2 and all other subjects and 
subject 3 compared to subjects 1, 2, 4 and 5 for placebo. There were also 
significant differences between tau determined for subjects 1 and 2 and subjects 
3,4,5 and 6 on melatonin treatment. The acrophase times calculated by the various 
analysis methods did not vary significantly, but they varied with study day for both 
placebo and melatonin treatment (p = 0.0001) and there was a significant 
difference in the acrophase times between placebo and melatonin treatment by 
repeated measures ANOVA (p = 0.0001).
There were no significant differences in the group tau determined by the various 
analysis methods for either placebo or melatonin administration (see Table 9.1 and 
Fig 9.2). “Demasking” using the self-correction and self-correction + melatonin 
factors appeared to advance the acrophase times whilst not affecting the overall 
tau.
Table 9.1 Fragmented Sleep Study Tau Determined by Various 
“Demasking” Techniques.
Placebo
Subject Masked Masked Hourly Self-Corr Sleep Norm-Sleep Self-Corr Norm-Sleep
Sleep & MT & MT
1 24.43 ± 0.25** 24.38 ± 0.30* 24.56 ± 0.28** 24.36 ± 1.53
2 24.06 ± 0.42 24.12 ± 0.40 23.84 ± 0.51 24.13 ± 0.45
3 24.54 ± 0.32** 24.55 ± 0.32** 24.78 ± 0.43** 24.91 ± 0.59*
4 24.36 ± 0.18** 24.36 ± 0.18** 24.43 ± 0.33* 24.51 ±0.26**
5 24.15 ± 0.38 24.20 ± 0.36 24.56 ± 0.32** 24.38 ± 0.32*
6 24.47 ± 0.27** 24.47 ± 0.50 24.50 ± 0.30* 24.57 ± 0.39
Group 24.33 ± 0.19** 24.34 ± 0.18** 24.44 ± 0.08*** 24.48 ± 0.25**
Melatonin
Subject Masked Masked Hourly Self-Corr Sleep Norm-Sleep Self-Corr Norm-Sleep
Sleep & MT & M T
1 24.17 ± 0.27 24.27 ± 0.20* 24.64 ± 0.39* 24.40 ± 0.40 24.51 ± 0.79 24.83 ± 0.70*
2 23.87 ± 1.96 24.81 ± 0.74* 24.35 ± 0.35* 24.20 ± 0.87 24.45 ± 0.52 24.70 ± 0.35**
3 23.91 ± 0.27 23.97 ± 0.25 23.97 ± 0.25 24.03 ± 0.22 23.86 ± 0.32 23.94 ± 0.33
4 24.10 ± 0.17 24.10 ± 0.17 24.18 ± 0.26 23.98 ± 0.20 24.28 ± 0.35 23.91 ± 0.30
5 23.85 ± 0.26 23.89 ± 0.26 ' 24.15 ± 0.25 24.25 ± 0.28 23.99 ± 0.22 24.03 ± 0.73
6 24.09 ± 0.09 24.10 ± 0.10* 23.98 ± 0.10 23.93 ± 0.12 23.95 ± 0.14 23.90 ± 0 .1 7
Group 24.00 ± 0.23 24.21 ± 0.07 24.21 ± 0.16 24.13 ± 0.18 24.13 ± 0.22 24.01 ± 0.38
Significance level of fitted regression line *** =<0.001 ** =<0.01 * =<0.05
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Fig 9.2
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The data used for further analysis were demasked hourly temperature means self­
corrected for sleep and melatonin where appropriate. The edited temperature data 
were analysed further using cosinor and spectral analysis (sections 3.1.4 and 3.1.5).
9.2.3 Activity and Sleep Data
Raw activity data were edited as described in section 3.1.1. Sleep parameters were 
determined using Action3 software (Ambulatory Monitoring Inc.) and analysed as 
described in sections 3.1.2 and 3.1.3.
Edited activity data were analysed further using cosinor, and spectral analysis 
(sections 3.1.4, and 3.1.5).
9.2.4 Performance Data
All performance data collected were analysed for any changes in performance 
across the treatment periods and any differences in performance between the 
various treatments, using daily means as described in section 3.1.6. Results from 
the performance data analysis are not reported here for the reasons stated in 
section 3.1.6.
9.3 RESULTS
9.3.1 Compliance
Overall subject compliance with recording of activity and sleep data and collection of 
urine samples was good. Temperature recording was poor in 3/6 subjects with only 
49.55, 58.99 and 65.39% of the theoretical maximum data collected. Subjects were 
seen to be wearing the probes and loggers, but the probes were simply hooked 
inside their underwear and not inserted correctly as shown by the temperature 
values recorded.
The overall mean percentages (± SEM) of the theoretical data collected for the 
various parameters were as follows:
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Temperature 70.76 ± 6.2%
Activity 92.9 ±1.6%
Sleep 98.7 ± 0.8%
aMT6s 83.4 + 3.1%
Performance 71.3 ± 3.2%
The theoretical maximum number of performance sessions was based on the 
assumption of a sleep-wake cycle of 16h wake:8h sleep giving a maximum number 
of sessions of 8 per day, with 12 on constant routine days.
Data lost due to equipment malfunction can be summarised as follows:
a. activity lost data: No lost data
b. temperature lost data: S3 40h Placebo; S4 24h Placebo, 23h Recovery, 
21 h Constant routine, 24h Baseline & 24h Melatonin; S5 68h Recovery, 
24h Baseline & 36h Melatonin; S6 23h Constant routine.
9.3.2 Calculation of Melatonin Administration Time
The required time for melatonin administration was calculated from the temperature 
data collected during the three day baseline periods. The calculations had to be 
made whilst the experiment was running, consequently a simple analysis technique 
was used. The masked temperature nadir was estimated by cosinor analysis and by 
calculating the time of the midpoint of the 10 lowest temperature values recorded. 
The aim was to administer the first dose of melatonin 10 hours before the calculated 
midpoint nadir, which approximates to the time of maximum core body temperature, 
and is within 1-2h of the masked temperature acrophase time by cosinor analysis. 
The mean value for each of the three baseline days was calculated and used to 
determine the time of administration. The calculated values are shown in Table 9.2. 
The temperature data were edited and demasked after the experiment and the time 
of administration relative to the demasked temperature acrophase calculated 
retrospectively. These values are also shown in Table 9.2.
The study design required that all subjects were given medication at the same clock 
time, therefore the timing of melatonin administration could not be precise for each
325
individual. The chosen time of administration of the active pill for both treatment 
periods was 19:30h, to comply as closely as possible to the criteria set out in the 
previous paragraph.
From Table 9.2 it can be seen that all the treatments were given within an hour of 
the maximum temperature value calculated from the raw data, apart from Subject 1 
on Placebo treatment. Indeed, most treatments were within approximately 0.5h of 
this point. Apart from Subject 3 on Melatonin treatment for masked data, and 
Subjects 3 and 6 on Melatonin treatment for demasked data, all the initial treatments 
fell within 2h of the calculated acrophase times.
Table 9.2 Timing of Treatment in Relation to Temperature Acrophase
PLACEBO TREATMENT 
Mean Baseline Values for Timing of Treatment
Subject 1 Subject 2 Subject 3 Subject 4 Subject 5 Subject 6
Nadir Raw Data 3.91 6.05 6.00 5.37 6.05 6.06
Maximum Raw Data 17.91 20.38 20.00 19.37 20.05 20.06
Masked Acrophase 18.22 18.40 18.00 18.98 18.98 17.69
Demasked Acrophase 17.80 17.57 18.95 17.96 19.17 18.22
Admin.Time/Raw Data Maxm. 1.59 -0.88 -0.50 0.13 -0.55 -0.56
AdminTime/Masked Acrophase 1.28 1.10 1.50 0.52 0.52 1.81
Admin.Time/Demasked Acrophase 1.70 1.93 0.55 1.54 0.34 1.28
MELATONIN TREATMENT 
Mean Baseline Values for Timing of Treatment
Subject 1 Subject 2 Subject 3 Subject 4 Subject 5 Subject 1
Nadir Raw Data 5.14 5.79 6.13 5.42 6.00 5.28
Maximum Raw Data 19.14 19.79 20.13 19.42 20.00 19.28
Masked Acrophase 17.85 18.04 17.09 18.44 18.86 17.73
Demasked Acrophase 18.35 19.90 16.88 17.80 20.18 16.80
Admin.Time/Raw Data Maxm. 0.36 -0.29 -0.63 0.08 -0.50 0.22
AdminTime/Masked Acrophase 1.65 1.46 2.41 1.06 0.64 1.77
Admin.Time/Demasked Acrophase 1.15 -0.40 2.62 1.70 -0.68 2.70
= before, + = after demasked temperature acrophase.
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Fig 9.4 FRAGMENTED SLEEP STUDY
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Fig 9,5
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9.3.3 Individual Data
Summary raster double plots were produced for all subjects giving an overall record 
of the sleep-wake cycle and activity, temperature and aMT6s acrophase times. 
(See Figs 9.3 - 9.5).
9.3.3.1 Rest-Activity
Visual inspection of these plots indicated that the sleep-wake cycle was regulated 
as required during the baseline and recovery days. 5/6 subjects showed a tendency 
towards free-running rhythms in sleep onset times on placebo treatment, 4/6 
showed consolidated sleep episodes with melatonin treatment. S2 and S5 clearly 
exhibited fragmented sleep during melatonin treatment.
9.3.3.2 Temperature
In the majority of subjects (5/6) a trend for free-running demasked temperature 
rhythms can be seen with placebo treatment. 3/6 show demasked temperature 
rhythms synchronised to 24h with melatonin treatment. S3 appears to have a 
shortened temperature tau during melatonin administration.
9.3.3.3 aMTSs
5/6 aMT6s rhythms showed a tendency for free-run on Placebo treatment. The 
endogenous excretion rate was within the normal range for age (13.14 ± 9.8pg/24h 
to 54.0 ± 6.0|ig/24h). The excretion of aMT6s during melatonin treatment was used 
to determine the percentage of active pills taken (94.4%) and to evaluate individual 
clearance. Only 2 active pills were not taken due to subjects being asleep. Those 
subjects receiving melatonin during the first treatment period returned to baseline 
levels of aMT6s within 48h.
Detailed analysis of periodicity under Placebo or Melatonin treatment is not 
conclusive as each subject only received 6 days of each treatment. In the baseline 
study reported in Chapter 5 the results indicated that a minimum of 10 days was
330
required on any treatment to obtain a conclusive free-running period. However, the 
calculated periods are shown in Table 9.4 and Table 9.5.
Table 9.3 Amount of aMT6s excreted (ngs)
Subject Mean Endogenous Mean aMT6s
Number aMT6s Excreted per 24h Excreted per 24h during
Melatonin Treatment
1 12.48 ±0.44 2086.10 ±201.32
2 8.54 ±0.52 3363.69 ±312.82
3 10.37 ±0.50 2618.16 ±266.18
4 14.32 ±0.68 2342.15 ±118.39
5 14.53 ± 0.93 3743.51 ± 510.79
6 13.72 ±0.61 2119.66 ±322.33
9.3.3.4 Constant routine data
Simplified constant routines were carried out over a 24h period on Day 1-2, Day 12- 
13 at the end of the first treatment. Day 17-18 at the end of the recovery period and 
Day 28-29 at the end of the second treatment. This was to determine accurate 
phase positions for these days to determine whether individuals had shown a free- 
run during the treatment or had returned to the baseline phase position prior to the 
second treatment period. The results are shown in Table 9.6.
Inspection of the temperature and aMT6s acrophase times recorded
during the constant routines indicated that all 6 subjects exhibited free-running 
rhythms with a tau greater than 24h for these parameters during placebo treatment. 
Activity acrophase times were not consistent in indicating a free-run. With melatonin 
treatment the demasked temperature acrophase time suggests a phase advance of 
the temperature rhythm in 4/6 subjects (S2,3,4 & 5). The aMT6s acrophase times 
determined during the constant routine immediately after the end of melatonin 
treatment were not suitable for use as a phase marker as the exogenous melatonin 
was not completely cleared and skewed the data.
In most individuals the demasked temperature and aMT6s phase positions had not 
returned to baseline values after the 3 day recovery period.
331
Table 9.4
PLACEBO TREATMENT
Individual and Group Periodicities Determined by
Various Analysis Methods
Parameter Subject Days Regression Spectral
Activity 1 6 - 1 2 24.26 ±0.15** 24.15
2 6 - 1 2 23.97 ± 0.68 23.42
3 2 2 - 2 8 24.32 ± 0.14** 24.85
4 2 2 - 2 8 24.29 ± 0.25* 25.02
5 6 - 1 2 23.83 ± 0.83 24.20
6 2 2 - 2 8 24.11 ± 0.14 24.32
Group n=6 2 4 J 3 ±  0.32 24.33
Parameter Subject Days Regression Spectral
Temperature 1 6 - 1 2 24.56 ± 0.28** 24.06
2 6 - 1 2 23.84 ± 0.51 24.25
3 2 2 - 2 8 24.78 ± 0.43** 25.80
4 2 2 - 2 8 24.43 ± 0.33* 23.55
5 6 - 1 2 24.56 ± 0.32** 24.75
6 2 2 - 2 8 24.50 ± 0.30* 25.02
Group n=6 24.44 ± 0.08*** 24.57
Parameter Subject Days Regression
aMT6s 1 6 - 1 2 24.68 ± 0.53*
2 6 - 1 2 24.04 ± 0.40
3 2 2 - 2 8 Insufficient Data
4 2 2 - 2 8 24.37 ± 0.32*
5 6 - 1 2 24.45 ± 0.69
6 2 2 - 2 8 ■ 24.02 ± 0.16
Group n=6 24.30 ± 0.26*
Parameter Subject Days Regression
Sleep Onset 1 6 - 1 2 24.09 ± 0.53
2 6 - 1 2 23.77 ± 1.24
3 2 2 - 2 8 23.85 ± 0.24
4 2 2 - 2 8 24.52 ± 0.36*
5 6 - 1 2 23.97± 1.13
6 2 2 - 2 8 24.16 ± 0.48
Group n=6 24.07 ± 0.44
Parameter . Subject Days Regression
Sleep Offset 1 6 - 1 2 24.57 ± 0.74
2 6 - 1 2 24.46 ± 0.63
3 2 2 - 2 8 24.21 ± 0.64
4 2 2 - 2 8 24.25 ± 0.30
5 6 - 1 2 24.71 ± 1.04
6 2 2 - 2 8 24.24 ± 0.41
Group n=6 24.39 ± 0.21**
Significance level of fitted regression line *** =<0.001 ** = <0.01 * = <0.05
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Table 9.5
MELATONIN TREATMENT
Individual and Group Periodicities Determined by
Various Analysis Methods
Parameter Subject Days Regression Spectral
Activity 1 2 2 - 2 8 24.17 ± 0.27 23.75
2 2 2 - 2 8 Irregular Sleep
3 6 - 1 2 23.97 ± 0.29 24.45
4 6 - 1 2 23.98 ± 0.18 22.50
5 2 2 - 2 8 Irregular Sleep
6 6 - 1 2 24.26 ± 0.18** 23.85
Group n=6 24.09 ± 0.09* 23.64
Parameter Subject Days Regression Spectral
Temperature 1 2 2 - 2 8 24.51 ± 0.79
2 2 2 - 2 8 Irregular Sleep
3 6 - 1 2 23.86 ± 0.32 24.10
4 6 - 1 2 , 24.28 ± 0.35 22.95
5 2 2 - 2 8 Irregular Sleep
6 6 - 1 2 23.95 ± 0.14 24.46
Group n=6 24.13 ± 0.22 23.84
Parameter Subject Days Regression
Sleep Onset 1 2 2 - 2 8 23.89 ± 0.55
2 2 2 - 2 8 Irregular Sleep
3 6 - 1 2 23.98 ± 0.40
4 6 - 1 2 24.01 ± 0.26
5 2 2 - 2 8 Irregular Sleep
6 6 - 1 2 24.38 ± 0.66
Group n=6 24.06 ± 0.38
Parameter Subject Days Regression
Sleep Offset 1 2 2 - 2 8 24.04 ± 0.50
2 2 2 - 2 8 Irregular Sleep
3 6 - 1 2 24.34 ± 0.50
4 6 - 1 2 24.13 ± 0.50
5 2 2 - 2 8 Irregular Sleep
6 6 - 1 2 24.06 ± 0.19
Group n=6 24.14 ± 0.32
Significance level of fitted regression line *** =<0.001 ** = <0.01 * = <0.05
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Table 9.6 Constant Routine Data
Subject 1 Activity Demasked Temperature aMT6s
Acrophase Acrophase Acrophase
CR1 Day 1-2 17.70 17.20 2.90
Treatment PLACEBO
CR2 Day 12-13 20.35 22.23 8.90
CR3 Day 17-18 21.92 20.60 7.90
Treatment MELATONIN
CR4 Day 28-29 9.56 No Data 11.90
Subject 2 Activity Demasked Temperature aMT6s
Acrophase Acrophase Acrophase
CR1 Day 1-2 19.65 19.13 5.00
Treatment PLACEBO
CR2 Day 12-13 18.70 21.68 9.70
CR3 Day 17-18 14.06 21.25 6.90
Treatment MELATONIN
CR4 Day 28-29 11.86 20.33 10.60
Subject 3 Activity Demasked Temperature aMT6s
Acrophase Acrophase Acrophase
CR1 Day 1-2 20.96 21.05 3.40
Treatment MELATONIN
CR2 Day 12-13 21.63 19.90 10.80
CR3 Day 17-18 18.22 18.18 4.30
Treatment PLACEBO
CR4 Day 28-29 15.40 19.82 6.90
Subject 4 Activity Demasked Temperature aMT6s
Acrophase Acrophase Acrophase
CR1 Day 1-2 21.50 20.33 5.20
Treatment MELATONIN
CR2 Day 12-13 20.78 19.20 11.60
CR3 Day 17-18 18.66 17.92 4.70
Treatment PLACEBO
CR4 Day 28-29 21.95 20.43 9.70
Subject 5 Activity Demasked Temperature aMT6s
Acrophase Acrophase Acrophase
CR1 Day 1-2 16.43 19.92 5.50
Treatment PLACEBO
CR2 Day 12-13 15.88 Insufficient Data 8.90
CR3 Day 17-18 19.95 21.38 6.00
Treatment MELATONIN
CR4 Day 28-29 17.83 21.13 17.60
Subject 6 Activity Demasked Temperature aMT6s
Acrophase Acrophase Acrophase
CR1 Day 1-2 16.13 18.45 4.70
Treatment MELATONIN
CR2 Day 12-13 18.04 21.23 13.40
CR3 Day 17-18 18.00 19.75 4.70
Treatment PLACEBO
CR4 Day 28-29 19.08 20.73 6.20
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9.4 Fragmented Sleep/W ake Cycle
Visual inspection of the raster plots for the sleep-wake cycle exhibited during 
fragmented sleep, both in this experiment and the melatonin administration study 
(Chapter 6), suggested that there were possibly two components showing different 
periodicity. This is illustrated in Figs 9.6 and 9.7, where the left panels show 
fragmented sleep on melatonin treatment and the right panels show consolidated 
sleep episodes in the same individuals on placebo treatment..
The varying periodicities suggested by spectral analysis are indicated by the lines 
marked on the raster plots. Regression analysis of these sleep onset times does 
indicate two significant periodicities as recorded in Table 9.7 with a 24h component 
for S5 melatonin study.
Table 9.7 Fragmented Sleep Onset Periodicities by 
Regression and Spectral Analysis
Melatonin Administration Study
Subject Analysis Period 1 Period 2
2 Regression 28.05 ± 0.64*** 20.37 ± 0.56***
2 Spectral 32.60 22.15
5 Regression 25.87 ± 0.25*** 21.03 ±0.88***
23.95 ± 0.42
5 Spectral 25.03 19.75
Fragmented Sleep Study
Subject Period 1 Period 2
2 Regression 30.55 ± 3.50** 19.02 ±0.46***
2 Spectral 30.75 20.5
5 Regression 30.33 ± 5.65* 20.01 ± 3.85*
5 Spectral 30.35 22.42
Significance level of fitted regression line *** = <0.001 ** = <0.01 * = <0.05
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Fig 9.7
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9.5 DISCUSSION
The experimental design used reproduced the fragmented sleep seen in the 
melatonin administration study (Chapter 6) in 2/6 individuals. Examination of the 
precise timing of the initial melatonin treatment in relation to the demasked 
temperature data suggests that the timing is more critical than originally thought. In 
designing this experiment it was considered that the window for treatment was as 
wide as within 1-2 hours of the temperature acrophase. However, retrospective 
analysis of the demasked temperature data shows that the two subjects exhibiting 
fragmented sleep in the melatonin administration study received the melatonin dose 
on 1.17h after and 0.75h before the demasked temperature acrophase. The two 
subjects showing fragmented sleep in this study received the initial melatonin 
treatment 0.40 and 0.68h before the demasked temperature acrophase. This is 
closer to the temperature acrophase than all the other subjects.
It was decided to treat all subjects at the same clock time, and thus use a 
compromise time of administration. It may be that the remaining four subjects were 
dosed outside the critical time window. The time of administration in these subjects 
was between 1.15 and 2.70h after the temperature acrophase which should be a 
phase advance position according to the published phase response curves (Lewy et 
al., 1992; Zaidan et al., 1994). All four individuals did indeed show an overall phase 
advance in the demasked temperature rhythm by comparison of the acrophase 
times calculated for the last baseline day before melatonin treatment and the first 
day of treatment.
Three of the four subjects showing fragmented sleep do not appear to have a 24h 
component to their sleep-wake cycle. The fourth, subject 5 in the melatonin 
administration study (Chapter 6), does have a 24h component by spectral analysis 
but displays a clearly abnormal sleep pattern with very short and very long sleep 
periods. A possible explanation for this is that administration of 5mg exogenous 
melatonin induces a long sleep period thus reducing the sleep debt, such that when 
the circadian component of the sleep process (Process 0) instigates a sleep 
episode it is only of a short duration because the sleep debt (homeostatic 
component) is low.
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A possible explanation for the two different periodicities seen in the remaining three 
subjects could be that the two oscillators involved in the sleep process (Wehr et al., 
1993) become uncoupled and free-run with different periodicities. The longer 
periods determined during the fragmented sleep study do not have a high 
significance, this is most probably due to the short data series available.
Melatonin administration at, or very close to, the temperature acrophase may induce 
a large phase advance which would greatly affect the evening (E) oscillator involved 
in the timing of sleep. The circulating levels of plasma melatonin would not have 
dropped to physiological levels by the morning and consequently could result in a 
delay of the morning (M) oscillator involved in sleep timing. Thus, the two oscillators 
might be pulled apart as the evening oscillator is phase advanced and the morning 
oscillator is phase delayed.
As an initial investigation of our hypothesis the experiment was successful. 
However, a future experiment is needed to test the theory more stringently. Each 
individual must be treated at a specific clock time calculated to fall within 0.5h of the 
demasked temperature acrophase. It is unknown what effect this disruption of the 
sleep-wake cycle has on sleep architecture. This could be investigated by inclusion 
of sleep EEG recording.
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CHAPTER 10
GENERAL DISCUSSION
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10.1 RATIONALE
The major aim of the work reported in this thesis was to investigate the factors 
involved in the maintenance of circadian rhythms, in the absence of a strong light- 
dark cycle, but with knowledge of clock time. Under dim light conditions the human 
endogenous clock generally runs with a periodicity longer than 24h. This natural 
tendency of the clock to delay is counteracted in the normal environment by 
exposure to bright light in the early morning which serves to phase advance the 
clock. In a series of experiments we investigated whether individuals maintained as 
a group under partial isolation conditions in constant dim light, but with knowledge of 
clock time, would exhibit free-running rhythms. If they did so we wished to assess 
whether all individuals would have the same tau and whether the free-run could be 
prevented, or rhythms resynchronised or “stabilised” to 24h, by daily timed melatonin 
administration or controlled light-dark cycles of varying intensities. Finally, melatonin 
administration and a controlled light-dark cycle were combined.
Results from these experiments have expanded our knowledge of the human 
circadian system in a number of ways.
10.2 INTRINSIC TAU
At the commencement of this work the human endogenous tau was thought to be 
approximately 25h with individuals maintained together exhibiting group synchrony 
(Wever, 1979). The results reported here suggest that the intrinsic tau of humans, 
as measured in constant dim light conditions with knowledge of clock time, is much 
shorter (24.26 ± 0.05h). A shorter tau has also been suggested in work published 
since our first study was completed (Campbell et a/., 1993; Czeisler et a/., 1995a; 
Klerman et a/., 1996). The shorter tau leads to smaller ranges of entrainment for 
human circadian rhythms and also the possibility that lower light intensities would be 
effective in phase-shifting the endogenous clock.
Subjects taking part in all the experiments reported here showed individual tau and 
no group synchrony was seen when free-running rhythms occurred. This indicates 
that in sighted individuals social interaction and knowledge of clock time is 
insufficient to synchronise the endogenous clock in the absence of a light-dark cycle
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of suitable intensity. This is also the case during the Antarctic winter (Kennaway & 
Van Dorp, 1991) and in blind subjects with no light perception (Lockley et al., 
1997a). It is important to note that whilst subjects did interact there was no imposed 
social interaction at set times during these experiments.
It is of interest to note that the two individuals with the latest dim light melatonin 
onset (DLMO), in the melatonin administration study (Chapter 6), also had the 
longest free-running tau. If this were to prove an accurate, reproducible correlation, 
it could prove a quicker and easier method for determining an estimate of individual 
endogenous tau. The human isolation experiments required to measure intrinsic tau 
are extremely tedious and labour intensive. It is not a methodology that can be 
extended for use on a routine basis, where knowledge of tau might be of diagnostic 
use in subjects suffering from a rhythm disorder. In one report an individual 
suffering from delayed sleep phase syndrome had a rectal temperature rhythm with 
a period of 24.7h (Ozaki et al., 1988). It may also be that individuals with a longer 
intrinsic tau, and/or delayed phase, are more suitable for evening/night shift-work, or 
delaying shift rotations, due to an increased tendency to phase delay.
With the identification of the human per gene (Tei et al., 1997) it may be possible to 
identify the genetic sequence responsible for endogenous tau which is thought to be 
hereditary. By comparing the sequences from individuals with known tau, of varying 
lengths, it may be feasible to devise a genetic method for predicting tau.
10.3 “CHRONOBIOTIC” EFFECTS OF MELATONIN
The experimental conditions used enabled the investigation of some of the 
“chronobiotic” effects of melatonin. This was possible because subjects were aware 
of clock time, thus allowing timed medication to be given.
5mg melatonin taken daily in the evening was able to stabilise the sleep-wake cycle 
in normal sighted individuals. It was also able to stabilise or possibly resynchronise, 
the sleep-wake cycle in free-running individuals, either by a phase advance or (less 
convincingly) by a phase-delay, depending on the circadian time of administration. 
The more robust endogenous temperature rhythm was not synchronised as had 
been shown previously in a blind individual (Folkard et al., 1990). Indeed, in some 
individuals the demasked temperature rhythm appeared to have a shortened tau
342
during the period of melatonin treatment. These results suggest that melatonin is 
not a primary zeitgeber of human circadian rhythms. The data collected shows 
slight day to day variation, which it could be argued, suggests that the endogenous 
clock is not completely synchronised, the rhythms are merely stabilised by the 
exogenous melatonin. It has been proposed that the term synchronised should be a 
very precise and specific description applied to the endogenous clock only. By this 
interpretation, if the clock were truly synchronised there would be no significant daily 
fluctuations seen.
However, by reference to the phase response curves for melatonin (Lewy et al., 
1992; Zaidan et al., 1994) it should be possible to maintain synchronisation of the 
endogenous clock by regular daily administration of endogenous melatonin. There 
is great individual variation seen in melatonin pharmacokinetics. In some individuals, 
5mg taken in the evening is not cleared and circulating plasma levels have not 
returned to baseline values by the normal melatonin offset time. This would result in 
a phase-delay of the offset time indicating a long night melatonin secretion profile. 
As humans have retained a photoperiodic response (Wehr et al., 1993) this would 
result in long scotoperiod signals being sent to the biological clock or, at least a 
phase delay signal partially countering the evening phase advance signal. This 
could be one reason why rhythms are not more robustly synchronised.
Smaller doses, or controlled infusion of melatonin should be investigated for 
synchronising properties. Investigation of individual pharmacokinetics is needed. 
Dosage could then be adjusted to ensure that the duration of the melatonin profile is 
not increased by the treatment.
In our subjects, under our experimental conditions, 5mg melatonin did not have 
acute hypnotic effects, irrespective of the circadian time of administration. Other 
studies on the sleep inducing effects of melatonin have reported varying results. 
Daytime administration is more likely to increase fatigue and sleep propensity 
compared to nighttime administration occurring after the onset of endogenous 
melatonin secretion (Cramer et al., 1974, Waldhauser et al., 1990; Dollins et al., 
1993b; Zhdanova et al., 1995; Zhdanova & Wurtman, 1997). These soporific effects 
of melatonin are now considered to be influenced by the ambient conditions and 
instructions given to the subjects. If individuals remain in dim light in a supine
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position and are asked to try and sleep, melatonin given during the day when 
endogenous levels are low, may well cause an increase in sleep propensity and a 
decrease in sleep latency. The objective and subjective measures of daytime 
sleepiness disappeared when individuals moved from a supine to a standing 
position (Cajochen, Krauchi and Wirz-Justice, 1997). In the studies reported here, 
individuals were not instructed when to go to sleep and consequently usually 
remained active for some time after administration. The absence of any sleep 
inducing effects of melatonin seen could be explained by the findings of Cajochen et 
al. (1997).
No individual studied suffered any side-effects from dosing with 5mg melatonin daily 
over 15 days. The safety of long term daily melatonin treatment is not known 
(Arendt, 1997 & Weaver, 1997). Treatment has to be continuous to be successful 
unless after effects prove to be efficacious. Therefore, although exogenous 
melatonin is useful to stabilise the sleep-wake cycle it may not be the method of 
choice for treating sleep or rhythm disorders over long periods. Short term use of 
melatonin to alleviate the symptoms of jet lag has not shown any detrimental effects 
and appears to be effective (e.g. Petrie et al., 1983; Arendt & Aldhous, 1988; 
Claustrat e/a/., 1992; Comperatore etal., 1996; Suhnere/a/., 1998).
Synthetically manufactured melatonin agonists could be the safer option for long 
term use in humans. S-20098 (N[2-7-methoxy-10-naphtalenyl]ethyl) acetamide is a 
synthetic melatonin agonist which is as potent as melatonin in displacing 2-iodo- 
melatonin from its binding sites in the SCN and pars tuberalis (Bonnefond et al., 
1993). In animal experiments it has been shown to entrain free-running activity 
rhythms in rats (Redman & Guardiola-Lemaître, 1993; Martinet et al., 1996), to 
produce dose-dependent phase shifts in both hamsters and mice according to a 
phase response curve (Van Reeth et al., 1994b & 1997), and been used as a 
treatment for “delayed sleep phase syndrome” in mice (Armstrong et al., 1993). S- 
20098 given in the early evening was able to induce phase advances in the DLMO 
and temperature rhythm of humans (Krauchi et al., 1997). It has also been shown to 
have similar effects to melatonin on EEG recordings (Cajochen et al., 1997). These 
are all acute effects of S-20098 administration. The experimental conditions 
developed in this thesis would enable human experiments to be performed to
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assess the effects of timed S-20098 (or other synthetic melatonin agonists or 
antagonists) administration on human circadian rhythms.
10.4 PHASE SHIFTING vs ENTRAINMENT BY LIGHT
Light of ~ 180 lux has been shown to produce phase shifts after 3 successive light 
exposures (Boivin et a/., 1996) but light of 200 lux in a 12:12 L:D schedule was 
unable to prevent free-running rhythms under our experimental conditions. This 
could be because light of a higher intensity is required to maintain entrainment than 
to produce a phase-shift. Phase-shifts produced by light exposure are dose 
dependent, based on intensity and duration (Rimmer et al., 1995; Klerman et al., 
1997). The light exposure in these phase-shift experiments was centred around the 
core body temperature minimum which is the most sensitive part of the PRC for light 
in humans. It is possible that the timing of the light pulse was critical in producing a 
phase shift with an intensity as low as ~ 180 lux. It would be of interest to 
investigate whether light pulses of this intensity given at other circadian times would 
be able to induce phase-shifts of the endogenous clock.
Phase-shifts have been shown to 3 successive treatments of 5h duration centred at 
all circadian times, including close to the temperature maximum which was 
considered to be a “dead zone” (Jewett et al., 1997). The light intensity used was ~ 
9,000 lux, against a background of 10-15 lux, and some phase shifts were small and 
may well not be reproduced with light of lower intensity.
In our experiments the 12:12 light-dark cycle was determined by clock time to give 
light exposure 08:00h - 20:00h. This we believed to be comparable to, or greater 
than, the average possible natural light exposure in an urban population. With 
reference to the mean demasked temperature acrophase time (18:39h ± 0.19h 
SEM) the average centre of the light exposure was 7.35h after the temperature 
minimum. Individuals received 12h light exposure (200 lux) each day. In the majority 
of cases most (if not all) of the light stimulus occurred during the phase advance 
portion of the PRC. As a phase delay was seen in 4/6 individuals it can be assumed 
that the light exposure was insufficient to induce a phase shift in the majority of 
individuals.
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1000 lux was able to both maintain synchrony and reentrain free-running rhythms by 
either phase advance or phase delay after a period of transients. The 1000 lux light 
schedule, either on its own or combined with timed melatonin administration, can be 
considered as maintaining synchronisation to the 24h day as there is very little 
variance seen in the data collected with these two treatments. It could be that when 
melatonin and light are combined it would be possible to lower the light intensity 
and/or reduce the melatonin dosage whilst still maintaining synchrony.
Light of 1000 lux is sufficient to suppress plasma melatonin to near daytime levels, 
but200 lux only gives 16% suppression of plasma melatonin (McIntyre etal., 1988 & 
1989a). It is not known whether suppression of melatonin is important in 
maintaining a tau of 24h. In our experiment no difference was seen in the amplitude 
of the aMT6s rhythm with 200 lux or 1000 lux. But any possible change in the 
plasma melatonin levels or secretion profile was not investigated.
10.5 RECOMMENDATIONS
Overall the results reported here suggest that melatonin has useful “chronobiotic” 
properties. It can be used to stabilise the sleep-wake cycle in free-running 
individuals, and to prevent free-running rhythms in people living under conditions of 
constant low light levels. However, as it does not appear to be a primary zeitgeber it 
is unable consistently to synchronise the endogenous clock. Care must be taken 
over the timing of administration as the fragmented sleep reported in some 
individuals is not a desirable effect. At this stage it cannot be recommended for long 
term use (months or years) since its safety has not been established. A single 
report on one blind individual has been published (Arendt, 1997). He took 5mg 
melatonin daily from 1986-1995 to stabilise a free-running sleep-wake cycle. On 
stopping treatment in 1995 blood samples were taken and no abnormalities were 
seen in routine haematology and biochemistry measurements. His endogenous 
aMT6s tau was identical to that originally determined in 1986. Although this 
suggests that melatonin treatment does not cause any hang over effects or adverse 
side effects, it is only one individual and more work is needed to establish 
melatonin's long term efficacy and safety .
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Although under our experimental conditions melatonin did not exhibit acute hypnotic 
effects, it may have a limited use in aiding individuals to sleep at the incorrect 
circadian phase (e.g. during shift-work) provided the ambient conditions are 
conducive to sleep.
The light-dark cycle, using light of 1000 lux, appeared successfully to synchronise 
human circadian rhythms. By increasing the light levels in the work place it is 
possible to improve performance and alertness whilst aiding adaptation to night 
shift-work (Czeisler et a/., 1982 & 1983; Eastman, 1987, 1990 & 1996; Deacon & 
Arendt, 1996a & 1996b).
10.6 FUTURE W ORK
Whilst the experiments reported in this thesis have answered a number of 
questions, they have also posed many more which it would be of interest to 
investigate further.
The timed administration of 5mg melatonin daily only exhibited weak zeitgeber 
effects. 5mg is a pharmacological dose which has been extensively used to treat 
circadian rhythm disorders (Arendt et al., 1987; Petrie et al., 1989; Folkard et al., 
1990; Dahlitz et al., 1991; Tzischinsky et al., 1993).The phase-shifting effects of 
melatonin are dose-dependent (Deacon & Arendt, 1995) with 5mg, the highest dose 
used to date, resulting in the greatest phase-shift. It would be interesting to 
investigate whether higher doses would have stronger zeitgeber effects or if lower 
doses, leading to physiological levels, would be sufficient to stabilise sleep-wake 
cycle in constant dim light conditions.
Recent pharmacokinetic studies in animals, including primates, (Cagnacci, 1997) 
have suggested that only pharmacological doses are sufficient to raise the 
cerebrospinal fluid levels of melatonin to those seen during the endogenous 
nocturnal peak. The cerebrospinal fluid is believed to be the route for melatonin to 
access the thermoregulatory sites in the hypothalamus. If this is the case the results 
from these studies would indicate whether the temperature suppression effects of 
melatonin are required to synchronise the endogenous clock. However since 
temperature suppression and the soporific effects of melatonin depend on posture,
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melatonin would appear likely to be most effective when combined with 
recumbency, imposed darkness and sleep times.
The conservation of photoperiodism in humans has been demonstrated by Wehr et 
al. (1993) where subjects were kept on a 14h dark schedule, imitating a short day 
profile. Human sleep became bimodal in the long artificial nights with the sleep 
period expanding and splitting into morning and evening bouts separated by a 
period of quiet wakefulness. The duration of the photoperiod also modified the 
nocturnal melatonin secretion profile. Similar results have been published by 
Vondrasova et al. (1997) and they suggest that photoperiodic history influences the 
timing of internal processes that control the duration of melatonin secretion. 
Illnerovà and Vanecek (1982) proposed the theory that in rats the duration of 
melatonin secretion was controlled by two oscillators, the evening (E) oscillator 
controlling the onset of melatonin secretion and the morning (M) oscillator the 
morning offset. If this two oscillator theory is correct it is possible that the two 
oscillators may be coupled but partly independent and not respond to phase-shifting 
stimuli in the same way, as has been shown for the pineal AANAT rhythm (Humlova 
& Illnerovà, 1990). If this theory translates to humans then the lengthening and 
splitting of sleep could be a melatonin dependent effect. Thus, it could be a possible 
explanation for the fragmented sleep reported in Chapters 6 and 9. A series of 
experiments could investigate this phenomenon further.
Simultaneous evening and morning melatonin administration could be used to 
produce a long duration melatonin profile of physiological levels. Melatonin is 
known to be able to change the timing of sleep in humans. Timed administration of 
exogenous melatonin can induce phase advances and phase delays in human 
circadian marker rhythms such as core body temperature and endogenous 
melatonin (e.g. Arendt et al., 1983; Lewy et al., 1992; Zaidan et al., 1994). The 
response seen is dependent on the timing of the dose and has been published in 
phase response curves. A phase advance in the evening onset can be achieved by 
melatonin administration in the late afternoon. A phase delay in the morning offset 
would result from melatonin administration in the early morning. A combination of 
evening and morning doses would, therefore, result in an artificial long duration 
melatonin profile, mimicking a short day photoperiod.
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If melatonin is an important determinant of sleep, the long duration melatonin 
secretion profile would be expected to influence human sleep in the same way as 
the long artificial scotoperiod (Wehr et a/., 1993). If the two oscillator model for the 
control of melatonin secretion is correct the sleep period would be increased, when 
sleep times are self-selected, and will show a bimodal pattern. Two bouts of sleep, 
in the evening and morning, separated by a period of quiet wakefulness would be 
seen.
A constant routine placed before and after the long duration melatonin treatment 
period, would determine whether the timing of the endogenous clock had been 
affected in any way. If the extension of the melatonin secretion profile acts in the 
same way as a long duration scotoperiod, there would be an increase in the length 
of the endogenous melatonin secretion profile. This result would indicate whether 
artificial long duration melatonin induced persistent changes in the timing of the 
internal processes involved in the control of melatonin secretion. If blood samples 
are collected throughout the constant routine assessments, any effect of the long 
duration melatonin on endocrine function could be measured.
The fragmented sleep seen in Chapters 6 and 9 may be an example of bimodal 
sleep as two distinct periodicities could be seen in the data collected. A further 
experiment is needed to determine if our hypothesis, that the time of melatonin 
administration relative to the core temperature acrophase is responsible for the 
fragmented sleep, is correct. The time of administration must be calculated from 
demasked temperature data and subjects must be dosed within one hour of the 
temperature acrophase. Individual dose times must be applied to ensure the timing 
is accurate. It would be of interest to include polysomnography to ascertain whether 
there is any change in sleep structure when fragmented sleep is seen.
If melatonin treatment is capable of inducing bimodal sleep or of splitting sleep into 
two or more components, it could have several applications. By separating the two 
oscillators it may be possible to produce two bouts of high quality sleep, either side 
of a work period, thus improving performance during night work hours. Uncoupling 
of the two oscillators may also help to achieve faster adaptation to large forced 
phase shifts. If humans do retain an intact photoperiodic response, long term 
melatonin administration may cause photoperiodic effects similar to those seen in
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some animals. This could include changes in the reproductive system, in other 
hormones, the immune system and the occurrence or suppression of some cancers 
which are known to be photoperiod dependent.
A symmetrical light-dark cycle with a light intensity of 1000 lux was capable of 
maintaining synchrony to the 24h day (Chapter 8). Light of 200 lux was insufficient, 
but light of ~ IBOlux has produced phase shifts (Boivin et ai, 1996). It is possible 
that the light intensity required to entrain circadian rhythms is greater than that 
needed to induce phase-shifts or melatonin suppression. A range of experiments 
could be carried out to determine the optimum light level, or indeed spectral 
composition, of the light needed to maintain synchrony to the 24h day. The range of 
entrainment of human circadian rhythms is dependent on the light intensity and 
intrinsic period of the individuals concerned (Wever, 1983). It may be that the light 
intensity needed for synchronisation to the 24h day is also dependent on each 
individual's intrinsic tau.
In some situations it may be that a skeleton photoperiod would be of more practical 
use. A skeleton photoperiod has been shown to mimic a long summer day length in 
Antarctica (Broadway et a/., 1987) with endogenous melatonin as phase marker. It 
would be interesting to investigate whether periods of moderately bright light (1,000 
lux or less) timed to occur at either end of the 24h day are sufficient to maintain 
synchrony in dim ambient lighting conditions.
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SUMMARY The light/dark (L/D) cycle is a major synchronizer of human circadian rhythms. In 
the absence of a strong L/D cycle, synchrony with 24 hours can nevertheless be 
maintained in a socially structured environment, as shown in Polar regions (Broadway 
et al. 1987) and by some blind subjects (Czeisler et aï. 1995a). The relative contribution 
of other time cues to entrainment in dim light has not been fully explored. The present 
study investigated the behaviour of melatonin (assessed as 6-sulphatoxymelatonin); 
rectal temperature; activity and sleep (actigraphy and logs) in constant dim light (L/ 
L) with access to a digital clock. 6 normal healthy males were maintained as a group 
in partial temporal isolation with attenuated sound and ambient temperature for 21 
days. All 6 subjects showed free-running periodicity for 6-sulphatoxymelatonin and 
5/6 subjects for temperature, activity and sleep offset. The average period (tau) was 
24.26 +  0.049, substantially shorter than in previous experiments with a self selected 
L/D cycle but similar to a recent study conducted in very dim light. One subject 
maintained a rigid sleep/wake cycle throughout whilst his 6-sulphatoxymelatonin 
rhythm free-ran. Total sleep time, from actigraph data, did not change but sleep 
efficiency decreased during the experiment. The subjects did not show group 
synchronization.
These results confirm previous data indicating the importance o f the L/D cycle in 
human entrainment and underline the lesser role of social cues and knowledge of 
clock time. This particular approach will permit the administration of timed medication 
to sighted humans under free-running conditions.
KEYWORDS 6-sulphatoxymelatonin, activity, chronobiotic, circadian rhythms, core 
body temperature, light, melatonin, sleep
INTRODUCTION
A primary factor in maintaining human circadian rhythms 
synchronized with the 24-h day is the L/D cycle (Campbell et 
al. 1995). Other time cues such as imposed behaviour (for 
example the necessity o f working at specific times during the 
day) and knowledge of clock time also appear to play a role 
(Mills 1964; Lobban 1965; Wever 1979; Broadway et al. 1987; 
Czeisler et al. 1995a). Extensive experiments by a number of
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Endocrinology and Metabolism Group, School of Biological Sciences, 
University of Surrey, Guildford, Surrey GU2 5XH, UK., Tel.:+44/ 
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groups (e.g. Wever et al. 1983; Czeisler et al. 1986; Minors et 
al. 1991) have widely characterized the human circadian system 
and its response to different L/D conditions in both 
environmental isolation and constant routine conditions. In 
general the rhythms of core body temperature, and cortisol 
have been used as phase markers o f the endogenous clock. More 
recently plasma melatonin and urinary 6-sulphatoxymelatonin 
(aM T6s) have been investigated (Wever 1989; Shanahan and 
Czeisler 1991). Melatonin is less subject to masking problems 
than any of the aforementioned markers and there is substantial 
evidence that urinary 6-sulphatoxymelatonin is a good 
qualitative and quantitative reflection of melatonin secretion 
(Arendt et al. 1985; Bojkowski et al. 1987; Deacon and Arendt 
1994a; Ross et al. 1994).
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Figure 1. Diagrammatic representation of the partial environmental 
isolation facility. The building is light-tight and indoor lighting is 
provided by a ceiling diffuser over the entire area. This was 
maintained at <8 lux at all times. Sound and temperature variations 
(21-29°C) were attenuated, visits by experimenters were intermittent 
and randomized to occur at all times of day. A digital clock 
recording local time was present in the kitchen. 1, sleeping; la, PC/ 
games; 2, kitchen/TV/video; 3, washroom; 4, double door lock; 5, 
PC/performance area; 6, observer room/living/experimental.
We wished to develop a model environment for human 
circadian studies, partly in order to give timed medication to 
groups of subjects for lengthy periods under free-running 
conditions. Complete environmental isolation implies 
ignorance of clock time and timed administration o f medication 
compromises the nature of the experiment. Constant routine 
conditions are inappropriate for continuous long-term 
assessments. There is evidence from Polar regions that human 
circadian rhythms free-run in winter (in the absence of natural 
sunlight) with knowledge of clock time but without imposed 
behaviour (Kennaway & Van Dorp 1991). Thus we have 
evaluated human circadian rhythms in partial environmental 
isolation, constant very dim light and with a knowledge of 
clock time using activity-rest, sleep/wake, 6- 
sulphatoxymelatonin and core body temperature for assessment 
of rhythms.
METHODS 
Study design
Six normal healthy males, S1-S6 (aged 26 ±2.71 y) under no 
medication and all non-smokers were recruited as subjects. All 
subjects gave informed written consent and the study protocol 
was approved by the local Ethics Committee. The subjects 
were maintained together as a group, for 21 days in a closed 
environment, comprising a sleeping area, kitchen, washroom 
and computer room (Fig. 1). Constant dim light (L/L) 4.09 ±  0.8 
lux was imposed after an initial 24-h acclimatization period. 
Illumination was provided by overhead banks of full spectrum
lights (Osram Biolux emitting 400-700 nm) supplied by Siemens 
Lighting Limited to give uniform light levels throughout the 
unit. Light levels were measured every 3-4 days using a hand 
held lux meter following the CIS Code 1984 (Appendix 11 Field 
measurements of lighting) for determining average illuminance. 
Sound and temperature (range 21-29°C) were attenuated, and 
contact with experimenters was intermittent and random. 
Videos and recorded TV programs were available and a digital 
clock was present in the kitchen area. Food was self-selected 
and cooked by the subjects from a broad range of fresh and 
frozen ingredients and ready-prepared microwaveable meals. 
An exercise bike, weights and a punch bag were available for 
use at any time. Three individuals made use of these facilities 
on 1-3 occasions. Subjects were under observation 24 h a day 
to note compliance and voice contact could be made at any 
time via an intercom.
Core body temperature (BT) was monitored continuously 
by means of a rectal probe connected to a Grant Memory 
Logger (Grant Instruments Cambridge Ltd, UK) recording 
every 6min. Activity (A) was logged every 20 s by means of 
wrist-mounted accelerometers (Mini-Motionloggers, 
Ambulatory Monitoring Inc, New York). Daily activity logs 
were kept on paper with each 24 h divided into half-hourly 
epochs. The predominant activity of each period was recorded 
under the following categories: drink/meal; showering; exercise; 
light activity; relaxing (e.g watching videos); stress and sleep. 
Subjective sleep logs were completed noting time of going to 
bed (h), time taken to fall asleep (min), number of night 
awakenings, time of waking up and sleep quality (1-6 on a 
visual analogue scale). All urine passed was collected into 
separate containers for fixed 4 hourly intervals (08.00-12.00,
12.00-16.00, 16.00-20.00, 20.00-24.00, 24.00-04.00, 04.00-
08.00 hours) except for sleep periods longer than 4 h. Here the 
oversleep collection was placed in the container appropriate 
to the 4 h interval on waking. For the purposes of calculation 
the excretion rate was assumed to be constant during the entire 
sleep period. An average number of collections per subject per 
day was 4.7+0.32 s.e.m. (Sl-4, S6). S5 produced less urine 
samples per day due to his extended sleep periods. All volumes 
collected were measured and an aliquot frozen for measurement 
o f 6-sulphatoxymelatonin (aMT6s), the major metabolite of 
melatonin. Using an identical procedure, calculated phase shifts 
in aM T6s have been shown to correlate closely to those of 
plasma melatonin acrophase or onset (Ross et al. 1994; Deacon 
and Arendt 1994a). Subjects were allowed to eat and sleep 
whenever they wished, the only imposed behaviour being 
computer based performance tests every 3 h whilst awake. 
Individuals were never disturbed when sleeping.
Analysis
Urinary 6-sulphatoxymelatonin levels were measured by 
radioimmunoassay (Aldhous and Arendt 1988) and the 
excretion rate (ng/h) calculated. The assay limit of detection 
was 0.25 ng/mL and quality control values of 2.84, 21.67 and
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Figure 2. Summary double plots to show sleep/ 
wake cycle, and temperature, activity and 
6-sulphatoxymelatonin acrophase times in 6 
subjects (S1-S6) maintained for 21 days in 
continuous dim light (<8 lux) with knowledge of 
clock time.
45.23 ng/mL showed coefficients of variation of 9.6%, 11.4% 
and 7.5%, respectively.
Temperature data was edited to remove all readings below 
36.0°C in order to eliminate false readings from displacement 
of the probe, and all values recorded within an hour of 
showering or exercising as noted on the activity diaries. 36.0°C 
was chosen as the mean lowest temperature recorded during 
the main sleep episodes was 36.25 ±0.07°C. Activity data was 
edited in the same way with readings 10 min before and after 
downloading the loggers being discarded. For the analysis of 
periodicity, sleep times of 3 h or less were removed. Such 
short sleeps were considered unrepresentative of the sleep/wake 
periodicity. Edited activity and temperature data and aMT6 s 
excretion rates were subjected to cosinor analysis (Nelson et 
al. 1979; Minors and Waterhouse 1989) using single day, 2- 
day and 3-day non-overlapping windows, and 3-day moving 
window data bins together with spectral analysis using Action3 
software from Ambulatory Monitoring Inc. The acrophase 
times derived from the cosinor analysis were further assessed
by linear regression analysis to determine individual periods 
(tau =  x) over the study period. Only acrophase times with 
significant fits (P<0.05) were used. These were associated with 
percentage rhythms >70% for temperature and aMT6 s or 45% 
for activity.
Sleep onset and offset times for each individual were identified 
from the sleep logs and confirmed by means of the actigraphy 
records. In most cases subjects also recorded time in bed 
electronically by an event marker mounted on the actigraph. 
The data were subjected to linear regression analysis to 
determine individual tau. Sleep periods were analysed by 
Action3 to give total time in bed, total sleep time, wake time 
after sleep onset and sleep efficiency. Automatic sleep scoring 
in Action3 is based on an algorithm (Cole et al. 1992) which 
examines activity 6 min before and 4 min after the epoch being 
scored before rating it as sleep or wake. This methodology 
gives >80% agreement with EEG recordings in normal subjects.
Significant changes over the course of the study were assessed 
by repeated measures ANOVA using individual raw data (sleep)
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Figure 3. Changes in activity mean group acrophase times and sleep 
onset and offset times over 20 day study period, mean +  s.e.m. 
Activity =  24.30 (Days 1-17) « =  6, Sleep onset time =  24.12, « =  6; 
sleep offset times =  24.18, « =  6. Repeated measures ANOVA showed 
a significant delay in acrophase, sleep onset and offset times with 
study day as factor and 5,19 degrees of freedom ( f =0.0001).
or cosinor derived parameters (temperature, activity and 6- 
sulphatoxymelatonin) with study day as factor (5,19 degrees 
of freedom).
Linear regression analysis was performed on the daily group 
mean activity, temperature and 6-sulphatoxymelatonin 
acrophase times as well as sleep onset and offset times.
RESULTS
With the exception of performance data, compliance was good, 
with >80% data points present in all parameters when recording 
equipment functioned correctly. D ata lost was as follows: 
Actigraphs: S3 lost 3 days and 15 h, S6 lost 15-20h and S2 
lost 6h . Temperature loggers: 82 and 85 lost 12-15 h and 83 
lost last 2 days. Temperature recording in 81 provided data 
for analysis from Days 1-8 only due to technical problems 
with the probe. As only 42.3-53.4% of the theoretical number 
of performance test sessions possible were completed, this data
P  10
- 0 —  Temperature Acrophase 
■ 0 —  aMTSs Acrophase
0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20
Trial Day
Figure 4. Changes in temperature and aMT6 s mean group 
acrophase times over the 20-d study period, mean ±  s.e.m. 
Temperature=24.30 n =  5, a M T 6s= 24.26 n — 6. Repeated measures 
ANOVA showed a significant delay in acrophase times with study 
day as factor and 5,19 degrees of freedom (P=0.0001).
was discarded. It is possible that some short sleeps were 
deliberate avoidance of performance tests.
Individual periodicities derived from single day, 2-day, 3-day 
non-overlapping windows and 3-day moving window cosinor 
analysis did not differ significantly (ANOVA) and the results 
for 3-day moving window data are reported here. Data derived 
from cosinor analysis and spectral analysis showed similar 
periodicities (P>0.05, paired students Mest). 81eep 
characteristics (total time in bed, total sleep time, wake after 
sleep onset and sleep efficiency) are reported using data from 
single days.
Individual data
8ummary double plots were produced for all subjects (Fig. 2) 
to give an overall record of the sleep-wake cycle and activity, 
temperature and aM T6s acrophase times. Visual inspection 
suggests that free-running rhythms were obtained in all 
parameters with the exception of subject 83. In the latter case 
only aM T6s appears to deviate from 24 h. Possible
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Figure 5. Graphs showing changes in sleep 
parameters during the 20-d study period ±  s.e.m. 
(a) Total time in Bed (mins), (b) Total sleep time 
(mins), (c) Wake after sleep onset (mins), (d) 
Sleep efficiency (total sleep time as a percentage 
of total time in bed). Repeated measures 
ANOVA (study day as factor d.f. 5,19) wake 
after sleep onset showed a significant increase 
P=0.019, whilst sleep efficiency showed a 
significant decrease f =0.002.
desynchronization of sleep/wake from aMT6 s is evident during 
the last few days of the study in S4 and S5 and for the second 
half of the study in subject S6.
Full results obtained from linear regression analysis and 
spectral analysis for each parameter and subject are shown in 
Table 1. Individual tau derived from linear regression analysis 
o f acrophase times was considered to be significantly different 
from 24 h if P<0.05 and upper and lower limits at 95% 
confidence were greater than 24 h. These results can be 
summarized in the following way:
Activity 5 subjects SI, 82, S4-S6 deviated significantly from 
24 h by cosinor and spectral analysis. Subjects S4 and S5 
showed a definite ‘end effect’ apparently adjusting their sleep/ 
wake cycle to coincide with the outside world during the last 
few days of the study. Therefore, only Days 1-15 and 1-17, 
respectively, were used for analysis. Two periodicities were seen
in data from S6. Separate analysis o f Days 1-11 and 11-21 
gave taus o f 25.00 and 12.06 (spectral analysis) and 24.30 and
12.00 by cosinor analysis, respectively.
Temperature 5 subjects SI, S2, S4—S6, deviated significantly 
from 24 h by regression analysis and all subjects free-ran by 
spectral analysis.
aM T 6s  All subjects showed periodicity significantly longer 
than 24 h by regression and spectral analysis.
In subjects 81,2,4,5,6 it was 3-10 days before the activity, 
temperature and aMT6 s rhythms showed a steady periodicity 
which was significantly different from 24 h.
Sleep onset times 81, 82 and 84 showed a clear free-run longer 
than 24 h; 83 remained synchronized; 85 showed a tendency 
to free-run (P<0.4) whilst for 86 sleep became fragmented and 
apparently desynchronized.
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Table 1 Linear regression and spectral analysis of individual activity, temperature and aMT6s acrophase times (decimal hours) (3 day moving 
window) +  sleep onset and offset times (single day)
Subject Days Sleep
on.set
Sleep
offset
Activity
Reg
Activity
Spectral
Temp.
Reg
Temp
Spectral
aMT6s
Reg
aMT6s
Spectral
1 1-20 D l-8
24.51+0.21*** 24.55 +  0.12*** 24.45 +  0.04*** 24.60 24.36 +  0.14*** 24.50 24.41+0.07*** 24.46
2 1-20 24.25 +  0.13*** 24.37 +  0.16*** 24.32 +  0.04*** 24.45 24.19+0.02*** 24.42 24.21+0.19* 24.30
3 1-20 24.01+0.06 24.04+0.02*** 24.04 +  0.04 23.92 24.02 +  0.06 24.10 24.19+0.06*** 24.00
4 1-15 24.37 +  0.25** 24.54 +  0.21*** 24.37 +  0.09*** 24.56 24.35+0.05*** 24.42 24.43 +  0.10*** 24.82
5 1-17 24.10 +  0.23 24.31+0.07*** 24.18 +  0.07*** 24.15 24.40 +  0.06*** 24.36 24.31+0.19** 24.15
6 1-20 24.09 +  0.33 23.99+0.44*** 24.17 +  0.10** 24.30 24.35 +  0.05*** 24.35 24.40 +  0.12*** 24.60
Group analysis
n — 6 1-20 24.12 +  0.10* 24.18+0.07*** 24.20 +  0.08*** 24.30 +  0.03*** 24.26 +  0.04***
Significance level *** =  <0.001; ** =  <0.01; * =  <0.05. Subject 6 showed tau of 24.30; 25.00 days 1-11 (cosinor and spectral), 12.00; 12.06 days 
12-20 (cosinor and spectral).
Table 2 Mean value ±  s.e.m. and linear regression analysis o f sleep parameters (single day)
Subject Days Time in bed 
( mins)
Total sleep 
time (mins)
WASO
(mins)
Efficiency
1 1-20 512.53 +  26.95 476.58 +  24.26 6.77+ 0.93 93.23 +  0.93
2 1-20 545.80 +  30.78 516.30 +  29.31 29.50+ 3.53* 94.55 +  0.54*
3 1-20 559.53 +  12.36 498.35 +  14.25 61.18+ 6.70** 88.93 +  1.40**
4 1-20 608.71+28.92* 481.24+19.46 127.48 +  12.07** 79.69 +  1.13**
5 1-20 701.05 +  28.71* 598.55 +  21.43 102.50 +  14.66 85.88 +  1.65
6 1-20 563.26 +  33.9* 502.68 +  29.17 60.58 +  12.00 89.58 +  1.63**
Group analysis 
n =  6 1-20 585 +  30.80** 513.54+ 9.33 75.45+ 6.57** 88.79 +  0.73***
Significance level *** =  <0.001; ** =  <0.01; * =  <0.05
Sleep offset times SI, S2, S3, S4, S5 showed significant free- 
run, longer than 24 h whilst S6 offsets were erratic.
Sleep Parameters The percentage of time spent ‘sleeping’ per 
24 h varied in a non-systematic manner throughout the study 
in all subjects except S3 (mean=41.76%+ 7.26% s.e.m.). Total 
time in bed increased significantly in S4 and S5 but the total 
sleep time did not vary during the study in any individual. 
Although a direct comparison in the same subjects is not 
possible, it is interesting to note that the average total sleep 
time was 513.54 +  9.33 (s.e.m.) minutes, whereas the age and 
sex matched normal value is 424.64 min (Williams et al. 1974). 
However, S2, S3 and S4 showed a significant increase in wake 
after sleep onset with a concomitant decrease in sleep efficiency 
(Table 2).
sleep time did not change by ANOVA, however, wake after 
sleep onset increased (P< =  0.019, Days 1-20, N=6, factor: 
day of study, d.f. 5,19) whilst sleep efficiency decreased (P=
0.002, Days 1-20, N =6, factor: day of study, d.f. 5,19 Fig. 5).
Grouped results for amplitude showed a significant increase 
for temperature (P<0.01, regression and ANOVA, Days 1-20 
N=5), and for 6-sulphatoxymelatonin only by regression 
analysis (P<0.0001, Days 1-20, N=6), in the course of the 
study. There were no changes in aetivity amplitude.
There was a strong positive correlation between temperature 
and 6-sulphatoxymelatonin acrophases (r^  = 0.94, P<0.0001) 
with a less striking correlation for amplitude (r^  =  0.55, P =  
0.02).
The overall mean periodicity for all parameters was 
24.26 ±  0.049 h (average of cosinor and spectral analysis).
Grouped data
Activity, sleep onset and offset times, temperature and aMT6 s 
all showed periodicity significantly different from 24 h by linear 
regression analysis and time dependent changes by repeated 
measures ANOVA (P<0.0001, Days 1-20, N —6, factor: day 
of study, d.f. 5,19; Figs 3 and 4). Total time in bed and total
D ISCUSSIO N
The subjects studied were infantry soldiers who normally lead 
a highly structured life but at times may be required to work 
long and/or irregular hours. Within the group one subject (S2) 
was senior to the others. Thus one might anticipate, first, that 
all the subjects would attempt to maintain a 24-h rhythmicity
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out of habit, secondly that they would synchronize within 
the group, and thirdly, that the senior-ranking subject would 
attempt to impose a regime on the others. In fact, none of 
these predictions was upheld. The records suggest that S2 
attempted to remain on 24 h for the first week but could 
not maintain synchronization. Subject 3 who succeeded in 
maintaining a 24-h sleep/wake cycle, nevertheless showed clear 
free-run in melatonin sulphate. It is important to note, however, 
that his core temperature appeared to be synchronized. 
Masking was reduced as much as possible by eliminating 
temperature data associated with showers and exercise, but the 
presumption is that apparent entrainment was due to masking 
by the sleep/wake cycle. This phenomenon is also seen in S5 
on Days 17-21, who attempted to resynchronize to the normal 
day prior to leaving the unit. Subject 4 also shows this ‘end 
effect’ but with insufficient temperature data to make 
comparisons during the last days of the study. During the 
study subjects slept longer than the average for age and sex. 
Whether this is primarily a function of the light conditions, to 
a non-stimulating environment or to other factors is unknown.
Melatonin production is masked by sufficient intensity of 
bright light, and to a small extent by posture (Deacon and 
Arendt 1994b). In the present study conditions where light 
intensity is low and controlled, measurement of melatonin or 
urinary aMT6 s is likely to provide a reliable estimate of the 
phase of the endogenous clock, as previously suggested by 
Wever (1989). This is illustrated by the apparently motivated 
adjustment of the sleep/wake cycle in S3 throughout the study 
and 84 and 85 towards the end of the study, where melatonin 
continued to free-run but temperature was influenced by the 
sleep/wake cycle.
The subjects did not synchronize as a group. This is illustrated 
by the calculated periodicities. Perhaps more striking is a 
comparison of sleep times on particular days. On Day 14/15, 
for example, the subjects’ major sleep episode occurred (in 
numerieal subject order) at 08.00-16.25; 01.00-14.25;
24.00-09.25; 06.00-16.20; 02.30-13.40 and 09.45-17.00 hours. 
It is conceivable that in this particular group interpersonal 
relations inhibited group activity. However, in three subsequent 
experiments with similar groups and environmental conditions 
group synchronization has not been observed either (Middleton 
et al. 1995).
The mean grouped free-running periodicity (24.26) is 
considerably lower than that reported by Wever for the 
endogenous human pacemaker (24.9 ±0.2). This is conceivably 
due to our particular experimental conditions and subjects. 
However, we note that Campbell et al. (1993) reported a shorter 
tau in nappers as opposed to non-nappers with a self-selected 
light dark cycle when subjects were permitted to eat and nap 
when they liked. Czeisler et al. (1995b) and Klerman et al. 
(1996) also report shorter tau (24.1-24.2 h) for the endogenous 
human clock under very dim light conditions (<15 lux), forced 
desynchronization and using constant routines for evaluation 
of rhythm status. It has been suggested that the self selected 
L/D cycles used by Wever and co-workers may have unduly 
lengthened tau by phase delays induced by evening bedside
lights when subjects were told to eat regularly three times a 
day and naps were not allowed. It has been shown (Van Reeth 
et al. 1994) that suitably timed exereise can induce significant 
phase changes; however, in this study, whilst three of the 
subjects exercised briefly (82, 84 and 85), no subject exercised 
after Day 5. Thus it is felt that this minimum use of the exercise 
facilities is unlikely to have modified the results.
The general conclusion is that in 5 out of 6 subjects all 
variables free-ran with individually variable periodicity. 
Deliberate adjustment of the sleep/wake cycle did not entrain 
the endogenous clock as shown by the 6-sulphatoxymelatonin 
measurements. A period of 10 days was required for free run 
to be manifested as significantly different from 24 h in subjects 
1,2 and 4-6.
This experimental approach should permit the assessment 
of phase-shifting and entraining agents such as melatonin, 
combinations of melatonin and light-pulse treatment and 
melatonin analogues under development. It allows a group 
of free-running subjects to receive timed medication under 
controlled but not onerous conditions. Moreover it has direct 
applicability to some situations encountered outside the 
laboratory. For example, free-running rhythms are found in 
the dim winter light of high latitudes when behaviour is not 
restricted. It requires only a small effort of the imagination 
to extrapolate the polar situation to Northern or 8outhern 
temperate zones in winter when individuals may well spend 
very little or indeed any time in natural light. Many blind 
subjects also show free-running rhythms in a normal 
environment with a non 24-h sleep/wake disorder. With 
reference to military situations, the maintenance of rhythm s in 
dim light situations is clearly important to optimize alertness 
and performance at specific times of day.
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Melatonin and fragmented sleep patterns
S ir— A s a result o f  m edia publicity m any people are reported 
to be se lf m edicating with the horm one m elatonin in 
countries where it is freely available. W e report here data 
which suggest that in som e circum stances m elatonin may 
have deleterious effects on sleep.
In experiment 1, 10 healthy m en, aged 26 0 (S D  2 71) 
years, were m aintained together as a group in a closed  
environm ent in constant dim  full-spectrum  light (< 8  Ix, 
Siem ens Lighting Ltd), attenuated sound and temperature 
(range 2 1 -2 9 °C ), and random intermittent contact with 
experimenters. A digital clock recording local time was 
present. T he m en were told to eat and sleep when they 
wished. T hey were under video observation 24 h a day to 
note com pliance. T hey took three capsules per day, if  awake, 
at 12 00 h, 2 0 0 0  h, and 04 00 h. In a double-blind crossover 
design the 20 00 h capsule contained 5 m g m elatonin (Sigma 
F D  5250 in gelatine-lactose) or placebo for 16 days, with a 
period o f at least 4 weeks between treatments. In experiment 
2, another 6 persons (m en aged 25-67 [SD  3-3] years) were 
kept in the closed environm ent for two periods o f  11 days 
separated by recovery tim es o f  4 days. After a 3-day baseline 
period in normal lighting (> 3 0 0  Ix, 07 0 0 -2 3  00 h) they took  
three capsules per day as in experim ent 1 (days 5 -1 0 ). 
Activity was m onitored every 20 s (wrist recorders and 
A ction 3 software,' Ambulatory M onitoring Inc, N ew  York). 
D aily  sleep logs and activity diaries were also kept. 
Autom atic sleep scoring was carried out with Action 3 
software. T he autom atic sleep scoring is based on an 
algorithm devised by Cole et al,' which shows above 80% 
correlation  w ith e lectroencephalogram -generated  data. 
Periodicity o f  sleep tim ing was determ ined by spectral 
analysis and linear regression, and sleep tim es were double  
plotted in the Raster format to show rhythmicity. Individuals 
were never disturbed when sleeping.
During placebo treatment in both experiments 15 o f  16 
subjects (one withdrew during placebo treatment) showed a 
consolidated sleep-wake cycle (spectral analysis). T he time 
series in experiment 1 was sufficiently long to show a 
significant deviation from 24 h (p<0-05, regression analysis). 
D uring m elaton in  treatm ent m ost subjects retained a 
consolidated  sleep-w ake cycle, synchronised to 24  h. 
H owever in experiment 1, 2 out o f  10, and in experiment 2, 2 
out o f 6 m en displayed a highly irregular sleep-wake cycle 
throughout the period o f m elatonin treatm ent (figure). 
Subjects A , C , and D  sh ow ed no 24 h s leep -on set  
com ponent by spectral analysis. Individual B does have a 
24 h com ponent but the presence o f  very short sleeps 
interspersed with long or very long sleeps is clearly abnormal.
T he effect may be theoretically explicable if  m elatonin acts 
primarily on the tim ing m echanism s o f  sleep. There is good  
evidence in animals,^ and in hum an beings,’ that two coupled  
“oscillators” (evening and morning) may be responsible for 
the tim ing o f  sleep. In our experim ents, if  exogenous 
m elatonin given during the evening constitutes a sleep-onset 
signal largely acting through the evening “oscillator”, it may 
be capable o f  detaching or uncoupling these two com ponents 
o f  sleep (which then behave erratically). Conceivably in a 
normal environment the light-dark cycle and other factors
Sleep CmWake I I Baseline
Experiment 1 A
Subject w ithdrew
12 20 04 12 20 04 12 12 20 04 12 20 04 12 
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Experiment 1 B
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Figure: Sleep periods (black bars) on consecutive days, double 
plotted to show rhythmicity, In four Individuals (A-D) receiving 
melatonin (WIT) or placebo (P) at 2000 h
m ight supply sufficiently strong tim e cues to m aintain  
coup ling . W hatever the m ech anism , it is clear that 
indiscriminate use o f  m elatonin could lead to undesirable 
effects.
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Abstract In humans, the pineal hormone melatonin can phase shift a number of 
circadian rhythms (e.g., "fatigue," endogenous melatonin, core body tempera­
ture) together with the timing of prolactin secretion. It is uncertain, however, 
whether melatonin can fully entrain all human circadian rhythms. In this study, 
the authors investigated the effects of daily melatonin administration on sighted 
individuals kept in continuous very dim light. A total of 10 normal, healthy males 
were maintained in two separate groups in partial temporal isolation under 
constant dim light (< 8 lux) with attenuated sound and ambient temperature 
variations but with knowledge of clock time for two periods of 30 days. In these 
circumstances, the majority of individuals free run with a mean period of 24.3 h. 
In a double-blind, randomized crossover design, subjects received 5 mg mela­
tonin at 20:00 h on Days 1 to 15 (Melatonin 1st) followed by placebo on Days 16 
to 30 (Placebo 2nd) or vice versa (Placebo 1st, Melatonin 2nd) during Leg 1 with  
treatment reversed in Leg 2. The variables measured were melatonin (as 6- 
sulphatoxymelatonin), rectal temperature, activity, and sleep (actigraphy and 
logs). In the experiment, 9 of the 10 subjects free ran with Placebo 1st, whereas 
Melatonin 1st stabilized the sleep-wake cycle to 24 h in 8 of 10 individuals. In 
addition, 2 individuals showed irregular sleep with this treatment. In some 
subjects, there was a shortening of the period of the temperature rhythm without 
synchronization. Melatonin 2nd induced phase advances (5 of 9 subjects), phase 
delays (2 of 9 subjects), and stabilization (2 of 9 subjects) of the sleep-wake cycle 
with subsequent synchronization to 24 h in the majority of individuals (7 of 9). 
Temperature continued to free run in 4 subjects. Maximum phase advances in 
core temperature were seen when the first melatonin treatment was given  
approximately 2 h after the temperature acrophase. These results indicate that 
melatonin was able to phase shift sleep and core temperature but was unable to 
synchronize core temperature consistently. In the majority of subjects, the sleep- 
wake cycle could be synchronized.
Key words 6-sulphatoxymelatonin, activity, circadian rhythms, core body temperature, 
light, melatonin, sleep
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INTRODUCTION
In humans, the pineal hormone melatonin can 
phase shift a number of circadian rhythms (e.g., "fa­
tigue," endogenous melatonin, core body tempera­
ture) together with the timing of prolactin secretion 
(Arendt et al., 1984, 1985; Deacon et al., 1994; Sack 
et al., 1987,1991; Wright et al., 1986). A human phase 
response curve (PRC) using endogenous melatonin as 
a phase marker has been described in two reports 
(Lewy et al., 1992; Zaidan et al., 1994). Its effects are 
dose related over the range of 0.05 to 5 mg; acute 
administration of 5 mg at 17:00 h is more effective at 
phase advance than are lower doses (Deacon and 
Arendt, 1995). It remains questionable, however, 
whether melatonin can fuUy entrain all human cir­
cadian rhythms. Probably the best examples are found 
in the investigation of the effects of melatonin in blind 
people. Daily administration to 1 free-running blind 
man, exposed to aU ambient time cues with the excep­
tion of die light:dark (LD) cycle, stabilized his sleep- 
wake cycle, especially sleep onset, but failed to entrain 
endogenous melatonin, cortisol, or core body tem­
perature rhythms (Arendt et al., 1988; Folkard et al.,
1990). Subsequent reports have indicated that in many 
visually impaired people, melatonin can stabilize the 
sleep-wake cycle (e.g., Jan et al., 1994; Sack et al., 1991; 
Tzischinsky et al., 1992), but only 1 individual has 
shown possible entrainment of a strongly endogenous 
rhythm such as melatonin (Sack et al., 1991). In a pre­
liminary report, Lewy and coworkers have suggestive 
evidence for entrainment of a free-running sighted 
individual (McArthur et al., 1995). However, inspec­
tion of their data suggests that they shortened tau 
rather than inducing full synchronization.
Within the framework of an investigation into the 
properties of melatonin, w e studied the effects of daily 
melatonin administration to sighted individuals kept 
in continuous very dim light and knowledge of clock 
time. The study protocol and conditions were de­
signed to allow timed treatments under free-running 
conditions. In these circumstances, the majority of 
ind ividuals free run w ith  a mean tau of 24.3 h 
(M iddleton et al., 1996a).
MATERIALS A ND METHODS
Subjects
A total of 10 normal subjects were recruited from 
male soldiers stationed atPamborough,United Kingdom. 
All subjects were healthy, taking no medication except
for minor analgesics, and were ages 23.90 ± 0.75 years. 
Prior to the experiment, subjects were screened for 
normal amplitude and timing of melatonin produc­
tion with reference to in-house laboratory values. 
Round-the-clock urine collections were made with 
samples taken every 4 h and overnight. Excretion rates 
of 6-sulphatoxymelatonin (aMT6s, the major metabolite 
of melatonin) were measured by radioimmunoassay 
(RIA) (Aldhous and Arendt, 1988). Each individuaTs 
dim light melatonin onset was determined by taking 
half-hourly blood samples between 19:00 and 02:00 h 
in lighting conditions < 50 lux. Plasma melatonin lev­
els were determined by RIA (Fraser et al., 1983), and 
onset time was calculated as the time at which plasma 
melatonin levels reached values twice the level of the 
assay limit of detection (5 pg/m l). Subjects were 
considered suitable for inclusion in the experiment if 
the plasma dim light melatonin onset fell between 
21:00 and 24:00 h and if 24-h aMT6s output was within 
the normal range (12.81 ± 9.6 | i g /24 h, n =  177) with 
acrophase times between 02:00 and 06:00 h. All indi­
viduals screened satisfied these requirements and par­
ticipated in both legs of the study.
All subjects gave informed written consent, and the 
study protocol was approved by the Army Personnel 
Establishment Ethical Committee.
General Conditions
The subjects were maintained in two groups of 6 
and 4 individuals in partial environmental isolation. 
The general experimental conditions have been de­
scribed elsewhere (Middleton et al., 1996a). Briefly, the 
unit consists of a large communal sleeping room with 
partially screened beds, a fully equipped kitchen, a 
computer room for performance testing, a room for 
watching videos, and an ablution area with a shower 
and toilet for each individual together with exercise 
machines. Air-conditioning ensured a temperature 
range of 21 to 29°C (mean = 22.5 ± 1.26°C), and sound 
was attenuated. The entire area was light tight, and 
illumination was provided by overhead banks of full 
spectrum lights (Osram Biolux) and diffusers (Siemens 
Lighting Ltd.) to give uniform light levels throughout 
the unit. Average light intensity at eye level could be 
controlled over the range of 0 to 2000 lux. Dim light 
(L:L, mean = 4.09 ± 0.80 lux) was im posed after an 
initial 24-h acclimatization period (ligjits on 07:00-23:00 h, 
approxim ately 500 lux). The experim ents were 
conducted between September and March with a 
minimum of 6 weeks between legs.
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Contact with experimenters was intermittent and 
random. A digital clock recording real time was pre­
sent in the kitchen area. Food was self-selected and 
cooked by the subjects from a broad range of fresh and 
frozen ingredients and ready-prepared microwavable 
meals. Subjects were under observation 24 h a day to 
note compliance, and voice contact could be made at 
any time via an intercom. Subjects were instructed to 
eat and sleep when they wished and never were dis­
turbed when sleeping. Initial experiments suggested 
that when subjects were aware of the impending end 
of an experiment, they attempted to force themselves 
into synchrony with 24 h in preparation for release. In 
consequence, they were not informed of the precise 
length of the experiment but were told the maximum  
time period would be 33 days. In these conditions, 
subjects in our previous experiments showed free- 
running rhythms that differed significantly from 24 h 
within 10 days of the start of dim light (Middleton 
et al., 1996a).
Treatment
The light intensity throughout the unit was main­
tained at 4.09 ± 0.8 lux for the duration of the experi­
ment (30 days each leg). The subjects took coded pills 
every 8 h  (12:00, 20:00, and 04:00 h) when awake. 
Capsules taken at 12:00 and 04:00 h always were pla­
cebos. In a double-blind, randomized crossover de­
sign, they received melatonin (5 m g in gelatin lactose, 
Penn Pharmaceuticals Ltd., Tredegar, United Kingdom) 
in the 2000-h capsule for the first 15 days (Melatonin 
1st) and placebo (gelatin lactose) for the second 15 
days of the study (Placebo 2nd) or vice versa (Placebo 
1st, Melatonin 2nd). In a second leg, the treatment 
order was reversed.
Sample Collection and Recording
Throughout the experiments, except when shower­
ing and defecating, core body temperature (T) was 
monitored continuously by means of a rectal probe 
connected to a Grant memory Logger (Grant Instru­
ments Ltd., Cambridge, United Kingdom) recording 
every 6 min. A ctivity (A) w as logged  every 20 sec 
by m eans of wrist-mounted accelerometers (Mini- 
Motionloggers, Ambulatory Monitoring Inc., New  
York). All urine passed over 4-hour intervals or during 
the sleep period was collected and measured, and an 
aliquot was frozen for measurement of aMT6s, the 
major metabolite of melatonin. The subjects kept daily
sleep diaries recording bedtime, latency, number and 
duration of night awakenings, wake-up time, and 
sleep quality. In a similar manner, they recorded their 
main activities, including meals and drinks, at half- 
hour intervals during each 24-h period.
Analysis
Urinary aMT6s levels were measured by RIA 
(Aldhous and Arendt, 1988), and the excretion rate 
(nanograms/hour) and total excretion per 24 h (micro­
grams) were calculated. Temperature data were edited 
to remove values below 36°C and readings associated 
with showers or exercise. The data were then de­
masked. Activity, temperature readings, and aMT6s 
excretion rates were subjected to 3-day moving-window  
cosinor analysis (Minors and Waterhouse, 1988) and 
spectral analysis using Action3 software (Ambulatory 
Monitoring Inc.). This method of analysis describes 
time-series data in terms of the power at each of a 
range of underlying frequencies. Under our experi­
mental conditions, the spectral peak would be ex­
p ected  to fa ll b e tw e en  23 and  25 h. The range  
of frequencies investigated was 0 to 36 h, and the time 
of the highest peak was considered to be the period of 
the data under analysis.
Acrophase times determined by cosinor analysis 
were further assessed by linear regression with day as 
the independent variable to determine individual pe­
riods (tau = t) over the study period. Only data with 
significant fits {p <  .05) and percentage rhythms > 70% 
for temperature and aMT6s and > 40% for activity 
were used (100% = aU points falling on the calculated 
curve). During melatonin treatment, urinary aMT6s 
derived  from exogenou s m elatonin  com pletely  
masked the endogenous profile, and no cosinor analy­
sis was performed on aMT6s for these sections. Auto­
matic sleep scoring of manually tagged "in bed" 
intervals was carried out using ActionS software. The 
"in bed" intervals were marked using the event mark­
ing of the activity recordings and by eye from the 
activity trace. They were then confirmed by reference 
to the sleep logs and activity diaries.
Sleep onset and offset times for each individual also 
were assessed by linear regression analysis and spec­
tral analysis to determine tau.
Demasking of Core Body Temperature
The method used was based on that described by 
Folkard (1988, 1989). Temperature data from 6-min 
readings were binned into hourly intervals after edit­
ing to remove raised values due to exercise and low ­
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ered values due to incorrect wearing of the probes. 
Two factors were then taken into account: the effects 
of sleep and the effects of melatonin administration.
Sleep-Wake Cycle
In the case of sleep, the following approach was 
used. Given that there can be wide individual differ­
ences in the effects of masking, w e determined indi­
vidual correction factors for sleep. For this, w e  
calculated the mean hourly temperature for the first 3 
days of placebo administration when this was ihe first 
treatment and calculated the differences from normal­
ized demasked hourly temperature values supplied 
by S. Folkard (Body Rhythms and Shiftwork Centre, 
University of Wales, Swansea, United Kingdom) 
(Folkard, 1988,1989). These values were then used to 
correct the masked data. The normalized demasked 
hourly temperature values are expressed for each 
hour after wake-up and then for each hour after sleep 
onset for 8 h  sleep in 24 h.
However, in this series of experiments, sleep fre­
quently was longer than the 8 h  used to determine the 
average correction factors. To take this into considera­
tion, we assumed that for a sleep period in excess of 8 h, 
temperature would not be suppressed more than the 
maximum with an 8-h sleep period and similarly that 
temperature would not be increased more than the 
maximum found over a 16-h wake period. The correc­
tion factor profile was proportionally expanded to 
cover the length of sleep or wake present, and hourly 
correction values were determined by interpolation. 
For sleep and wake periods shorter than 8 and 16 h, 
respectively, the correction factors were applied di­
rectly. Apart from subjects showing irregular sleep 
(Subjects 2 and 5), the sleep periods ranged between 5 
and 12 h  and the wake periods between 9 and 22 h in 
length.
Melatonin Administration
Differences in the mean hourly temperature data 
for the first 3 days of placebo and for the first 3 days 
of melatonin administration (in each case when these 
were the first treatments given) were obtained for each 
subject and used to correct the masked data.
Repeated measures analysis of variance (ANOVA) 
followed by Duncan's multiple range post hoc test 
were used to evaluate any differences in acrophase 
times derived from the masked and demasked data. 
One-way ANOVA was used to estimate differences in 
tau derived from the different analyses.
Linear regression analysis and spectral analysis 
were carried out on individual and mean grouped 
activity, temperature and aMT6s acrophase times, and 
sleep onset and offset times. Grouped mean data were 
further analyzed by repeated measures ANOVA.
RESULTS
Compliance
Subject 2 withdrew during the Placebo 1st, Melatonin 
2nd leg, and Subject 6 withdrew during Placebo 2nd 
treatment in both cases for family reasons. Subject 5 
had problems with the rectal probe during the Placebo 
1st, Melatonin 2nd leg, and so insufficient data were 
present for analysis, and Subject 9 had a faulty tem­
perature logger during the initial days of Placebo 1st. 
Overall, mean percentages of 75.9 ± 2.9%, 92.0 ± 1.6%, 
95.6 ± 1.2%, and 88.7 ± 2.4% of the theoretical amounts 
of data for T, A , sleep, and aMT6s, respectively, were 
present.
Temperature Analysis
There were very few significant differences be­
tween tau derived from masked and demasked data. 
However, because 2 individuals (Subjects 4 and 7) 
showed significant differences between masked and 
demasked temperature data on Placebo 1st, Melatonin 
2nd treatments, and because 3 show ed differences 
on a single treatment (Subject 1: Placebo 1st; Subject 6: 
Melatonin 2nd; Subject 8: Melatonin 2nd), the demasked 
data, individually corrected for sleep and (where ap­
propriate) melatonin, were retained for discussion.
Activity, Sleep, and Temperature
Inspection of the individual records (as plotted in 
Fig. 1) and reference to the calculated periodicities 
showed that 9 of 10 subjects free ran under Placebo 1st 
by our criteria; that is, the period calculated by linear 
regression analysis of acrophase times or sleep onset 
and offset times was greater than 24 h  (p < .05), and 
95% confidence limits do not encompass 24 h. The 
Melatonin 1st treatment stabilized the sleep-wake cycle 
to 24 h in 8 of 10 individuals; however, 2 of 10 showed  
highly irregular sleep during the entire period of 
melatonin treatment. Crossover to placebo in these 2 
subjects, and also to the Placebo 1st treatment, was 
accompanied by a reasonably consolidated sleep-
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wake cycle. The Melatonin 2nd treatment induced 
phase advances (5 of 9 subjects), phase delays (2 of 9 
subjects), and stabilization (2 of 9 subjects) of the rest 
activity cycle with subsequent synchronization to 24 h 
in the majority of individuals. However, 1 subject 
(Subject 7) who delayed and synchronized with mela­
tonin treatment subsequently desynchronized with a 
rapid second phase delay. Figure 1 shows examples of 
stabilization of sleep-wake to 24 h with Melatonin 1st 
in Subject 8 (Panel A), irregular sleep with Melatonin 
1st in Subject 2 (Panel B), phase advance with Melatonin 
2nd in Subject 3 (Panel C), phase delay with Melatonin 
2nd in Subject 6 (Panel D), and double phase delay 
with Melatonin 2nd in Subject 7 (Panel E). Table 1 
shows the individual periods derived from cosinor 
and spectral analyses for each of the variables in each 
of the treatments. Synchronization was considered to 
be present when the periodicity derived by regression 
analysis of cosinor-derived parameters was not sig­
nificantly different from 24 h. In the case of temperature, 
both phase advances and phase delays were initially 
induced by melatonin treatment. With Melatonin 1st, 8 
of 10 subjects appeared to be synchronized by melatonin, 
although a shortening of tau without synchronization 
to 24 h also is a possible interpretation. With Melatonin 
2nd, 3 subjects continued to free run with shortened 
tau and 1 did so with lengthened tau compared to 
placebo. There were no overall differences in tempera­
ture amplitude with treatment on analysis of individ­
ual demasked temperature data by repeated measures 
ANOVA.
In view  of the heterogeneous nature of the response 
to melatonin and the different circadian times (CTs) on 
the day of initial melatonin treatment, overall group­
ing of the data was considered inappropriate. Thus, 
group means for sleep onset, sleep offset, activity acro­
phase, and temperature acrophase were derived from 
the 6 subjects (Subjects 1 ,3 ,4 ,8 ,9 , and 10) who did not 
show either irregular sleep (Subjects 2 and 5) or phase 
delay with Melatonin 2nd (Subjects 6 and 7). These are 
illustrated in Fig. 2. Analysis of variance indicated a 
significant difference between the treatments on the 
Placebo 1st, Melatonin 2nd leg (p = .002) and a trend 
to a difference between the treatments on the Melatonin 
1st, Placebo 2nd leg (p = .06) whereby both sleep time 
and temperature were not different from 24 h with 
melatonin treatment but free ran with placebo treat­
ment. Comparison of treatments Placebo 1st and 
Melatonin 1st showed a significant difference for sleep 
onset, sleep offset, activity acrophase, and tempera­
ture acrophase by ANOVA (p < .001). ANOVAbetween
Placebo 2nd and Melatonin 2nd showed a significant 
difference in activity and temperature acrophase times 
(p < .001) but no significant difference in sleep onset or 
offset times.
It would be wrong to conclude that temperature (or, 
indeed, the sleep-wake cycle) was in fact fully syn­
chronized in all of these individuals under melatonin 
treatment. Temperature provides clearer data, and re­
gression analysis indicated that Subjects 3 and 8 had 
taus shorter than 24 h  with melatonin treatment, 
whereas Subject 4 had a tau on melatonin shorter than 
placebo but that nevertiieless was free running (Fig. 3).
Because CT of administration is the most obvious 
explanation for these different responses, w e investi­
gated the relationship of the time of the Melatonin 2nd 
treatment relative to calculated core body temperature 
maximum on the previous day. The 2 subjects who  
delayed with Melatonin 2nd received their first mela­
tonin treatment 5.15 and 6.20 h  before temperature 
maximum, a substantial delay of their temperature 
rhythms relative to all other subjects who were treated 
from 4.28 h before to 1.14 h after maximum T. In view  
of these relationships, we calculated a PRC for the 
phase shift in temperature induced by treatment with 
melatonin from the temperature acrophases on Days 
15 and 16 of the study. These data (from 8 subjects) are 
shown in Fig. 4, where it can be seen that a maximum  
phase advance is present when treatment is close to 
maximum T. Calculation of maximum T prior to 
Melatonin 1st is less reliable because only 1 day of data 
was available prior to treatment. However the data 
from Days 1 and 2 of the study also are shown in Fig. 4. 
The melatonin treatment time is shown relative to 
temperature acrophase (hours) and also as circadian 
phase (degrees), where 0“ is the calculated tempera­
ture nadir (Jewett et al., 1994).
aMT6s
During placebo treatment, aMT6s free ran in all 
subjects with Placebo 1st, Melatonin 2nd. In 5 of 9 
subjects, aMT6s free ran with Placebo ^ d .  Table 2 
shows the mean endogenous aMT6s per 24 h for each 
subject. The periodicity was closely coupled to that of 
temperature (r = .63, p =  .02), and there were no sig­
nificant differences in amplitude by repeated mea­
sures ANOVA in the course of treatm ent. The 
endogenous secretion in all subjects was within the 
normal range for age (13.14 ± 9.8 | i g / 24 h to 54.0 ± 6.0 
pg/24  h), and there were no obvious differences in 
endogenous secretion in relation to the responses ob-
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Figure 1. Examples of (A) stabilization of the sleep-wake cycle to 24 h with Melatonin 1st in Subject 8, (B) irregular sleep with Melatonin 
1st in Subject 2, (C) phase advance with Melatonin 2nd in Subject 3, (D) phase delay with Melatonin 2nd in Subject 6, and (E) double 
phase delay with Melatonin 2nd in Subject 7,
NOTE: aMT6s = 6-sulphatoxymelatonin.
served (Table 2). The excretion of aMT6s during mela­
tonin treatment first indicated compliance (97.4 ± 
0.6%) and also provided an estimate of individual
clearance (Table 2). There were no apparent relation­
ships between excretion of aMT6s and response with 
the exception of 1 subject (Subject 1), who had delayed
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Table 1. Summary of individual taus for all variables.
Subject Number
Temperature A ctiv ity aMT6s Sleep Onset Sleep Offset
Regressicm Spectral Regression Spectral Regression Spectral Regression Spectral Regression Spectral
Placebo 1st
1 24.48* 24.56 •24.12* 24.22 24.40* 24.42 24.26* 24.00 24.31* 24.35
2 24.19* 24.30 23.92 23.85 24.26* 24.15 24.40 24.52 23.99 24.00
3 24.16* 24.30 24.19* 24.35 24.50* 24.32 24.35* 24.28 24.16* 24.35
4 24.41* 24.75 24.14* 24.55 24.40* 24.30 24.25* 24.12 24.13* 24.60
5 24.14* 24.00 24.08 24.00 24.20* 23.96 24.12* 24.30
6 24.46* 24.36 24.47* 24.50 24.57* 24.72 24.39* 24.32 24.11 24.62
7 24.55* 24.30 24.15* 24.50 24.46* 24.23 24.15 24.25 24.19 24.70
8 24.29* 24.12 24.11* 24.50 24.28* 24.20 24.22* 24.00 24.15* 24.30
9 24.54* 24.42 24.20* 24.20 24.70* 24.30 24.10 24.05 24.32* 24.34
10 24.22* 24.30 24.13* 24.26 24.17* 24.10 24.15 23.62 24.07 24.12
Melatonin 2nd
1 24.00 23.75 24.00 24.02 24.17 24.22 24.15 24.32
2 (subject withdrew)
3 23.89 23.95 23.66 24.30 23.44* 24.00 23.66 23.85
4 24.15* 23.70 24.04 24.25 24.04 24.15 23.93 23.75
5 Insufficient data 23.86 24.02 23.81 23.95 23.88 23.96
6 25.20* 25.00 24.99* 24.60 24.11 24.10 25.59* 24.35
7 24.36* 26.20 25.44* 26.36 Double phase shift
8 23.52* 23.85 24.06 23.72 23.77* 24.00 24.00 24.06
9 24.09 23.92 24.48 23.73 23.87 24.16 23.61 24.10
10 24.02 24.36 24.02 24.36 24.16* 24.12 23.99 24.20
Melatonin 1st
1 24.15* 24.45 24.07* 23.96 24.04 23.75 24.05 24.20
2 23.85 23.92 24.01 23.75 Irregular sleep patterns
3 23.94 24.12 24.05* 24.26 24.07 24.30 23.98 24.32
4 24.00 24.00 24.07* 24.00 24.02 24.02 24.01 24.26
5 24.05 23.86 23.94 23.92 Irregular sleep patterns
6 24.08* 23.92 24.15* 24.20 24.01 23.90 23.93 24.22
7 24.02 24.00 24.03 24.26 24.05 23.80 24.03 24.30
8 23.97 23.85 24.02 24.25 24.02 23.92 23.87 24.06
9 24.01 23.55 24.03 24.15 23.91 23.91 24.00 23.36
10 24.26 24.28 24.02 24.02 24.05 23.70 24.01 24.10
Placebo 2nd
1 23.86 23.96 23.98 24.70 23.91 24.42 24.09 23.86 24.09 24.15
2 24.02 24.20 24.15 24.36 24.30* 24.40 24.24 24.15 24.20 24.02
3 24.24* 24.36 24.19* 24.45 24.33 23.85 24.21* 24.40 24.10 24.22
4 24.09* 24.16 23.92 24.32 24.29* 24.30 24.07 24.12 24.05 24.10
5 24.05 24.05 24.20* 24.20 Insufficient data 24.30* 24.52 24.15 24.22
6 24.00 24.05 24.44* 24.26 24.22 24.10 24.23 24.20 24.59 24.36
7 24.66* 24.85 24.22* 24.26 24.24* 24.30 24.03 24.10 24.03 24.62
8 24.37* 24.26 24.20* 24.15 24.11* 24.16 24.29* 24.25 24.20* 24.25
9 24.42* 24.35 24.30* 24.35 24.37* 24.15 24.37* 24.42 24.29* 24.40
10 24.02 24.12 24.11* 24.56 24.20 24.15 24.20 24.15 24.16* 24.20
NOTE: aMT6s = 6-sulphatoxymelatonin.
*Tau significantly different to 24 h (p < .05); upper and lower limits at 95% do not encompass 24:00 h.
clearance as indicated by a return to endogenous lev­
els 5 days after cessation of treatment compared to 
48 h (group mean) after stopping treatment in all other 
subjects. It is of interest to note (Table 1) that this 
subject had a substantially shorter tau when placebo 
was administered after melatonin than when placebo 
was administered first.
DISCUSSION
The dose of melatonin used in this study has been 
used extensively in the treatment of rhythm-related 
sleep disorder (e.g., Arendt et al., 1987; Dahlitz et al., 
1991; Jan et al., 1994) and in an acute dose-response 
study generated a larger phase shift than did more
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Figure 2. Group means ± standard errors derived from 6 subjects (Subjects 1 ,3 ,4 ,8 ,9 , and 10) who did not show either irregular sleep or 
phase delay for all treatments: (A) activity acrophase, (B) temperature acrophase, (C) sleep onset time, (D) sleep offset time.
physiological dose levels (Deacon and Arendt, 1995). 
Thus, it would seem appropriate to investigate its 
more formal properties in partial isolation. It is clearly 
desirable, in view  of the evidence for a PRC to mela­
tonin, that its administration be timed according to 
individual circadian phase. In the present study, de­
signed to investigate group effects, it was more prac­
tical and less disturbing to the subjects to keep the 
clock time of administration constant for all. The rela­
tionship to circadian phase could then be derived a 
posteriori following analysis of the temperature data.
The treatment time chosen was such that it was antici­
pated that it would fall in the phase advance window  
in the majority of subjects. In these experimental con­
ditions, we have shown previously (Middleton et al., 
1996a) that subjects free run and do not synchronize 
as a group. Such was the case in the present study with 
placebo administration. This suggests that there were 
no strong social masking pressures to sleep or to be 
awake at particular times. The mathematical demask­
ing procedures used for core temperature are not 
ideal, but the general approach used here has been
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Figure 4. Phase response curve for melatonin using temperature 
as the phase marker. Closed circles represent data derived from 
subjects receiving melatonin (MT) as a second treatment after 15 
days of placebo. Open circles represent data derived from mela­
tonin given as a first treatment after 1 day in  a normal lighkdark 
cycle (lights off 23:00-07:00 h). Melatonin treatment times relative 
to temperature acrophase (hours) and circadian phase (degrees) 
are shown.
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Figure 3. Regression analysis of demasked temperature acro­
phase times (Subjects 3,4, and 8) showing a shortening of tau with 
melatonin treatment. In the case of Sub j ect 8, tau was significantly 
shorter than 24 h.
validated in both entrained and phase-shifted condi­
tions with subjects sleeping at different circadian 
phases. (Folkard, 1988,1989).
Taken on a daily basis from the 2nd day of partial 
environmental isolation in dim light, melatonin ap­
pears to m aintain synchronization of the sleep- 
w ak e/ activity-rest cycle and core temperature in most 
individuals. The exception was the irregular sleep 
seen in 2 subjects. In Subjects 1 and 6, activity and 
temperature appeared to free run with Melatonin 1st 
but with a shorter tau than wifri Placebo 1st.
When melatonin is given after a period of free run, 
synchronization of sleep can take place by phase ad­
vance when the administration time falls within  
around 3 h before to 4 h after maximum T. It is of 
interest to note that synchronization takes place over 
a period of days (Fig. 1), indicating tiiat melatonin is 
not a strong and immediate sleep inducer. Although 
temperature appeared synchronized in 4 subjects 
within this group, detailed analysis suggests that tau 
may be shortened rather than synchronized. It is pos­
sible, in those subjects where tau for temperature was 
indistinguishable from 24 h, that a very slow  free run 
was present but was not detectable in this length of 
data series. Such considerations also apply to the 
sleep-wake cycle. It is of interest to note that when  
placebo was given after a period of melatonin treat­
ment, the recorded periodicity was shorter in 6 of 9 
subjects than during the Placebo 1st treatment (Table 1). 
This suggests that melatonin can have aftereffects on  
endogenous periodicity.
The apparent synchronization of the sleep-wake 
cycle over a period of days by phase delay in Subject 
6, and the partial synchronization in Subject 7 where
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Table 2. Amounts of aMT6s excreted (micrograms).
Subject
Number
Mean Endogenous 
oMT6s Excreted per 24 h
M eanaMTôs  
Excreted per 24 h during 
Melatonin Treatment
1 28.15 ±1.58 2957.86 ±194.59
2 22.69 ±1.08 2975.70±150.57
3 11.56 ±0.37 3310.82 ± 272.70
4 27.11 ± 1.82 3445.63 ±191.80
5 35.55 ±1.63 3284.49 ±213.44
6 15.35 ±1.21 2819.66 ±106.18
7 8.41 ±0.66 3295.52 ± 270.79
8 6.59 ±0.47 2379.64 ± 172.17
9 18.96 ±1.24 3808.88 ± 353.43
10 20.55 ±1.02 2129.35 ±143.55
NOTE: aMT6s = 6-sulphatoxymelatonin.
initial administration times were 5 to 6 h before maxi­
mum T, is less convincing (see Fig. 1D,E). Subject 6 in 
particular, although having a tau of sleep onset not 
significantly different from 24 h under melatonin, nev­
ertheless appears to have a shortened tau rather than 
entrainment. Subject 7 shows two clear phase delays 
and apparent short-term entrainment to melatonin 
administered shortly after sleep offset. There was no 
evidence for entrainment of temperature in either of 
Üiese subjects, although there were phase shifts to the 
initial melatonin treatment. These subjects had long 
free-running periods. Indeed, this was the reason for 
melatonin administration falling within a phase delay 
window: the T rhythm had moved much farther than 
that of the other 8 subjects. It is conceivable that the 
limits of entrainment of the sleep-wake cycle by mela­
tonin depend on individual tau such that a free run 
much longer (or possibly shorter) than 24 h is beyond 
the limits of entrainment. During melatonin adminis­
tration in Subject 7 in particular, the temperature 
rhythm appeared to be unstable, and it is likely that 
the major phase shifts seen in the sleep-wake cycle are 
a result of this constantly changing phase. Possible 
short-term entrainment by melatonin at sleep offset in 
Subject 7 m aybe an artifact. However, if this phenome­
non were to be observed in other subjects, then an 
explanation must be sought. Gillette and coworkers, 
using in vitro suprachiasmatic nucleus preparations, 
observed phase advances by melatonin at two CTs 
(McArthur et al., 1991), and a possible mechanism 
may relate to this observation. Only a longer period of 
investigation in more subjects will resolve some of 
these questions.
According to the PRC of Lewy et al. (1992), maxi­
mum phase advances to melatonin are seen within 5
to 8 h of evening melatonin onset (ca. 21:00 h  = CT 14). 
This corresponds closely to the maximum phase ad­
vance seen in core temperature in relation to maxi­
mum T in these experiments and also is consistent 
with the PRC of Zaidan et al. (1994).
The irregular sleep noted with Melatonin 1st in 2 
subjects was unexpected. These 2 subjects received 
melatonin 2.3 and 2.5 h after maximum T. In a normal 
environment, this would be expected to induce a 
phase advance. However, in a normal environment, 
the LD cycle and other time cues clearly wül modify 
any such response, and the net result will be a combi­
nation of zeitgeber effects. Because of these observa­
tions, w e performed a second small experiment 
designed to induce irregular sleep by administration 
of melatonin within 2 h of maximum T (Middleton 
et al., 1996b). In this case, 2 of 6 subjects showed a 
similar phenomenon. In the present study, there may 
be an analogy with the "squashing" of the amplitude 
of T and cortisol and large phase jumps of the circadian 
system induced by bright light given at or very close 
to minimum T in a constant routine (Jewett et al.,
1991). It is conceivable that melatonin may provoke a 
similar response if suitably timed with respect to the 
sleep-wake cycle. Another explanation may be that if 
the sleep-wake cycle is governed by two oscillators 
(Wehr et al., 1993), then melatonin may be able to 
uncouple such a system (Middleton et al., 1996b). 
Whatever the explanation, it is clear that melatonin 
does not act as a conventional sleep-inducing drug. 
Moreover, it will be important for its therapeutic uses 
to investigate this phenomenon further given that the 
sleeping patterns observed would be highly undesir­
able in normal life. Different doses and formulations 
clearly must be investigated.
We conclude that, as discussed previously (Arendt 
et al., 1985), melatonin has weak zeitgeber effects. It is 
able to phase shift sleep, its own rhythm, core tem­
perature, and other rhythms. Most evidence indicates 
that it is rarely able to synchronize core temperature 
or, indeed, its own rhythm (Folkard et al., 1990; Sack 
et al., 1991). Its effects on sleep suggest that, in some 
individuals, the sleep-wake cycle can be synchronized 
but that this may depend on a sufficiently short indi­
vidual tau. Its differential effects on temperature and 
sleep suggest either different target control systems or 
a major contribution of acute temperature suppres­
sion, mild sleepiness, and lowered alertness at the 
appropriate circadian phase. Only further experimen­
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tation can resolve these questions. Combined with 
other time cues, however, it is clearly able to hasten 
adaptation to phase shift (Deacon and Arendt, 1996).
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certificate. It must, therefore, be emphasized that they decision of the Licensing
Authority does not imply any positive assessment of safety, quality or efficacy or 
of those considerations which are the responsibility of Hospital Ethical committees 
and they physicial conducting the trial.
We shall be pleased to see a copy of any report which is proposed as a result of this
trial.
Yours sincerely
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